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Preface 
Hodgkin's lymphoma, previously known as Hodgkin's disease, is recognized as B cell 
derived cancer of lymphatic system. Although the disease had been described about 
180 years ago, its exact causes and pathophysiology still remains unknown. However, 
there have been some progresses in identifying some genetic and environmental risk 
factors in development of lymphoma. Considering recent advances in treatment of 
patients with lymphoma during last two decades, the disease is considered as a 
curable disease, but it is still a controversial subject. 
The current book consists of 11 chapters. Recent insights into the biology of Hodgkin's 
lymphoma, including historical aspects, epidemiology, pathophysiology, genetic 
defects, and prognostic indicators are explained in the chapters 1-3. Chapter 4 is a 
translational chapter from tumor microenvironment to immunotherapeutic approach, 
followed by the chapters 5-9, explaining treatment of early stage, advanced, and 
refractory Hodgkin’s lymphoma as well as MALT lymphoma, respectively. The 
chapter 10 briefly explains some adverse effects of chemotherapy and radiotherapy in 
the affected patients, while the final chapter is focused on survivorship in Hodgkin's 
lymphoma. These chapters are intended to help physicians as well as medical students 
to learn and understand the pathophysiology of Hodgkin's lymphoma as well as 
practical approach to diagnosis and management in clinical practice. 
The book is the result of valuable contribution of 20 scientists in this field and I would 
like to acknowledge the expertise of all contributors, for generously giving their time 
and considerable effort in preparing their respective chapters. I hope the book will be 
welcomed by the physicians, who wish to learn more about Hodgkin's lymphoma. 
Nima Rezaei, MD, PhD 
Research Center for Immunodeficiencies, 
Children's Medical Center, 
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Recent Insights into the Biology 
of Hodgkin's Lymphoma 
Diponkar Banerjee 
Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, 
Canada 
1. Introduction 
Hodgkin’s lymphoma (HL) is currently recognized as B cell derived lymphoma with 
histological and biomarker-based distinction from other types of B cell derived lymphoma 
(Swerdlow, S.H. et al., 2008). HL had a worldwide incidence of 67,887cases in 2008, with an 
age standardized rate of 1.0 per 100,000 (both genders) (http://globocan.iarc.fr/). Some of the 
information in this chapter has already been part of an earlier review article (Banerjee, D., 
2011) and is cited again for the sake of completeness, but this chapter also provides some 
historical or current data that was not included that review. 
2. Historical aspects of Hodgkin’s Lymphoma 
The earliest description of Hodgkin’s lymphoma (HL) in an autopsy patient is attributed to 
Malpighi who described an 18 year old female with prominent splenic nodules in his 1666 
publication (Malpighi, M., 1666). Thomas Hodgkin, whose name is now associated with this 
disease, was very careful to mention this fact in the published version of his paper “On some 
morbid appearances of the absorbent glands and spleen” (Hodgkin, T., 1832) read to the Royal 
Medical and Chirurgical Society of London on January 10th and 24th, 1832. The paper was read 
not by Hodgkin but by the Society secretary Robert Lee. This was because Hodgkin was not a 
member of the Society at the time and therefore was prohibited from presenting the paper in 
person or even being present in the room during Lee’s reading of his paper.  
Although the compound microscope had been invented in 1590 by spectacle-makers 
Zacharias Janssen and his son Hans (Uluç, K. et al., 2009), its use in pathology was non 
existent in Malpighi’s time. It is thus impossible to verify that Malpighi had indeed 
described what we now recognize as Hodgkin’s lymphoma. Even Hodgkin, who actually 
knew about light microscopy, having used it in a study published with Lister (Hodgkin, T. 
& Lister, J.J., 1827), did not use a microscope to study this disease. This is due to the fact that 
tissue processing, staining, and histopathology were not established techniques at the time.  
Two of Hodgkin’s original 7 cases were subsequently proven to be true examples of 
Hodgkin’s lymphoma by Fox (Fox, H., 1926) and again by Poston, this time demonstrating 
that the neoplastic cells indeed expressed CD15 (Poston, R.N., 1999). Case IV is likely to be 
an example of a peripheral T cell lymphoma with rare CD15+ Reed Sternberg-like cells. It is 
possible the other 4 cases were also HL but no tissue was available for histology or 





Hodgkin’s description of his 7 cases remained in obscurity for years even after being 
rediscovered and attributed to him by Bright (Bright, R., 1838) and Wilks (Wilks, S., 1856). It 
was through Wilks’ persistence that the disease was later recognized as Hodgkin’s disease 
(Wilks, S., 1859). Wilks had to put the term “Hodgkin’s disease” in the title of his paper to 
make the point (Wilks, S., 1865). 
Most of the cases that Hodgkin described were patients who died soon after admission to 
hospital with terminal disease. He did have an opportunity to treat one of the 7 patients 
with cascarilla and soda to “improve his general health” and iodine “as an agent most likely 
to affect the glands” but noted dryly in his report that the treatment “appeared to be 
productive of no advantage, on which account it is probable the patient withdrew himself 
from my observation” (Hodgkin, T., 1832). 
The first description of the histopathological features of HL was published by Theodor 
Langhans, (Langhans, T., 1872). Six years later, Greenfield published the histopathological 
features of HL in the English language (Greenfield, W., 1878). The detailed description of the 
characteristic multinucleated cells in this disease was described by Carl Sternberg (Sternberg, 
C., 1898) and Dorothy Reed (Reed, D., 1902) and are now called Reed-Sternberg cells. Gall and 
Mallory established HL as a neoplastic process (Gall, E. & Mallory, T., 1942). The first 
definitive evidence of the neoplastic nature of HL came in 1967 with the publication about the 
cytogenetics of HL (Seif, G.S. & Spriggs, A.I., 1967), further supported by a 1975 publication 
that showed clonal growth of Hodgkin cells (Boecker, W.R. et al., 1975). 
The histopathological classification of HL has undergone several changes over the years. 
The first attempt to classify HL was by Jackson and Parker who in 1947 proposed three 
categories – paragranuloma, granuloma and sarcoma subtypes (Jackson, H. & Parker, F., 
1947). Smetana and Cohen published the results of a retrospective review of mortality rates 
of HL cases culled from the records of the Armed Forces Institute of Pathology, classified 
according to the Jackson and Parker classification (Smetana, H.F. & Cohen, B.M., 1956). They 
did not describe how these patients had been treated. 
Further refinement of HL classification came with the publications of Lukes and Butler 
(Lukes, R.J. et al., 1966; Lukes, R.J. & Butler, J.J., 1966), who divided HL into 6 groups: 
lymphocytic and/or histiocytic, (L & H), nodular, lymphocytic and/or histiocytic (L & H), 
diffuse, nodular sclerosis (NS), mixed, diffuse fibrosis and reticular. This was later 
simplified at the Rye Conference into 4 categories: Lymphocyte predominance (LP), 
Nodular sclerosis (NS), Mixed cellularity (MC), and Lymphocytic depletion (LD) (Lukes, R. 
et al., 1966). The first system to separate nodular lymphocyte predominance from classical 
HL was published in 1994 as part of the Revised European-American lymphoma (REAL) 
classification system, including the addition of a provisional entity of lymphocyte-rich 
classical HL (Harris, N.L. et al., 1994). The 2001 and 2008 WHO classification systems 
accepted the new category which is no longer a provisional one (Jaffe, E.S. et al., 2001; 
Swerdlow, S.H. et al., 2008).  Recently, a comprehensive update of the histopathology and 
immunohistochemistry findings in HL has been published (Eberle, F.C. et al., 2009). 
The therapy of HL has also undergone numerous changes, starting with Thomas Hodgkin’s 
attempts with cascarilla and soda and iodine combination therapy on one patient (Hodgkin, 
T., 1832). Fowler’s solution (potassium arsenite), a panacea concocted in 1786 by Thomas 
Fowler (Sears, D.A., 1988) for all sorts of chronic conditions, was used to treat HL (Waxman, 
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from the University of Toronto published a case report of a young male patient with HL 
who had a remarkable response to colloidal arsenic (Hendrick, A.C. & Burton, E.F., 1937). 
More recently, Mathas et al. have shown that sodium arsenite rapidly down regulates 
constitutive IĸB kinase (IKK) as well as NF-ĸB activity and induces apoptosis in Hodgkin 
Reed-Sternberg (HRS) cell lines containing functional IĸB proteins and that arsenic trioxide 
induces tumour reduction in xenograft models of HL (Mathas, S. et al., 2003). The use of 
nitrogen mustard for the chemotherapy of HL was  introduced by in 1946 (Goodman, L.S. et 
al., 1946), with reports from others on the results of nitrogen mustard on HL in the forties 
(Alpert, L.K. & Peterson, S.S., 1947; Dameshek, W. et al., 1949). 
Immunotherapy was attempted in 1928 (Wallhauser, A. & Whitehead, J.M., 1928). Three HL 
patients were treated with saline extracts from affected lymph nodes by subcutaneous 
injections. Two of the 3 patients achieved complete remission, while the third relapsed after 
initial response, but responded to a second round of injections.  This report encouraged 
Hanrahan to try the same approach in 1930 with 9 patients but with less spectacular results 
(Hanrahan, E.M., 1930). Hanrahan used a preservative, tricresol (a mixture of three isomeric 
phenols derived from toluene: ortho-, meta- or para-methylphenol), in the extract, so one 
could speculate that whatever the active substance was in the HL tissue extract might have 
been damaged by tricresol. 
Radiotherapy for HL was reported in 1932 (Chevalier, P. & Bernard, J., 1932) and firmly 
established as an effective therapeutic modality by Vera Peters of the Ontario Cancer 
Institute (Peters, M.V., 1960, 1965, 1966; Peters, M.V. & Middlemiss, K.C., 1958). 
Modern therapy of HL has been described in recent reviews (Boleti, E. & Mead, G.M., 2007; 
Edwards-Bennett, S.M. et al., 2010; Eichenauer, D.A. et al., 2009; Federico, M. et al., 2009; 
Mendler, J.H. et al., 2008; Oflazoglu, E. et al., 2008) and not further discussed here. 
3. The cell of origin and the pathobiology of HRS cells 
The neoplastic cells of classical HL (cHL) (Hodgkin/Reed-Sternberg cells or HRS cells) are 
usually derived from germinal centre B cells, and rarely are of T cell origin; those of nodular 
lymphocyte predominance (NLPHL) HL (LP cells) cases are always of germinal centre B cell 
origin (Brauninger, A. et al., 2006; Caporaso, N.E. et al., 2009; Kuppers, R., 2009; Küppers, R., 
2009; Kuppers, R. et al., 2002; Mani, H. & Jaffe, E.S., 2009; Marafioti, T. et al., 2000; Seitz, V. et 
al., 2000).  
Despite the fact that cHL HRS cells are derived from germinal centre or post-germinal centre 
B cells, they lack B cell markers including the B cell receptor (BCR) (Schwering, I. et al., 2003) 
as they lose their B cell programming (Hertel, C.B. et al., 2002) through several mechanisms 
including promoter DNA methylation (Doerr, J.R. et al., 2005; Ushmorov, A. et al., 2006), 
inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 resulting in 
reprogramming of neoplastic B cells (Mathas, S. et al., 2006), loss of PU.1 expression 
associated with defective immunoglobulin gene transcription (Jundt, F. et al., 2002), down-
regulation of BOB.1/OBF.1 and Oct2 (Stein, H. et al., 2001) and upregulation of NOTCH1, a 
negative regulator of the B cell program (Jundt, F. et al., 2008).  At the same time non-B cell 
lineage proteins are upregulated (Atayar, C. et al., 2005; Dorfman, D.M. et al., 2005).  
The LP cells in NLPHL are derived from antigen-activated germinal centre B cells 





(Mottok, A. et al., 2005; Schmitz, R. et al., 2009), BCL6 protein (Falini, B. et al., 1996), and 
GCET1 (centerin), a germinal centre B cell associated serpin (Montes-Moreno, S. et al., 2008). In 
contrast to H/RS cells, LP cells retain most of their B cell programming; however, LP cells also 
show selective loss of the B cell phenotype such as down regulation of CD19, CD37, PAG and 
LCK (Dogan, A. et al., 2000; Masir, N. et al., 2006; Tedoldi, S. et al., 2007). The mechanism is not 
related to promoter methylation of the encoding genes (Tedoldi, S. et al., 2007).  
3.1 The role of the Epstein Barr virus in HL 
The Epstein-Barr virus was first identified in 1964 by Epstein, Achong and Barr (Epstein, M. 
et al., 1964).  Up to 40-60% of cHL cases may contain the EBV genome (Kapatai, G. & 
Murray, P., 2007), but since EBV infects 90% of the adult population worldwide (Cohen, J., 
2000), and is a B lymphocytotropic virus, it may be a passenger, but not a driver in HL.  
Comprehensive EBV-human protein interaction maps have been generated by Calderwood 
et al. (Calderwood, M.A. et al., 2007) who showed over 40 interactions between EBV 
proteins and over 170 interactions between EBV and human proteins.  
4. Genetic defects in primary immunodeficiency disorders (PID) and HL 
Mutations in the SH2D1A and ITK genes are associated with aberrant T and NK function 
that predisposes patients to serious EBV infections, and lymphoproliferative disease 
including HL in those that survive the initial fulminant infectious mononucleosis. Detailed 
reviews of these PIDs has been published recently (Rezaei, N., Hedayat, M., et al., 2011; 
Rezaei, N., Mahmoudi, E., et al., 2011) and some key points are summarized below. 
4.1 SH2D1A  
The small (128-amino acid) Src homology 2 domain protein 1A (SH2D1A, DSHP or SAP) is  
associated with  X-linked lymphoproliferative disease (XLP). The patients respond to the 
Epstein-Barr virus (EBV) infection with a fulminant, frequently fatal infectious 
mononucleosis syndrome (Purtilo, D.T. et al., 1975; Rezaei, N., Mahmoudi, E., et al., 2011).  
Most cases of XLP are due to mutations in the SH2D1A gene, which codes for the adaptor 
molecule called Signaling Lymphocytic Activation Molecule (SLAM; CD150)-associated 
protein (SAP) (Rezaei, N., Mahmoudi, E., et al., 2011). Patients with XLP and Sap null mice 
have defective natural killer and CD8+ T cell cytotoxicity, impairment of T cell cytokine 
production, activation-induced cell death, germinal centre formation and T NK cell 
development (Rezaei, N., Mahmoudi, E., et al., 2011). Survivors may develop 
agammaglobulinemia and B cell malignant lymphomas including HL (Rezaei, N., Hedayat, 
M., et al., 2011; Seemayer, T.A. et al., 1995). SH2D1A has been detected in 5 of 6 EBV 
negative classical HL cell lines including T cell derived HL cell lines (Kis, L.L. et al., 2003) 
and SH2D1A mRNA  found in HRS cells in HL tissue (Nichols, K.E. et al., 1998). The lack of 
EBV in HL cell lines expressing SH2D1A protein is unexplained (Kis, L.L. et al., 2003). 
4.2 IL-2–inducible T-cell kinase (ITK) 
IL-2–inducible T-cell kinase (ITK) is a cytoplasmic non-receptor tyrosine kinase expressed in 
thymocytes,  mature T cells,  NK cells, iNKT cells, and mast cells (Au-Yeung, B.B. & Fowell, 
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EBV in HL cell lines expressing SH2D1A protein is unexplained (Kis, L.L. et al., 2003). 
4.2 IL-2–inducible T-cell kinase (ITK) 
IL-2–inducible T-cell kinase (ITK) is a cytoplasmic non-receptor tyrosine kinase expressed in 
thymocytes,  mature T cells,  NK cells, iNKT cells, and mast cells (Au-Yeung, B.B. & Fowell, 
D.J., 2007; Au-Yeung, B.B. et al., 2006; Gadue, P. & Stein, P.L., 2002; Gomez-Rodriguez, J. et al., 
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2007; Grasis, J.A. et al., 2003; Iyer, A.S. & August, A., 2008; Qi, Q. et al., 2011). ITK mutations 
lead to fatal EBV induced lymphoproliferative disease characterized as hemophagocytic 
lymphohistiocytosis (HLH) and HL (Huck, K. et al., 2009; Stepensky, P. et al., 2011).  
5. Prognostic indicators derived from transcriptome, genome and host 
response patterns 
5.1 Gene copy number variation in HRS cells 
Complex chromosomal and genomic alterations occur in HRS cells of HL. My laboratory 
reported novel gains and losses of 9 novel regions in Hodgkin Lymphoma cell lines L428 
and KMH2, which shared gains in chromosome cytobands 2q23.1-q24.2, 7q32.2-q36.3, 
9p21.3-p13.3, 12q13.13-q14.1, and losses in 13q12.13-q12.3, and 18q21.32-q23. The genes 
located in  these regions include cell cycle associated genes, MAPK signaling pathway 
genes, those encoding tight junction proteins, Jak/Stat signaling pathway genes and tumour 
suppressor gene ING3 (Fadlelmola, F. et al., 2008). 
Steidl et al. compared patients that had failed primary treatment with those that responded 
as usual (Steidl, C., Telenius, A., et al., 2010). Gains of 16p11.2-13.3 were associated with 
treatment failure and shorter disease-specific survival. One of the genes mapping to this 
region is the multidrug resistance gene ABCC1 encoding multidrug resistance protein MRP1 
(Leslie, E. et al., 2001; Rosenberg, M. et al., 2001), and functional studies indicate that this 
does play a  role in chemoresistance (Steidl, C., Telenius, A., et al., 2010).  
5.2 Gene expression studies 
Devilard et al. using whole cells including the microenvironment, found a signature that can 
distinguish between good outcome Hodgkin's disease and bad outcome cases (Devilard, E. 
et al., 2002). Good outcome was associated with overexpression of genes involved in 
apoptotic induction and cell signaling pathways, including cytokines, whereas bad outcome 
was associated with overexpression of genes associated with fibroblast activation, 
angiogenesis, extracellular matrix remodeling, cell proliferation, and the down regulation of 
tumor suppressor genes.  
Sánchez-Aguilera et al. identified 145 genes predictive of outcome (Sanchez-Aguilera, A. et 
al., 2006). Four different signatures were obtained by supervised hierarchical clustering, 2 of 
which were associated with the host immune response of tumor microenvironment and the 
other 2 with the HRS cells based on known expression in HL cell lines and normal germinal 
centre B cells.  
Chetaille et al. studied 63 cHL cases (not enriched for HRS by microdissection, thus 
including cells from the microenvironment) using full transcriptome coverage  and found 47 
genes associated with adverse outcome, and 403 genes associated with favorable outcome 
(Chetaille, B. et al., 2009). Favorable outcome was associated with expressed genes of the “B-
cell” cluster, whereas genes associated with unfavorable outcome were in the “extracellular 
matrix” cluster. 
Global gene expression analysis of microdissected LP cells (L&H cells) from 5 cases of 





signatures were closer to T cell-rich B cell lymphoma and classical HL than to diffuse large B 
cell lymphoma, Burkitt lymphoma, and follicular lymphoma. There is increased expression 
of ABCC1 in LP cells, which as already discussed, encodes multidrug resistance protein 
MRP1 (Leslie, E. et al., 2001) and is also amplified and overexpressed in primary treatment 
refractory cHL (Steidl, C., Telenius, A., et al., 2010). 
5.3 Host microenvironment/immune response  
An increased number of CD68+ macrophages is associated with a shortened progression-
free survival, an increased risk of relapse after HDCT/ASCT, and shortened disease-specific 
survival. In multivariate analysis, CD68+ cells as a prognostic factor is superior to the 
International Prognostic Score for disease-specific survival. The absence of an increased 
number of CD68+ cells in patients with limited-stage disease predicted long-term disease-
specific survival of 100% in cHL patients treated with current treatment protocols (Steidl, C., 
Lee, T., et al., 2010). The immunohistochemistry (IHC) assay for CD68, which is widely 
available in clinical laboratories, can identify patients with HL who are likely to be 
refractory to first line therapy and was noted to be the first predictive in-vitro test for cHL 
(DeVita, V.T., Jr. & Costa, J., 2010).  
5.4 Mechanisms of chemoresistance 
The multidrug resistance gene ABCC1 in overexpressed in LP and HRS cells and HRS cells 
contain increased copy number of the ABCC1 gene (Brune, V. et al., 2008; Steidl, C., 
Telenius, A., et al., 2010). HL tumor samples contain a population of cells that increase efflux 
of Hoechst 33342 dye and are resistant to gemcitabine, a commonly used drug for the 
treatment of refractory HL. These cells have the phenotype of HRS cells and express 
multidrug resistance genes ABCG2 and MDR1 (ABCB1) (Shafer, J.A. et al., 2010).  
Genes encoding cytokine receptors (IL5RA, IL13RA1), markers expressed on antigen-
presenting cells (CD40, CD80), as well as genes with known association to chemoresistance, 
such as myristoylated alanine-rich protein kinase C substrate, and PRAME (preferentially 
expressed antigen in melanoma) are upregulated in chemoresistant cells (Staege, M.S. et al., 
2008). 
Chemoresistance in HL is also related to XIAP (X-linked inhibitor of apoptosis) an NF-
kappaB-independent target of bortezomib. Bortezomib sensitizes HL cells against a variety 
of cytotoxic drugs independent of NF-kappaB (Kashkar, H. et al., 2007).  
6. How the HRS cell, an abnormal B cell clone, survives the normal apoptotic 
process and immune destruction 
Normally B cells that fail to achieve productive or high affinity Ig gene rearrangements or 
lack BCR are destroyed during the germinal centre reaction (Gordon, J. et al., 1993; Guzman-
Rojas, L. et al., 2002; Hollowood, K. & Goodlad, J.R., 1998; Zhang, Q.P. et al., 2005). There are 
several excellent reviews on the topic of the germinal centre reaction and mechanisms of B 
cell apoptosis and survival during a normal antigen driven reaction (Elgueta, R. et al., 2010; 
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Vikstrom, I. & Tarlinton, D.M., 2011; Vinuesa, C.G. et al., 2010), so only a brief summary is 
provided in this chapter.  
6.1 The germinal center reaction 
The biologic or physiologic purpose of the germinal centre reaction is to generate long-term 
humoral immunity in the adaptive immune system against antigens expressed by 
pathogens, while, at the same time, eliminating autoreactive clones. The end result is the 
generation of long-lived antibody-secreting plasma cells and memory B cells which can 
rapidly trigger subsequent waves of plasma cell production when the same antigen/s are 
encountered again. The germinal centre reaction is a complex cascade of events, highly 
regulated, requiring crosstalk and collaboration between B cells, follicular helper T cells and 
antigen presenting cells including dendritic cells, macrophages and follicular dendritic cells 
(Cattoretti, G. et al., 2005; Elgueta, R. et al., 2010; Guzman-Rojas, L. et al., 2002; Jardin, F. et 
al., 2007; Kosco-Vilbois, M.H., 2003; Park, C.S. & Choi, Y.S., 2005; Phan, R.T. & Dalla-Favera, 
R., 2004; Schenka, A.A. et al., 2005; Siepmann, K. et al., 2001; Spender, L.C. et al., 2009; 
Tarlinton, D.M. & Smith, K.G., 2000; Zhang, Q.P. et al., 2005). 
6.2 The primary lymphoid follicle 
Primary lymphoid follicles appear in the second trimester of fetal life in humans and are 
composed of antigen-naive recirculating B cells that migrate through meshworks of 
follicular dendritic cells (FDC) with a transit time of 24 hours (Howard, J.C. et al., 1972). 
These antigen-naive B cells have already undergone recombination of gene fragments, with 
a theoretical repertoire of >1010 antigen binding receptors (Berek, C. & Milstein, C., 1988). 
When these B cells encounter an antigen, they increase their expression of the chemokine 
receptor CCR7 which facilitates their migration to the interface between T and B cells zones 
(Cyster, J.G., 2005; Okada, T. & Cyster, J.G., 2006). Here they can contact antigen-primed T 
cells, triggering a burst of proliferation of the activated B cells in the outer follicle, ultimately 
forming a germinal centre (Coffey, F. et al., 2009). HRS cells of cHL also express CCR7 which 
may explain why HRS cells tend to be located in interfollicular zones (Höpken, U.E. et al., 
2002). LP cells are CCR7- and therefore remain in germinal centers. 
6.3 Somatic hypermutation – Generation of higher affinity antibodies 
Activated B cells undergo a process of affinity maturation in the germinal center reaction. 
Rearranged immunoglobulin (Ig) variable region genes undergo random point mutations by 
a process called somatic hypermutation (SHM) in which single nucleotide substitutions are 
introduced at a rate of one mutation per 1000 base pairs per generation (Berek, C. & 
Milstein, C., 1988).  Both LP cells of NLPHL and HRS cells of cHL show evidence of SHM of 
Ig variable region genes (Liso, A. et al., 2006) and are therefore considered to be derived 
from antigen-activated B cells. 
6.4 Selection of high affinity B cells 
Since SHM is a random process, a wide range of antigen-binding affinities may result. A 





selected is required for optimal function. The default event seems to be death by apoptosis 
through the Fas/CD95 pathway unless the cells are rescued by signals from other cell types. 
Fas/CD95 triggers elimination of low-affinity and self-reactive B cell clones that arise during 
the germinal centre reaction through apoptosis (Defrance, T. et al., 2002). Prior to apoptosis, 
rapid activation of caspase-8 occurs in association with CD95 death-inducing signaling 
complex (DISC). c-FLIP(L), which protects B cells from Fas/CD95 triggered apoptosis is 
rapidly lost from the CD95 DISC unless the B cells are exposed to the survival signal 
provided by CD40L from follicular T helper cells (Hennino, A. et al., 2001). In cHL, over 80% 
of cases show constitutive expression of c-FLIP which protects the HRS cells from Fas/CD95 
triggered apoptosis without the need for CD40L survival signals (Mathas, S. et al., 2004; 
Thomas, R. et al., 2002; Uherova, P. et al., 2004). 
6.5 The role of the follicular helper T cell (TFH) 
The localization of T cells coexpressing HNK-1 (CD57) in the germinal centers (GC) of 
lymph nodes and spleens was reported by my laboratory (Banerjee, D. & Thibert, R.F., 
1983). Although expressing HNK-1 (CD57), which was initially thought to be human natural 
killer cell specific, these cells were not cytotoxically active. Under certain circumstances, we 
found that these cells could either suppress or enhance immunoglobulin production by 
pokeweed mitogen-activated tonsillar B cells (Banerjee, D. et al., 1988). Such cells are now 
recognized to be specialized CD4+ T cells called follicular helper T cells (TFH) that home to 
the germinal center and play a pivotal role in regulating the fate of B cell in the germinal 
centre reaction. They express cell surface antigens CD4, CD57, and CXCR5, produce IL-21, 
IL-6, IL-27, BCL-6, ICOS, CD40L, and PD-1 (Crotty, S., 2011). While germinal centre CD57+ 
CD4+ T cells have been shown to be a major T helper cell subset for GC-B cells in Ig 
synthesis, and have the capacity to induce activation-induced cytosine deaminase (AID) and 
class switch recombination (Kim, J.R. et al., 2005), the most effective subset of capable of 
inducing IgG production is the CXCR5hi  ICOShi  CD4+ T cell. The presence or absence of 
CD57 does not appear to affect this function (Rasheed, A.U. et al., 2006).  
Cells with the phenotype of TFH are usually found in contact with of NLPHL LP cells (Nam-
Cha, S.H. et al., 2009) forming characteristic rosettes. The expression of PD-1 is more 
frequent than that of CD57 by the T cell rosettes around LP cells (Churchill, H.R. et al., 2010). 
PD-1+ T cells are also reported in cHL and HRS cells express both ligands for PD-1 (CD279), 
B7-H1 (PDL1; CD274) and B7-DC (PDL2; CD273) (Yamamoto, R. et al., 2008). The function 
of PD-1+ T cells  in HL is unknown. In normal germinal center reactions, PD-1 signals 
enhance B cell survival (Good-Jacobson, K.L. et al., 2010), thus it is possible that PD-1+ TFH 
cells in both NLPHL and cHL provide additional survival signals. Another  protective effect 
of PD-1 could be mediated through its inhibition of cytotoxic T cells via overexpressed PD-1 
ligands CD273 or CD274 by the target cells of cytotoxic T cells (Norde, W.J. et al., 2011).  
6.6 IL-21 
HRS cells aberrantly express IL-21 and the IL-21 receptor. IL-21 activates STAT3 in HRS 
cells, up-regulates STAT3 target genes, and protects HRS cells from CD95 death receptor–
induced apoptosis. In addition, IL-21 through up-regulation of the CC chemokine 
macrophage-inflammatory protein-3α (MIP-3α) attracts CCR6+CD4+CD25+FoxP3+CD127lo 
regulatory T cells to migrate close to the proximity of HRS cells, protecting them from 
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IL-6 is a pleiotropic cytokine (also called B-cell stimulatory factor-2, IFN-b2, 26-kDa protein, 
Hybridoma/plasmacytoma growth factor and hepatocyte stimulating factor HSF) with 
biological activities in immune regulation, hematopoiesis, inflammation and neoplasia 
(Kishimoto, T., 2010). HL cells express multiple cytokines, including interleukin-6 (IL-6) 
(Tesch, H. et al., 1992). Increased serum levels are associated with advanced disease and 
worse prognostic scores (Vener, C. et al., 2000). HL cells produce IL-6 through constitutional 
activation of the PI3K signaling pathway which promotes expression of HLXB9, an EHG 
homeobox gene family member, which in turn activates IL6 (Nagel, S. et al., 2005). Thus HL 
cells, and presumably HRS cells in vivo, do not solely depend upon TFH for IL-6 supply but 
make their own, possibly benefiting from an autocrine loop. 
6.8 BCL-6 
The BCL6 proto-oncogene encodes a nuclear transcriptional repressor. It is important in 
germinal center (GC) formation and regulates lymphocyte function, differentiation, and 
survival. BCL-6 suppresses p53 in GC B-cells and protects B-cell lines from apoptosis 
induced by DNA damage. BCL-6 is thought to allow GC B-cells to sustain the low levels of 
physiological DNA breaks related to somatic mutation (SM) and immunoglobulin class 
switch recombination (Jardin, F. et al., 2007). BCL-6 is also an important regulator of the TFH 
cell program, being essential for CXCR5 expression and follicular homing by TFH cells (Yu, 
D. et al., 2009). 
BCL-6 expression is usually seen in NLPHL and about 30% of lymphocyte rich classical HL 
(LRCHL)  but not other forms of cHL (Nam-Cha, S.H. et al., 2009). However, in another 
study, none of the cases of LRCHL expressed BCL-6 (Brauninger, A. et al., 2003). 
6.9 Bfl-1 
Bfl-1 is a NF-κB target gene from the Bcl-2 family of apoptosis-regulating proteins. Bfl-1 is 
expressed in HRS cells in clinical biopsies and also expressed in HL cell lines. Bfl-1 can 
protect cultured H/RS cells from apoptosis induced by pharmacological inhibitors of NF-κB 
(Hinz, M. et al., 2001; Loughran, S.T. et al., 2011).  
7. Next generation whole genome sequencing and new insights into the 
pathobiology of HL 
Technological improvements now allow the analysis of entire genomes and transcriptomes 
at a sufficient resolution to detect point mutations at high speed and reduced cost (Cronin, 
M. & Ross, J.S., 2011). Two recent discoveries that are relevant to HL are highlighted in this 
review. 
7.1 MHC class II transactivator CIITA, PD-1 and PD-1 ligands  
In 15% of cHL, a gene fusion involving the major histocompatibility complex (MHC) class II 
transactivator CIITA (MHC2TA) and several partners has been reported (Steidl, C. et al., 





with downregulation of HLA Class II  expression which could help HRS cells evade 
immunosurveillance, CIITA also fuses with genes encoding CD274 (PDL1) and CD273 
(PDL2), leading to overexpression of both these PD-1 ligands by HRS cells. This could have 
two beneficial effects on HRS cell survival, the first through PD-1 survival signals from TFH 
cells to the neoplastic B cells and the second through inhibition of cytotoxic T cells as 
already discussed above. 
7.2 EZH2  
Mutations in EZH2, a polycomb group oncogene which encodes a histone 
methyltransferase, have been described in follicular lymphomas and diffuse large B cell 
lymphomas of germinal centre type. These mutations involve a single tyrosine (Y641) in the 
SET domain of the EZH2 protein reducing its enzyme action (Morin, R.D. et al., 2010). While 
HL cases were not included in this study, this protein may have a role in HL. Whereas the 
expression of the polycomb group gene encoded proteins BMI-1 and EZH2 genes is 
associated with resting or proliferating germinal centre B cells, respectively and not 
coexpressed, Hodgkin/Reed-Sternberg (H/RS) cells co-express BMI-1 and EZH2 (Dukers, 
D.F. et al., 2004; Raaphorst, F.M. et al., 2000).  
8. New targets for potential therapeutic approaches 
CD20, a B cell expressed phosphoprotein, is usually expressed by LP cells in NLPHL but 
variably positive in a minority of cHL cases as recently reviewed by Saini and others (Saini, 
K.S. et al., 2011). Despite CD20 negativity in most cases of cHL, patients refractory to all 
conventional HL therapies have responded to rituximab (Younes, A. et al., 2003).  An excellent 
review of the myriad of potential targets for novel therapies for treatment refractory HL has 
been published by Younes (Younes, A., 2009), and some of these, and the rationale for their use 
have been summarized in one of my recent review articles (Banerjee, D., 2011). 
My laboratory recently reported that a 21 kDa protein (Zhou, M. et al., 2008), which we 
subsequently identified as CYB5B, an outer mitochondrial membrane protein, is 
overexpressed in the cytoplasm and plasma membrane of HRS cells but not at the plasma 
membrane of normal reactive lymphocytes or bone marrow precursor cells (Murphy, D. et 
al., 2010). Gains in the CYB5B locus in HL cell lines KMH2 and L428 were detected. HL cell 
lines show increased CYB5B mRNA but reactive lymphocytes and bone marrow precursor 
cells show no increase in CYB5B mRNA in comparison to housekeeping genes. Due to its 
location at the plasma membrane of only neoplastic cells in cHL, diffuse large B cell 
lymphoma (DLBCL) and anaplastic large cell lymphoma (ALCL), CYB5B might be an 
attractive target for antibody based therapy as toxicity should be minimal since we have 
determined that normal, reactive lymphocytes and CD34+ bone marrow precursor cells do 
not express the protein at the plasma membrane (Murphy, D. et al., 2010). We are in the 
process of creating chimeric antibodies to determine whether they are effective in killing 
HRS cells in pre-clinical models. 
9. Discussion 
From Hodgkin’s first report in 1832 on what we now call Hodgkin’s Lymphoma, to this day, 





with downregulation of HLA Class II  expression which could help HRS cells evade 
immunosurveillance, CIITA also fuses with genes encoding CD274 (PDL1) and CD273 
(PDL2), leading to overexpression of both these PD-1 ligands by HRS cells. This could have 
two beneficial effects on HRS cell survival, the first through PD-1 survival signals from TFH 
cells to the neoplastic B cells and the second through inhibition of cytotoxic T cells as 
already discussed above. 
7.2 EZH2  
Mutations in EZH2, a polycomb group oncogene which encodes a histone 
methyltransferase, have been described in follicular lymphomas and diffuse large B cell 
lymphomas of germinal centre type. These mutations involve a single tyrosine (Y641) in the 
SET domain of the EZH2 protein reducing its enzyme action (Morin, R.D. et al., 2010). While 
HL cases were not included in this study, this protein may have a role in HL. Whereas the 
expression of the polycomb group gene encoded proteins BMI-1 and EZH2 genes is 
associated with resting or proliferating germinal centre B cells, respectively and not 
coexpressed, Hodgkin/Reed-Sternberg (H/RS) cells co-express BMI-1 and EZH2 (Dukers, 
D.F. et al., 2004; Raaphorst, F.M. et al., 2000).  
8. New targets for potential therapeutic approaches 
CD20, a B cell expressed phosphoprotein, is usually expressed by LP cells in NLPHL but 
variably positive in a minority of cHL cases as recently reviewed by Saini and others (Saini, 
K.S. et al., 2011). Despite CD20 negativity in most cases of cHL, patients refractory to all 
conventional HL therapies have responded to rituximab (Younes, A. et al., 2003).  An excellent 
review of the myriad of potential targets for novel therapies for treatment refractory HL has 
been published by Younes (Younes, A., 2009), and some of these, and the rationale for their use 
have been summarized in one of my recent review articles (Banerjee, D., 2011). 
My laboratory recently reported that a 21 kDa protein (Zhou, M. et al., 2008), which we 
subsequently identified as CYB5B, an outer mitochondrial membrane protein, is 
overexpressed in the cytoplasm and plasma membrane of HRS cells but not at the plasma 
membrane of normal reactive lymphocytes or bone marrow precursor cells (Murphy, D. et 
al., 2010). Gains in the CYB5B locus in HL cell lines KMH2 and L428 were detected. HL cell 
lines show increased CYB5B mRNA but reactive lymphocytes and bone marrow precursor 
cells show no increase in CYB5B mRNA in comparison to housekeeping genes. Due to its 
location at the plasma membrane of only neoplastic cells in cHL, diffuse large B cell 
lymphoma (DLBCL) and anaplastic large cell lymphoma (ALCL), CYB5B might be an 
attractive target for antibody based therapy as toxicity should be minimal since we have 
determined that normal, reactive lymphocytes and CD34+ bone marrow precursor cells do 
not express the protein at the plasma membrane (Murphy, D. et al., 2010). We are in the 
process of creating chimeric antibodies to determine whether they are effective in killing 
HRS cells in pre-clinical models. 
9. Discussion 
From Hodgkin’s first report in 1832 on what we now call Hodgkin’s Lymphoma, to this day, 
the pathobiology of HL continues to intrigue and  surprise us with the myriad ways in 
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which the LP and HRS cells defy all physiologic rules of B cell survival by exploiting the 
very signals that would normally stop undesirable B cells from surviving. The vast network 
of crosstalk and redundancy of pathways the tumour cells have successfully utilized keeps 
growing in complexity. These observations challenge our preconceived notions of cell 
lineage fidelity as defined by expressed cell surface proteins and other biomarkers. Indeed 
reprogramming and plasticity of B cells is a reality, thus neoplastic B cells derived from the 
germinal centre can assume various “identities” and confuse regulatory cells and pathways 
(Mathas, S., 2007). Eventually, classification of B cell lymphomas including HL will require, 
not just lineage determination and morphology-based classification and grading, but also 
the detailed mapping of  aberrant pathways in sufficient resolution for us to understand all 
the potential nodes that could be novel therapeutic targets. 
10. Conclusion 
HL is a unique set of B cell lymphomas that are characterized by the exploitation of 
redundant pathways, and crosstalk between regulatory cells that promote the growth and 
survival of defective B cells which, under normal conditions, would die during the germinal 
centre reaction. While this may seem an insurmountable level of complexity, the potential 
for effective novel targeted therapies to deal with refractory disease will be possible to attain 
when a comprehensive map of pathway pathology is feasible in the future. 
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1. Introduction 
Transcriptional analysis of cancer is a powerful and increasingly useful tool in biomedical 
research. Many studies are revealing transcriptional patterns using gene expression 
profiling (GEP) analyses, increasing our knowledge of cancer pathogenesis, identifying 
signatures related to prognosis and revealing the variation in responses to therapy.  
Gene-expression signatures have been identified for the most common types of non-
Hodgkin lymphomas. These studies have demonstrated the ability of these technologies to 
identify pathogenic mechanisms, new molecular targets and biological processes involved 
in lymphomagenesis (Margalit, Somech et al. 2005). Thus, in the last decade molecular 
subtypes of diffuse large B-cell, namely germinal center B-cell and activated B-cell-like 
types, have been identified, each of which has their particular prognostic and therapeutic 
implications. Likewise, GEP studies have identified relevant molecular characteristics in 
follicular lymphomas (Alizadeh, Eisen et al. 2000; Alizadeh, Ross et al. 2001), primary 
mediastinal large B-cell lymphomas (Rosenwald, Wright et al. 2003), Burkitt lymphomas 
(Dave, Fu et al. 2006; Hummel, Bentink et al. 2006) or mantle cell lymphomas (Rosenwald, 
Wright et al. 2003). Specific therapeutic targets are likely to emerge from these insights into 
the molecular pathogenesis of the different lymphomas. 
Regarding Hodgkin lymphoma (HL), GEP has provided vital clues and new insights into its 
pathogenesis (Devilard, Bertucci et al. 2002). More recently, GEP has also identified specific 
gene patterns related to tumor aggressivity and/or sensitivity to therapy (Sanchez-Aguilera, 
Montalban et al. 2006; Chetaille, Bertucci et al. 2009; Steidl, Lee et al. 2010). 
DNA microarray assays require well-preserved RNA, which is usually extracted from 
frozen tissue, so this technology is not adequate for clinical applications. However, new 
strategies for translating this information into clinical practice are currently being 
investigated, through the identification of smaller gene signatures and validation of them 
for clinical practice using simple, robust, and conventional assays such as quantitative real 
time PCR (qRT-PCR) (Sanchez-Espiridion, Sanchez-Aguilera et al. 2009; Sanchez-Espiridion, 
Montalban et al. 2010). 
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In this chapter we review recent advances in the understanding of HL biology, new data 
and improvements in the clinical management of patients in the future, from the application 
of high-throughput molecular analyses, including gene and microRNA (miRNA) 
expression, immunohistochemistry and others.  
2. Hodgkin lymphoma biology 
HL is currently classified as two distinct disease entities, nodular lymphocyte-predominant 
HL (NLPHL) and classical HL (cHL), which differ in their clinical presentation, age 
distribution and prognosis. From a biological point of view, NLPHL has been defined as a 
different disease entity, characterized by a distinct gene-expression signature similar to 
indolent B-cell non-Hodgkin lymphoma (NHL)(Brune, Tiacci et al. 2008). 
cHL represents a distinctive model of histological complexity, with a minor population of 
the characteristic Hodgkin and Reed-Sternberg (HRS) tumor cells diluted in a reactive 
inflammatory background composed of non-neoplastic B- and T-cells, macrophages, 
eosinophils, neutrophils and plasma cells. This microenvironment is very probably essential 
for HRS cell survival, as indicated by the difficulty of growing HRS cells in culture or in 
immunodeficient mice (for a review see (Herreros, Sanchez-Aguilera et al. 2008)). 
Also, HRS cells are latently infected by Epstein-Barr virus (EBV) in 40-60% of patients, 
contributing to cHL pathogenesis (Khan 2006; Kapatai and Murray 2007).   
The complex relationship between the HRS cells and their microenvironment is only 
partially understood, although important, if fragmentary, advances are being made. 
Essentially, this microenvironment represents an ineffective TH2-type immune response, in 
which a large number of chemokines and cytokines are involved (Skinnider and Mak 2002). 
HRS cells attract many cells into the lymphoma tissue, resulting in an inflammatory 
microenvironment that probably promotes the survival of HRS cells and helps them to 
escape attack from cytotoxic T or NK cells. A better understanding of these essential cellular 
interactions may inspire novel approaches for a targeted therapy of this malignancy. 
2.1 HRS cells  
The tumoral HRS cells are unique in the extent to which they have lost the characteristic B-
cell–associated gene expression pattern. Deregulation of transcription factor networks plays 
a key role in this reprogramming process. These HRS cells show strong constitutive activity 
of the NF-kappaB transcription factors. Multiple mechanisms probably contribute to this 
deregulated activation, including signaling through particular receptors and genetic lesions, 
thus identifying NF-kappaB inhibition as an interesting therapeutic approach to this 
lymphoid malignancy (Kuppers 2009). 
2.2 Hodgkin lymphoma microenvironment 
There are various lines of evidence suggesting an active role of this “microenvironment” in 
tumor biology through bidirectional signaling between the HRS and inflammatory cells that 
promotes proliferation and survival of neoplastic cells (Kuppers 2009). A complex network 
of cytokines and cell-contact-mediated interactions between tumor and inflammatory cells 
are thought to be involved and may rescue HRS cells from the proapoptotic state arising 
from their characteristic BCR deficiency by providing alternative survival signals (Figure 1). 
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Fig. 1. Chemical crosstalk between HRS cells and the microenvironment. B: B-cell; T: T-cell; 
Th2: T-helper 2-cells, MΦ: Macrophage; Eo: Eosinophil. 
This variable microenvironment gives rise to a prominent and abnormal immune reaction, 
for which reason the biology of HL can be considered unique among lymphomas. Many 
studies of HL have, therefore, focused on the cellular composition of this microenvironment, 
not only to gain more insight into the pathobiology of the disease, but also to explore 
whether these immune-related cells in some way contribute to outcome prediction. 
The tumor microenvironment is an important factor in the development and progression of 
cancer. Recent evidence suggests that cellular composition can significantly modify clinical 
outcome in hematological malignancies and particularly in follicular lymphoma and cHL 
(Dave, Wright et al. 2004; Alvaro, Lejeune et al. 2005). The exact functional role of the 
microenvironment in the pathophysiology of cHL remains a matter of debate, especially 
with regard to the role of Th2 and T-reg cells, which have a paradoxically favorable 
prognostic value (Alvaro-Naranjo, Lejeune et al. 2005; Alvaro, Lejeune et al. 2005; Kelley, 
Pohlman et al. 2007). A growing number of immunohistochemical (IHC) studies have 
attempted to evaluate the composition and prognostic significance of the various cellular 
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components, with particular interest in tumor-infiltrating lymphocytes. More recently, GEP 
studies based on DNA microarrays have demonstrated their ability to define more 
accurately the interaction pathways of HRS cells with nonmalignant reactive and stromal 
cells in cHL lymphoma tissues (see below). Therefore, a complete understanding of cHL, 
requires that both cellular components be considered.  
3. Prognostic markers: Limitations and new challenges 
3.1 The conventional international prognostic score: Current limitations 
cHL is assumed to be a curable tumor, but a substantial proportion of patients with 
advanced disease do not respond favorably to the current standard chemotherapy regimens 
based on adriamycin (Canellos, Anderson et al. 1992). Historically, outcome in cHL patients 
has been predicted using standard clinical variables such as bulk disease, patient age, 
number of nodal sites and erythrocyte sedimentation rate. The most widely used and 
reproducible prognostic score is based on clinical and analytical parameters that make up 
the International Prognostic Score (IPS). This consists of seven clinical variables, including 
serum albumin less than 4 g/dl, hemoglobin less than 10.5 g/dl, male gender, age 45 or 
above, stage IV disease, white blood cell count at least 15,000/mm3, and absolute 
lymphocyte count less than 600/mm3.  
This clinical measure, although widely accepted, still does not accurately identify, at 
diagnosis, a significant fraction of patients with very poor prognosis (Gobbi, Zinzani et al. 
2001) and it´s not applicable to patients with early-stage HL (Hasenclever and Diehl 1998).  
Additionally,  other study noted that the IPS score had no significant prognostic influence in 
modern series of patients and that only age and stage IV disease remained significant in 
multivariate analyses (Sanchez-Espiridion, Montalban et al. 2010). A re-evaluation of the 
IPS, together with the identification of new biological prognostic factors in larger 
populations of patients, is necessary to improve patients stratification into clearly defined 
risk groups for which risk-adapted therapeutic strategies are suitable. 
3.2 Risk stratification and new approaches to clinical guidance: Biological prognostic 
factors and markers in cHL 
HL is generally a curable tumor; so, research currently focuses on identifying patients with a 
low probability of cure who might benefit from more novel and/or intensive treatment 
strategies, and those with a better prognosis who are suitable for less toxic therapies. To 
establish a more rational risk-adapted treatment strategy the identification of truly high-risk 
populations requires supplementation with molecular markers. In this context, biological 
factors may serve as prognostic markers and provide novel targets for cHL therapy. 
Moreover, the addition of biological markers to the already recognized clinical prognostic 
factors (including those of the IPS) may improve patient risk stratification. 
This chapter summarizes new insights into cHL biology in a clinical context and the role 
that new technologies have played in identifying biological markers with future prognostic 
and therapeutic applications. 
Many markers have recently been identified as prognostic factors in HL, including surface 
receptors, intracellular proteins, cytokines, and genetic abnormalities (amplifications, 
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deletions, epigenetic silencing), or alterations in miRNA in HRS cells and surrounding 
inflammatory cells. Technical advances such as microarray-based gene and miRNA 
expression profiling, RT-PCR platforms, comparative genomic hybridization (CGH), SNP 
arrays, microdissection and IHC studies have led to new discoveries (see below). Their 
integration with the classical parameters will further improve the understanding of the 
disease and the management of patients.  
Gene expression profiling studies in cHL  
It has been difficult to identify biological markers for several reasons, including the scarcity of 
large and confirmatory prospective trials, the lack of reproducibility and feasibility of assays 
and the negligible improvement upon already used clinical risk factors (IPS or others). The 
characteristic histological heterogeneity and scarcity of tumoral cells have also hindered 
molecular studies in HL. However, several studies have analyzed GEP in whole tissue sections 
and identified specific transcriptional patterns in the tumoral cells and the non-tumoral 
microenvironment. Additionally, other studies in HL have demonstrated differential gene 
expression patterns between HRS cells and normal mature B-cells, providing vital clues for 
understanding the pathogenesis of the disease (Kuppers, Klein et al. 2003).   
DNA microarrays are currently the best developed and most widely used high-throughput 
molecular technique for identifying biological markers that rely on array-based gene 
expression analyses using whole-tissue sections. IHC staining has been used as a validation 
tool, but the technique has inherent limitations, such as the poor reproducibility of the 
results generated.  
Gene expression studies in cHL initially focused on elucidating HRS cell-specific genes and 
the biological mechanisms underlying cHL pathogenesis (Kuppers, Klein et al. 2003). 
Subsequently, the relationship between cell microenvironment and HRS cells with clinical 
outcome was investigated (Devilard, Bertucci et al. 2002; Sanchez-Aguilera, Montalban et al. 
2006; Chetaille, Bertucci et al. 2009) (Table 1). These studies reported prognostic signatures 
related to tumor HRS and microenvironment cells, identifying genes that, although not 
completely overlapping, did suggest the involvement of the same cellular subpopulations 
(macrophages, B-cells, T-cells) as those affecting clinical outcome (for a recent review 
(Bertucci, Chetaille et al. 2011)).  
The first study to suggest the existence of correlations between gene expression profiles, 
mainly microenvironment-related genes, and prognosis was that of Devilard et al. 
(Devilard, Bertucci et al. 2002). They measured the mRNA expression levels of around 1,000 
genes in 34 benign and malignant lymphoid samples including 21 cHL tissue samples and 
identified three molecular groups of HL. Samples from patients with bad outcomes 
clustered together, whereas the two other groups contained most of the good outcome cases. 
These good outcome cases overexpressed genes involved in apoptosis induction and cell 
signaling (including cytokines), while the bad outcome samples were characterized by 
upregulation of genes involved in fibroblast activation, angiogenesis, extracellular matrix 
remodeling, cell proliferation and downregulation of tumor suppressor genes. However, the 
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Table 1. Gene expression profiling studies in cHL. 
A second important study was published by our group (Sanchez-Aguilera, Montalban et al. 
2006), which used gene expression analysis to identify specific gene signatures associated with 
favorable or unfavorable clinical outcomes. We identified a 145-gene signature related to poor 
treatment response. These genes were grouped into four clusters representing genes expressed 
either by the tumor cells (regulation of mitosis and cell growth/apoptosis) or the tumor 
microenvironment. Thus, some genes reflect cell populations that participate in previously 
reported immune responses (ten Berge, Oudejans et al. 2001; Alvaro, Lejeune et al. 2005), 
including those expressed by T-cells (CD8B1, CD3D, CD26, SH2D1A), macrophages 
(ALDH1A1, LYZ, STAT1) and plasmacytoid dendritic cells (ITM2A). Other genes are involved 
in extracellular matrix adhesion and remodeling of the extracellular matrix (TIMP4, SPON1, 
LAMB1). Genes involved in fibroblast function and chemotaxis, and molecules expressed 
either by antigen-presenting cells (CR1, HLA-DR3) or specific populations of B-cells (IRTA2, 
VDR) were also identified in this research. This study was the first to present evidence of the 
important role of tumor-associated macrophages within a prognostic context in HL. The other 
half of the genes identified were mainly expressed by the HRS cells and are involved in 
apoptosis regulation (CYCS, CASP14, HSPA1L), signal transduction (PDCD10, PRKACB), 
metabolism and cell growth (COX7A2, MYCN, DCK) and in the regulation of the mitotic 
checkpoint (MAD2L1, BUB1, STK6, CDC2, CHEK1, TOP2A). Additionally, the link with 
survival was validated for eight genes (ALDH1A1, STAT1, SH2D1A1, TOP2A, RRM2, PCNA, 
MAD2L1, CDC2) by IHC in an independent set of 235 samples. Finally, alterations in the 
regulation of the mitotic checkpoint in HRS cells were also validated.  
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In another study, Chetaille et al. (Chetaille, Bertucci et al. 2009) analyzed gene expression 
data from a set of 63 cHL tissue samples with both early and advanced stages, including 
control tissues (lymphadenitis) and cHL cell lines and cHL samples from patients. Available 
clinical data allowed the comparison of profiles from 41 cases with favorable outcome and 
21 with unfavorable outcome, identifying a set of 450 genes associated with survival. The 
authors found that expression of genes associated with B-cells and apoptosis was associated 
with good prognosis, whereas genes involved in stroma remodeling were correlated with 
poor prognosis. An independent set of 146 samples was analyzed by IHC, enabling the 
prognostic significance of some of the identified markers including FOXP3, CD20 and 
TOP2A to be validated. These proved to have a remarkably strong prognostic value for 
BCL11A in the series. Additionally, a gene signature associated with the EBV status of 
samples was identified. This seems to be characteristic of the Th1 antiviral immune 
response, thus providing new clues about the differences between EBV+ and EBV– cases. 
The influence of EBV infections on HL and the knowledge obtained from GEP is discussed 
in more detail below. 
Finally, a study performed by Steidl et al. (Steidl, Lee et al. 2010)  reported the results of a 
retrospective study using IHC and GEP. Initial analyses of RNA isolated from 130 frozen 
specimens identified a GEP significantly associated with primary treatment failure that 
included increased gene signatures related to tumor-infiltrating macrophages, angiogenic 
cells, adipocytes, HRS cells, with overexpression of matrix metallopeptidases (like MMP1) 
and underexpression of gene signatures related to germinal center B-cells. A validation 
study using IHC showed that low percentages of CD68+ macrophages (< 5 percent) 
correlated with higher progression-free survival (PFS), with a 100 percent disease-specific 
survival (DSS) rate observed for patients with limited-stage disease (stages IA and IIA) and 
absence of tumor-infiltrating macrophages.  
These data are consistent with a previous observation made by Chetaille et al. (Chetaille, 
Bertucci et al. 2009), which showed reduced presence of background small B-cells (≤ 10 
percent) and overexpression of MMP1 associated with shorter survival. Interestingly, in 
multivariate analyses, CD68+ macrophages remained an independent adverse prognostic 
factor for DSS, outperforming the IPS. 
RT-PCR models 
It is now feasible to apply multigenic predictive molecular tests in a routine setting by using 
alternative techniques, like quantitative RT-PCR. An assay for patients with advanced cHL 
has recently been described that incorporates a limited number of genes and pathways from 
both tumor and microenvironment cell components, designed for routine formalin-fixed 
paraffin-embedded (FFPE) samples (Sanchez-Espiridion, Montalban et al. 2010). Thirty 
genes were chosen on the basis of the findings of two previous studies (Sanchez-Aguilera, 
Montalban et al. 2006; Sanchez-Espiridion, Sanchez-Aguilera et al. 2009) and their 
deployment in 282 FFPE samples enabled a prognostic model to be developed. The model 
included 11 genes from four functional pathways (apoptosis, cell cycle regulation, 
macrophage activation and interferon regulatory factor-IRF4). This 4-cluster/11-gene 
signature was included in a final algorithm (defined as molecular risk score, MRS) that was 
able to identify subgroups of patients with different probabilities of treatment failure.   
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One of the well established clinical variables (stage IV) was also included in the score, thus 
combining the main molecular characteristics of the treatment response-related tumors and 
tumor burden estimates into a single scoring system. The multivariate Cox model indicated 
that most patients with stage IV cHL and with a high MRS (≥ 0.3) will have a very poor 
outcome, with a 5-year FFS probability of 24.3 percent and overall survival (OS) probability 
of 76.3 percent (Sanchez-Espiridion, Montalban et al. 2010). This assay represented another 
interesting, although preliminary, attempt to translate gene profiling results into routine 
practice, providing a tool for further exploring and refining the already available biological 
and clinical prognostic markers. 
 
Reference Technique HRS cells signatures Microenvironmental signatures 
Sanchez-Aguilera, 
Montalban et al. 2006 GEP 




adhesion and cell-cell 
signaling 
Chetaille, Bertucci et 
al. 2009 GEP 
BCR signaling,  apoptosis, 
cell metabolism Stroma remodeling genes 
Sanchez-Espiridion, 
Sanchez-Aguilera et al. 
2009 
RT-PCR array 
Cell cycle (G2-M and G1 
pathway), histones, 





Montalban et al. 2010 RT-PCR array Cell cycle, apoptosis 
Macrophage activation, 
IRF4 
Steidl, Lee et al. 2010 GEP HRS cell-related genes 
Macrophages, monocytes , 
metalloproteinases, 
angiogenic cells 
GEP: gene expression profiling; RT-PCR: reverse-transcription polymerase chain reaction 
Table 2. Gene expression signatures outcome related in cHL.   
Comparative genomic hybridization (CGH) and SNP array studies  
Several studies have assessed the association between SNPs and the risks of developing 
HL. One of these compared 200 HL cases and 220 controls to examine the relationship 
between genetic polymorphisms in cytokine genes and the susceptibility to developing 
HL (Monroy, Cortes et al. 2011). It describes a set of four genes (COX2, IL18, ILR4, IL10) 
out of 38 that are correlated with an increased risk of developing cHL. Once more, this 
highlights the importance of aberrant cytokine signaling in HL pathogenesis. The authors 
also showed that genetic variants in DNA repair genes are significantly associated with 
the risk of developing cHL  
Array CGH (aCGH) studies showed genomic imbalances in cHL cases affecting several 
genes belonging to the main cell-survival pathways known to be activated in HL (JAK/ 
STAT, NF-KB, API-Jun-B). However, the correlation between these genes and clinical 
outcomes was not calculated. A recent study by Steidl et al. (Steidl, Telenius et al. 2010) 
reported copy number gains on chromosome 16p as being less frequent in patients with 
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One of the well established clinical variables (stage IV) was also included in the score, thus 
combining the main molecular characteristics of the treatment response-related tumors and 
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outcome, with a 5-year FFS probability of 24.3 percent and overall survival (OS) probability 
of 76.3 percent (Sanchez-Espiridion, Montalban et al. 2010). This assay represented another 
interesting, although preliminary, attempt to translate gene profiling results into routine 
practice, providing a tool for further exploring and refining the already available biological 
and clinical prognostic markers. 
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Table 2. Gene expression signatures outcome related in cHL.   
Comparative genomic hybridization (CGH) and SNP array studies  
Several studies have assessed the association between SNPs and the risks of developing 
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also showed that genetic variants in DNA repair genes are significantly associated with 
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Array CGH (aCGH) studies showed genomic imbalances in cHL cases affecting several 
genes belonging to the main cell-survival pathways known to be activated in HL (JAK/ 
STAT, NF-KB, API-Jun-B). However, the correlation between these genes and clinical 
outcomes was not calculated. A recent study by Steidl et al. (Steidl, Telenius et al. 2010) 
reported copy number gains on chromosome 16p as being less frequent in patients with 
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primary refractory disease and strongly associated with prognosis after ABVD 
chemotherapy. These results could be related to the presence of the multidrug resistant gene 
ABCC1 located in this chromosomal region (16p13.11). In addition, frequent losses on 4q27 
(IL2/IL21 genes) and 17p12, and gains on 19q13.3 (BCL3/RELB) have also been described as 
being associated with ABVD resistance (Slovak, Bedell et al. 2011).  
Immunohistochemical markers and gene expression studies  
Some of the markers identified by GEP have been identified as being of potential use, 
leading to their clinical application by IHC techniques, especially those associated with the 
complex reactive inflammatory infiltrate.  
BCL2. The relationship between BCL2 expression and patient outcome in HL is a controversial 
issue with studies reporting BCL2 expression to be independently associated with reduced FFS 
in addition to other clinical prognostic variables (age over 45 years, stage IV disease, low 
albumin and elevated lactate dehydrogenase) (Rassidakis, Medeiros et al. 2002), whereas 
others have not demonstrated the same relationship (Montalban, Garcia et al. 2004). 
p21 and p53. Similarly to BCL2, other markers like p21 and p53 have been associated with 
treatment outcomes (Sup, Alemany et al. 2005). 
MMP11 is a marker of matrix metallopeptidases expressed by tumor-associated 
macrophages, found to be associated with treatment failure by GEP and IHC (Steidl, Lee et 
al. 2010) with good discriminatory power with respect to patient outcome. More than 1% 
MMP11 staining by IHC predicted reduced PFS survival in both univariate and multivariate 
analyses.  
CD20 encodes a B-lymphocyte cell-surface antigen and has been evaluated by IHC in several 
studies (Chetaille, Bertucci et al. 2009; Steidl, Lee et al. 2010), which revealed a positive 
association of an increased number of tumor-infiltrating CD20+ cells with both prolonged 
PFS and DFS. Similar findings, in which high numbers of CD20+ cells present in the 
inflammatory background were correlated with improved event-free survival (EFS) and OS 
were reported by Chetaille (Chetaille, Bertucci et al. 2009). No correlation with the number 
of CD20+ HRS cells and patient outcome was found in Steidl’s study (Steidl, Lee et al. 2010) 
or another one of 598 patients (Rassidakis, Medeiros et al. 2002). However, a small study 
performed by Portlock et al. (Portlock, Donnelly et al. 2004) in a set of 248 samples showed 
that both time to treatment and OS were significantly lower in patients treated with ABVD 
with CD20+ cells.   
Tzankov et al. found that the presence of more than 10 percent of CD20+ HRS cells was 
associated with worse patient outcomes in patients treated from 1974 to 1980 whereas there 
was no effect on FFS in patients treated from 1981 to 1999 (Tzankov, Krugmann et al. 2003). 
Thus, the prognostic relevance of CD20 in HL might depend on other factors, such as the 
therapeutic modality and the criteria used to define CD20 positivity. As is the case with 
many other identified markers, these results need further validation in prospective studies 
to determine their reproducibility. 
CD68 is a macrophage marker encoding a transmembrane glycoprotein that is strongly 
expressed by human monocytes and tissue macrophages. It is a member of the 
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lysosomal/endosomal-associated membrane glycoprotein (LAMP) family. In the 
aforementioned study (Sinha, Adhikari et al. 2001) the initial finding of a tumor infiltrating 
macrophage gene signature associated with treatment failure prompted an additional IHC 
validation of CD68 expression relation with clinical outcome. In univariate analysis, the 
presence of a large number of infiltrating CD68+ cells was correlated with reduced PFS and 
DFS. Remarkably, this marker is better than the IPS in predicting DFS in multivariate analysis 
(p=0.003 vs. p=0.030) and as such is currently a matter under further investigation in many 
studies that are attempting to validate its predictive value (Kamper, Bendix et al. 2011). 
Similar findings correlating the presence of tumor-infiltrating macrophages with adverse 
patient outcomes have also been  described in follicular lymphoma (Dave, Wright et al. 
2004; Farinha, Masoudi et al. 2005), suggesting that interactions between the malignant 
lymphoma cells and the microenvironment are critical to the pathogenesis and progression 
of these diseases.  
Despite these results, the use of CD68 alone as a marker is currently a matter of interest, 
with several studies having produced contradictory results (Azambuja, Natkunam et al. 
2011). Nevertheless, there is no doubt about their prognostic value in cHL.  
CD163 is a monocyte/macrophage-specific protein in the scavenger receptor cysteine-rich 
superfamily that appears to be involved in anti-inflammatory functions believed to be 
predominantly associated with M2 (macrophages). This marker has been found to be 
correlated with outcome in several studies in a similar manner to CD68 (Steidl, Lee et al. 
2010; Kamper, Bendix et al. 2011). However, it is considered to be more specific and thus 
more accurate for macrophage identification than CD68.  
T-cells. The presence of T-cells in the inflammatory infiltrate also seems to influence patient 
outcomes and several studies have examined the ratio of regulatory T-cells (CD4+, CD25+ 
and FOXP3 expression) and cytotoxic T-cells (TIA-1+ or granzyme B expression) in 
relationship to OS and DFS rates (Alvaro, Lejeune et al. 2005). The ratio of regulatory 
FOXP3+ T-cells to cytotoxic T/NK (natural killer cells) with granzyme B expression 
independently predicts patient survival.  
Other markers. A variety of other prognostic markers have been described in HL. Increased 
serum levels of soluble CD30 (Zanotti, Trolese et al. 2002), IL-10, BAFF, TNFα, TARC and 
VEGF have all been associated with adverse patient outcomes (Casasnovas, Mounier et al. 
2007). In several studies, combining the CD30 level with the IPS gave improved predictive 
values (Ma, Ding et al. 2009; Renna, Mocciaro et al. 2009). 
3.3 Influence of EBV  
Finally, it is essential to mention studies concerning the role of EBV infection in cHL. Before 
the use of GEP by DNA arrays, only a few differences had been found between the EBV + 
and EBV- microenvironments, and these had not been comprehensively characterized.  
GEP studies looking for EBV-induced alterations showed that Epstein-Barr nuclear antigen 
1 (EBNA1) upregulated the expression of a chemokine (CCL20) in EBV+ cHL cells, 
ultimately leading to increased chemotaxis of T-regulatory cells (Baumforth, Birgersdotter et 
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al. 2008). Additionally, Chetaille et al. (Chetaille, Bertucci et al. 2009) demonstrated that 
EBV+ and EBV- cHL cases can be clearly separated from each other by a robust gene 
signature involving innate immunity and antiviral responses in EBV+ cases. Thus, EBV+ 
cases overexpressed antiviral genes such as NS1BP, PLSCR1 and OAS, together with TLR8 
receptor and MDA5 helicase, which are both, involved in the recognition of viruses and 
mediate innate immunity against viral infection. The molecular profile of EBV+ tumors 
(overexpression of IFNG, CXCL9, CXL10, and CXCL11/ITAC) also provided evidence of 
intratumoral Th1 activity in EBV+ cHL cases, which might be orchestrated by IFNG. 
Nonetheless, EBV+ patients did not have a better outcome, suggesting that the intratumoral 
immune reaction described is inadequate for eliminating tumor cells.  
ITK (IL-2–inducible T-cell kinase) deficiency, a novel primary immunodeficiency disease 
characterized by severe EBV associated immune dysregulation commonly progresses to 
cHL with a variable treatment response (Rezaei, Hedayat et al. 2011). Additionally, three 
cases EBV-positive HL associated to this deficiency were subsequently found to harbor a 
homozygous nonsense mutation in the ITK gene (Stepensky, Weintraub et al. 2011). 
Additionally, the study of Steidl et al. (Steidl, Lee et al. 2010) showed that CD68 and CD163 
markers were both associated with latent EBV infection of the malignant cells, thus 
highlighting the potential prognostic implications of EBV infection. Despite these results, the 
impact of EBV infection on clinical outcome remains unclear; more studies are needed to 
elucidate its exact role in cHL patients.  
4. miRNAs: A new approach to elucidating the biology of Hodgkin’s 
lymphoma  
Several studies have demonstrated the role of miRNA deregulation in cancer pathogenesis 
and treatment response in several tumor models. Others confirm that miRNAs are good 
biomarkers for cancer diagnosis and prognosis, including hematological malignancies. 
miRNAs are small, noncoding RNAs that regulate the expression of multiple mRNAs by 
binding to the 3’ untranslated region (UTR) of their target genes. miRNAs are the best 
characterized members of a family of noncoding RNAs (ncRNAs) that are now the object of 
intense investigation. They function by targeting mRNA and inducing its degradation or 
inhibiting its translation. A number of studies suggest that miRNAs may regulate around 
30% of the genome. As a consequence they are implicated in almost every cellular process, 
and, in fact miRNA expression has been shown to be tissue-specific, playing key roles in the 
control of the various biological processes such as differentiation, proliferation and others, 
all of which are involved in cancer pathogenesis. The deregulated expression of miRNA in 
tumoral samples compared with their normal counterparts, and their frequent genomic 
location in fragile chromosomal sites, also points to their role in the development of cancer. 
In fact, specific miRNA signatures have been identified for some tumor types, and they are 
thought to have tumor suppressor or oncogenic properties (for which reason they are 
termed “oncomirs”), as well as metastasis regulatory functions. miRNAs are encoded by 
intronic or intergenic regions. They are first transcribed to pri-miRNA, then processed to 
pre-miRNA by the Drosha complex, and subsequently exported to the cytoplasm, where the 
RNase Dicer cleavages them to generate a double strand molecule of 21-25 nucleotides. One 
of the two chains is then joined to the RNA-induced silencing complex (RISC), which 
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interacts with Argonaute proteins and binds to 3’UTR on target mRNAs, inducing their 
degradation and/or blocking translation (Esquela-Kerscher and Slack 2006). 
Altered miRNA expression has a role in hematopoietic malignancies. One of the first pieces 
of evidence of the role of miRNAs in cancer came from a study of B-cell chronic lymphocytic 
leukemia where miR-15 and miR-16 were downregulated due to hemi- or homozygous 
chromosomal deletion at 13q14 (Calin, Dumitru et al. 2002). As mentioned before, several 
miRNA loci reside on chromosomal fragile sites, which are frequently altered in cancer. 
These include the miR-15a/16 cluster, which is also deleted in pituitary adenomas, miR-143 
and miR-145, which are located in the 5q33 that is deleted in lung cancer (Calin and Croce 
2006), and the miR-17-92 cluster, which is frequently amplified in B-cell lymphomas (Ota, 
Tagawa et al. 2004; He, Thomson et al. 2005) and lung cancers (Hayashita, Osada et al. 2005). 
Expression of specific miRNAs is implicated in B-cell and hematological differentiation, and 
regulates germinal center formation (Kluiver, Kroesen et al. 2006; Thai, Calado et al. 2007; 
Zhou, Wang et al. 2007). It is possible that miRNA losses and gains have a significant role in 
MCL by regulating CCND1 mRNA expression (Chen, Bemis et al. 2008). Another study in 
MCL showed that the most essential pathways and genes in MCL pathogenesis are 
potentially targeted simultaneously by multiple miRNAs, suggesting that transcriptional 
regulation by miRNAs in MCL is the result of the concurrent deregulation of multiple 
miRNAs with related targets (Di Lisio, Gomez-Lopez et al. 2010).  
Furthermore, they may constitute markers of differentiation stage, malignant 
transformation, sensitivity or resistance to specific drugs. Their capacity as prognostic 
markers has also been demonstrated in lymphomas. Montes-Moreno et al. have developed a 
model based on miRNA expression, valid for FFPE samples, that uses RT-PCR to predict OS 
and PFS in chemoimmunotherapy-treated DLBCL patients, improving the prediction just 
based on clinical variables (Montes-Moreno, Martinez et al. 2011).  
Some attempts have been made to elucidate specific miRNA signatures for the characteristic 
HRS cells and their microenvironment. Preliminary work showed that miRNA losses and 
gains may explain some of the biological and clinical features of different lymphoma types, 
and recent analyses of miRNA expression in cHL-derived cell-lines and tumors have also 
demonstrated deregulated expression of some miRNAs in this malignancy. Overexpression 
of BIC/miR-155 has been found in cHL cell lines and samples by qRT-PCR analysis 
(Kluiver, Poppema et al. 2005) but not in other NHL types, except some PMBL and DLBCL 
samples. miRNA profiling of cHL-derived cell lines performed with qRT-PCR and 
microarrays has revealed specifically expressed miRNAs that include miR-17-92 cluster 
members, miR-16, miR-21, miR-24 and miR-155  (Gibcus, Tan et al. 2009) and a significant 
downregulation of miR-150 in cHL. The authors also demonstrated the targeting of IKBKE 
by miR-155, among others, in cHL cell lines; thus, miR-155 expression in HL might represent 
an attempt to reduce NFkappaB activity in this lymphoma. In primary tumors, comparison 
of miRNA profiles of microdissected HRS cells from cHL patients, four common cell lines 
(HDLM2, L540, KMH2 and L1236) and CD77+ germinal center B-cells (used as normal 
counterparts) yielded a distinct cHL signature of 12 overexpressed and three 
underexpressed miRNAs (Van Vlierberghe, De Weer et al. 2009) including some of the 
previously described miRNAs, including miR-21 and miR-155. Additionally, a 25-specific 
miRNA signature differentiating cHL and reactive lymphoid nodes was presented by 
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Navarro et al. (Navarro, Gaya et al. 2008). When studying cell lines, some of the miRNAs in 
the samples and cell lines were found to be different, suggesting that this could be due to 
the microenvironment or to the immortalization process of the cell lines. They also identified 
some miRNAs (miR-96, miR-128a, miR-128b) whose expression was related to the presence 
of EBV, although no prognostic implication of the identified specific EBV-related miRNAs 
was demonstrated.  
These results imply that a small subset of miRNAs may define tumor entities better than 
microarray expression data from thousands of messenger RNAs, and suggest that miRNAs 
may play an important role in the biology of cHL, and may be useful in the development of 
therapies targeting miRNAs in tumor cells.  
Although cHL-specific miRNA signatures have been proposed, their potential prognostic 
role remains unclear. There are few observations that link miRNA deregulation and clinical 
characteristics of the patients. Overexpression of miR-328 has been found in advanced cHL 
stages (III-IV stages) (Navarro, Gaya et al. 2008), and lower miR-138 levels. However, the 
potential prognostic role of miRNA signatures in cHL has not yet been sufficiently well 
investigated in larger series of patients. 
Taken together, these findings suggest that miRNAs may play significant roles in HL 
pathogenesis, and could help to explain its biology, being additionally useful for patient risk 
stratification and development of new therapeutic approaches. Thus, the relevance of 
miRNA expression in cHL and its putative value for outcome prediction is worthy of further 
investigation. 
Recently, our group has identified specific profiles from tumor cells and their non-tumoral 
microenvironment by miRNA expression studies. Initial analyses suggest that clinical 
outcome can be predicted by models that integrate miRNA signatures. These preliminary 
findings suggest a possible role for miR-21 and miR-30d as potential targets to overcome 
treatment resistance in cHL (Sánchez-Espiridión B, Figueroa V et al. 2011). 
5. Perspectives  
An increasing body of knowledge in cHL pathogenesis, and the complex relationship 
between the tumoral HRS cells and the microenvironment has been built up from gene and 
miRNA profiling studies. The correlations that these studies identify, spotlighting tumor-
infiltrating macrophages in classic HL, reinforce the critical roles of microenvironmental and 
immunomodulatory interactions between RS and non-tumor cells, stromal, cytokine, and 
membrane molecules in disease pathobiology and treatment responsiveness. As we have 
seen in this chapter, these studies have led to remarkable discoveries such as the relevance 
of B-cells and macrophages in patient outcome, and to the identification of several new 
prognostic markers. All these results, including the optimization of new technologies such 
as RT-PCR in FFPE tissues and miRNA profiling, are clinically promising. However, further 
validation in large and independent series of patients is needed for them to be included as 
part of clinical routine. There is no doubt that their integration with results generated by 
other modern high-throughput molecular analyses (such as proteomics) will further 
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Hodgkin's lymphoma (HL), formerly called Hodgkin's disease, is a malignant tumor of the 
lymphatic system (Schnitzer, 2009). It was first recorded by Thomas Hodgkin in 1832, when 
he described seven patients suffering from enlargement of lymph nodes and spleen as a new 
disease entity (Thomas et al, 2002).  
Understanding of its pathogenesis remains unclear (Mueller, 1991). The cellular origin of 
this lymphoma was failed to be clearly identified by molecular biology studies. The 
characteristic Reed Sternberg cell is thought to be derived from the histiocytes, granulocytes 
and reticulum cells (Lee et al, 1993). But other studies suggest that these cells represent 
immature lymphoid cells (Diehl et al, 1990).  
Hodgkin's lymphoma was described microscopically for the first time by langhans in 1872 
(Langhans, 1872). Jachson and Parker (1947) described the first histological classification of 
Hodgkin's lymphoma in 1947, later on this classification was revised at Rye in 1966 and in 
1994 the Rye classification was incorporated into the revised European–American 
lymphoma classification (REAL). Accordingly, Hodgkin's lymphoma was classified into 
nodular lymphocyte predominant, nodular sclerosing, mixed cellularity, lymphocyte 
depletion and lymphocyte – rich classical disease (Cartwright and Watkins, 2004). 
2. Incidence 
The incidence of Hodgkin's lymphoma shows marked heterogeneity with respect to age, 
gender, race, geographic area, social class and histological subtype (Burke, 1992). Hodgkin's 
lymphoma is listed as a rare disease by the office of rare diseases (ORD) of the National 
Institutes of Health (NIH). This means that it affects less than 200.000 people in the US 
population. About 8000 new cases of Hodgkin's lymphoma occur each year in the United 
States. 1500 people in the US die from Hodgkin's lymphoma each year. It is more common 
in Caucasians (Lee et al, 1993). Asians have lower incidence than other races (Glaser and 
Hsu, 2002). The annual incidence of Hodgkin's lymphoma appears stable over the past 
several decades. Incidence in the United Kingdom is about 2.4 per 1000.000 per year. 
Worldwide prevalence rates vary, with more than 5.5 per 100.000 in Yemen and Lebanon 
and less than 1 per 100.000 in china and Japan. At least some of this variation appears to 






The incidence of Hodgkin's lymphoma has increased among adolescents and young adults 
in the Nordic countries in the past few decades, whereas it has decreased strikingly among 
those aged 40 years or more (Hjalgrim et al, 2001). In developing countries, Hodgkin's 
lymphoma appears more during childhood and its incidence decreases with age, while in 
developed countries, young children are rarely affected by Hodgkin's lymphoma in contrast 
with young adults where incidence increase with age (Thomas et al, 2002). It has a bimodal 
age distribution in both sexes, peaking in young adults (aged 15-34 y) and older individuals 
(>55years) (IARC, 1997). In the United States, Nodular sclerosing subtype predominates in 
young adults, while Mixed cellularity subtype is more common in children (aged 0-14 y) 
and older individuals (Grufferman and Delzell, 1984; IARC, 1997 & Muller and Grufferman, 
1999). From 2004-2008, the median age at diagnosis for Hodgkin's lymphoma was 38 years 
of age and approximately 12.3% were diagnosed under age 20 years and 27.7% above 55 
years of age. 
There are two peaks in the age-specific incidence of Hodgkin's lymphoma. For males there 
is one in men aged 30-34 and another in older men aged 75-79 years. For women the two 
peaks occur in women aged 20-24 and 70-79 (Yung and Linch, 2003). 
Hodgkin's lymphoma is the third most common cancer in people aged 15-29 years, and the 
sixth most commonly diagnosed cancer in children under 14 years (Yung and Linch, 2003 & 
Hoffbrand et al, 2011).  
The bimodal incidence curve has been postulated to represent two etiology processes. The 
first hypothesis suggests an infectious cause of the disease in young adults and other 
environmental causes for older age groups (Cole et al, 1968). 
Low childhood rates and high young adulthood rates were found in the USA and West 
Europe. The Baltic States and central and Eastern European countries had higher childhood 
rates than those seen in the United States and Europe, but had similar rates in young adults. 
The pattern in Latin America and other developed countries is more, whilst the rates in Asia 
remain low (Cartwright and Watkins, 2004). 
A significant increase in the incidence of Hodgkin's lymphoma in adolescents and young 
adults was observed in Nordic countries (Langhans, 1872), India (Reed, 1902) and North 
America in the period between 1960 and 1997 (Cartwright and Watkins, 2004). Also, 
decrease rates has been reported in older adults. 
Hodgkin's lymphoma is most common in children and young adults, between the ages of 15 
and 40. 
The mortality rates are low (0.4 per 100000 per year in the United Kingdom) due to the 
excellent response to treatment. Mortality increases with age and in Countries with less 
access to treatment (Hoffbrand et al, 2011). 
4. Male : Female ratio 
Overall male to female ratio is 1.4:1 (Hoffbrand et al, 2011). It is the third most commonly 
diagnosed cancer in people aged 15-29 years. There is a slight overall male predominance in 
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The mortality rates are low (0.4 per 100000 per year in the United Kingdom) due to the 
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access to treatment (Hoffbrand et al, 2011). 
4. Male : Female ratio 
Overall male to female ratio is 1.4:1 (Hoffbrand et al, 2011). It is the third most commonly 
diagnosed cancer in people aged 15-29 years. There is a slight overall male predominance in 
the incidence of Hodgkin's lymphoma, which is most marked in the childhood form (Spitz et 
 
Epidemiology of Hodgkin's Lymphoma 
 
51 
al, 1989). In adolescents, the incidence between males and females are roughly equal. Data 
from Norway showed that a sex ratio of 1:1 is seen in the 15-34 age group which increase to 2:1 
in the 50 and over group (MacMahon, 1966). Hodgkin's lymphoma is nearly twice as common 
in males. It is higher in males than females and higher in whites than other races (Shenoy et al, 
2011). Men are affected by Hodgkin's lymphoma slightly more than women among all 
subtypes except for the nodular sclerozing subtype (Thomas et al, 2002). The observed male 
predominance is particularly evident in children, in whom 85% of the cases are in males. 
5. Season 
May studies have revealed peaks in the early months of the years especially in February and 
March (Douglas, 1998; Neilly et al, 1995; & Newell et al, 1985). 
6. Race 
Both Blacks and Asians had lower incidence rates than whites, which may suggest genetic 
resistance possibly related to HLA type. Hodgkin's lymphoma is relatively rare in Japan 
(age-adjusted incidence of 0.3 per 100.000 males) and China (age-adjusted incidence of 0.2 
per 100.000 males) in comparison to North America and Europe. Within the European 
Union the highest rates are in Austria and Greece and the lowest rates are in Spain and 
Slovakia, (Glaser and Hsu, 2002 & Shenoy et al, 2011). 
7. Relation to infections 
Hodgkin’s lymphoma is a complex of related conditions that are part mediated by infectious 
diseases, immune deficits and genetic susceptibilities. The descriptive epidemiology of 
Hodgkin's lymphoma suggests an infectious disease process underlying its aetiology in 
children and young adults (MacMahon, 1966). There is a relationship between Hodgkin's 
lymphoma and Epstein-Barr virus (EBV) infection (Evans and Gutensohn, 1984; Mueller et 
al, 1989 & Swerdlow, 2003). The mechanisms underlying this association are unknown and 
the virus has never been isolated from or identified in most of Hodgkin's lymphoma tissue 
(Cartwright and Watkins, 2004 & Gruffeman and Delzell, 1984). 
Patients with a history of infectious mononucleosis due to Epstein-Barr virus may have an 
increased risk of Hodgkin's lymphoma (Alexander et al, 2000; Hjalgrim et al, 2000 & Mueller 
and Grufferman, 1999). 
EBV is the main candidate suggested as the infection causing Hodgkin's lymphoma for 
several years. However EBV genome has been found only within the tumor in about 20-40% 
of Hodgkin's lymphoma cases with a prior diagnosis of infectious mononucleosis (Landgren 
and Caporaso 2007). Several studies suggest that EBV may be a transforming agent in 
Hodgkin's lymphoma. Patients with a history of EBV infection are at a 2-3 fold higher risk 
for development of Hodgkin's lymphoma (Thomas et al, 2002). Mueller et al. (1989) 
analyzed EBV titers in pre-disease sera and found an enhanced level of EBV activation prior 
to onset of Hodgkin's lymphoma. 
Many authors using novel molecular techniques found that EBV DNA is present in 
Hodgkin's lymphoma cases more frequently in developing countries than in developed 
countries (Glaser et al, 1997 & Zarate et al, 1995). In Western countries, about 50% of 





Reed-Sternberg cells in EBV positive patients show an expression pattern of EBV-encoded 
genes, termed type 2 latency, which resembles that found in endemic nasopharyngeal 
carcinoma or a subset of T-cell lymphomas (Thomas et al, 2002). Activated NFkB was found 
to be a characteristic feature of Reed-Sternberg cells (Bargou et al, 1996). This activation 
results in massive spontaneous apoptosis of Reed-Sternberg cells by downregulation of an 
antiapoptotic signaling network (Hinz et al, 2001). Many reports have noted geographic and 
familial clustering of Hodgkin's lymphoma (Smith et al, 1977; Vianna et al, 1971 & Vianna 
and Polan, 1973). Swedish investigators suggested that early exposure to viral infection may 
play a role in the pathogenesis of the disease (Chang et al, 2004). 
EBV strain subtypes identified within Reed-Sternberg cells vary geographically. EBV type 1 
is predominant in the United Kingdom, South America, Australia and Greece, whereas EBV 
type 2 is predominant in Egypt (Wrinreb et al, 1996). Mixed cellularity Hodgkin's 
lymphoma is more likely to be EBV-associated than nodular sclerosis subtype.  
Many studies have found significant increase in risk of Hodgkin's lymphoma among 
patients with AIDS in the developed countries (Grulich et al, 1999 & Serraino et al, 2000). In 
contrast, these increased risk have not been observed in Africa (Chokunonga et al, 1999; 
Dolcetti et al, 2001 & lazzi et al, 1998). In addition, other studies have demonstrated an 
increased incidence in HIV-positive intravenous drug users (Andrieu et al, 1993; Roithmann 
et al, 1990 & Rubio, 1994). 
Also, Human Herpes virus 6 (HHV-6), HHV-7, HHV-8 and cytomegalovirus infections were 
demonstrated in Hodgkin’s lymphoma patients (Gompels et al, 1993; Josephs et al, 1988 & 
Salahuddin et al, 1986). 
Patients with HIV infection have a 15- fold increase risk to develop Hodgkin's lymphoma 
than the general population (Biggar et al, 2006). They usually present at a more advanced 
age with associated extranodal involvement and B symptoms (Glaser et al, 2003). 
8. Socio-economic status 
The childhood form of Hodgkin's lymphoma tends to increase with increasing family size 
and decreasing socio-economic status. The young adult form is associated with a higher 
socioeconomic status in industrialized countries. The risk decreases significantly with 
increased sibship size and birth order (Westergard et al, 1997). It has been suggested that the 
risk of Hodgkin's lymphoma may be correlated to higher social classes in children and 
young adults (Alexander et al, 1991a & Alexander et al, 1991b). Reports regarding the socio-
economic status in older adults are conflicting (DeLong et al, 1984; Glaser et al, 2001 & 
Gutensohn, 1982).  
9. Occupational exposures 
It is not possible to conclude that a causal relationship exists between the various 
occupational exposures and risk of Hodgkin's lymphoma. Although one study reported that 
the physicians had a risk 80% higher than that of controls (Vianna et al, 1974), yet other 
studies did not found this increased risk (Grufferman et al, 1976; Matanoski et al, 1975 & 
Smith et al, 1974). Some studies reported an increased risk of Hodgkin's lymphoma in white 
men employed in woodworking or wood-related industries (Fonte et al, 1982; Milham and 





Reed-Sternberg cells in EBV positive patients show an expression pattern of EBV-encoded 
genes, termed type 2 latency, which resembles that found in endemic nasopharyngeal 
carcinoma or a subset of T-cell lymphomas (Thomas et al, 2002). Activated NFkB was found 
to be a characteristic feature of Reed-Sternberg cells (Bargou et al, 1996). This activation 
results in massive spontaneous apoptosis of Reed-Sternberg cells by downregulation of an 
antiapoptotic signaling network (Hinz et al, 2001). Many reports have noted geographic and 
familial clustering of Hodgkin's lymphoma (Smith et al, 1977; Vianna et al, 1971 & Vianna 
and Polan, 1973). Swedish investigators suggested that early exposure to viral infection may 
play a role in the pathogenesis of the disease (Chang et al, 2004). 
EBV strain subtypes identified within Reed-Sternberg cells vary geographically. EBV type 1 
is predominant in the United Kingdom, South America, Australia and Greece, whereas EBV 
type 2 is predominant in Egypt (Wrinreb et al, 1996). Mixed cellularity Hodgkin's 
lymphoma is more likely to be EBV-associated than nodular sclerosis subtype.  
Many studies have found significant increase in risk of Hodgkin's lymphoma among 
patients with AIDS in the developed countries (Grulich et al, 1999 & Serraino et al, 2000). In 
contrast, these increased risk have not been observed in Africa (Chokunonga et al, 1999; 
Dolcetti et al, 2001 & lazzi et al, 1998). In addition, other studies have demonstrated an 
increased incidence in HIV-positive intravenous drug users (Andrieu et al, 1993; Roithmann 
et al, 1990 & Rubio, 1994). 
Also, Human Herpes virus 6 (HHV-6), HHV-7, HHV-8 and cytomegalovirus infections were 
demonstrated in Hodgkin’s lymphoma patients (Gompels et al, 1993; Josephs et al, 1988 & 
Salahuddin et al, 1986). 
Patients with HIV infection have a 15- fold increase risk to develop Hodgkin's lymphoma 
than the general population (Biggar et al, 2006). They usually present at a more advanced 
age with associated extranodal involvement and B symptoms (Glaser et al, 2003). 
8. Socio-economic status 
The childhood form of Hodgkin's lymphoma tends to increase with increasing family size 
and decreasing socio-economic status. The young adult form is associated with a higher 
socioeconomic status in industrialized countries. The risk decreases significantly with 
increased sibship size and birth order (Westergard et al, 1997). It has been suggested that the 
risk of Hodgkin's lymphoma may be correlated to higher social classes in children and 
young adults (Alexander et al, 1991a & Alexander et al, 1991b). Reports regarding the socio-
economic status in older adults are conflicting (DeLong et al, 1984; Glaser et al, 2001 & 
Gutensohn, 1982).  
9. Occupational exposures 
It is not possible to conclude that a causal relationship exists between the various 
occupational exposures and risk of Hodgkin's lymphoma. Although one study reported that 
the physicians had a risk 80% higher than that of controls (Vianna et al, 1974), yet other 
studies did not found this increased risk (Grufferman et al, 1976; Matanoski et al, 1975 & 
Smith et al, 1974). Some studies reported an increased risk of Hodgkin's lymphoma in white 
men employed in woodworking or wood-related industries (Fonte et al, 1982; Milham and 
Hesser, 1967; Olsen and Sabroe, 1979 & Petersen and Milham, 1974). Conflicting results were 
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reported regarding the association between Hodgkin's lymphoma and benzene exposure, 
rubber and chemical industries (La Vecchia et al, 1989; Lagorio et al, 1994; Rushton and 
Alderson, 1983; Schnatter et al, 1993; Sorahan et al, 1989 & Vianna and Polan, 1979). 
Smoking more than 14 cigarettes per day was associated with a 50% increased risk (Adami 
et al, 1998 & Paffenbarger et al, 1977). 
10. Familial incidence and genetic susceptibility 
There is 3 to 9 fold increased risk of developing Hodgkin's lymphoma in family members of 
these patients (Haim et al, 1982 & Mack et al, 1995). Razis et al. (1959) were the first to report 
a three fold risk in first-degree relatives of patients with Hodgkin's lymphoma. 
Swedish Cancer registry reported that Hodgkin's lymphoma was the fourth in a list of 
cancers with high familial incidence (Lindeiof and Eklund, 2001). Many oncogenes and 
tumor–suppressor genes have been studied, but no consistent mutation pattern has been 
identified (Thomas et al, 2002). Translocation [t (2;14) (P13;q32.3)] involving the BcL 11 a 
gene was reported in classic Hodgkin's lymphoma (Martin-Subero et al, 2002). 
Numerical and structural chromosomal alterations are frequent in Hodgkin's lymphoma 
patients but they lack any consistent pattern (Thomas et al, 2002). However, molecular 
clonal alterations such as gene amplifications or deletions reflect a distinct pattern of genetic 
instability. 
Aggregation in families and persons with specific human leukocyte antigen (HLA) type 
indicates genetic susceptibility (Burke, 1992 & Maggioncalda et al, 2011). Several reports 
recorded aggregation and clustering of Hodgkin's lymphoma patients in the same families and 
races which may suggest a genetic predisposition or exposure to a certain etiologic agent. 
The Antigens were found to be associated with Hodgkin's lymphoma: A1, B5 and B18 which 
might indicate that a disease susceptibility gene lies in or near the major histocompatibility 
region. These associations suggest that this disease is a result of genetic environmental 
interaction (Bodmer, 1973; Chakravarti et al, 1986; Robertson et al, 1987 & Svejgaard et al, 
1975). Also, concordance of Hodgkin's lymphoma in first degree relatives and in parent-
child pairs has been noted in many studies (Claser and Jarren, 1996) especially if they are of 
the same sex. 
Familial Hodgkin's lymphoma lacked the classic bimodal age distribution and has a peak 
between 15 and 34 years. It represents about 4.5% of all new cases (Kerzin-Storrar et al, 1983). 
Evidence of genetic susceptibility of this disease was supported by the finding that 
monozygotic twins have a 99-fold increased risk in contrast to dizygotic twins who have no 
increased risk to it (Mack et al, 1995). We found significant increase in the frequency of HLA 
DRB1*0403 and *1202 and DQ131*0604, *0201 and *0203 alleles which may confer 
suscepilibity (Al-Tonbary et al, 2004). Similar results were reported by Klitz et al. (1994) who 
reported a significant association of HLA class II alleles with Hodgkin's lymphoma and 
Harty et al. (2002) who reported that the DRB1*1501 allele is related to the development of 
familial Hodgkin's lymphoma particularly the familial nodular sclerosis type. The 
association of Hodgkin's lymphoma with different HLA-DRB1 and –DRQ1 alleles may be 
explained by three possibilities, first one implies that genes determining Hodgkin's 
lymphoma are located close to the major histocompatibility loci, and are thus transmitted 





cross-tolerance to a self-component (Woda and Rappaport, 1981). The third possibility is 
that the immunogenic responsiveness to oncogenic viruses may be linked to genes coding 
for HLA antigens (Zimadahl et al, 1999). In conclusion, certain environmental factors in 
addition to HLA genotypes might play a role in the occurrence of Hodgkin's lymphoma 
indicating a genetic–environmental interaction. 
 
 Age group of Hodgkin's Lymphoma 
Ethnic 
origin Country 
0–14 years 15–34 years 35–59 years Above 60 years 
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Table 1. Age standardized (World) incidence rates /100 000/year for Hodgkin's lymphoma 
in males and females (IARC, 1997 and Cartwright & Watkins, 2004). 
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WHO Africa region 5879 0.9 4893 0.8 0.9 
WHO East Mediterranean 
region 7663 1.4 6004 1.2 0.9 
Less developed regions 40137 0.7 23698 0.5 0.7 
WHO South-East Asia region 11682 0.7 6276 0.4 0.6 
WHO Western Pacific region 8476 0.4 3478 0.2 0.5 
World 67887 1 30205 0.4 0.4 
WHO Europe region 19342 2 5898 0.5 0.3 
More developed regions 27750 2 6507 0.4 0.2 
WHO Americas region 14802 1.5 3649 0.3 0.2 
Table 2. Age-standardized incidence and mortality rates ranked by mortality to incidence 
ratio (case fatality ratio). Calculations are based on data from GLOBOCAN 2008.  
11. Hormonal factors 
Hormonal factors might have a role in the aetiology of this disease as evidenced by the male 
predominance in patients over 30 years and the higher risk in women aged less than 45 
years at diagnosis (Cartwright and Watkins, 2004). In addition, prolonged use of human 
growth hormone was considered as a risk factor for Hodgkin's lymphoma. 
12. Conclusion 
Hodgkin's lymphoma is a malignant tumor of the lymphatic system. It arises from germinal 
center or post germinal center B cells. It has a unique cellular composition, containing a 
minority of neoplastic cell (Reed- Sternberg cells and their variants) in an inflammatory 
background. By 1902, the characteristic giant cells of Hodgkin's lymphoma were recognized 
by Sternberg and Reed.  
The incidence of Hodgkin's lymphoma shows marked heterogeneity with respect to age, 
gender, race, geographic area, social class and histological subtype. 
 About 3200 deaths were attributed to Hodgkin's lymphoma annually in the United 
States. 
 About 8000 new cases of Hodgkin's lymphoma occur each year in the United States. 
 It is nearly twice as common in males. 
 It is more common in Caucasians 
 There are 3 age periods: 0-14 years, 15-34 years and over 50 years. 
 A significant peak in months of February and March were observed 
 There is no direct person to person spread of Hodgkin's lymphoma 
The descriptive epidemiology of Hodgkin's lymphoma suggests an infectious disease 
process underlying its aetiology in children and young adults. There is a relationship 
between Hodgkin's lymphoma and Epstein-Barr virus infection. The mechanisms 
underlying this association are unknown and the virus has never been isolated from or 





risk of Hodgkin's lymphoma among patients with AIDS. Also human herpes virus 6 (HHV-
6), 7,8 and CMV infections were demonstrated in patients with Hodgkin's lymphoma than 
in controls. Mixed cellularity subtype is more likely to be EBV-associated than nodular 
sclerosis subtype. 
The higher the socioeconomic status of person, the greater the risk in the young adult 
disease. It is not possible to conclude that a causal relationship exists between the 
occupational exposures and risk of Hodgkin's lymphoma. Smoking more than 14 cigarettes 
per day was associated with a 50% increased risk. Increased incidence in males may suggest 
hormonal background. Several reports record aggregation of Hodgkin's lymphoma patients 
within the same family. 
Several studies of HLA typing showed that some AGs were associated with Hodgkin's 
lymphoma. This association might indicate that a disease susceptibility gene lies in or near 
the major histocompatibility region. These associations suggest that this disease is a result of 
genetic environmental interaction. 
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1. Introduction 
Hodgkin’s lymphoma (HL) is a highly curable disease and the reported results in last years 
relative to patient’s survival were continuously improved. Cure rates > 90% for early HL 
and > 70% for those with advanced HL are expected. Nevertheless, there are high-risk 
patients (about 35%) refractory to initial treatment or relapse after achieving complete 
remission. The current approaches to identify these patients employ pathologic, clinical and 
classical biologic prognostic factors. The relative scarcity of markers that could reliably 
predict long-term survival generates excessive treatments with both radio- and 
chemotherapy for many patients. In this condition, the identification of innovative biologic 
markers that could help to design appropriately tailored treatment strategies for classic HL 
(cHL) patients at high risk of treatment failure and patients with low-risk disease remains a 
crucial challenge.  
The presence of a characteristic inflammatory microenvironment in response to tumoral 
cells not only distinguishes HL from other lymphomas, but even more, this is the main 
characteristic that makes HL a separate entity itself allowing its diagnosis. However, the 
functional role of the microenvironment in the pathophysiology of HL remains a matter of 
debate. The ability of the immune system to act as a double-edge weapon, protective or 
stimulating, indicates that tumoral clearance requires the effective coordination of the 
different elements of the immune system in an appropriate balance in quantity and quality. 
Therefore, current cancer research in HL aims to develop methods to increase the 
effectiveness of host antitumoral immune response, or at least prevent that various 
cytokines and growth factors from different subpopulation of infiltrating reactive immune 






Biological therapy (also called immunotherapy, biotherapy or biological response modifier 
therapy) is one of the most promising strategies. These therapies use the body’s immune 
system, either directly or indirectly, to fight HL or to help lessen the side effects of some 
cancer treatments for HL. Current biological therapy treatments for HL may be used either 
alone or in conjunction with other modalities such surgery, radiation and chemotherapy. 
This chapter summarizes the data on clinical, histological, pathological and biological 
factors in HL, with special emphasis on the improvement of prognosis and their impact on 
therapeutical strategies. The recent advances in our understanding of HL biology and 
immunology seem indicate that infiltrated immune cells in the tumoral microenvironment 
may play different, even opposite, functions according to the signals it senses. Strategies 
aimed at interfering with the crosstalk between H/RS cells and their cellular partners have 
been taken into account in the development of new immunotherapy’s that target different 
cell components of HL microenvironment. The current standard approaches with the use of 
combined modality therapy and systemic chemotherapy as well as the promising role of 
future response-adapted strategies is reviewed. 
2. Histopathological diagnostic parameters 
As classified by the World Health Organization (WHO), HL exists in 5 types (Swerdlow et 
al., 2008b). Four of these—nodular sclerosis (NSHL), mixed cellularity (MCHL), lymphocyte 
depleted (LDHL), and lymphocyte rich (LRHL)—are referred to as cHL. The fifth type, 
nodular lymphocyte predominant Hodgkin disease (NLPHL), accounts for 4–5% of all HL 
cases and is a distinct entity with unique clinical features and a different treatment 
paradigm. Regarding cHL, NSHL represents the most common histological type in 
European countries, accounting for 40–70% of cases whereas MCHL account for about 30%.  
Histologically, cHL is characterized by a minority of neoplastic cells (1-2%) named H/RS 
cells embedded in a rich background composed of a variety of reactive, mixed inflammatory 
cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils, and histiocytes 
(Figure 1A). Thus, the presence of an appropriate cellular background—along with the 
results of immunophenotyping—is basic for the diagnosis. Evidence has accumulated that 
H/RS cells harbor clonally rearranged and somatically mutated immunoglobulin genes, 
indicating their derivation, in most cases, from germinal center (GC) B-cells (Kuppers, 2002; 
Kuppers et al., 2003; Staudt, 2000; Thomas et al., 2004). Some HL cases have been identified 
in which the H/RS is of T-cell origin but these are rare, accounting for 1-2% of cHL. Under 
normal conditions, GC B-cells, that lack a functional high affinity antibody, undergo 
apoptosis in the germinal center. H/RS cells show a characteristically defective B-cell 
differentiation program, lose the capacity to express immunoglobulin and, therefore, should 
die. However, H/RS cells escape apoptosis and instead proliferate, giving rise to the tumor 
and the immune response that characterizes (Kuppers, 2002; Kuppers et al., 2003; Staudt, 
2000; Thomas et al., 2004). Gray zones between cHL and some types of diffuse B-cell 
lymphoma, especially primary mediastinal large B-cell lymphoma have been appreciated 
during these last 20 years (Campo et al., 2011). Both share a close biologic relationship and 
similar profiling at the epigenetic level (Eberle et al., 2011). 
Concerning the phenotypic findings, expression of the CD30 molecule by H/RS cells is seen 
in more than 98% of cHLs although the intensity of the immunostaining can vary from one 
case to another, and even within the same case. CD30 molecule appears also to be a possible 
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Fig. 1. Reed-Sternberg cell (A: black arrow) seen in a cellular background rich in 
lymphocytes of a classical Hodgkin lymphoma.  Popcorn cell (B: black arrow) with typically 
lobated nuclei seen in a Nodular lymphocyte predominant Hodgkin lymphoma. 
for therapeutic purposes. Preliminary studies have shown that these immunotoxins have 
remarkable cytotoxic activity (Falini et al., 1992; Foyil & Bartlett, 2010; Tazzari et al., 1992). 
CD15, characteristic but not specific for H/RS, is detected in about 80% of cHL patients 
(Ascani et al., 1997; Foyil & Bartlett, 2010; Pileri et al., 1991; Pileri et al., 1995). H/RS cells 
usually lack CD45 (Falini et al., 1990; Filippa et al., 1996; Korkolopoulou et al., 1994), 
whereas B and, to lesser extent, T cell markers are seen in a proportion of cases. In 
particular, CD20 is found in 30%–40% of cHL cases (usually EBV negative) (Filippa et al., 
1996), and CD79a is found even less often (Tzankov et al., 2003a; Tzankov et al., 2003c; 
Watanabe et al., 2000). Positivity (usually weak) for one or more T cell marker is detected in 
a minority of cases in H/RS cells (Casey et al., 1989; Falini et al., 1987). Under these 
circumstances, single cell PCR studies have shown T-cell receptor (TCR) gene 
rearrangement in only three instances, with clonal Ig gene rearrangements occurring in most 
cHL cases with T-cell marker expression (Marafioti et al., 2000; Muschen et al., 2000). In 
contrast to that seen in NLPHL, the elements of cHL show variable expression of the BCL6 
molecule (Stein et al., 2008b). Antibodies against the nuclear-associated antigens Ki-67 and 
proliferating cell nuclear antigen (PCNA) stain most H/RS cells, suggesting that a large 
number of neoplastic cells enter the cell cycle (Gerdes et al., 1987; Sabattini et al., 1993).  
NLPHL differs greatly from the common type in terms of morphology, phenotype, 
genotype, and clinical behavior (Piccaluga et al., 2011). The only feature shared by NLPHL 
and cHL is the low number of neoplastic cells. The neoplastic population consists of large 
elements called lymphocytic/histiocytic or popcorn cells (Figure 1B) (Mason et al., 1994). 
However, these neoplastic cells have a characteristic profile, which differs greatly from that 
of cHL (Anagnostopoulos et al., 2000; Harris et al., 2000; Harris et al., 1994). In particular, 
they are CD45+, CD20+, CD22+, CD79a+, J chain+/−, EMA+/−, and CD15−.  CD30 positivity is 
rare and, when detected, weak. Popcorn cells regularly express the transcription factor 
OCT2 and its coactivator BOB.1 (Stein et al., 2001). Although NLPHL is characterized by a 
more preserved B-cell phenotype compared to the classical variant, a certain degree of 
defectivity was also described since a downregulation of several markers associated with 
the B-cell lineage (CD19, CD37, CD79b, and LYN) and with the germinal center maturation 






cHL, NLPHL has a higher age of onset (30-40 years), a higher incidence in males, a tendency 
for peripheral distribution, lack of B symptoms in the majority of cases, and mostly early-
stage disease (Diehl et al., 1999; Nogova et al., 2008).  
3. Clinicobiological prognostic parameters  
The high curability rates of HL coupled with increasing awareness of late treatment related 
morbidity, especially in young population, has highlighted the importance of some 
clinicobiological risk factors that might guide the therapeutical strategies. Although these 
factors are probably the clinical translation of some alterations at the molecular  level, to 
date there exist global consensus based upon these clinicobiological characteristics in order 
to decide the total amount of treatment to administer to every single patient, especially with 
respect to the type and number of cycles of chemotherapy, and thus to apply more intensive 
treatments to those cases with higher risk of relapse and, on the contrary, to avoid 
unnecessary treatment in patients with good prognosis. 
3.1 Staging and clinical risk categories 
Selection of treatments depends on initial risk stratification. In this sense, stage remains the 
most important factor in the initial approach for treatment of HL, being the Ann Arbor 
system with Cotswolds modifications the current staging system used for patients with HL 
(Table 1) (Diehl et al., 2004). 
 
Stage I — Involvement of a single lymph node region (I) or of a single extralymphatic organ 
or site (Ie). 
Stage II — Involvement of two or more lymph node regions on the same side of the 
diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or 
tissue (IIe). The number of anatomic regions should be indicated by a subscript  
Stage III — Involvement of lymph node regions or lymphoid structures on both sides of the 
diaphragm (III) which may include the spleen (IIIs) or limited, a contiguous extralymphatic 
organ or site (IIIe) or both (IIIes). This may be subdivided into stage III-1 or III-2: stage III-1 
is used for patients with involvement of the spleen or splenic hilar, celiac or portal nodes; 
and stage III-2 is used for patients with involvement of the paraaortic, iliac, inguinal, or 
mesenteric nodes. 
Stage IV — Diffuse or disseminated foci of involvement of one or more extralymphatic 
organs or tissues, with or without associated lymphatic involvement. 
Table 1. Ann-Arbor/Costwolds staging system. 
In clinical practice, HL is classified in early and advanced disease (Connors, 2005). Early 
disease includes stages I-II and it is generally divided into favorable and unfavorable 
categories based upon the presence or absence of certain clinical features, such as age, 
erythrocyte sedimentation rate (ESR), B symptoms, and large mediastinal adenopathy. 
Cooperative research groups have used diverse definitions of favorable and unfavorable 
prognosis disease (Table 2) (Specht & Hasenclever, 1999). 
However, probably the most commonly used definition of favorable/unfavorable disease is 





cHL, NLPHL has a higher age of onset (30-40 years), a higher incidence in males, a tendency 
for peripheral distribution, lack of B symptoms in the majority of cases, and mostly early-
stage disease (Diehl et al., 1999; Nogova et al., 2008).  
3. Clinicobiological prognostic parameters  
The high curability rates of HL coupled with increasing awareness of late treatment related 
morbidity, especially in young population, has highlighted the importance of some 
clinicobiological risk factors that might guide the therapeutical strategies. Although these 
factors are probably the clinical translation of some alterations at the molecular  level, to 
date there exist global consensus based upon these clinicobiological characteristics in order 
to decide the total amount of treatment to administer to every single patient, especially with 
respect to the type and number of cycles of chemotherapy, and thus to apply more intensive 
treatments to those cases with higher risk of relapse and, on the contrary, to avoid 
unnecessary treatment in patients with good prognosis. 
3.1 Staging and clinical risk categories 
Selection of treatments depends on initial risk stratification. In this sense, stage remains the 
most important factor in the initial approach for treatment of HL, being the Ann Arbor 
system with Cotswolds modifications the current staging system used for patients with HL 
(Table 1) (Diehl et al., 2004). 
 
Stage I — Involvement of a single lymph node region (I) or of a single extralymphatic organ 
or site (Ie). 
Stage II — Involvement of two or more lymph node regions on the same side of the 
diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or 
tissue (IIe). The number of anatomic regions should be indicated by a subscript  
Stage III — Involvement of lymph node regions or lymphoid structures on both sides of the 
diaphragm (III) which may include the spleen (IIIs) or limited, a contiguous extralymphatic 
organ or site (IIIe) or both (IIIes). This may be subdivided into stage III-1 or III-2: stage III-1 
is used for patients with involvement of the spleen or splenic hilar, celiac or portal nodes; 
and stage III-2 is used for patients with involvement of the paraaortic, iliac, inguinal, or 
mesenteric nodes. 
Stage IV — Diffuse or disseminated foci of involvement of one or more extralymphatic 
organs or tissues, with or without associated lymphatic involvement. 
Table 1. Ann-Arbor/Costwolds staging system. 
In clinical practice, HL is classified in early and advanced disease (Connors, 2005). Early 
disease includes stages I-II and it is generally divided into favorable and unfavorable 
categories based upon the presence or absence of certain clinical features, such as age, 
erythrocyte sedimentation rate (ESR), B symptoms, and large mediastinal adenopathy. 
Cooperative research groups have used diverse definitions of favorable and unfavorable 
prognosis disease (Table 2) (Specht & Hasenclever, 1999). 
However, probably the most commonly used definition of favorable/unfavorable disease is 
the one proposed by the European Organization for the Research and Treatment of Cancer 
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(EORTC). Patients with one of the risk factors mentioned above are considered to have 
unfavorable prognosis early stage HL. This stratification is highly pertinent and useful since 
patients with favorable prognosis disease may have acceptable outcomes with less intensive 
therapy than that required for those with unfavorable prognosis early stage or advanced 
stage disease (Engert et al., 2010).  
 
EORTC: age 50 or older; large mediastinal adenopathy; with an ESR of more than 50/h and 
B symptoms (or with an ESR of more than 30 mm/h in those who have B symptoms); and 
disease with four or more regions of involvement  
GHSG: Three or more sites of disease; extranodal extension; mediastinal mass measuring 
one-third the maximum thoracic diameter or greater; and ESR more than 50 mm/h (more 
than 30 mm/h if B symptoms present)  
NCCN: large mediastinal adenopathy; bulky disease lager than 10 cm; B symptoms; ESR 
more than 50 mm/h; and disease with four or more regions of involvement 
NCI-C: age 40 or older; ESR more than 50 mm/h; and disease with four or more regions of 
involvement 
Table 2. Definitions of unfavorable disease by different cooperative research groups. 
Among patients with advanced stage HL (stage III/IV, and for some groups stage II plus 
bulky nodal disease), prognosis is largely determined by the International Prognostic Score 
(IPS) (Hasenclever & Diehl, 1998). The IPS was created by the IPS Project on Advanced 
Hodgkin's Disease based upon the total number of seven potential unfavorable features at 
diagnosis: serum albumin less than 4 g/dL, hemoglobin less than 10.5 g/dL, male gender, 
age over 45 years, stage IV disease, white blood cell count ≥15,000/microL, and lymphocyte 
count less than 600/microL and/or less than 8 percent of the white blood cell count.  
In this system, one point is given for each of the above characteristics present in the patient, 
for a total score ranging from zero to seven, representing increasing degrees of risk. When 
applied to an initial group of 5141 patients with HL treated with combination chemotherapy 
ABVD-like with or without radiotherapy, event-free survival rates at five years correlated 
well with IPS (Table 3) (Hasenclever & Diehl, 1998).  
 
No factors —84% (7 percent of patients) 
One factor — 77% (22 percent of patients) 
Two factors — 67% (29 percent of patients) 
Three factors — 60% (23 percent of patients) 
Four factors — 51% (12 percent of patients) 
Five or more factors — 42% (7 percent of patients)  
Table 3. Event free survival correlated with IPS. 
Consequently, different treatment policies are indicated upon the presence of these 
clinicobiological parameters, with application of more aggressive approaches when more 
risk factors are present.  
3.2 Positron Emission Tomography (PET) and correlation with clinical outcomes 
In the last years, F fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has 





the course of antineoplastic therapy. Monitoring clinical evolution with PET is emerging as a 
new powerful predictor of outcome that can eventually diminish the amount of treatment to 
administer, sparing unnecessary cycles of chemotherapy or radiotherapy, or, on the 
contrary, making advisable the indication of more intensified treatments.  
Some trials have revealed that interim PET scans after one to three cycles of chemotherapy 
may predict long term outcomes in HL (Hutchings et al., 2005). In a prospective trial 
including 260 patients with advanced HL treated with ABVD, PET scans were made per 
protocol after 2 cycles of treatment (Gallamini A et al, 2007). This study demonstrated that 
patients with an interim negative PET scan had excellent prognosis, with two year event free 
survival rates of 95%, compared with 13% in those cases with PET positive. On multivariate 
analysis, interim PET status was the only significant prognostic factor, showing superiority 
over the classical IPS model (Gallamini et al., 2007). 
After these findings, next question is how to incorporate the interim PET results in the 
global management of treatment of HL in order to tailor a risk-adapted treatment strategy to 
the individual patient. There are several prospective trials ongoing in the United States and 
in Europe in early and advanced disease, testing different therapeutic approaches 
depending on PET scan findings. Their results are eagerly awaited to definitely establish 
finer tune therapeutic strategies in this disease. 
4. Role of virus in HL 
A negative association has been observed between HL and repeated early common 
infections (Rudant et al., 2010). Viruses are etiologically associated with a significant number 
of human leukaemia/lymphomas. Recognition of virus involvement in these malignancies 
is important as prevention of infection can lead to a reduction in the number of individuals 
at risk of disease. Early epidemiologic data suggested that HL develops among persons with 
a delayed exposure to a ubiquitous infectious agent such as Epstein-Barr virus (EBV) or 
among persons with acquired less common new infections such as human deficiency virus 
(HIV). The role of mediators of immunity genes may be important in the lack of adequate 
immune control of infectious agents. Several cytokines and interleukins are produced by 
neoplastic cells in lymphomas. 
EBV, a  herpesvirus with a worldwide distribution,  is present in H/RS cells of 40%–60% of 
cHL lesions and contributes to their pathogenesis (Kapatai & Murray, 2007; Khan, 2006). 
EBV positivity is higher with MCHL (60-70%) than with NSHL (15-30%). EBV+ H/RS cells 
express the latent membrane proteins 1, 2A y 2B (LMP1, LMP2A, LMP2B), the EBV nuclear 
antigens 1 (EBNA1), and the EBER RNAs, but consistently lack EBNA2 (latency II) (Jarrett, 
2002, 2006). LMP1 is likely to contribute to survival and proliferation of H/RS cells through 
activation of NF-κB and AP-1 (Kilger et al., 1998; Lam & Sugden, 2003). The role of LMP2A 
is more difficult to predict. Although LMP2A can deliver a survival signal in B-cells, H/RS 
cells have down-regulated many B-cell specific molecules including intracellular 
components involved in this signaling pathway (Kilger et al., 1998; Schwering et al., 2003). 
LMP2A may indeed contribute to this ‘loss of B-cell signature’, since cDNA microarray 
analysis of LMP2A expressing B-cells reveals a similar pattern of downregulated genes 
(Portis et al., 2003). It is also possible that EBNA1 and the EBERs contribute to the rescue of 
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is important as prevention of infection can lead to a reduction in the number of individuals 
at risk of disease. Early epidemiologic data suggested that HL develops among persons with 
a delayed exposure to a ubiquitous infectious agent such as Epstein-Barr virus (EBV) or 
among persons with acquired less common new infections such as human deficiency virus 
(HIV). The role of mediators of immunity genes may be important in the lack of adequate 
immune control of infectious agents. Several cytokines and interleukins are produced by 
neoplastic cells in lymphomas. 
EBV, a  herpesvirus with a worldwide distribution,  is present in H/RS cells of 40%–60% of 
cHL lesions and contributes to their pathogenesis (Kapatai & Murray, 2007; Khan, 2006). 
EBV positivity is higher with MCHL (60-70%) than with NSHL (15-30%). EBV+ H/RS cells 
express the latent membrane proteins 1, 2A y 2B (LMP1, LMP2A, LMP2B), the EBV nuclear 
antigens 1 (EBNA1), and the EBER RNAs, but consistently lack EBNA2 (latency II) (Jarrett, 
2002, 2006). LMP1 is likely to contribute to survival and proliferation of H/RS cells through 
activation of NF-κB and AP-1 (Kilger et al., 1998; Lam & Sugden, 2003). The role of LMP2A 
is more difficult to predict. Although LMP2A can deliver a survival signal in B-cells, H/RS 
cells have down-regulated many B-cell specific molecules including intracellular 
components involved in this signaling pathway (Kilger et al., 1998; Schwering et al., 2003). 
LMP2A may indeed contribute to this ‘loss of B-cell signature’, since cDNA microarray 
analysis of LMP2A expressing B-cells reveals a similar pattern of downregulated genes 
(Portis et al., 2003). It is also possible that EBNA1 and the EBERs contribute to the rescue of 
H/RS cells from apoptosis (Kennedy et al., 2003; Young & Rickinson, 2004). 
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Immunologic reactions (cytotoxic responses) against EBV can occur in the peripheral blood of 
some cHL patients (Khan, 2006). It has been estimated that EBV-specific T-cells might 
constitute up to 5% of circulating CD8+ T-cells (Hislop et al., 2002; Rickinson & Kieff, 2001). 
The intratumoral immunological alterations induced by EBV+ H/RS cells remain unclear.  The 
abnormal network of cytokines/chemokines and/or their receptors in H/RS cells is involved 
in the attraction of many of the microenvironmental cells into the lymphoma background. 
There is increasing evidence suggesting a change in the balance between Th1 and Th2 cells in 
the pathogenesis of HL and that this change induces reactivation of latent viral infections, 
including EBV. For example, interleukin like IL-1  is produced by H/RS cells in culture (Hsu 
et al., 1989) and IL-3 have demonstrated to present significant biological activity as growth and 
antiapoptotic factor for H/RS cells (Aldinucci et al., 2005). Serum levels of the receptor 
antagonist IL-1 (IL-1r ) are elevated in HL patients, patients with B symptoms have 
significantly lower levels of IL-1r than those without symptoms (Gruss et al., 1992). IL-10 is a 
pleiotropic cytokine that protects hematopoietic cells from apoptosis induced by 
glucocorticoids and doxorubicin. H/RS cells express functional IL-10 receptors and elevated 
IL-10 levels may inhibit apoptosis of H/RS cells. Elevated serum IL-10 levels have been found 
in up to 50% of HL patients and have been associated with inferior failure free survival (FFS) 
and overall survival (OS) in patients treated with ABVD or BEACOPP chemotherapy (Rautert 
et al., 2008; Sarris et al., 1999; Vassilakopoulos et al., 2001; Viviani et al., 2000). Elevated serum 
IL-10 levels confer a poor survival and may add to the prognostic value of the IPS in prediction 
of outcomes in HL (Axdorph et al., 2000). CCL17/TARC is a chemokine secreted by H/RS 
cells and its chemotactic properties may explain the infiltration of reactive T lymphocytes in 
HL (Niens et al., 2008; Peh et al., 2001; van den Berg et al., 1999).  Elevated CCL7/TARC levels 
have been seen in the majority of patients with HL (Niens et al., 2008). Persistent elevation of 
TARC after completion of treatment has been associated with poorer survival and could be 
important for treatment monitoring (Hnatkova et al., 2009; Weihrauch et al., 2005). EBV-
infected H/RS cells were shown to stimulate also the stromal production of particular 
chemokines such as the interferon-inducible chemokine IP-10 (CXCL10) (Teichmann et al., 
2005), Rantes/CCL5 (Aldinucci et al., 2008; Fischer et al., 2003), the ligand CCL28 (Hanamoto 
et al., 2004),  CCL20 that is capable of attracting regulatory T cells (Baumforth et al., 2008) and 
the macrophage-derived chemoattractant (MDC)/CCL22 (Niens et al., 2008). It has been also 
suggested that immunologic reactions against EBV can occur in the peripheral blood of some 
cHL patients (Khan, 2006). However, no comprehensive characterization of intratumoral 
immunologic alterations induced by EBV+ H/RS cells has been described so far. EBV was 
shown to contribute to HL patients survival (Kapatai & Murray, 2007). The observation of 
Th1/antiviral response in EBV+ cHL tissues provides a basis for novel treatment strategies 
(Chetaille et al., 2009; Skinnider & Mak, 2002). 
Although HL is not considered an acquired immunodeficiency syndrome (AIDS)-defining 
neoplasm, HIV-infected patients treated with highly active antiretroviral therapy (HAART) 
present a higher incidence of HL compared with the population without HIV infection 
(Powles & Bower, 2000; Powles et al., 2009). Almost 100% of HIV-associated cases are EBV-
positive and, in these patients, EBV is found more frequently in H/RS cells (Powles & 
Bower, 2000). HIV-HL exhibits pathological features that are different from those of HL in 
‘‘general population’’(Carbone et al., 2009; Grogg et al., 2007) while is characterized by the 
predominance of unfavorable histological subtypes (MCHL and LDHL) (Carbone et al., 





is the widespread extent of the disease at presentation and the frequency of systemic B-
symptoms. At the time of diagnosis, 70–96% of the patients have B-symptoms, and 74–92% 
have advanced stages of disease with frequent involvement of extranodal sites, the most 
common being bone marrow (40–50%), liver (15–40%), and spleen (around 20%) (Tirelli et 
al., 1995). The widespread use of HAART has resulted in substantial improvement in the 
survival of patients with HIV infection and lymphomas because of the reduction of the 
incidence of opportunistic infections and the opportunity to allow more aggressive 
chemotherapy. Moreover, the less-aggressive presentation of lymphoma in patients treated 
with  HAART compared with untreated patients may also favorably change the outcome for 
HIV-infected patients with lymphomas (Vaccher et al., 2003).  In fact, compared with 
patients who never received HAART, patients in HAART before the onset of cHL generally 
are older, have less B-symptoms, and a higher leukocyte and neutrophil counts and 
hemoglobin level (Chimienti et al., 2008). 
5. Antitumoral immunity 
Tumors are more than an accumulation of neoplastic cells; they might be more properly 
considered as a functional tissue immunologically mediated and formed by a complex tissue 
network in which neoangiogenesis, infiltrating immune competent cells, stromal cells, and a 
differentiated and specific extracellular matrix constitute the tumor microenvironment with 
the capacity of regulating cancer development (Alvaro et al., 2010; Tlsty & Coussens, 2006). 
The interplay between the host immune system, malignant cells, and all other components 
of tumoral stroma determine proliferation, invasion, angiogenesis, and remodelling of 
extracellular matrix and metastasis. 
The hypothesis of immunesurveillance postulates that one of the principal functions of the 
immune system would be recognizing neoplastic cells and eliminating them before they 
form tumors (Burns & Leventhal, 2000). In these conditions, the absence of an effective 
immune system increases the risk of developing cancer. If the immune system is a complex 
system of different types of cells and molecules whose primary function is to act as an 
effective tumor suppressor, it is certain that the system may behave inefficiently, as 
indicated by the fact of tumors in immunocompetent individuals. Thus, in addition to the 
concept of immunosurveillance arises of immunostimulation (Ichim, 2005). Although 
various mechanisms could induce immunosuppression (virus, transplant ..), the increasing 
likelihood of cancer (Burnet, 1957) in immunologically intact individuals suggests that the 
immune response might not only be ineffective but may itself contribute to tumor 
progression (Prehn, 1972). That is, the immune system has the ability to act as a double-
edged sword, indicating that tumor elimination requires a good coordination of the various 
elements of the immune system. 
The products of mutated or deregulated genes of tumoral cells contribute to the growth and 
invasion of tumoral cells, as well as to the expression of proteins with the ability to stimulate 
the immune response. The immunogenic capacity of the tumor can be evaluated by means 
of the study of the reactive infiltration, which is mainly composed by innate immune cells. 
The nature, function and specificity of the effector cells that drive the antitumoral immune 
response have been widely studied. Innate immunity is represented essentially by dendritic 
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complement proteins, whereas adaptive immune cells are represented by B lymphocytes, 
CD4+ T-helper lymphocytes and CD8+ cytotoxic lymphocytes (CTL). The general 
mechanisms for tumor suppression have been principally attributed to CD4+ T helper 
lymphocytes. Cytokines and lymphokines from CD4+ T cells can also activate CD8+ CTL, 
NK cells and macrophages, which have all been shown to be involved in tumor immunity 
(Adam et al., 2003; Gonthier et al., 2004; Ikeda et al., 2002; Peipp & Valerius, 2002; Smyth et 
al., 2002). Immunoregulatory cytokines such as IL-10 and TGF- play an important role in 
immune tolerance, and it seems that suppressor effect of regulatory T cells (CD4+CD25+) on 
the development of tumor associated antigen-reactive lymphocytes is independent of 
cytokines (Aldinucci et al., 2005).  Contributing to the complexity of the interactions between 
the reactive background and malignant cells, immune cells present in the local infiltrate 
have proved capable of modulating apoptosis and of inducing proliferation of tumoral cells 
via death receptors, cytotoxic granule liberation, and withdrawal of growth factors or 
production of immunosuppressive cytokines (Atkinson & Bleackley, 1995; Berke, 1995; de 
Visser & Kast, 1999; Skinnider & Mak, 2002). The efficacy of tumoral–immune cells 
interactions depends on several factors, such as the expression of MHC class I molecules 
and immunogenic epitopes in tumoral cells, the type of immune cell and the accessibility of 
tumor cells.  
Tumor antigens recognized by T cells (generally CD8+ lymphocytes) represent the principal 
target of antitumoral immunity and are presented by MHC class I molecules; that is to say, 
that tumoral cells behave as antigen presenting cells (APC), presenting their own antigens to 
T cells. Naturally, professional APC can also present antigens to CD4+ lymphocytes through 
MHC class II molecules (Quezada et al., 2010). Dendritic cells (DC) and other APC are 
dispersed between tissues as sentinels or alarm systems ready to detect the presence of 
foreign antigens. While in the tumor microenvironment IL-12 production tends to be 
suppressed, resulting in a decrease in Th1 activity, DCs represent probably the most 
important regulators of naïve T cells, with a great capacity to produce and release IL-12. In 
their process of polarization, DCs are under the influence of inflammatory mediators such 
as prostaglandins produced by macrophages, fibroblasts, and tumor cells. A new route of 
junction between innate and adaptive immunity through the interaction between DC and 
NK cells has been suggested (Adam et al., 2005). Actually, at least four distinct CD4 T cells 
subsets have been described: Th1, Th2, Th17, and regulatory T cells, each one with a unique 
cytokine secretion pattern and function (Zhu & Paul, 2008). Their primary roles is providing 
cytokines for the development of CTL, in addition to being able to secrete tumor necrosis 
factor (TNF) and interferon (IFN)-gamma, which can increase the expression of MHC class I 
by the tumor cell and therefore increase its sensitivity to CTL lysis. Among natural CTL, 
natural killer cells (NK cells) can be activated directly by contact with the tumor or as a 
result of the stimulus provided by cytokines. In addition, lymphokine-activated killer cells 
(LAK) are a group of NK cells derived from peripheral blood cells or tumor infiltrating 
lymphocytes (TIL) in patients with high concentrations of IL-2 and show a high capacity, 
nonspecific in this case, to lyse tumor cells. Others cellular mediators such as the 
macrophages are also capable of lysing tumor cells by releasing a large amount of lysosomal 
enzymes and reactive oxygen metabolites. Once activated they also produce cytokines such 
as TNF that exerts its cytotoxic activity triggering apoptosis in a similar way to that 





6. Molecular markers 
In HL, a striking feature of both NLPHL and cHL entities is that the malignant cells account 
for only around 1% of the tumor mass (Stein et al., 2008a). However, notable significant 
differences exist between these entities in terms of natural history, relation to EBV, cell 
morphology, phenotype, molecular characteristics, and clinical behavior (Farrell & Jarrett, 
2011; Maggioncalda et al., 2011). 
There is compelling evidence that H/RS cells are clonal B cells that have lost their B cell 
phenotype. Effectively, H/RS cells, from nearly all cHL cases, and malignant popcorn cells 
from NLPHL have detectable rearrangements of Ig heavy andor light chain genes, 
confirming a B cell origin (Kuppers et al., 1996; Kuppers et al., 1994) and, in any given case, 
the rearrangements are identical, proving the clonal nature of the disease (Kanzler et al., 
1996; Kuppers et al., 1994; Marafioti et al., 2000). Furthermore, the Ig variable (IgV) gene 
regions show evidence of somatic hypermutation, revealing a GC or post-GC origin 
(Kuppers, 2002). It was also suggested that cHL and B cell non-Hodgkin lymphoma (BNHL) 
arisen from a common precursor (pre-GC or GC B cell) since both generally harbor identical 
IgV gene rearrangements but have distinct somatic Ig gene mutations (Brauninger et al., 
2006). Intraclonal IgV gene diversity is observed in popcorn cells, indicating ongoing 
somatic hypermutation, whereas identical somatic hypermutations were observed in H/RS 
cells indicating a later stage of B cell differentiation (Kanzler et al., 1996; Kuppers et al., 1994; 
Marafioti et al., 2000). Around 25% of cHL cases present non-functional Ig genes due to 
“crippling” mutations (Brauninger et al., 2006; Kanzler et al., 1996; Kuppers et al., 1994; 
Kuppers et al., 2001). H/RS cells harbor uncommonly rearranged T cell receptor genes 
(<2%), suggesting a T cell origin in a small minority of cases (Muschen et al., 2001; Muschen 
et al., 2000; Seitz et al., 2000). At phenotypic level, markers of B lineage (CD20, CD19, CD79, 
surface Ig) and transcription factors (OCT2, BOB1 and PU1) are generally down-regulated in 
H/RS cells (Hertel et al., 2002; Schwering et al., 2003), and expression of the B cell-specific 
transcription factor PAX5 is usually retained (Foss et al., 1999). In contrast, popcorn cells 
express B cell markers including CD20, CD79, PAX5, OCT2 and BOB1. The global 
suppression of the B cell signature results from transcriptional reprogramming (Kuppers et 
al., 2003; Mathas et al., 2006; Nie et al., 2003; Renne et al., 2006; Smith et al., 2005; Ushmorov 
et al., 2006; Ushmorov et al., 2004).  
Mature B cells lacking B cell receptors would normally die by apoptosis, and therefore 
H/RS cells must have developed mechanisms to facilitate survival. The escape from 
apoptosis and transcriptional reprogramming of H/RS cells are interlinked and seem 
important to disease pathogenesis. EBV gene products appear to contribute to H/RS cell 
survival, proliferation and reprogramming through dysregulation of several signaling 
networks and transcription factors such as intrinsic overexpression of CD30 (Horie et al., 
2002), deleterious mutations of the genes encoding IB proteins (IB(Emmerich et al., 
1999; Emmerich et al., 2003; Jungnickel et al., 2000; Lake et al., 2009; Wood et al., 1998) and 
amplification of the chromosomal region including the c-Rel gene (Barth et al., 2003; Joos et 
al., 2002; Martin-Subero et al., 2002). In cHL EBV-associated cases, the virus can contribute 
directly to activation of NF-B though its protein latent membrane protein 1 (LMP-1), which 
mimics CD40 signaling. Mutations of genes encoding inhibitors and regulators of NF-B 
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In HL, a striking feature of both NLPHL and cHL entities is that the malignant cells account 
for only around 1% of the tumor mass (Stein et al., 2008a). However, notable significant 
differences exist between these entities in terms of natural history, relation to EBV, cell 
morphology, phenotype, molecular characteristics, and clinical behavior (Farrell & Jarrett, 
2011; Maggioncalda et al., 2011). 
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1996; Kuppers et al., 1994; Marafioti et al., 2000). Furthermore, the Ig variable (IgV) gene 
regions show evidence of somatic hypermutation, revealing a GC or post-GC origin 
(Kuppers, 2002). It was also suggested that cHL and B cell non-Hodgkin lymphoma (BNHL) 
arisen from a common precursor (pre-GC or GC B cell) since both generally harbor identical 
IgV gene rearrangements but have distinct somatic Ig gene mutations (Brauninger et al., 
2006). Intraclonal IgV gene diversity is observed in popcorn cells, indicating ongoing 
somatic hypermutation, whereas identical somatic hypermutations were observed in H/RS 
cells indicating a later stage of B cell differentiation (Kanzler et al., 1996; Kuppers et al., 1994; 
Marafioti et al., 2000). Around 25% of cHL cases present non-functional Ig genes due to 
“crippling” mutations (Brauninger et al., 2006; Kanzler et al., 1996; Kuppers et al., 1994; 
Kuppers et al., 2001). H/RS cells harbor uncommonly rearranged T cell receptor genes 
(<2%), suggesting a T cell origin in a small minority of cases (Muschen et al., 2001; Muschen 
et al., 2000; Seitz et al., 2000). At phenotypic level, markers of B lineage (CD20, CD19, CD79, 
surface Ig) and transcription factors (OCT2, BOB1 and PU1) are generally down-regulated in 
H/RS cells (Hertel et al., 2002; Schwering et al., 2003), and expression of the B cell-specific 
transcription factor PAX5 is usually retained (Foss et al., 1999). In contrast, popcorn cells 
express B cell markers including CD20, CD79, PAX5, OCT2 and BOB1. The global 
suppression of the B cell signature results from transcriptional reprogramming (Kuppers et 
al., 2003; Mathas et al., 2006; Nie et al., 2003; Renne et al., 2006; Smith et al., 2005; Ushmorov 
et al., 2006; Ushmorov et al., 2004).  
Mature B cells lacking B cell receptors would normally die by apoptosis, and therefore 
H/RS cells must have developed mechanisms to facilitate survival. The escape from 
apoptosis and transcriptional reprogramming of H/RS cells are interlinked and seem 
important to disease pathogenesis. EBV gene products appear to contribute to H/RS cell 
survival, proliferation and reprogramming through dysregulation of several signaling 
networks and transcription factors such as intrinsic overexpression of CD30 (Horie et al., 
2002), deleterious mutations of the genes encoding IB proteins (IB(Emmerich et al., 
1999; Emmerich et al., 2003; Jungnickel et al., 2000; Lake et al., 2009; Wood et al., 1998) and 
amplification of the chromosomal region including the c-Rel gene (Barth et al., 2003; Joos et 
al., 2002; Martin-Subero et al., 2002). In cHL EBV-associated cases, the virus can contribute 
directly to activation of NF-B though its protein latent membrane protein 1 (LMP-1), which 
mimics CD40 signaling. Mutations of genes encoding inhibitors and regulators of NF-B 
such as inactivating mutations of the TNF- induced protein 3 (TNFAIP3) gene have been 
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detected in a large proportion of EBV-negative cases (Kato et al., 2009; Schmitz et al., 2009). 
Others genomic lesions affecting different signaling pathways in H/RS cells (JAK-STAT, 
PI3K–Akt–mTOR, MAPK–MEK–ERK and AP1–JunFos) have also been demonstrated 
(Dutton et al., 2005; Emmerich et al., 1999; Joos et al., 2003; Juszczynski et al., 2007; Kube et 
al., 2001; Skinnider et al., 2002; Weniger et al., 2006; Zheng et al., 2003). In cHL and primary 
mediastinal B-cell lymphoma, genomic breaks of the major major histocompatibility 
complex (MHC) class II transactivator CIITA have been demonstrated to be highly recurrent 
(15% and 38% respectively) (Steidl et al., 2011b). The functional consequences of CIITA gen 
fusions is the downregulation of surface HLA class II expression and overexpression of 
ligands of the receptor molecule programmed cell death 1 (CD274/PDL1 and 
CD273/PDL2). These receptor-ligand interactions have been shown to impact anti-tumour 
immune responses in several cancers, whereas decreased MHC class II expression has been 
linked to reduced tumour cell immunogenicity.  
Several of these recurring genetic lesions appear correlated with disease outcome (Slovak et 
al., 2011). Nonrandom DNA copy number alterations in cHL (H/RS cells CD30+) have been 
identified in the molecular karyotypes of cHL as comparing with the genomic profiles of GC 
B cells. Frequent gains (>65%) were associated with growth and proliferation, NF-κB 
activation, cell-cycle control, apoptosis, and immune and lymphoid development. Frequent 
losses (>40%) observed encompassed tumor suppressor genes, transcriptional repressors 
and SKP2 (Slovak et al., 2011).  
Thus, multiple transcriptional and signaling pathways are disrupted in HL, and are thought 
to cooperate to increase H/RS cell proliferation, reduce apoptosis and promote a favorable 
cellular microenvironment through the release of multiple cytokines and chemokines. These 
findings may be useful prognostic markers in the counselling and management of patients 
and for the development of novel therapeutic approaches in primary refractory HL.  
7. Biological factors: Immune response in HL  
The tumor microenvironment consists of a specific mixture of immune cells that express a 
distinctive profile for each tumor type, from which the efficacy of the immune response 
against the tumor is eventually derived (Alvaro et al., 2009). Exist increasing evidence of the 
importance of the microenvironment in the molecular pathogenesis of HL (Steidl et al., 
2011a), and a promising therapeutic target has been raised focused on this approach. The 
presence of a characteristically rich inflammatory background particularly distinguishes HL 
from other lymphoproliferative syndromes. Differences in gene expression profiles of 
malignant cells in lymphoproliferative syndromes do not always determine the 
aggressiveness of the lymphoma, while recent contributions determine that HL represents 
the prototypical tumor in which the interplay between H/RS and the reactive 
microenvironment determines not only the histological morphology and classification but 
also the clinicopathological features and prognosis of these patients. Quantitative analysis of 
infiltrating immune cells reveals undisclosed relationships between the relative proportion 
of these cells and HL clinical outcome, illustrating how factors other than tumoral 
cellularity, or the immunophenotype and molecular anomalies present in the H/RS cells, 





7.1 Patterns of immune response in HL and prognosis 
An abnormal pattern with overexpression of cytokines and their receptors is characteristic in 
H/RS cells. This pattern explains the abundant mixture of inflammatory cells, stromal 
changes and the predominance of Th2 cells between the various subpopulations of 
lymphoid cells in the tumoral microenvironment of HL (Swerdlow et al., 2008b). A 
predominance of CD4+ T lymphocytes in the background of tumoral cells in addition to a 
high number of cytotoxic cells (CD8, CD57, TIA-1) has been observed in the majority of HL-
tissues (Figure 2) (Alvaro-Naranjo et al., 2005; Oudejans et al., 1997; Poppema et al., 1998).  
 
Fig. 2. Immunohistochemical staining of inflammatory background in HL: T lymphocytes 
(CD4 and CD8), NK cells (CD56 and CD57) and cytotoxic cells (GrB and TIA-1).  
Regardless of the classic clinical and pathological features, a high proportion of infiltrating 
CD8+ and CD57+ cells as well as a low number of infiltrating CTL (evaluated by the presence 
of Granzyme B and TIA-1) appear to be associated with a favorable outcome for HL patients 
(without B symptoms and lower clinical stages) and better response to treatment (Alvaro-
Naranjo et al., 2005; Alvaro et al., 2005; Ansell et al., 2001). It is unclear to date whether the 
presence of CD8+ T cells correlates with the antitumor cytotoxic response. Nevertheless, it 
has been suspected that CD8+ T cells may be recruited in an antigen-non-specific mode in 
HL (Willenbrock et al., 2000).  
Although the activation status of infiltrating cells have been demonstrated to be 
independent of the degree of malignancy in HL (Bosshart, 2002), others studies have shown 
that the presence of activated cytotoxic T cells (granzyme B+) is associated with unfavorable 
follow-up in these patients (Kanavaros et al., 1999; Oudejans et al., 1997; ten Berge et al., 
2001). A higher level of not activated cytotoxic cells (TIA-1+) has been observed in advanced-
stage cHL without prognostic value (Camilleri-Broet et al., 2004). However, TIA-1+ CTL 
associated with the presence of regulatory T cells FOXP3+ appears to play an important role 
in monitoring HL patients (Alvaro et al., 2005). Variations in the level ofcytotoxic TIA-1+ and 
regulatory T cells observed during the course of the disease could be implicated in the 
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Regardless of the classic clinical and pathological features, a high proportion of infiltrating 
CD8+ and CD57+ cells as well as a low number of infiltrating CTL (evaluated by the presence 
of Granzyme B and TIA-1) appear to be associated with a favorable outcome for HL patients 
(without B symptoms and lower clinical stages) and better response to treatment (Alvaro-
Naranjo et al., 2005; Alvaro et al., 2005; Ansell et al., 2001). It is unclear to date whether the 
presence of CD8+ T cells correlates with the antitumor cytotoxic response. Nevertheless, it 
has been suspected that CD8+ T cells may be recruited in an antigen-non-specific mode in 
HL (Willenbrock et al., 2000).  
Although the activation status of infiltrating cells have been demonstrated to be 
independent of the degree of malignancy in HL (Bosshart, 2002), others studies have shown 
that the presence of activated cytotoxic T cells (granzyme B+) is associated with unfavorable 
follow-up in these patients (Kanavaros et al., 1999; Oudejans et al., 1997; ten Berge et al., 
2001). A higher level of not activated cytotoxic cells (TIA-1+) has been observed in advanced-
stage cHL without prognostic value (Camilleri-Broet et al., 2004). However, TIA-1+ CTL 
associated with the presence of regulatory T cells FOXP3+ appears to play an important role 
in monitoring HL patients (Alvaro et al., 2005). Variations in the level ofcytotoxic TIA-1+ and 
regulatory T cells observed during the course of the disease could be implicated in the 
progression of HL (Alvaro et al., 2005).  
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Fig. 3. Representation of the two immune patterns observed in HL significantly associated 
with their clinicopathological features. The immunesurveillance pattern (A) with a high 
proportion of infiltrating T lymphocytes, NK cells, DCs, activated CTL but low proportion 
of resting CTL and TAM is associated with a favorable outcome. The immune escape 
pattern (B) with a high proportion of infiltrating resting CTL and TAM, but low proportion 
of T lymphocytes, NK cells, DCs and activated CTL is associated with an unfavorable 
outcome. MC, mixed celularity; NS, nodular sclerosis; CR, complete response.  
Association of tumor-associated macrophages (TAM) CD68+ with adverse clinical outcomes 





Recently, a gene expression profile analysis performed on 130 biopsy samples from patients 
with HL identified a signature of TAM and monocytes that was predictive of treatment 
failure (Steidl et al., 2010). In this study the sensitivity and specificity of this GEP signature 
for outcome in this cohort was greater than that of the International Prognostic Score (IPS). 
After these findings, biopsy samples from an independent cohort of 166 patients were 
evaluated with immunohistochemistry for the presence of CD68 expressing macrophages 
using a score from 1 to 3, from lower to higher infiltration (Steidl et al., 2010). When 
compared with those with low CD68 expression, patients with tumors that demonstrated an 
increased number of CD68 expressing macrophages had shorter median progression-free 
survival (PFS), lower rate of 10-year disease-specific survival (60 versus 89%), and higher 
failure rate of secondary treatment with curative intent (63 versus 13%). It has been also 
recently demonstrated that high level of CD68 correlated with poorer survival, event-free 
survival (EFS) and with the presence of EBV in the tumor cell population (Kamper et al., 
2011). These results suggest a new pathological prognostic factor to be considered, however 
it is unclear at this time how CD68 status should affect patient management.   
A plausible explanation for the extensive inflammatory infiltrate present in HL secretion could 
be a variety of cytokines produced by both tumor cells and surrounding stromal tissue. CD4+ 
T cells produce Th2 cytokines that could contribute to local suppression of the cellular immune 
response mediated by Th1. However, the categorization of CD4+ T cells in Th1 and/or Th2 is 
an oversimplification (Marshall et al., 2004) as regulatory T cells with CD4+CD25+ phenotype 
not only play a regulatory role of autoimmunity, but also have suppressive effects on the 
development of antigen-reactive lymphocytes associated with the tumor (Wei et al., 2004). The 
H/RS cells secrete high amounts of chemokine, thymus and activation-regulated chemokine 
(TARC) and macrophages-derived chemokine (MDC) in particular, which attract lymphocytes 
expressing CCR4 receptor, such as Th2 (Skinnider & Mak, 2002). These cytokines may 
contribute to the pathogenesis of the disease initiated and sustained the presence of the 
reactive infiltrate. Alternatively, immune cells can produce cytokines responsible for 
proliferation and survival of tumor, producing a positive feedback between the tumoral cells 
and immune system. The composition of the infiltrate may also differ depending on the state 
of immunosuppression of HL patients. Moreover, HIV infection affects, for direct or indirect 
mechanisms, both reactive changes as neoplastic lymphoid tissue. Recently we have seen a 
significant loss of intratumoral T cells CD4+ (CD4/CD8 ratio reversal) and a decrease in 
intratumoral activated CTL in patients with HIV-infected HL (Bosch Princep et al., 2005). A 
low proportion of CD4+ cells appears also to be significantly related to EBV status, probably 
due to the relation with the local tumor-associated suppression of EBV-specific T-cell 
responses observed in EBV+ HL cases (Frisan et al., 1995).   
7.2 Immune response regulation in HL 
Tumors employ a plethora of immunosuppressive mechanisms, which may act in concert to 
counteract effective immune responses. Different mechanisms have been suggested to 
account for the CTL-mediated apoptosis resistance of H/RS cells, such as the 
downregulation of MHC class I molecules of the H/RS cells, prevention of recognition of 
tumor-associated antigens by CTLs (Poppema & Visser, 1994), or the local secretion of both 
IL-10 and transforming growth factor-b by H/RS cells (Newcom et al., 1988; Ohshima et al., 
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low proportion of CD4+ cells appears also to be significantly related to EBV status, probably 
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responses observed in EBV+ HL cases (Frisan et al., 1995).   
7.2 Immune response regulation in HL 
Tumors employ a plethora of immunosuppressive mechanisms, which may act in concert to 
counteract effective immune responses. Different mechanisms have been suggested to 
account for the CTL-mediated apoptosis resistance of H/RS cells, such as the 
downregulation of MHC class I molecules of the H/RS cells, prevention of recognition of 
tumor-associated antigens by CTLs (Poppema & Visser, 1994), or the local secretion of both 
IL-10 and transforming growth factor-b by H/RS cells (Newcom et al., 1988; Ohshima et al., 
1995), which are able to inhibit CTL function. In this respect, it appears that the blockage of 
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the Granzyme B pathway of apoptosis through the overexpression of serine protease 
inhibitor PI-9/SPI-6 is an important additional mechanism for immune escape by tumors 
(Medema et al., 2001). The expression of PI9 tends to be associated with a high percentage of 
activated CTLs, especially in HL (Bladergroen et al., 2002), suggesting that PI9 may play a 
role in protecting against Granzyme B-induced apoptosis, and partially explaining why 
tumors expressing high levels of PI9 have a particularly poor clinical outcome, irrespective 
of the number of Granzyme B+ cells in the inflammatory infiltrate. 
Different subsets of immune cells contribute also to this immunosuppressive network, 
including CD4+CD25+ regulatory T cells. In HL, it has been initially proposed that CD4+ T 
cells produce cytokines of Th2 type that could contribute to local suppression of the cellular 
immune response mediated by Th1 cells (Bladergroen et al., 2002; Poppema et al., 1999). 
However, the categorization of CD4+ T cells in Th1 and/or Th2 constitutes an 
oversimplification and it has been shown that regulatory T cells with CD4+CD25+ phenotype 
not only play a role in controlling autoimmunity, but also have suppressive effects on 
lymphocyte development tumor associated antigen reagents (Curiel et al., 2004; Fontenot et 
al., 2003; Suri-Payer et al., 1998). Functional and molecular characterization of these cells has 
been facilitated by the identification of markers such as FOXP3 and others (Shimizu et al., 
2002; Sutmuller et al., 2001; Takahashi et al., 2000). FOXP3 encodes a transcription factor 
known as Scurfina, specifically expressed by T cells CD4+CD25+(Karube et al., 2004), that 
acts converting naïve regulatory T cells CD4+CD25- phenotype to CD25+ (Hori et al., 2003). 
More recently, it was suggested that regulatory T cells and PD1+ T cells interact with H/RS 
cells (Alvaro et al., 2005; Teichmann et al., 2005; Yamamoto et al., 2008), which produce the T 
regulatory attractant galectin-1 and the PD-1 ligand, PDL-1 (Yamamoto et al., 2008). On the 
other hand, the observation of numerous CXCR3+ lymphocytes in some HL tumors has 
raised the possibility of an occasional Th1-predominant immune response (Alvaro-Naranjo 
et al., 2005).  
The regulatory T cells can inhibit the production of both IL-2 to regulate the high expression 
of IL-2Rα (CD25), ie, delay or block the activation of CD8+ cells and natural killer (NK) cells 
against tumor antigens (Azuma et al., 2003; Wolf et al., 2003). The immunosuppressive 
properties of regulatory T cells appear to be particularly important because of its large effect 
on cellular cytotoxicity represented by CTLs and NK cells. The presence of low numbers of 
FOXP3+ cells and a consequent high rate of TIA-1+ cells in the infiltrate represents an 
independent prognostic factor negatively affecting the survival of the disease. Furthermore, 
when the disease relapses and progresses, larger number of TIA-1+ cells and lower 
proportion of FOXP3+ on the reactive background of the tumor are also prone to be seen 
(Alvaro et al., 2005). 
8. Apoptotic and cell cycle pathways in HL 
The aberrant expression of proteins involved in regulation and execution of apoptosis and 
cell cycle of lymphocytes has been demonstrated in several types of lymphoma and the 
importance of the level of apoptosis and proliferation in clinically aggressive 
lymphoproliferative syndromes (Bai et al., 2005; Bai et al., 2003; Garcia et al., 2003; Sanchez-
Beato et al., 2003). These anomalies are probably not sufficient to explain the development of 
lymphomas, even if the effectiveness of therapy is presumed to be mediated by activation of 





controlling apoptosis and proliferation of H/RS cells and biological factors such as EBV 
detection, which influence the clinical aggressiveness of the disease (Bargou et al., 1997; 
Garcia et al., 1999; Hinz et al., 2002; Hinz et al., 2001; Izban et al., 2001; Kupper et al., 2001; 
Leoncini et al., 1997; Mathas et al., 2002; Montesinos-Rongen et al., 1999; Morente et al., 1997; 
Sanchez-Beato et al., 1996).  These studies have demonstrated alterations of the p53, Rb and 
p27 tumor suppressor pathways (Bai et al., 2005; Garcia et al., 1999; Guenova et al., 1999; 
Hinz et al., 2001; Lauritzen et al., 1999; Montesinos-Rongen et al., 1999; Morente et al., 1997; 
Sanchez-Beato et al., 1996; Sanchez-Beato et al., 2003; Tzardi et al., 1996), overexpression of 
cyclins involved in the G1/S and G2/M transition such as cyclins E, D2, D3, A and B1 
(Garcia et al., 2003; Kolar et al., 2000; Leoncini et al., 1997; Ohshima et al., 1999; Teramoto et 
al., 1999; Tzankov et al., 2003b), overexpression of cyclin-dependent kinases such as CDK1, 2 
and 6 (Garcia et al., 2003) and overexpression of the anti-apoptotic proteins c-FLIP, bcl-xl, c-
IAP2 and surviving (Brink et al., 1998; Garcia et al., 2003; Kanavaros et al., 2000; Kuppers, 
2002; Kuppers et al., 2003; Staudt, 2000; Thomas et al., 2004).  
These findings raised the questions of how H/RS cells escape apoptosis, acquire self-
sufficiency in growth signals and proliferate (Kuppers, 2002; Kuppers et al., 2003; Staudt, 2000; 
Thomas et al., 2004). The physiologic relevance of the deregulation of the cell cycle and 
apoptosis regulators in cHL could be related to the different probabilities of survival of HL 
patients. Many studies have analyzed the clinical relevance of the expression of cell cycle and 
apoptosis regulators in cHL using IHC or gene expression profiling (Brink et al., 1998; 
Devilard et al., 2002; Garcia et al., 2003; Montalban et al., 2000; Morente et al., 1997; Smolewski 
et al., 2000).  Shorter survival was significantly associated with high proliferation index (Ki67), 
high expression of bcl2, bcl-xl, bax and p53, low expression of Rb and caspase 3 and high 
apoptotic index (Montalban et al., 2004; Rassidakis et al., 2002a; Rassidakis et al., 2002b; Sup et 
al., 2005; Abele et al., 1997; Brink et al., 1998; Garcia et al., 2003; Montalban et al., 2004; Morente 
et al., 1997; Smolewski et al., 2000). Evidence has accumulated that the constitutive activation 
of the NF-B pathway in H/RS cells is of particular importance for explaining the apoptosis 
deregulation in cHL by up-regulating an anti-apoptotic gene expression program (Bai et al., 
2005; Hinz et al., 2002; Hinz et al., 2001; Mathas et al., 2002). By gene expression profiling, the 
good outcome cHL were characterized by up-regulation of genes involved in apoptosis 
induction (APAF, bax, bid, caspase 8, p53, TRAIL) and cell signaling, including cytokines and 
transduction molecules (IL-10, IL-18, STAT3), while the bad outcome cHL were characterized 
by upregulation of genes involved in cell proliferation (Ki67) and by down-regulation of 
tumor suppressor genes PTEN (Phospatase and Tensin homolog deleted on chromosome 10) 
and DCC (Deleted in Colorectal Cancer) (Devilard et al., 2002). 
Within the complexity of the interactions between the reactive substance and tumor cells, 
immune cells present in the infiltrate have been shown to modulate the apoptosis and 
proliferation of tumor cells via apoptotic receptors, cytotoxic granule release, growth factors 
or immunosuppressive cytokines (Atkinson & Bleackley, 1995; Berke, 1995; de Visser & 
Kast, 1999; Famularo et al., 1994; Hahne et al., 1996). IHC study has demonstrated that the 
antiapoptotic profile observed in H/RS cells is associated with a general increase in CD4+ T 
cells infiltrating (related to Bcl-XL and Mcl-1) and an overall decline CD8+ T lymphocytes 
infiltrating, NK cells and dendritic cells (related to Bcl-XL and Bax) (Alvaro et al., 2008). 
Alterations observed in the G1-S checkpoint of H/RS cell cycle, in the principal tumor 
suppressor pathways Rb-p16INK4a and p27KIP1, and the high rate of proliferation (MIB1, 
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2005; Hinz et al., 2002; Hinz et al., 2001; Mathas et al., 2002). By gene expression profiling, the 
good outcome cHL were characterized by up-regulation of genes involved in apoptosis 
induction (APAF, bax, bid, caspase 8, p53, TRAIL) and cell signaling, including cytokines and 
transduction molecules (IL-10, IL-18, STAT3), while the bad outcome cHL were characterized 
by upregulation of genes involved in cell proliferation (Ki67) and by down-regulation of 
tumor suppressor genes PTEN (Phospatase and Tensin homolog deleted on chromosome 10) 
and DCC (Deleted in Colorectal Cancer) (Devilard et al., 2002). 
Within the complexity of the interactions between the reactive substance and tumor cells, 
immune cells present in the infiltrate have been shown to modulate the apoptosis and 
proliferation of tumor cells via apoptotic receptors, cytotoxic granule release, growth factors 
or immunosuppressive cytokines (Atkinson & Bleackley, 1995; Berke, 1995; de Visser & 
Kast, 1999; Famularo et al., 1994; Hahne et al., 1996). IHC study has demonstrated that the 
antiapoptotic profile observed in H/RS cells is associated with a general increase in CD4+ T 
cells infiltrating (related to Bcl-XL and Mcl-1) and an overall decline CD8+ T lymphocytes 
infiltrating, NK cells and dendritic cells (related to Bcl-XL and Bax) (Alvaro et al., 2008). 
Alterations observed in the G1-S checkpoint of H/RS cell cycle, in the principal tumor 
suppressor pathways Rb-p16INK4a and p27KIP1, and the high rate of proliferation (MIB1, 
BCL6) are also strongly associated with higher infiltration of the overall immune response 
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against the tumor (Alvaro et al., 2008). These results point to the regulation of proteins 
involved in apoptosis and proliferation of tumor cells by direct interactions between these 
cells and the surrounding inflammatory microenvironment.  
These infiltrated cells are able to activate apoptotic caspase proteolytic cascade through TNF 
receptor superfamily interactions (FasL/Fas and CD40/CD40L). The different members of 
this superfamily share common cell signaling pathways that mediate the activation of 
nuclear factor NF-κB and mitogen-activated protein kinases. In this case, CD40/CD40L 
interactions are known to induce the upregulation of Bcl-XL and Mcl1 expression and to 
mediate the activation of NF-B (Hinz et al., 2001; Hong et al., 2000; Inoue et al., 2000; Kater 
et al., 2004; Lee et al., 1999; Metkar et al., 2001). CTLs are also able to trigger a second 
proapoptotic pathway through the protease granzyme B, which, once released from CTLs, is 
translocated into the target cell by perforin, where it activates the effector caspase cascade 
(Thome & Tschopp, 2001). On the other hand, the wide variety of cytokines and chemokines 
present in HL tumoral tissue (IL-2, IL-4, IL-6, and IL-13), responsible for the massive influx 
of activated immune cells (Poppema et al., 1999), has been shown to regulate the expression 
of the various members of Bcl2 family, such as the antiapoptotic Bcl2 homologues Bcl-XL 
and Mcl1 and the proapoptotic Bax (Akbar et al., 1996; Jourdan et al., 2000; Puthier et al., 
1999; Song et al., 2002; Tang et al., 2002).  
Likewise for the apoptotic markers, the physiologic signals present in the reactive 
microenvironment also interfere with components of the G1-CDK checkpoint (cyclin D3, 
CDK6, and p27) (Malumbres & Barbacid, 2001; Wagner et al., 1998). The constitutively 
activated NF-B has also been shown to induce changes in the expression of a set of proteins 
regulating cell cycle progression and gene transcription, including cyclin D1, p53, p16 
INK4a, and p27KIP1 (Hinz et al., 2001; Sanchez-Beato et al., 2003). Cytotoxic cells are able to 
induce directly the permanent down-regulation of p27KIP1, probably as a consequence of 
increased degradation mediated by SKP2, a ubiquitin ligase for p27KIP1 (Blanchard et al., 
1997; Ren et al., 2005; Wagner et al., 1998). Related with the heightened proliferative state in 
these tumors is the high level of expression of Bcl6, a multifunctional regulator that is able 
not only to down-regulate cyclin D2 and p27KIP1 expression (Shaffer et al., 2000) but also to 
repress Bcl-XL (Tang et al., 2002).  
The presence of EBV was significantly associated with the overexpression of STAT1 and 
STAT3. STAT3 was found to be associated with a low infiltration of CD4 T lymphocytes and 
a high infiltration of activated cytotoxic cells. Although STAT1 is considered to be a 
potential tumor suppressor (promoting apoptosis), STAT3 is thought to be an oncogene 
because it leads to the activation of cyclin D1 and Bcl-XL expression and is involved in 
promoting cell cycle progression and cellular transformation and in preventing apoptosis 
(Calo et al., 2003).  
The physiologic relevance of these relationships could be related to the different 
probabilities of survival of HL patients. Different sets of deregulated immune and tumoral 
genes have shown to be associated with a therapeutically unfavorable response in HL 
patients (Sanchez-Aguilera et al., 2006). For example, altered expression of bcl-2 and the bcl-
2 family of proteins (e.g., bcl-Xl, BAX) in H/RS cells may prevent apoptosis and explain 
resistance to treatment-induced apoptosis. Under these conditions, the concomitant analysis 
of the immune infiltrate and the apoptotic/proliferative pathways of tumoral cells should 





cell growth. Possible molecules that interfere with these molecular links, particularly some 
enzymes representative of the immune metabolic state or tumoral cell cycle (Sanchez-
Aguilera et al., 2006), might be pharmaceutically manipulated and could be candidates for 
new therapeutic targets pertinent to patient care.  
9. HL in immunosuppressed patients  
Epidemiologic and molecular findings suggest that cHL is not a single disease but consists 
of more than one entity and may occur in different clinical settings. According to the 
acknowledged international literature (Swerdlow et al., 2008a), cHL arises either in the 
general population (Stein et al., 2008a) but also in the immunosuppressed host, specifically 
in HIV-infected individuals (Raphael et al., 2008), and in post-transplant patients, most often 
in renal post-transplant patients (Swerdlow et al., 2008c). 
From a clinical perspective, HIV-infected HLs have some peculiarities. Firstly, it must be 
distinguished two eras, before and after the widespread use of highly active antiretroviral 
therapy (HAART) (Powles et al., 2009). Before HAART, HIV-HL patients were generally 
diagnosed with an aggressive presentation. Advanced stages were the rule at diagnosis with 
frequent involvement of extranodal sites, particularly bone marrow, liver and spleen. In 
addition, up to 95% of patients had systemic B symptoms when diagnosed, and 
consequently survival rates were extremely disappointing (Tirelli et al., 1995). Nevertheless, 
introduction of HAART have led to forms of presentation less aggressive, a dramatic 
reduction in the incidence of opportunistic infections, and finally it have allowed to 
complete curative treatment with chemotherapy in most of the patients (Carbone et al., 
2009). Regarding chemotherapy, optimal treatment for HIV-HL has not been definitely 
established due to the relatively low incidence of this disease. However, little phase II 
studies with few patients have found that, in this modern HAART era, standard ABVD 
treatment may be safely administered with or without growth-colony stimulating factors 
(G-CSF) support (Xicoy et al., 2007), although some groups argue in favor of G-CSF 
introduction from the beginning to minimize risks. Prophylaxis against Pneumocystis 
jiroveci infection with trimethoprim-sulfamethoxazole is also strongly recommended in all 
these patients. Other more intensive regimens like BEACOPP or Stanford V with 
consolidation radiotherapy have been tested with acceptable results in terms of complete 
responses (100% and 81%, respectively), although a higher incidence of opportunistic 
infections and hematologic toxicity were registered. Finally, even the use of high dose 
chemotherapy and autologous stem cell transplantation have been demonstrated feasible in 
HL-HIV relapsed patients with curative purposes (Carbone et al., 2009). To conclude, it 
must be said that clinical outcomes of patients with HIV-HL has improved after HAART 
introduction, with higher curability rates when a combined antineoplastic and antiretroviral 
strategy is followed and completed. 
Post-transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of 
monoclonal or polyclonal lymphoproliferative lesions that occur in immunosuppressed 
recipients after solid-organ or bone marrow transplantation. cHL occurs in the post-
transplant setting, most often in renal transplant patients, is almost always EBV-positive and 
should complete the diagnostic criteria for cHL (Adams et al., 2009; Knight et al., 2009; 
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immunosuppression and/or antiviral agents (Dharnidharka et al., 2004; Goyal et al., 1996; 
Krishnamurthy et al., 2010). Clinically, the majority of patients are men and all ages are 
affected. Generally, the time from transplant to the onset of the disease ranges from few 
months (4–6 months) to several years, with a median time of 113 months. Half cases 
presented as extranodal masses, especially in the liver or in the lung even if other extranodal 
sites (especially tonsil) can be involved. The best therapeutic approach is not well defined 
yet. Recently, rituximab has gained favor in the treatment of PTLD because of its targeting 
of CD20-positive B cells, with fairly promising results (Pham et al., 2002). 
The iatrogenic lymphoproliferative disorders are lymphoid proliferations or lymphomas 
that arise in patients treated with immunosuppressive drugs. Among iatrogenic 
lymphoproliferative disorders, other than PTLD, there is an increase in frequency of cHL 
and lymphoid proliferations with Hodgkin-like features. Thus, lesions containing RS-like 
cells but do not fulfill the criteria of CHL, the so-called Hodgkin-like lesions, have been 
included in this setting (Gaulard et al., 2008). Because CHL has only recently been 
recognized as an iatrogenic complication, few cases have been reported in the medical 
literature (Gaulard et al., 2008). 
10. Antineoplastic therapy in HL: From classical to biological therapies  
Chemotherapy and radiotherapy remain the cornerstone of HL treatment. Especially, 
polychemotherapy schedules have increased the survival rates in these patients along the 
last decades. Nevertheless, up to 30% and 10% of patients will recur and die of HL in 
advanced and early disease respectively, and unlike what happened in non Hodgkin 
lymphomas, newer active compounds against HL have not been introduced in clinic since 
the early 1970s. In addition, patients exposed to chemotherapy and radiation fields are at 
highest risk of lethal second malignancies (Friedberg, 2011). Therefore it would be more 
than desirable having new therapeutic drugs and strategies for a better control of the disease 
and minimizing toxicity of therapy, especially when relapses occur. 
10.1 Conventional treatment 
Nowadays HL is considered one of the most oncological curable diseases, as a matter of fact 
of its extremely chemo and radiosensitivity. Among chemotherapy options, ABVD 
(doxorubicin, bleomycin, vinblastine and dacarbazine) represent the standard schedule for 
HL treatment in the majority of centers worldwide. However the management of advanced-
stage cHL is often predicated on the IPS, and thus escalated BEACOPP (bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) is 
another schedule to consider, especially in high-risk patients with IPS scores of 4 or greater 
(Diehl et al., 2003). Therefore, an apparently more effective initial treatment may be 
unattractive because of increased toxic effects (Connors, 2011) and highest risk of second 
malignancies, especially in relation with large radiation fields (Ng et al., 2002). 
Canellos et al showed in 1992 that ABVD was equally effective and less toxic than MOPP 
(mechlorethamine, vincristine, procarbazine, prednisone)  or MOPP alternating with ABVD, 
and this has subsequently become the chemotherapy of choice worldwide (Canellos et al., 
1992). Although standard ABVD can cure most of HL, advanced stage- high risk patients 





Diehl, 1998). The HD9 trial conducted by Diehl et al showed that among patients with 
advanced-stage cHL, ABVD is insufficient for patients with an IPS of 4 or more (Diehl A et 
at, 2003). In this trial of the German Hodgkin Study Group (GHSG), 1,195 patients with 
advanced-stage HL were recruited and randomized between COPP-ABVD, standard 
BEACOPP, and escalated BEACOPP. For patients with an IPS of 4 or greater, the more 
intensive regimen improved the freedom from treatment failure from 59% to 82% and OS 
from 67% to 82%. It is important to underscore that there was no significant difference for 
the more favorable groups. A 10-year update of this study confirms superiority of escalated 
BEACOPP over COPP-ABVD for the high-risk patients (Diehl et al., 2003). However, there is 
increased late toxicity with escalated BEACOPP, with more risk of sterility, infections and 
secondary leukaemia’s, and thus universal application of this schedule for advanced-stage 
disease remain difficult to implement.  
In addition of chemotherapy, radiotherapy is another treatment modality frequently used in 
HL. It is generally indicated in early disease, regardless of the favorable/unfavorable 
stratification, and when bulky disease is present, or there remain residual foci of disease 
after chemotherapy in advanced HL. 
10.2 Impact of chemotherapy and radiotherapy on tumoral microenvironment 
In the last few years, many interesting data have emerged about the enormous impact of the 
antineoplastic treatments into the immune microenvironment of the tumors, which 
demonstrate a sort of cancer vaccination effect (Haynes et al., 2008). In this sense, 
chemotherapeutics like anthracyclines (included in all of the upfront standard treatments of 
HL) and radiotherapy seem to induce a type of apoptotic death via calreticulin exposure and 
release of the pro-inflammatory factor High Mobility Group Box-1 (HMGB1) with well 
known immune stimulating properties (Tesniere et al., 2008). 
Anthracyclines can induce a highly potent immune response by increasing antigen 
(neoantigens) threshold and presentation (via antigen presenting cells), with enhancement 
of T-cell response and generation of memory T cells (Obeid et al., 2007a). Other 
chemotherapeutics like cyclophosphamide, etoposide and taxanes have also proved to have 
an immunogenic effect in preclinical models (Tsavaris et al., 2002), however evidence is 
scarce and further investigation is required.  
These new concepts might serve to consider chemotherapeutics like anthracyclines as less 
empirical and more specific drugs, and thus it would be desirable to customize 
chemotherapies taking into account their potential effects on microenvironment. In this 
sense, there is an interesting field of clinical research to discover that may combine classical 
CT agents with immunogenic effects with boosting costimulators molecules like cytokines 
(GM-CSF, IL2) (de la Cruz-Merino et al., 2008). Specifically in the case of the anthracycline´s 
effect on cancer cells, the calreticulin exposure do not induce DC maturation which is, on the 
contrary, one of the main effects of cytokines like GM-CSF that induce selective DC 
maturation and activation, giving a strong rationale to combine these two therapeutic 
modalities (anthracyclines and GM-CSF). These combinatorial strategies may eventually 
sustain immunogenic effect of tumoral cell death. Regarding to this, biomarkers of immune 
activity should be of the greatest interest, in order to serve as proof of principle of efficacy 
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an immunogenic effect in preclinical models (Tsavaris et al., 2002), however evidence is 
scarce and further investigation is required.  
These new concepts might serve to consider chemotherapeutics like anthracyclines as less 
empirical and more specific drugs, and thus it would be desirable to customize 
chemotherapies taking into account their potential effects on microenvironment. In this 
sense, there is an interesting field of clinical research to discover that may combine classical 
CT agents with immunogenic effects with boosting costimulators molecules like cytokines 
(GM-CSF, IL2) (de la Cruz-Merino et al., 2008). Specifically in the case of the anthracycline´s 
effect on cancer cells, the calreticulin exposure do not induce DC maturation which is, on the 
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with an earlier detection of the eventual benefits of oncological treatments in patients. 
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Furthermore, monitoring changes detected during oncological treatments in blood samples, 
especially in immunophenotype, regulatory T cells amount and TCD8/regulatory T cells 
ratio, may represent interesting biomarkers to analyze and validate in the future. 
As happen with chemotherapy, the intrinsic radiosensitivity of malignant lymphocytes is 
extremely high. Although the underlying mechanisms which explain it are not fully 
elucidated, recently new evidence is emerging about some changes induced by radiation at 
a molecular level, which may provoke a type of cell death highly immunogenic (Formenti & 
Demaria, 2009). Ionising radiation has different immune effects regarding the dose 
administered, and while in the case of low doses the final effect is mostly protumorigenic, at 
higher doses with cytotoxic activity, cell death may induce tumoral neoantigens which can 
be embraced by DC, and thus activate an effective adaptive immune response (Apetoh et al., 
2007). As with anthracyclines, the two critical mediators of this process seem to be 
translocation of calreticulin to the cell surface and release of HMGB1 by the dying cells 
(Formenti & Demaria, 2009). Both of them trigger danger signals which activate immune 
mechanisms. In addition, surviving cancer cells after radiation show increased expression of 
death receptors, adhesion molecules (ICAM-1) and major histocompatibility complex class I 
(MHC-I), which activate APCs (Obeid et al., 2007b). 
To conclude, some groups argue that these immune effects are the major determinants of the 
therapeutical success of the antineoplastic treatments in oncological diseases, including HL. 
10.3 Modern therapeutic approaches targeting the tumor microenvironment 
Apart from chemotherapy and radiotherapy, other biological compounds with significant 
effects upon tumor microenvironment like unconjugated and conjugated monoclonal 
antibodies, radioimmunconjugates, immunotoxins and novel immunomodulatory 
compounds like lenalidomide are under clinical investigation, and at this moment they 
represent the most promising therapeutical strategies in HL. Recently, Kasamon et al 
revised this topic (Kasamon & Ambinder, 2008) and pointed out three major HL therapeutic 
targets: EBV, CD20 and CD30.  
As previously cited, up to 40-60% of cHL might be associated with EBV and thus some EBV 
antigens expressed on HL cells like latent membrane protein 1 and 2 (LMP1 and LMP2) 
have been postulated as eventual immunotherapeutic targets. Some interesting results have 
been obtained with the use of adoptive cellular immunotherapy with EBV-specific CTL 
among patients with EBV-associated posttransplant lymphoproliferative diseases (Haque T 
et al., 2007), rendering a proof of principle of activity for this approach. In a small study of 
16 patients with relapsed or high risk EBV+ lymphoproliferative diseases that included cases 
of HL, infusions of autologous LMP2- specific CTL induced clinical responses with tumor 
regression in 5 of 6 patients with previously detectable tumor (Lucas et al., 2004). 
After elucidation of the B cell origin of H/RS in classical HL, targeting B cell antigens on HL 
has gained renewed interest. Specifically in classical HL, the monoclonal antibody anti-
CD20 Rituximab has shown activity as single agent or combined with chemotherapies like 
ABVD and gemcitabine in different clinical settings (Kasamon & Ambinder, 2008). Impact of 
rituximab on tumor microenviroment by depleting benign CD20+ cells, is postulated as the 
main antineoplastic mechanism of action of this drug in HL, independently of CD20 





lymphocyte predominant Hodgkin lymphoma, with impressive clinical results (Rehwald et 
al., 2003; Ekstrand et al., 2003) that merit further investigation. 
Among new molecular targets in HL, the member of the tumor necrosis factor (TNF)-
receptor family CD30 merits special consideration. CD30 is expressed abundantly on RS 
cells of HL, and in other numerous lymphoid malignancies of B-, T-, and natural killer (NK)-
cell origin (Deutsch et al., 2011). Regarding its biological activity CD30 has pleiotropic 
biologic functions, being capable of promoting cell proliferation and survival as well as 
inducing antiproliferative responses and cell death. Final effects of CD30 activation seem 
largely dependent  on the microenvironment context (Deutsch et al., 2011). Unconjugated 
anti-CD30 antibodies have been tested in phase I and II studies showing limited clinical 
activity (Kasamon & Ambinder, 2008).  On the contrary, another attractive approach as it is 
the use of antibody–drug conjugates (ADCs) have rendered better results.  
Brentuximab vedotin (SGN-35) is an ADC consisting of chimeric anti-CD30 antibody cAC10 
(SGN-30) conjugated to the tubulin destabilizer monomethylauristatin E (MMAE) (Okeley et 
al., 2010). In an initial phase I dose escalation study, brentuximab vedotin was administered 
at a dose of 0.1–3.6 mg/kg every 3 weeks to 45 patients with relapsed or refractory CD30-
positive lymphomas, primarily HL and ALCL (Younes et al., 2010). Brentuximab vedotin 
was well tolerated and associated mainly with grade 1 or 2 adverse events including 
neutropenia and peripheral neuropathy. Objective response was observed in 17 (38%) 
patients, including 11 (24%) complete remissions, with a median duration of response of 9.7 
months. Tumor regression was observed in 86% of patients. The maximum tolerated dose 
was 1.8 mg/kg, and of 12 patients who received this dose, six patients (50%) had an 
objective response (Younes A et al, 2010). A second phase I study, with weekly brentuximab 
vedotin resulted in an objective response rate of 59% and rapid median time to response. 
Anti-tumor activity was similar to that observed for dosing once every 3 weeks. However, 
significant peripheral neuropathy was observed with continued weekly dosing, so the 
administration every 3 weeks was preferred for phase II studies (Deutsch et al., 2011). 
Clearly, brentuximab vedotin is an exciting new agent in the setting of relapsed HL and 
other lymphoid neoplasms CD30+. Multiple clinical trials are ongoing including different 
clinical settings and combinations with chemotherapy, in order to find the safer and more 
successful way of administering this drug. 
11. Body’s own power protection challenges in HL 
Evidences in the literature suggest that targeting elements of the tumor microenvironment, 
or signaling pathways in tumor cells activated as a consequence of stromal interactions, may 
prove a useful therapeutic strategy to prevent tumor development and progression. 
However, given the tumor cells’ ability to circumvent various therapeutic agents when 
given as monotherapy, the success of these agents is likely to be seen when used in 
combination with existing treatments. 
Apart from the infiltrating immune competent cells, the complex tissue network of the 
tumor microenvironment is also formed by neoangiogenesis, stromal cells, and a 
differentiated and specific extracellular matrix. Among stromal cells, there are 
macrophages—derived from hematopoietic stem cells, fibroblasts, adipocytes, and 
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or signaling pathways in tumor cells activated as a consequence of stromal interactions, may 
prove a useful therapeutic strategy to prevent tumor development and progression. 
However, given the tumor cells’ ability to circumvent various therapeutic agents when 
given as monotherapy, the success of these agents is likely to be seen when used in 
combination with existing treatments. 
Apart from the infiltrating immune competent cells, the complex tissue network of the 
tumor microenvironment is also formed by neoangiogenesis, stromal cells, and a 
differentiated and specific extracellular matrix. Among stromal cells, there are 
macrophages—derived from hematopoietic stem cells, fibroblasts, adipocytes, and 
osteoblasts.  In order to delay or circumvent tumor progression, a number of strategies are 
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being developed to disrupt tumor-stroma interactions (Hiscox et al., 2011). Macrophages 
and fibroblasts within the tumor microenvironment present an important point for 
therapeutic intervention by using agents which reverse their phenotype or block key growth 
factor receptors (Allavena et al., 2005; Banciu et al., 2008; Hagemann et al., 2008; Hiscox et 
al., 2011; Karin & Greten, 2005). On the other hand, the regulation of adhesion between 
cancer cells and the surrounding matrix by different kind of integrins activates tumor cell 
signaling pathways that result in growth progression, invasion and migration (Green et al., 
2009; Hiscox et al., 2011; Inoki et al., 2002; Kim et al., 2009; Parsons et al., 2008; Stupp & 
Ruegg, 2007).  
The different immunotherapeutic models that have been tested for the treatment of HL 
include unconjugated monoclonal antibodies (Ansell et al., 2007; Bartlett et al., 2008; Klimm 
et al., 2005), immunotoxins (Falini et al., 1992; Kreitman et al., 2000),  
radioimmunoconjugates (Klimm et al., 2005; Schnell et al., 2005) and, most recently, 
immunomodulatory compounds (Bollard et al., 2004; Borchmann et al., 2002; Davies et al., 
2001; Hartmann et al., 2001; Hartmann et al., 1997; Maier & Hammond, 2006; Roskrow et al., 
1998). Some strategies, in particular radioimmunotherapeutic approaches and 
immunotoxins have already shown significant effectivity (Friedberg, 2011). First experiences 
with relatively non-toxic immunomodulatory compounds have implemented a whole new 
kind of immunotherapy in NLPHL where the anti-CD20-antibody Rituximab might be the 
future effective but less toxic treatment (Ekstrand et al., 2003; Schulz et al., 2008). 
The integration of the new biologic markers evaluated in HL, that clearly driving force for 
an abnormal local and systemic antitumor immunity in HL, make of HL an ideal candidate 
for immunotherapeutic strategies (Rathore & Kadin, 2010; Younes, 2009). The pro-survival 
and pro-death receptors expressed by tumoral cells are currently being explored for novel 
treatment strategies by using a variety of naked and conjugated monoclonal antibodies. 
Furthermore, signaling pathways triggered by these receptors and other intracellular 
proteins can now be therapeutically inhibited by a variety of small molecules. Nowadays, 
the present challenge remains to know the best way to implement immunotherapeutic 
concepts into the current treatment concepts of HL in order to conserve or even improve the 
good long term survival in these patients and to reduce toxicity and long-term side-effects. 
12. Conclusion 
Although the relatively good prognosis and high current overall cure rate of cHL, it is 
important to underscore that clinicobiological factors still remain the main information to 
guide treatment policies in HL. Due to the fact that this disease is commonly diagnosed in 
young population, and antineoplastic treatments may induce worrying iatrogenic 
consequences in terms of secondary tumors (solid and hematologic malignancies), 
cardiopathies or respiratory long-term morbidities among others, it is indispensable to 
administer always the minimum effective and curative therapy. In this sense, beyond the 
well known clinical risk factors, interim information in the course of chemotherapy of PET 
scans will probably aid in the next future to apply a less empiric and more tailored and 
personalized treatment. Since early 90´s ABVD schedule represent the standard treatment of 
HL for curative purposes worldwide and little has changed in clinical practice in the last 
two decades. However there is room for improvement since a significant percentage of 





The recent research activities led to a better understanding of the phenotype, molecular 
characteristics, histogenesis, and possible mechanisms of HL lymphomagenesis. There is 
complete consensus on the B-cell derivation of the tumor in most cases, and on the relevance 
of EBV infection and defective cytokinesis in at least a proportion of patients. The influence 
of the cellular components of the microenvironment and that of the elaborate network of 
interactions they produce, on the clinical course of HL, has progressively emerged over the 
past decades. The expression of a variety of cytokines and chemokines by the tumoral cells 
is believed to drive an abnormal immune response and additional factors secreted by 
reactive cells in the microenvironment help to maintain the inflammatory milieu. In these 
conditions, tumoral cells manipulate microenvironment, permitting them to develop their 
malignant phenotype fully and evade host immune response attack. The interplay between 
tumoral cells and the reactive microenvironment determines not only the histological 
morphology and classification but also the clinicopathological features and prognosis of 
these patients. Genes and proteins expression signatures derived from immune cells have 
demonstrated to correlate well with response to treatments the outcome of HL patients 
respectively. This could be critical to the development of adoptive T-cell therapies that 
target the virus or different cell components of HL microenvironment. In aggressive HL, the 
development of prognostic systems modelled on the integration of biologic prognostic 
markers appears essential for more appropriate risk stratification.  
New knowledge about impact of chemotherapy upon microenvironment has changed old 
paradigms, conferring to some cytotoxic agents like anthracyclines immunogenic properties 
that can explain the final mechanism of action of these drugs. These discoveries are 
extremely important since give a strong rationale to exploit this activity in the context of 
combinatorial strategies that might include other immunogenic agents like cytokines and 
monoclonal antibodies, among others. Therefore, it is conceivable to hypothesize that 
chemotherapy can still improve its efficacy in HL in the next future. Furthermore, recently 
new molecules have shown impressive clinical activity in HL. It is the case of the antibody-
drug conjugate anti-CD30 brentuximab vedotin that have obtained very promising results in 
relapsed CD30+ lymphomas, and thus has given place to ongoing phase III confirmatory 
studies.  
To summarize, the incorporation of PET scans in HL diagnostic and follow-up algorithms, 
the widespread use of the new prognostic molecular and biological factors at diagnosis, the 
new highly effective molecules and the recent knowledge regarding chemotherapy effects 
on microenviroment, permit forsee a different and customized therapeutical approach to HL 
in the next future. 
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1. Introduction 
Hodgkin lymphoma (HL) is an uncommon lymphoid malignancy which accounts for about 
0.5% to 1% of all cancers. In 2010, an estimated 8,490 new cases and 1,320 deaths will occur 
in the United States (Jemal, Siegel, Xu, et al, 2010). HL incidence appears to be stable over the 
past few decades, in contrast to the incompletely understood continued increase in 
frequency of non-Hodgkin lymphomas. HL has a bimodal incidence with most patients 
diagnosed in the third decade, followed by another peak in adults aged 55 years or older. 
There has been correlation between incidence of certain histologic sybtypes of HL and age 
and sex; for example, nodular-sclerosis HL is more common  in women and young adults in 
contrast to mixed cellularity HL which is more common in men and lymphocyte-rich HL 
which is more common in older males (Correa, O'Conor, Berard, et al, 1973).  
The cause of HL remains unknown, but there has been some progress in identifying risk 
factors in development of HL. Factors associated with HL include genetic predisposition 
(increased incidence in certain ethnic populations such as Jews and in first degree relatives 
such as siblings, twins and children), viral exposures, and immune suppression (Bernard, 
Cartwright, Darwin, et al, 1987; Glaser & Jarrett, 1996; Lynch, Marcus & Lynch, 1992; Mack, 
Cozen, Shibata, et al, 1995). Epstein-Bar virus (EBV) has been implicated in the etiology of 
HL based on epidemiological and serologic studies (Weiss, Strickler, Warnke, et al, 1987), as 
well as by the detection of the EBV genome in tumor specimens of about half of HL nodes. 
Moreover, HIV-infected patients have been noted in many studies to have a significantly 
increased risk of HL with the majority of patients presenting with advanced stages, having 
extranodal involvement and unfavorable histological subtypes, and associated with a poorer 
outcome after initial therapy (Levy, Colonna, Tourani, et al, 1995; Tirelli, Errante, Dolcetti, et 
al, 1995). 
The past few decades have seen major advances in treatment of HL using both, radiation 
therapy (RT) and chemotherapy. With advances in combination chemotherapy regimens and 
RT techniques over the past four-five decades, HL has changed from an incurable disease to 
one with the best survival rates to date among other cancers. HL is currently curable in 85% to 
95% of cases, depending on disease stage at time of diagnosis and other risk factors (Diehl, 
2007). In the H8-F trial, Ferme’ et al. reported a 10-year overall survival (OS) estimates of 97% 
in early-stage disease (Ferme, Eghbali, Meerwaldt, et al, 2007). In fact, cure rates for HL have 
increased so extensively that the overriding treatment considerations often relate to long-term 
toxicity, especially for patients with early- or intermediate-stage disease (Hoppe, Advani, Ai, et 





the potential long-term effect of treatments remain an important consideration as well. New 
innovative treatment strategies are clearly needed for the refractory and recurrent disease, as 
the cure rates in these patients are still low, especially for those who relapse after autologous 
stem cell transplantation (ASCT). 
In this chapter, we will discuss briefly the initial workup and staging at the time of 
diagnosis with brief review of the role of positron emission tomography (PET) scan in HL. 
We will then go through the revised response criteria, followed by a thorough review for the 
management of early stage HL including the various definitions of the favorable and 
unfavorable risk groups as determined by major study groups. Management of HL in 
specific populations such as the NLPHL, elderly, and pregnant patients will be reviewed in 
this chapter as well.  
2. Diagnosis/staging 
Hodgkin lymphomas are defined as lymphomas containing one of the characteristic types of 
Reed-Stenberg (RS) cells in a background of nonneoplastic cells. Based on the morphology 
and immunophenotype of the RS cells and the composition of the cellular background, the 
WHO classification system published in 2001 divided HL into two disease entities: classical 
HL (cHL) which accounts for 95% and nodular lymphocyte-predominant HL (NLPHL) 
which accounts for 5% of all HL cases. cHL is further divided into 4 subtypes: nodular 
sclerosis (grades I or II), mixed cellularity, lymphocyte depleted, and lymphocyte-rich cHL 
(Diehl V, 2005b; Harris, Jaffe, Diebold, et al, 1999; Jaffe ES, 2001). cHL and NLPHL share the 
same diagnostic workup, though they have different natural history and distinctive 
morphologic and immunophenotypic features (Table 1), and ultimately different approach 
of therapy. 
 
  Classic HL NLPHL 
Pattern Diffuse, interfollicular, nodular Nodular, at least in part 
Tumor cells Diagnostic RS cells; mononuclear or lacunar cells L&H or popcorn cells 
Background Lymphocytes (T cells > B cells), histiocytes, 
eosinophils, plasma cells 
Lymphocytes (B cells > 
T cells), histiocytes 
Fibrosis Common Rare 
CD15, CD30 + – 
CD45 & CD57 + 
T cells – + 
EMA – + 
CD20 ± + 
EBV (in RS cells) + (~50%) – 
Nuclear bcl-6 
protein – + 
Ig genes (single-
cell PCR) Rearranged, clonal, mutated, "crippled" 
Rearranged, clonal, 
mutated, ongoing 
EBV, Epstein-Barr virus; EMA, epithelial membrane antigen; Ig, immunoglobulin; L&H, lymphocytes 
and histiocytes; PCR, polymerase chain reaction; RS, Reed-Sternberg. 
Adapted from De Vita et al. Cancer. Principles & practice of oncology. Philadelphia: Lippincott 
Williams and Wilkins; 2005. 
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Table 1. Morphologic and Immunophenotypic Features of cHL Compared to NLPHL. 
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Diagnosis of HL should always be established by a tissue biopsy; though a core needle 
biopsy may be adequate, an excisional lymph node biopsy is preferred and highly 
recommended. FNA alone is generally insufficient for the evaluation of architecture and for 
immunophenotyping, and should be avoided (Caraway, 2005; Hehn, Grogan & Miller, 2004; 
Meda, Buss, Woodruff, et al, 2000). Rarely, multiple LN biopsies may be necessary for the 
diagnosis, as the cytokines associated with HL can produce reactive hyperplastic changes in 
adjacent lymph nodes (Ansell & Armitage, 2006).  
Though it might not be necessary for typical cases of cHL, immunohistochemistry staining is 
recommended for accurate diagnosis of any case of HL with atypical features and many cases 
of NLPHL. cHL is usually positive for CD15 and CD30, but negative for CD3 and CD45. 
NLPHL usually stains positive for CD45 and CD20, but negative for CD15, and rarely 
expresses CD30 (Hoppe, Advani, Ai, et al, 2011)(Table 1). Also, in contrast to NLPHL, the RS 
cells of cHL lack the nuclear bcl-6 protein associated with follicle center B cells (Falini B, 1995). 
Staging of HL is based on the Ann Arbor staging system that was developed in 1971 
(Carbone, Kaplan, Musshoff, et al, 1971) and further modified in 1989 through a consensus 
meeting held in Cotswolds, England (Lister, Crowther, Sutcliffe, et al, 1989) (Table 2). 
 
Stage Definition/Disease Involvement 
I Involvement of a single lymph node region (I) or a single extralymphatic site (IE).  
II Involvement of two or more lymph node regions on the same side of the diaphragm 
(II) or localized involvement of only one extranodal organ or site and of ≥1 lymph 
node regions on the same side of the diaphragm (IIE).  
III Involvement of lymph node regions on both sides of the diaphragm (III), which may 
also be accompanied by involvement of the spleen (IIIS) or by localized involvement 
of an extranodal organ or site (IIIE) or both (IIIS + E).  
IV Diffuse involvement of one or more extranodal organs or sites, with or without 
associated lymph node involvement.  
Each Stage may be subdivided into: 
A No symptoms. 
B General symptoms include any of the following: fever (unexplained temperatures 
>38°C over the preceding one month), drenching night sweats, unexplained loss of 
>10% body weight within the preceding 6 months.  
X Bulky disease which is defined by any nodal mass with a maximal dimension ≥10 cm 
or a mediastinal mass exceeding one third of the widest transverse transthoracic 
diameter measured on a standard PA chest radiography.  
E Involvement of a single extranodal site that is contiguous or proximal to the known 
nodal site.  
Table 2. Modified Ann Arbor Staging System for HL. 
Initial staging evaluation starts with a detailed history and physical examination. History 
should focus on the presence or absence of systemic B symptoms (unexplained fevers >38 °C 





body weight within the preceding 6 months), performance status, pruritus, alcohol intolerance, 
and any history of prior cancers and treatments received (chemotherapy and/or RT). Of 
notice, cHL compared to NLPHL, presents more commonly with B symptoms (about one third 
of patients with HL), pruritus, alcohol-induced pain, and extra nodal disease involvement. 
Physical examination should be focused on all lymphoid regions in addition to the liver and 
spleen.  
The National Comprehensive Cancer Network (NCCN) established certain laboratory and 
radiographic studies which are recommended at the initial evaluation of patients with HL. 
These include (NCCN, v.2.2011) CBC with differential and platelets, ESR, LDH, albumin, 
liver and kidney function tests, and a pregnancy test for women of childbearing age. An 
adequate bone marrow (BM) biopsy should be performed for stages IB-IIB and stages III-IV 
disease. More invasive procedures such as liver biopsy, diagnostic laparotomy, or 
splenectomy are restricted to a very small subgroup of patients where initial staging is 
inconclusive. Radiographic studies should include at least chest x-ray and diagnostic 
computed tomography (CT) of the chest, abdomen and pelvis. CT-PET scan has become an 
integral part of initial staging as well. Neck CT is recommended if RT is planned. 
2.1 Role of PET in HL 
The role of PET in HL has been markedly evolving over the past few years. It has been used 
and shown to have high positivity and specificity for initial staging and restaging in patients 
with lymphoma (Isasi, Lu & Blaufox, 2005; Seam, Juweid & Cheson, 2007). In a review done 
by Juweid ME (Juweid, 2006a), the use of PET scan in HL results in a modification of disease 
stage (usually upstaging) in about 15-20% of patients with an impact on management in 
about 5-15%. However, it remains unclear whether patients would benefit from a 
subsequent change in the treatment plan, and therefore, the value of PET for initial staging 
of HL patients outside a clinical trial is still debatable. On the other hand, as reviewed by 
Juweid, response assessment after completion of therapy is currently the most widely 
utilized application of restaging PET in HL and can be considered the standard of care for 
post treatment assessment of patients with HL. In this setting, PET shows an excellent 
negative predictive value between 91 and 95% in several studies, but the positive predictive 
value is substantially lower and considerably more variable averaging approximately 65% 
(de Wit, Bohuslavizki, Buchert, et al, 2001; Juweid, 2006a; Weihrauch, Re, Scheidhauer, et al, 
2001). To decrease the false positive results, the International Harmonization Project (IHP), 
recommends that PET not be performed for at least 3 weeks following chemotherapy and 
preferably 8-12 weeks after completion of radiotherapy (Juweid, 2006b). The role of PET 
scan for routine post therapy surveillance remains controversial, primarily because of the 
potential for a disproportionate fraction of false-positive findings, potentially resulting in 
increasing cost without proven benefit from earlier PET detection of disease compared to 
standard surveillance methods (Cheson, Pfistner, Juweid, et al, 2007; Jerusalem, Beguin, 
Fassotte, et al, 2003). 
Another evolving and interesting use of PET scan is in the assessment of early response; 
interim PET scan findings has been significantly correlated with treatment outcomes in 
terms of progression-free survival (PFS) and OS. Recently, PET scanning was proposed to 
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terms of progression-free survival (PFS) and OS. Recently, PET scanning was proposed to 
assist in determining the choice of therapy. Patients with negative PET scans after 2-3 cycles of 
 
Treatment of Early Stage Hodgkin Lymphoma 
 
117 
treatment are being considered for an abbreviated course of chemotherapy alone, whereas 
those with positive PET scan are treated in a more standard fashion with the combined 
modality. The ongoing United Kingdom (RAPID trial) is testing whether PET scanning can 
guide therapy in early HL after 3 cycles of chemotherapy; PET-negative patients are 
randomized to involved field RT (IF-RT) versus observation while PET-positive are treated 
with 4th cycle ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by IFRT. The 
recently initiated EORTC/GELA H10 Intergroup trial is comparing ‘standard therapy’ to PET-
based response-adapted therapy (i.e. PET after 2 cycles ABVD) for favorable and intermediate 
group patients with early-stage HL. 
3. Response criteria 
Uniform and standardized criteria for assessment of initial treatment response are essential 
since they guide for additional treatment and are required for interpreting and comparing 
clinical trials. Hence, the International Working Group (IWG) published guidelines for non-
Hodgkin’s lymphoma response criteria first time in 1999 (Cheson, Horning, Coiffier, et al, 
1999; Cheson, Pfistner, Juweid, et al, 2007). The HL study groups have adopted these IWG 
criteria which were based on the size reduction of the enlarged lymph nodes (as measured 
with CT scan) and the extent of BM involvement; bone marrow aspirate and biopsy should 
only be performed to confirm a CR if they were initially positive or if it is clinically indicated 
by new abnormalities in the peripheral blood counts or blood smear. 
The IWG guidelines were revised in 2007, by the IHP, after incorporating the PET scans, 
immunohistochemistry, and flow cytometry in the definitions of response for both NHL and 
HL (Table 3). Using the revised system, response is simplified to complete response (CR), 
partial response (PR), stable disease (SD), relapsed disease, or progressive disease (PD) (see 
table 3). CRU (complete response uncertain) category was eliminated from the new 
guidelines, based on the improved ability of PET scans to distinguish between viable tumor 
and necrosis or fibrosis in residual masses present after treatment (Buchmann, Reinhardt, 
Elsner, et al, 2001; Jerusalem, Beguin, Fassotte, et al, 1999; Jerusalem, Warland, Najjar, et al, 
1999; Wirth, Seymour, Hicks, et al, 2002).  
More recently integrated PET/CT scan, which combines a PET and a CT scan in a single 
study, has been shown to provide at least equal information to that obtained separately by 
PET and CT scans. This is supported mostly by retrospective and small trials (Juweid, 
2006a). The recent increase in use of combined PET/CT scans may further help in distinction 
between viable and nonviable tumors. 
4. Treatment 
4.1 Background 
Traditionally, treatment modality for HL had been chosen based on clinical stage. Early-
stage HL includes the limited stages I, II, and IIIA  whereas advanced HL includes stage IIIB 
and stage IV, according to the Cotswolds modification of the Ann Arbor classification 
(Josting, Wolf & Diehl, 2000). Major advances in treatment modalities over past 3 decades 
made early stage HL highly curable with rates achieving up 97% after 10-year follow up as 
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early stage HL made the focus of recent studies on minimizing acute and late therapy related 
toxicities without decreasing the excellent treatment outcomes. Hence, there have been various 
attempts to modify different treatment modalities such as omitting RT, decreasing the dose 
and/or field of RT, and modifying the chemotherapy. In order to maintain efficacy and 
decrease toxicity, clinical investigators, through major randomized studies, were able to 
identify adverse prognostic factors that may predict treatment outcomes in different groups of 
patients. We will discuss and define below these risk groups according to published data from 
major study groups in Europe and North America. Subsequently, we will discuss the 
management of early stage HL according to different risk groups. 
4.2 Definitions of favorable and unfavorable early-stage HL 
In addition to the clinical stage and B symptoms which have traditionally known to be of 
prognostic value, various other adverse factors have been identified based on large cohorts 
over several years. As there have been different approaches to treat HL among major study 
groups which ultimately lead to different prognostic variables, various definitions for 
different risk groups do exist among these cooperative research groups. 
In Europe, three different risk groups are defined: early-stage favorable, early-stage 
unfavorable (intermediate) and advanced-stage HL (Table 4). The NCCN  divides HL into 3 
groups: early-stage favorable (stage I-II with no B symptoms or large mediastinal 
adenopathy), early-stage unfavorable (stage I-II with large mediastinal mass, with or 
without B symptoms; stage I-II with B symptoms; numerous sites of disease; or significantly 
elevated ESR), and advanced-stage disease (stage III-IV). However, some centers in 
Northern America define only two risk groups, namely limited-stage (IA and IIA without 
bulky disease) and advanced-stage HL [III and IV; B symptoms; bulky disease (≥10 cm)] 
(Fuchs, Diehl & Re, 2006). 
NCCN unfavorable risk factors for stage I-II disease include bulky mediastinal disease 
(mediastinal mass ratio >0.33) or bulky disease >10 cm, B symptoms, ESR >50 and more 
than 3 nodal sites of disease. NCCN further classifies unfavorable stage I-II disease into 
stage I-II (unfavorable with bulky disease) and unfvaorable stage I-II with bulky disease and 
unfvaorable stage I-II with non-bulky disease. The European Organization for Research and 
Treatment of Cancers (EORTC) definitions of favorable and unfavorable early stage HL are 
very similar to those for early stage HL in the German HL Study Group (GHSG) (Table 4) 
(Carde, Burgers, Henry-Amar, et al, 1988; Loeffler, Pfreundschuh, Ruhl, et al, 1989; Mauch, 
Tarbell, Weinstein, et al, 1988; Tubiana, Henry-Amar, Carde, et al, 1989). The EORTC criteria 
differs by substituting age ≥50 years in place of the extra nodal disease criterion and 
specifying ≥4 involved regions rather than ≥3, as in GHSG (Noordijk, Carde, Dupouy, et al, 
2006). Moreover, the National Cancer Institute of Canada (NCIC) and the Eastern 
Cooperative Oncology Group (ECOG) subdivided early-stage HL into risk categories, with 
‘low risk’ being NLPHL and nodular sclerosis histology, age <40 years, erythrocyte 
sedimentation rate (ESR) <50, and ≤3 disease regions. ‘High risk’ group patients were all 
other cases with stage I-II disease, except those with bulky disease > 10 cm, which are 
assigned to advanced-stage disease (Table 4) (Evens, Hutchings & Diehl, 2008; Meyer, 
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Abbreviations: CS, clinical stage; EORTC, European Organization for Research and Treatment of 
Cancer; ESR, erythrocyte sedimentation rate; GELA, Groupe d'Etude des Lymphomes de l'Adulte; 
GHSG, German Hodgkin Study Group; LDHL, lymphocyte depleted HL; MCHL, mixed cellularity HL; 
MMR, mediastinal mass ratio, maximum width of mass/maximum intrathoracic diameter; 
NCIC/ECOG, National Cancer Institute of Canada/ Eastern Cooperative Oncology Group; NCCN, 
National Comprehensive Cancer Network; NLPHL, nodular lymphocyte-predominant Hodgkin's 
lymphoma; RF, risk factor 
aB symptoms include fever with temperature >38oC, drenching night sweats, and unexplained weight 
loss of >10% body weight within 6 months. 
 bSource: Derived from Table 21.2 by Srour S.A. and Fayad L.E. (Srour & Fayad, 2010).  
Table 4. Unfavorable Factors and Treatment Groups According to Major Study Groups and 
NCCN. 
4.3 Treatment of early stage cHL 
Treatment of HL is becoming more standardized in the current era of rapidly evolving 
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4.3 Treatment of early stage cHL 
Treatment of HL is becoming more standardized in the current era of rapidly evolving 
medical literature and with the marked advances in high technique imaging studies. The 
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most accepted standard of care to date is the combined modality treatment (CMT) with 
chemotherapy and radiotherapy (Table 5). However, there has been some controversy 
about the best RT field/dose and/or the best chemotherapy regimens. We will discuss 
below some of these issues. 
Histology Prognostic Group Recommended Treatment 
Early Stage cHL Favorablea 
Chemotherapyb, d + 20 Gy to 30 Gy IF-RT (most 
commonly accepted protocol) 
or 
Chemotherapy alone with 4-6 cycles of ABVD 
(category 2Be per NCCN Guidelines) 
 Unfavorablea Chemotherapyc, d+ 30 Gy to 36 Gy IF-RT 
Early Stage 
NLPHL 
CS IA Local LN excision (limited data) or IF-RT alone (preferred option) 
CS IIA Regional RT or IF-RT alone
f (preferred option  by most 
investigators) 
 CS IB–IIB Chemotherapyg followed by IF-RT 
aSee Table 4 for the definitions of favorable and unfavorable prognostic groups 
bFor favorable early stage cHL, the most commonly used regimens are the ABVD (2 to 4 cycles) and the 
Stanford V regimen (2 cycles) 
 cFor unfavorable early stage cHL, either ABVD is given for 4 to 6 cycles or Stanford V for 3 cycles 
dSee Table x for the chemotherapy regimen abbreviations and dosages 
eCategory 2B, per NCCN, is defined as follows: the recommendation is based on lower-level evidence 
and there is nonuniform NCCN consensus (but no major disagreement) 
fIn the setting of non-bulky CS IIA NLPHL 
gGiven the rarity of NLPHL, no large randomized trials regarding the best chemotherapeutic regimen 
are done. ABVD is widely used based on data for cHL. Immunotherapy with rituximab has been shown 
recently to have excellent response rates in NLPHL. See text for further details. 
CS, clinical stage; IF-RT, involved field radiation therapy; NCCN, National Comprehensive Cancer 
network; RT, radiation therapy 
Table 5. Recommended Treatments for Early Stage HL Commonly Adopted in Europe and 
USA. 
4.3.1 Radiotherapy alone 
It was first noticed in 1950, by Peters (Peters, 1950), that aggressive RT might cure patients 
with limited stage HL. It was not then until early 1960’s when extended field RT (EF-RT) 
was adopted as standard of care for early stage HL. However, EF-RT was complicated by 
high relapse rates (Horwich, Specht & Ashley, 1997) and serious long-term side effects 
including pulmonary dysfunction, heart disease and secondary cancers (Gustavsson, 
Osterman & Cavallin-Stahl, 2003). Hence, in an attempt to lessen toxicity and improve 
treatment outcomes, several studies over the past 3 decades addressed those concerns 
through modifying the radiation field/dose and/or incorporating chemotherapy to RT. 
Multiple randomized studies revealed that combined modality treatment (RT plus 
chemotherapy) has superior outcomes and less toxicity to RT alone. Of importance are the 
two randomized studies by Press et al (Press, LeBlanc, Lichter, et al, 2001) and Engert et al 
(Engert, Franklin, Eich, et al, 2007) which compared RT alone in early stage favorable HL to 





chemotherapy (doxorubicin + vinblastine) followed by subtotal lymphoid irradiation (STLI) 
to STLI alone with freedom from treatment failure (FFTF) of 94% vs. 81% after 3 years of 
follow up in favor to combined modality arm. Engert et al compared EF-RT alone to 
combined modality with 2 cycles of ABVD followed by EF-RT. Superior outcomes were in 
favor to the combined therapy after 7 years of follow up with FFTF of 88% vs. 67%.  
Therefore, treatment with large radiation fields alone has been abandoned and the 
availability of less toxic and more effective chemotherapy made the combined modality 
therapy the standard of care in treating early HL over the past 10-15 years. The only 
exception is those patients with stage IA NLPHL who might benefit from RT alone as will be 
discussed below. 
4.3.2 Early stage favorable cHL 
Almost all investigators in Europe and US now agree that patients with favorable early 
stages HL should receive combined modality therapy. However, there is still no consensus 
as to what chemotherapy should be used, how many cycles should be delivered, and how 
much RT should be administered, if at all. The application of chemotherapy prior to 
irradiation not only led to better treatment results but also enabled the reduction of EF-RT to 
IF-RT in this group of patients (Bonadonna, Bonfante, Viviani, et al, 2004; Diehl V, 2005a; 
Hagenbeek A, 2000; Noordijk EM, 2005) and also lead to a meaningful reduction (up to 50%) 
in the effective prescribed radiation dose (Yahalom, 2006). 
Among other regimens (chemotherapy regimens abbreviations are listed in Tables 6-8), 
ABVD and Stanford V have been favored as frontline regimens in the combined modality 
with RT in the early stage HL (see Table 6 for regimen details and dosages). ABVD was first 
introduced by Bonadonna et al in 1975 for patients who failed MOPP with very promising 
results. Hence, Santoro and colleagues (Santoro, Bonadonna, Valagussa, et al, 1987) 
compared then three cycles of MOPP vs. ABVD as frontline therapy followed by EF-RT and 
three additional chemotherapy cycles in an attempt to improve outcomes and decrease 
toxicities associated with MOPP. ABVD arm had superior outcomes with better freedom 
from progression (FFP) rates (81% vs. 63%) and lower rates of sterility and leukemia. Since 
then, many studies were conducted by major study groups in Europe and USA and 
compared the combination of either EF-RT or IF-RT with different chemotherapy regimens 
like ABVD, MOPP, MOPP/ABV, EBVP, COPP and BEACOPP, among others. Table 7 
summarizes some of the major studies addressed the combined modality treatment with the 
treatment outcomes. 
The Stanford V regimen, which incorporated the active agents from ABVD and MOPP into a 
brief dose-intense regimen, is one of the relatively new regimens that also has been proven, 
combined with radiotherapy, to be highly effective in early stage favorable and unfavorable 
or locally extensive HL with low toxicity profile.  
The number of chemotherapy cycles (2 to 4 ABVD versus 2 to 3 Stanford V), and the 
intensity of radiation, have been addressed by multiple randomized studies to date with 
major impact on current therapy guidelines. Bonadonna et al (Bonadonna, Bonfante, Viviani, 
et al, 2004) revealed a noninferiority outcomes with 4 cycles of ABVD followed by IF-RT 
compared to same chemotherapy followed by EF-RT after 12 years of follow up (FFP rates of 
93% for ABVD followed by EF-RT vs. 94% for ABVD followed by IF-RT). Horning S 
(Horning SJ, 2004), in a single arm study, showed as well that the 8-week modified 
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follow up in favor to combined modality arm. Engert et al compared EF-RT alone to 
combined modality with 2 cycles of ABVD followed by EF-RT. Superior outcomes were in 
favor to the combined therapy after 7 years of follow up with FFTF of 88% vs. 67%.  
Therefore, treatment with large radiation fields alone has been abandoned and the 
availability of less toxic and more effective chemotherapy made the combined modality 
therapy the standard of care in treating early HL over the past 10-15 years. The only 
exception is those patients with stage IA NLPHL who might benefit from RT alone as will be 
discussed below. 
4.3.2 Early stage favorable cHL 
Almost all investigators in Europe and US now agree that patients with favorable early 
stages HL should receive combined modality therapy. However, there is still no consensus 
as to what chemotherapy should be used, how many cycles should be delivered, and how 
much RT should be administered, if at all. The application of chemotherapy prior to 
irradiation not only led to better treatment results but also enabled the reduction of EF-RT to 
IF-RT in this group of patients (Bonadonna, Bonfante, Viviani, et al, 2004; Diehl V, 2005a; 
Hagenbeek A, 2000; Noordijk EM, 2005) and also lead to a meaningful reduction (up to 50%) 
in the effective prescribed radiation dose (Yahalom, 2006). 
Among other regimens (chemotherapy regimens abbreviations are listed in Tables 6-8), 
ABVD and Stanford V have been favored as frontline regimens in the combined modality 
with RT in the early stage HL (see Table 6 for regimen details and dosages). ABVD was first 
introduced by Bonadonna et al in 1975 for patients who failed MOPP with very promising 
results. Hence, Santoro and colleagues (Santoro, Bonadonna, Valagussa, et al, 1987) 
compared then three cycles of MOPP vs. ABVD as frontline therapy followed by EF-RT and 
three additional chemotherapy cycles in an attempt to improve outcomes and decrease 
toxicities associated with MOPP. ABVD arm had superior outcomes with better freedom 
from progression (FFP) rates (81% vs. 63%) and lower rates of sterility and leukemia. Since 
then, many studies were conducted by major study groups in Europe and USA and 
compared the combination of either EF-RT or IF-RT with different chemotherapy regimens 
like ABVD, MOPP, MOPP/ABV, EBVP, COPP and BEACOPP, among others. Table 7 
summarizes some of the major studies addressed the combined modality treatment with the 
treatment outcomes. 
The Stanford V regimen, which incorporated the active agents from ABVD and MOPP into a 
brief dose-intense regimen, is one of the relatively new regimens that also has been proven, 
combined with radiotherapy, to be highly effective in early stage favorable and unfavorable 
or locally extensive HL with low toxicity profile.  
The number of chemotherapy cycles (2 to 4 ABVD versus 2 to 3 Stanford V), and the 
intensity of radiation, have been addressed by multiple randomized studies to date with 
major impact on current therapy guidelines. Bonadonna et al (Bonadonna, Bonfante, Viviani, 
et al, 2004) revealed a noninferiority outcomes with 4 cycles of ABVD followed by IF-RT 
compared to same chemotherapy followed by EF-RT after 12 years of follow up (FFP rates of 
93% for ABVD followed by EF-RT vs. 94% for ABVD followed by IF-RT). Horning S 
(Horning SJ, 2004), in a single arm study, showed as well that the 8-week modified 
Stanford V chemotherapy (rather than the standard 12 –week cycle) followed by IF-RT has  
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Regimen Dosage and schedule Frequencya 
ABVDb 
Doxorubicin 25 mg/m2 IV on days 1 and 15 
Bleomycin 10 units/m2 IV on days 1 and 15 Repeat cycle every 28 days 
Vinblastine 6 mg/m2 IV on days 1 and 15  
Dacarbazineb 375 mg/m2 IV on days 1-5  
Standard BEACOPPc   
Bleomycin 10 units/m2 IV on day 8  
Etoposide 100 mg/m2 IV on days 1, 2, and 3  
Doxorubicin 25 mg/m2 IV on day 1 Repeat cycle every 21 days 
Cyclophosphamide 650  mg/m2 IV on day 1  
Vincristined 1.4 mg/m2 IV on day 8 
 Procarbazine 100 mg/m2 PO on days 1-7 
Prednisone 40 mg/m2 PO on days 1-14 
Esc-BEACOPPc 
Bleomycin 10 mg/m2 IV on day 8 Repeat cycle every 21 days 
Etoposide 200 mg/m2 IV on days 1, 2, and 3  
Doxorubicin 35 mg/m2 IV on day 1 
 
Cyclophosphamide 1200 mg/m2 IV on day 1 
Vincristined 1.4 mg/m2 IV on day 8 
Procarbazine 100 mg/m2 PO on days 1-7 
Prednisone 40 mg/m2 PO on days 1-14 
Filgrastime 300 mcg/day starting on day 8 
STANFORD Vf 
Doxorubicin 25 mg/m2 IV on days 1 and 15 
Repeat cycle every 28 days 
Vinblastineg 6 mg/m2 IV on days 1 and 15 
Mechlorethamine 6 mg/m2 IV on day 1 
Vincristineg 1.4 mg/m2 IV on days 8 and 22 
Bleomycin 5 units/m2 IV on days 8 and 22 
Etoposide 60 mg/m2 IV on days 15 and 16 
Prednisoneh 40 mg/m2 PO every other day 
aThe duration of chemotherapy and number of cycles are determined by the stage of the disease and the 
prognostic stratification (see text for details) 
bABVD regimen was used first as described in the table by Bonadonna G et al (Bonadonna G et al., 
1975). On subsequent studies, dacarbazine was administered on days 1 and 15 rather than on days 1-5 
(Canellos GP et al., 1992)  
cDerived from Diehl V et al. 2003 
dMaximum dose 2 mg. 
eFilgrastrim is given subcutaneously starting on day 8 and continuing until WBC ≥13,000/mm3on 3 
consecutive days. The dose is 300 mcg/day for patients with body weight <75 kg and 400 mcg/day for 
those ≥75 kg 
fDerived from Bartlett NL et al. 1995 
gVinblastine dose reduced to 4mg/m2 and vincristine dose to 1mg/m2 during cycle 3 for patients 50 
years of age or older 
hPrednisone is started on day 1 and continued every other day. It is tapered by 10 mg/dose every other 
day starting on day 14 of the third cycle 











Engert A et al. (2007) 
GHSG HD7 
A: RT alone (30 Gy EF-RT or 
40 Gy IF-RT) 311 87 months 
7-yr FFTF, 67%; 
7-yr OS: 92% 
 
B: 2 ABVD + RT (30 Gy EF-
RT or 40 Gy IF-RT) 316  
7-yr FFTF: 88%; 
7-yr OS: 94% 
Engert A et al. (2010) 
GHSG HD10, 1998–
2003 
A: 2 ABVD + IF-RT (30 Gy) 295 
91 months 
for OS and 
79 months 
for FFTF 
8-yr FFTF: 85.5 
8-yr OS: 93.6 
 B: 2 ABVD + IF-RT (20 Gy) 299  
8-yr FFTF: 85.9 
8-yr OS: 95.1 
 C: 4 ABVD + IF-RT (30 Gy) 298  
8-yr FFTF: 87.2 
8-yr OS: 94.4 
 D: 4 ABVD + IF-RT (20 Gy) 298  
8-yr FFTF: 89.9 
8-yr OS: 94.7 
Advani RH et al. (2010) 
Stanforda 
A: Stanford V for 8 wk + IF-
RT (mostly 30 Gy, but some 





8.5 years 10-yr FFP: 100% 10-yr OS: 97% 
Press OW et al. (2001) 
SWOG 9133/CALGB 
9391 
A: 3 (doxorubicin + 
vinblastine) + STLI (S) (36–40 
Gy) 
165 3.3 years 3-yr FFS:  94% 3-yr OS: 98% 
 B: STLI (S) (36–40 Gy) 161  
3-yr FFS: 81% 
3-yr OS: 96% 
Ferme C et al. (2007) 
EORTC/GELA H8F 
A: 3 MOPP/ABV + IF-RT (36 
Gy) 270 92 months 
10-yr EFS: 93% 
10-yr OS 97% 
 B: STLI (S) 272  
10-yr EFS 68%; 
10-yr OS 92% 
Horning SJ et al. (1999) 
Stanforda 
Stanford V for 8 wk + 
modified IF-RT (30 Gy) 65 16 months 
3-yr FFP: 94.6% 
3-yr OS: 96.6% 
Noordijik EM et al. 
(2006) 
EORTC/GELA H7F 
A: 6 EBVP + IF-RT (36 GY) 164 9 years 10-yr EFS: 88%; 10-yr OS: 92% 
 B: EF-RT 165  
10 yr FFTF: 78%; 
10 yr OS: 92% 
Meyer RM et al. (2005) 
NCIC-CTG/ECOG A: EF-RT alone 64 4.2 years 
5-yr EFS: 88% 
5-yr OS: 100% 
 B: 4-6 cycles of ABVD alone 59  
5-yr EFS: 87% 
5-yr OS: 97% 
Eghbali H et al. (2005) 
EORTC-GELA H9-F A: 6 EBVP + IF-RT (36 Gy) 239 51 months 
4-yr EFS: 88% 
4-yr OS: 99% 
 B: 6 EBVP + IF-RT (20 Gy) 209  
4-yr EFS: 85% 
4-yr OS: 100% 
 C: 6 EBVP alone 130  
4-yr EFS: 69% 
4-yr OS: 98% 
Wirth A et al. (2011) 
ALLG/TTROGa 
3 ABVD followed by 30 Gy 
IF-RT ?75 5.9 years 5-yr FFP: 97% 
ABV, doxorubicin (Adriamycin), bleomycin, vinblastine; ABVD, doxorubicin, bleomycin, vinblastine, 
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Wirth A et al. (2011) 
ALLG/TTROGa 
3 ABVD followed by 30 Gy 
IF-RT ?75 5.9 years 5-yr FFP: 97% 
ABV, doxorubicin (Adriamycin), bleomycin, vinblastine; ABVD, doxorubicin, bleomycin, vinblastine, 
dacarbazine; ALLG/TTROG, Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation 
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Oncology Group; AV, doxorubicin and vinblastine; AVD, doxorubicin, vinblastine, dacarbazine; 
CALGB, Cancer and Leukemia Group B; EF-RT, extended-field radiotherapy; EBVP regimen, 
epirubicin, bleomycin, vinblastine, and prednisone; ECOG, Eastern Cooperative Oncology Group; EFS, 
event-free survival; EORTC, European Organization for Research and Treatment of Cancer; FFP, 
freedom from progression; FFS, failure-free survival; FFTF, freedom from treatment failure; GELA, 
Groupe d'Etude des Lymphomes de l'Adulte; GHSG, German Hodgkin Study Group; IF-RT, involved-
field radiation therapy; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; OS, overall 
survival; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; RFS, relapse-free 
survival; RT, radiotherapy; Stanford V, mechlorethamine, doxorubicin, vinblastine, prednisone, 
vincristine, bleomycin, VP-16; STLI (S), subtotal nodal irradiation (splenic irradiation); SWOG, 
Southwest Oncology Group; VAPEC-B, doxorubicin, cyclophosphamide, etoposide, vincristine, 
bleomycin, prednisone; yr, year. 
aUsed GHSG definition for early stage favorable HL 
Table 7. Selected Trials in Favorable Early Stage HL Derived from Major Study Groups. 
comparable outcomes to more intense regimens with FFP of 96% and OS of 98% after a 
median follow-up of 5.7 years. 
Furthermore, one of the recent “practice changing” important studies, the GHSG HD 10 
trial by Engert A et al (Engert, Plutschow, Eich, et al, 2010), randomized 1370 patients (age 
range, 16 to 75) with early stage favorable HL in a 4 arm study into 2 or 4 cycles of ABVD 
followed by 20 or 30 Gy IF-RT. Favorable disease included patients with no bulky disease, 
no extranodal extension, and without elevated ESR (see Table 4 for definitions of risk 
groups). With a median follow-up of 79-91 months, there were no significant differences 
in FFTF and OS in the 4 arms with FFTF rates in the range of 85.5% to 89.9% and OS  
rates in the range of 93.6% to 95.1% (Table 7). Furthermore, patients who received only  
two cycles of ABVD and low dose of radiation have less adverse events and acute toxic  
effects. 
The HD 13 randomized trial is trying to address the question, in order to decrease toxicity 
from ABVD, whether the number of drugs can be reduced. Patients in this study are 
randomly assigned to one of the 4 arms: ABVD, ABV, AVD, or AV chemotherapy followed 
by 30 Gy of IF-RT. An interim safety analysis in 2006 showed increased failure rates in the 
ABV and AV arms, hence those arms were closed. Until further evidence, dacarbazine 
should be considered an integral part of the ABVD regimen in early stage favorable HL. 
Future analyses of the HD 13 study would hopefully answer the question whether ABVD 
and AVD are equivalent or not (Borchmann & Engert, 2010). 
4.3.3 Early stage unfavorable cHL 
The standard of care based on multiple randomized studies remains the combined modality 
treatment with chemotherapy and RT, as for the early stage favorable HL. However, there 
has been a trend towards more intense therapy than early favorable stage HL with some 
investigators suggesting therapy approaches similar to those adopted for advanced HL. 
However, giving the high cure rates and prolonged CR rates, there have been many 
randomized studies trying to address the need for less intense chemotherapy and/or RT in 
order to decrease long term toxicity from RT and maintain the best response rates. Table 8 
summarizes some of the major studies addressing the therapeutic approaches for early stage 





4.3.3.1 Brief historical background for chemotherapy use in early stage unfavorable cHL 
Various chemotherapeutic regimens have been investigated in the combined modality 
treatment for early stage unfavorable HL since early 1980’s. However, studies didn’t 
identify significant survival advantages among different modalities. Based on data 
derived from major studies in advanced HL, ABVD has been favored in most recent 
studies as first line therapy combined with RT in this population. ABVD has been favored 
for its superior outcomes and low late toxicity profile compared to other more intense 
regimens. Stanford V has been studied as well with some promising data and more 
recently ABVD has been compared to more intense regimens such as BEACOPP in early 
stage unfavorable HL. 
Earlier studies in unfavorable HL patients compared CMT with MOPP to ABVD and 
MOPP-like combinations. One of the earlier studies is the Milan study (Santoro, Viviani & 
Zucali, 1983) which randomized patients in a split fashion for 3 cycles of MOPP followed by 
subtotal nodal irradiation followed by another 3 cycles of MOPP versus same course but 
with ABVD rather than MOPP. No significant differences in FFP were noticed initially. 
However, the EORTC H6U trial (Cosset, Ferme, Noordijk, et al, 1996) showed a better 10-
year FFTF with ABVD compared to MOPP, though there was no significant survival 
advantage as in many other subsequent studies. 
In an attempt to improve efficacy and reduce toxicity, few studies were conducted with 
modified combinations such as reducing alkylating agents or total cumulative dosage of 
chemotherapy. However, inferior outcomes were noticed in the unfavorable early stage HL 
with these approaches (Table 8).  
One of such experiences was the Cancer and Leukemia Group B 9051 phase II study 
(Wasserman, Petroni, Millard, et al, 1999) which tested three cycles of etoposide, vinblastine, 
and doxorubicin (EVA) followed by subtotal lymphoid irradiation in 59 patients with CS I-
III disease and unfavorable features (bleomycin was eliminated). CR rate was about 66% 
with high relapse rate of 20%.  
In a more recent study (the EORTC H7U trial) conducted by the EORTC group (Noordijk, 
Carde, Dupouy, et al, 2006), 389 patients with unfavorable prognosis early stage HL were 
randomized to receive CMT with six cycles of epirubicin, bleomycin, vinblastine, and 
prednisone (EBVP) and IF-RT versus 6 cycles of mechlorethamine, vincristine, procarbazine, 
prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV hybrid) and IF-RT. The 
EBVP regimen, given one time per month (compared with two times per month for ABVD), 
was anticipated to be a less toxic regimen. However, the 10-year EFS rate was 88% in the 
MOPP/ABV arm compared with 68% in the EBVP arm (P < .001), leading to 10-year OS 
rates of 87% and 79%, respectively (P = .0175). Also, the failure-free survival rate at three 
years was significantly lower with EBVP (72 versus 88 percent) and further entry into the 
trial was discontinued. 
4.3.3.2 Popular chemotherapy regimens, number of cycles, and dose/field of radiation 
Recent studies, focused on the more popular regimens such as the ABVD, Stanford V, and 
BEACOPP, and as well on the number of cycles and dose/field of RT in order to enhance 
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EBVP regimen, given one time per month (compared with two times per month for ABVD), 
was anticipated to be a less toxic regimen. However, the 10-year EFS rate was 88% in the 
MOPP/ABV arm compared with 68% in the EBVP arm (P < .001), leading to 10-year OS 
rates of 87% and 79%, respectively (P = .0175). Also, the failure-free survival rate at three 
years was significantly lower with EBVP (72 versus 88 percent) and further entry into the 
trial was discontinued. 
4.3.3.2 Popular chemotherapy regimens, number of cycles, and dose/field of radiation 
Recent studies, focused on the more popular regimens such as the ABVD, Stanford V, and 
BEACOPP, and as well on the number of cycles and dose/field of RT in order to enhance 
the outcomes and decrease toxicities (Table 8). 
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Cosset J et al. (1996) 
EORTC H6U A: 3 MOPP + mantle RT + 3 MOPP 165  
10-yr FFP: 68% 
10-yr OS: 87% 
  B: 3 ABVD + mantle RT + 3 ABVD 151  10-yr FFP: 90% 10-yr OS: 87% 




A: 3 MOPP + STLI/TLI + 3 MOPP 33  5-yr FFP: 66% 
  B: 3 ABVD + STLI/TLI + 3 ABVD 36  5-yr FFP: 72% 
Pavlovsky S et al. 
(1997) 
GATLA 
A: 3 CVPP + IF-RT (30 Gy) + 3 
CVPP 92  
5-yr EFS: 85% 
5-yr OS: 95% 
  B. 3 AOPE + IF-RT (30 Gy) + 3 
AOPE 84  
5-yr EFS: 66% 
5-yr OS: 87% 
Noordijik EM et al. 
(2006) 
EORTC H7U 
A: 6 EBVP II + IF-RT (36 GY) 194 9 years 10-yr EFS: 68%; 10-yr OS: 79% 
  B: 6 MOPP/ABV + IF-RT 195  5-yr EFS, 88%; 5-yr OS 87% 
Meyer RM et al. 
(2005) 
NCIC-CTG/ECOG 
A: 2 ABVD followed by EF-RT 139 4.2 years 5-yr EFS: 88% 5-yr OS: 92% 
 B: 4-6 ABVD alone 137  5-yr EFS: 85% 5-yr OS: 95% 
Eich HT et al. 
(2010) 
GHSG HD11 
A: 4 ABVD + IF-RT (30 Gy) 356 6.8 years 
5-yr FFTF: 85.3% 
5-yr OS: 94.3% 
 
  
B: 4 ABVD + IF-RT (20 Gy) 347  
5-yr FFTF: 81.1% 
5-yr OS: 93.8% 
 
  C: 4 baseline BEACOPP + IF-RT 
(30 Gy) 341  
5-yr FFTF: 87% 
5-yr OS: 94.6% 
 
  D: 4 baseline BEACOPP + IF-RT 
(20 Gy) 351  
5-yr FFTF: 86.8% 
5-yr OS: 95.1% 
 
Advani RH et al. 
(2010) 
Stanforda 
A: Stanford V for 8 wk + IF-RT (20 
or mostly 30 Gy) 55 8.5 years 
10-yr FFP: 89% 
10-yr OS: 96% 
Wirth A et al. 
(2011) 
ALLG/TTROGa 
4 ABVD followed by 30 Gy IF-RT 
for: 
A. Stage IA-IIA with any risk 
factor 










A. 5-yr FFP: 89% 
 
B. 5-yr FFP: 73% 
 
Zittoun R et al. 
(1985) 
A: 3 MOPP + IF-RT (40 Gy) + 3 
MOPP 82  
6-yr DFS: 87% 











  B: 3 MOPP + EF-RT (40 Gy) + 3 
MOPP 91  
6-yr DFS: 93% 
6-yr OS: 91% 




A: 4 ABVD + STLI 66 116 months 12 yr FFP: 93% 12-yr OS: 96% 
  B: 4 ABVD + IF-RT 70  12-yr FFP: 94% 12-yr OS: 94% 




A: 6 MOPP/ABV + IF-RT (36 Gy) 336 92 months 10-yr EFS: 82% 10-OS: 88% 
  B: 4 MOPP/ABV + IF-RT (36 Gy) 333  10-yr EFS: 80% 10-yr OS: 85% 
  C: 4 MOPP/ABV + STLI 327  10-yr EFS: 80% 10-yr OS: 84% 
Engert A et al. 
(2003) 
GHSG HD8 
A: 4 COPP/ABVD + 30 Gy EF-RT 
(+ 10 Gy to bulky disease) 532 54 months 
5-yr FFTF: 85.8% 
5-yr OS: 90.8% 
  A: 4 COPP/ABVD + 30 Gy IF-RT 
(+ 10 Gy to bulky disease) 532  
5-yr FFTF: 84.2% 
5-yr OS: 92.4% 
ABV, doxorubicin (Adriamycin), bleomycin, vinblastine; ABVD, doxorubicin, bleomycin, vinblastine, 
dacarbazine; ALLG/TTROG, Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation 
Oncology Group; AOPE, doxorubicin, vincristine, prednisone, etoposide; BEACOPP, bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; COPP, 
cyclophosphamide, vincristine, procarbazine, prednisone; CVPP, cyclophosphamide, vinblastine, 
procarbazine, prednisone; DFS, disease-free survival; EBVP, epirubicin, bleomycin, vinblastine, 
prednisone; ECOG, Eastern Cooperative Oncology Group; EF-RT, extended-field radiotherapy; EFS, 
event-free survival; EORTC, European Organization for Research and Treatment of Cancer; FFP, 
freedom from progression; FFTF, freedom from treatment failure; GATLA, Grupo Argentino de 
Tratamiento de la Leucemia Aguda; GELA, Groupe d'Etude des Lymphomes de l'Adulte; GHSG, 
German Hodgkin Study Group; IF-RT, involved-field irradiation; MOPP, mechlorethamine, vincristine, 
procarbazine, prednisone; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; OS, 
overall survival; Stanford V, mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, 
bleomycin, VP-16; RT, radiation therapy; STLI, subtotal nodal irradiation; TLI, total lymphoid 
irradiation.  
aUsed GHSG definitions for favorable and unfavorable early stage HL 
bIncluded unfavorable stage I and all clinical stage II patients 
Table 8. Selected Trials in Unfavorable Early Stage HL Derived from Major Study Groups. 
Trying to address the number of cycles and/or radiation field, Ferme C, et al. randomized 
996 patients with early unfavorable HL in the GELA H8U trial into one of the following 
three arms: six cycles of the hybrid MOPP/ABV regimen plus IF-RT versus four cycles plus 
IF-RT versus 4 cycles plus subtotal nodal irradiation (STNI). All arms had similar 5-year EFS 
and 10-year OS rates (Ferme, Eghbali, Meerwaldt, et al, 2007). Hence, 4 cycles of 
chemotherapy followed by IF-RT was proposed as standard treatment for early stage 
unfavorable HL. EF-RT versus IF-RT has been addressed as well by the large HD8 
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6-yr OS: 91% 
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A: 6 MOPP/ABV + IF-RT (36 Gy) 336 92 months 10-yr EFS: 82% 10-OS: 88% 
  B: 4 MOPP/ABV + IF-RT (36 Gy) 333  10-yr EFS: 80% 10-yr OS: 85% 
  C: 4 MOPP/ABV + STLI 327  10-yr EFS: 80% 10-yr OS: 84% 
Engert A et al. 
(2003) 
GHSG HD8 
A: 4 COPP/ABVD + 30 Gy EF-RT 
(+ 10 Gy to bulky disease) 532 54 months 
5-yr FFTF: 85.8% 
5-yr OS: 90.8% 
  A: 4 COPP/ABVD + 30 Gy IF-RT 
(+ 10 Gy to bulky disease) 532  
5-yr FFTF: 84.2% 
5-yr OS: 92.4% 
ABV, doxorubicin (Adriamycin), bleomycin, vinblastine; ABVD, doxorubicin, bleomycin, vinblastine, 
dacarbazine; ALLG/TTROG, Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation 
Oncology Group; AOPE, doxorubicin, vincristine, prednisone, etoposide; BEACOPP, bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; COPP, 
cyclophosphamide, vincristine, procarbazine, prednisone; CVPP, cyclophosphamide, vinblastine, 
procarbazine, prednisone; DFS, disease-free survival; EBVP, epirubicin, bleomycin, vinblastine, 
prednisone; ECOG, Eastern Cooperative Oncology Group; EF-RT, extended-field radiotherapy; EFS, 
event-free survival; EORTC, European Organization for Research and Treatment of Cancer; FFP, 
freedom from progression; FFTF, freedom from treatment failure; GATLA, Grupo Argentino de 
Tratamiento de la Leucemia Aguda; GELA, Groupe d'Etude des Lymphomes de l'Adulte; GHSG, 
German Hodgkin Study Group; IF-RT, involved-field irradiation; MOPP, mechlorethamine, vincristine, 
procarbazine, prednisone; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; OS, 
overall survival; Stanford V, mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, 
bleomycin, VP-16; RT, radiation therapy; STLI, subtotal nodal irradiation; TLI, total lymphoid 
irradiation.  
aUsed GHSG definitions for favorable and unfavorable early stage HL 
bIncluded unfavorable stage I and all clinical stage II patients 
Table 8. Selected Trials in Unfavorable Early Stage HL Derived from Major Study Groups. 
Trying to address the number of cycles and/or radiation field, Ferme C, et al. randomized 
996 patients with early unfavorable HL in the GELA H8U trial into one of the following 
three arms: six cycles of the hybrid MOPP/ABV regimen plus IF-RT versus four cycles plus 
IF-RT versus 4 cycles plus subtotal nodal irradiation (STNI). All arms had similar 5-year EFS 
and 10-year OS rates (Ferme, Eghbali, Meerwaldt, et al, 2007). Hence, 4 cycles of 
chemotherapy followed by IF-RT was proposed as standard treatment for early stage 
unfavorable HL. EF-RT versus IF-RT has been addressed as well by the large HD8 
randomized trial from the German Hodgkin's Lymphoma Study Group (Engert, Schiller, 
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Josting, et al, 2003), where 1204 patients were randomly assigned to receive four cycles of 
COPP/ABVD followed by either IF-RT or EF-RT. At 5-years of follow-up, there was no 
significant difference in FFTF and OS between the 2 groups, but increased acute toxicity 
with the EF-RT group (leukopenia, thrombocytopenia, and GI toxicities). 
ABVD and BEACOPP have been compared head to head in early stage unfavorable HL. In 
the EORTC/GELA H9U study (Noordijk EM, 2005) patients were randomly assigned to 6 
cycles of ABVD or 4 cycles of ABVD or 4 cycles of baseline BEACOPP, all followed by 30 Gy 
IF-RT. At an interim analysis with a median follow-up of 4 years, no EFS and OS differences 
were noted, but increased toxicity with baseline BEACOPP. More recently, the final analysis 
of the GHSG HD11 trial (Eich, Diehl, Gorgen, et al, 2010) has been published with similar 
results to the H9U study, but with more information about the RT dosage. In this 4-arm 
study, 1395 patients with early stage unfavorable HL were randomized to either 4 cycles of 
ABVD or 4 cycles of baseline BEACOPP. Patients in each group of chemotherapy were then 
randomized to either 20 or 30 Gy IF-RT. At a median follow-up of 7.5 years, the OS was 
similar in all 4 arms. FFTF and PFS were similar as well between the 2 chemotherapy arms 
with the 30 Gy IF-RT. Baseline BEACOPP arm with 20 Gy IF-RT showed superior FFTF 
compared to ABVD followed by same RT. However, treatment-related toxicity was more 
frequently observed in the baseline BEACOPP arm and hence the BEACOPP is not adopted 
as new standard of care. 
More recently, Wirth and colleagues (Wirth, Grigg, Wolf, et al, 2011) reported the results of 
the Australian Leukemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group 
which tested combined modality treatment in stages I-II HL with IF-RT, with the number of 
cycles of ABVD determined by risk group (according to GHSG). 150 patients were classified 
into three groups as follows: group 1 with no risk factors who received 3 cycles of ABVD 
and IF-RT, group 2 with stages IA-IIA disease and any of the risk factors and group 3 
included patients with stage IB-IIB; groups 2 and 3 received the same therapy with 4 cycles 
of ABVD and IF-RT. With a median follow-up of 5.9 years, the 5-year FFP and OS were 
comparable to those in the HD10 and HD11 trials for groups 1 and 2, but not group 3 which 
showed lower 5-year FFP and OS of 73% and 85%, respectively. The lower rates in group 3 
may be explained by the inclusion of stage IIBX disease (44% of patients) in this study (those 
were excluded from HD10 and HD11 studies). 
As with ABVD and BEACOPP, clinical studies has shown promising response rates with the 
Stanford V regimen. Advani RH, et al (Advani, Hoppe, Baer, et al, 2009) updated recently 
the initial results of the G4 study published by Horning SJ et al (Horning SJ, 2004). Among 
the 87 patients with non-bulky stage IA-IIA HL, 47 patients had unfavorable risk factors 
(according to GHSG criteria). At a median follow-up of 9 years, the FFP and OS rates for the 
whole group were 94% and 96%, respectively. However, FFP was 100% for favorable disease 
patients compared to 89% of those with unfavorable factors, but with no significant OS 
differences. Hence, Stanford V (8 weeks; 2 cycles) and 30 Gy IF-RT is considered safe and 
highly effective in this group of patients.  
Few other studies confirmed as well that combined modality with Stanford V regimen is 
highly effective for locally extensive and advanced HL with low toxicity profile. More 
recently, the MSKCC study (Edwards-Bennett, Jacks, Moskowitz, et al, 2010) tested 126 
patients with either locally extensive or advanced disease with 12-week Stanford V 





disease. The 5-and 7-year OS rates were 90% and 88%, respectively. On the other hand, at 
least 3 randomized trials were conducted comparing combined modality treatment with 
Stanford V versus ABVD. The final results confirm that ABVD should stay the standard 
therapy, but offers Stanford V as an acceptable and effective alternative (NCCN, v2.2011). 
4.3.4 Chemotherapy alone 
Giving the high cure rates and long term survivors of early stage HL with combined 
modality therapy, but with continued increased risk of long term complications from RT 
such as premature heart disease, lung toxicity, and secondary malignancies, many 
investigators have initiated randomized studies trying to omit RT in such good risk patients. 
Data from few randomized studies and as well few other single arm studies will be 
discussed briefly (these were summarized by a recent review by Straus DJ, 2011). 
One of the earliest randomized studies is the prospective trial by Pavlovsky S, et al 
(Pavlovsky, Maschio, Santarelli, et al, 1988). A total of 104 patients with unfavorable clinical 
stages I-II HL were randomized for chemotherapy alone with 6 cycles of CVPP 
(cyclophosphamide, vincristine, procarbazine, and prednisone) versus 6 cycles of CVPP 
sandwiched with 30 Gy dose of IFRT. Combined modality treatment had higher rates of 
disease-free survival (75% vs. 34%) and a trend toward higher OS rates (84% vs. 66%). 
Another prospective study was conducted by the Memorial Sloan Kettering Cancer Center 
(Straus, Portlock, Qin, et al, 2004) which randomized 152 patients with non-bulky stages I-II 
and stage IIIA disease to 6 cycles of ABVD with or without RT. There were no significant 
differences, but increased tendency for inferior outcomes in CR rates (87% vs. 91%), FFP 
rates (81 vs. 86%), and OS at 60 months (90% vs. 97%) for ABVD alone compared to the 
combined modality arm.  
A phase II trial by the NCIC and ECOG study group (Meyer, Gospodarowicz, Connors, et al, 
2005) randomized 399 patients with non-bulky early stage IA-IIB HL to 4-6 cycles of ABVD 
alone (favorable or unfavorable) vs. RT based therapy (STLI alone if favorable HL and 
ABVD followed by STLI if unfavorable). An interim analysis after median follow-up of 4.2 
years revealed better outcomes (FFP and EFS) in the RT alone plus combined modality 
therapy arms compared to the chemotherapy alone arm, but no survival benefit. In a subset 
analysis of patients with unfavorable prognostic factors, FFP was superior for those treated 
with the combined modality compared to chemotherapy alone (95% vs. 88%), but with no 
survival differences.  
The fourth 3-arm randomized study is the EORTC-GELA H9-F (Eghbali, Raemaekers & 
Carde, 2005) which randomized early stage favorable HL patients (total of 783 patients) to 
chemotherapy alone with epirubicin, bleomycin, vinblastine, and prednisone (EBVP) versus 
EBVP followed by 20 Gy of IF-RT versus EBVP followed by 36 Gy IF-RT. EBVP has an 
inferior outcome compared to the combined modality with both the 20 Gy and 36 Gy IF-RT 
with 4-year EFS rates of 69%, 85%, and 88%, respectively. The EBVP alone arm was then 
discontinued though there was no survival differences. 
Of the retrospective analyses, Canellos GP et al (Canellos, Abramson, Fisher, et al, 2010) 
reported a PFS and OS of 92% and 100%, respectively, in a series of 75 patients with early 
stages IA-IIA and stage IIB disease (median follow-up was 52 months). Another 
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least 3 randomized trials were conducted comparing combined modality treatment with 
Stanford V versus ABVD. The final results confirm that ABVD should stay the standard 
therapy, but offers Stanford V as an acceptable and effective alternative (NCCN, v2.2011). 
4.3.4 Chemotherapy alone 
Giving the high cure rates and long term survivors of early stage HL with combined 
modality therapy, but with continued increased risk of long term complications from RT 
such as premature heart disease, lung toxicity, and secondary malignancies, many 
investigators have initiated randomized studies trying to omit RT in such good risk patients. 
Data from few randomized studies and as well few other single arm studies will be 
discussed briefly (these were summarized by a recent review by Straus DJ, 2011). 
One of the earliest randomized studies is the prospective trial by Pavlovsky S, et al 
(Pavlovsky, Maschio, Santarelli, et al, 1988). A total of 104 patients with unfavorable clinical 
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(cyclophosphamide, vincristine, procarbazine, and prednisone) versus 6 cycles of CVPP 
sandwiched with 30 Gy dose of IFRT. Combined modality treatment had higher rates of 
disease-free survival (75% vs. 34%) and a trend toward higher OS rates (84% vs. 66%). 
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and stage IIIA disease to 6 cycles of ABVD with or without RT. There were no significant 
differences, but increased tendency for inferior outcomes in CR rates (87% vs. 91%), FFP 
rates (81 vs. 86%), and OS at 60 months (90% vs. 97%) for ABVD alone compared to the 
combined modality arm.  
A phase II trial by the NCIC and ECOG study group (Meyer, Gospodarowicz, Connors, et al, 
2005) randomized 399 patients with non-bulky early stage IA-IIB HL to 4-6 cycles of ABVD 
alone (favorable or unfavorable) vs. RT based therapy (STLI alone if favorable HL and 
ABVD followed by STLI if unfavorable). An interim analysis after median follow-up of 4.2 
years revealed better outcomes (FFP and EFS) in the RT alone plus combined modality 
therapy arms compared to the chemotherapy alone arm, but no survival benefit. In a subset 
analysis of patients with unfavorable prognostic factors, FFP was superior for those treated 
with the combined modality compared to chemotherapy alone (95% vs. 88%), but with no 
survival differences.  
The fourth 3-arm randomized study is the EORTC-GELA H9-F (Eghbali, Raemaekers & 
Carde, 2005) which randomized early stage favorable HL patients (total of 783 patients) to 
chemotherapy alone with epirubicin, bleomycin, vinblastine, and prednisone (EBVP) versus 
EBVP followed by 20 Gy of IF-RT versus EBVP followed by 36 Gy IF-RT. EBVP has an 
inferior outcome compared to the combined modality with both the 20 Gy and 36 Gy IF-RT 
with 4-year EFS rates of 69%, 85%, and 88%, respectively. The EBVP alone arm was then 
discontinued though there was no survival differences. 
Of the retrospective analyses, Canellos GP et al (Canellos, Abramson, Fisher, et al, 2010) 
reported a PFS and OS of 92% and 100%, respectively, in a series of 75 patients with early 
stages IA-IIA and stage IIB disease (median follow-up was 52 months). Another 
nonrandomized study from Spain (Rueda Dominguez, Marquez, Guma, et al, 2004) included 
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unselected 80 patients with early stage HL treated with 6 cycles of ABVD. The progression-
free and overall survival at 7 years reported in 65 patients without B symptoms or 
mediastinal bulky disease were 88% and 97%, respectively. 
More recently, a systematic review with meta-analysis of randomized controlled trials 
comparing chemotherapy alone with CMT in patients with early stage HL. Randomized 
studies comparing chemotherapy alone to the same chemotherapy regimen plus RT were 
only included. A total of 1245 patients were included. Authors concluded that adding RT to 
chemotherapy improves tumor control and OS in patients with early stage HL (Herbst, 
Rehan, Skoetz, et al, 2011). 
Until further randomized trials are published, there will be no consensus to adopt 
chemotherapy alone as front line therapy for early stage HL. Enrollment in randomized 
clinical trials should be highly recommended. Currently, there are few ongoing randomized 
studies trying to answer that question. Armitage (Armitage, 2010) summarized four major 
randomized clinical trials which are incorporating interim PET scans to guide further 
therapy with or without IF-RT.  
Based on available data and until further studies show convincing evidence for the opposite, 
we think combined modality treatment with chemotherapy and RT should remain the 
standard of care for early stage HL. Exceptions can be made for individual cases with either 
chemotherapy alone or RT alone. Of significance, and as noted by Armitage (Armitage, 
2010), it appears that the actual choice of treatment modality is greatly affected by a 
physician’s comfort with a particular treatment and by cumulative clinical experience- not 
just by data published in the literature. 
4.4 Treatment of early stage NLPHL 
4.4.1 Introduction 
As discussed above, NLPHL is a rare subtype of HL with distinctive morphologic and 
immunophenotypic features compared to cHL. NLPHL accounts for 5% of HL cases with 
around 500 new diagnoses in US annually. Many retrospective analyses showed different 
natural history and more indolent course than cHL. Given the rarity of NLPHL, there are no 
randomized studies to establish standard of care for management of NLPHL. It has been 
managed historically similarly to cHL, however distinctive features are more recognized 
currently with some changes in the approach of management. 
4.4.2 Presentation and prognosis 
Generally, NLPHL is characterized by early presentation (stages I-II), indolent course with 
no constitutional symptoms, favorable prognosis, and occasional late relapses. The 
extremely favorable prognosis on some cases is reflected by data which showed that 
patients with stage IA may be treated with LN excision followed by a “watch and wait” 
approach or with IFRT alone (Diehl, Sextro, Franklin, et al, 1999; Nogova, Reineke, Eich, et al, 
2005; Schlembach, Wilder, Jones, et al, 2002; Wilder, Schlembach, Jones, et al, 2002; Wirth, 
Yuen, Barton, et al, 2005) and that some patients with Stages IIIA-IVA may benefit as well 
from the “watch and wait” approach until they become symptomatic without jeopadarizing 





The largest analysis to describe patients with NLPHL and identify certain prognostic factors 
is the recent report by Nogova , et al (Nogova, Reineke, Brillant, et al, 2008) who reviewed 
all NLPHL patients registered in the GHSG database, comparing patient characteristics and 
treatment outcome with cHL patients. A total of 394 patients with NLPHL were identified 
with 63 % having early stage favorable, 16 % has early stage unfavorable, and 21% has 
advanced stage. At a median follow-up of 50 months, FFTF (88% vs 82%) and OS (96% vs 
92%) were found better with NLPHL compared to cHL, respectively. Among patients with 
NLPHL, FFTF were superior in patients with early favorable HL compared to those with 
early unfavorable HL and advanced HL (93% vs 87% vs 77%, respectively). The following 
factors were found negative prognostic factors: age (≥ 45), advanced stage, hemoglobin 
<10.5 g/dl, and lymphopenia. In another, but smaller series, Diehl V et al (Diehl, Sextro, 
Franklin, et al, 1999) reported similar favorable outcomes for early stage disease NLPHL 
compared to more advanced stages. 
4.4.3 Treatment options 
IF-RT or regional RT alone has been accepted by most investigators in Europe and US as a 
valid choice in the setting of non-bulky stage IA-IIA NLPHL, and is adopted as first line 
therapy by the NCCN guidelines. This is based on many retrospective analyses which 
showed excellent long term outcomes and no added benefit with combined modality 
therapy as for cHL. The Australasian Radiation Oncology Lymphoma Group (Wirth, Yuen, 
Barton, et al, 2005) described the long term outcomes of 202 patients with stage I-II NLPHL 
treated with RT alone. At a median follow-up of 15 years, the FFP and OS rates for the 
whole group were 82 % and 83 %, respectively. Various RT fields were used in this 
population with a median RT dose of 36 Gy. Another small series of 36 patients reported 
treatment outcomes with RT alone for non-bulky stage IA-IIA NLPHL (Schlembach, Wilder, 
Jones, et al, 2002). In this small series, 20 patients with stage IA received either IF-RT or EF-
RT alone. At a median follow up of 8.8 years, the 5-year relapse-free and OS rates were 95% 
and 100%, respectively.  
Treatment outcomes for early stage NLPHL with RT with or without chemotherapy have 
been reported in few other retrospective analyses. Chen RC et al (Chen, Chin, Ng, et al, 2010) 
reported recently the outcomes from 113 patients with stage I-II NLPHL treated with RT 
alone (93 patients), combined modality (13 patients), or chemotherapy alone (7 patients). 
Among the 106 patients treated with RT, 25 received limited-field, 35 regional-field, and 46 
received EF-RT. At a median follow-up of 136 months, 10-year PFS rates were 85% (stage I) 
and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II 
respectively. PFS and OS did not differ among patients who received limited-field, regional-
field, or extended-field RT. In contrast, six of seven patients who received chemotherapy 
alone developed early disease progression. In a multivariate analysis, extent of RT was not 
significantly associated with PFS. Addition of chemotherapy to RT didn’t improve the 
outcomes as well. 
Nogova L et al (Nogova, Reineke, Eich, et al, 2005) reported a retrospective analysis, from 
the GHSG, which included 131 patients with stage IA NLPHL treated with either IF-RT 
alone (45 patients), ER-FT alone (45 patients), or the RT combined with two to four cycles of 
ABVD chemotherapy (41 patients). At a median follow-up of 78 months for EF-RT, 17 
months for the IF-RT, and 40 months for the combined modality, the estimated 24-month 
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RT alone. At a median follow up of 8.8 years, the 5-year relapse-free and OS rates were 95% 
and 100%, respectively.  
Treatment outcomes for early stage NLPHL with RT with or without chemotherapy have 
been reported in few other retrospective analyses. Chen RC et al (Chen, Chin, Ng, et al, 2010) 
reported recently the outcomes from 113 patients with stage I-II NLPHL treated with RT 
alone (93 patients), combined modality (13 patients), or chemotherapy alone (7 patients). 
Among the 106 patients treated with RT, 25 received limited-field, 35 regional-field, and 46 
received EF-RT. At a median follow-up of 136 months, 10-year PFS rates were 85% (stage I) 
and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II 
respectively. PFS and OS did not differ among patients who received limited-field, regional-
field, or extended-field RT. In contrast, six of seven patients who received chemotherapy 
alone developed early disease progression. In a multivariate analysis, extent of RT was not 
significantly associated with PFS. Addition of chemotherapy to RT didn’t improve the 
outcomes as well. 
Nogova L et al (Nogova, Reineke, Eich, et al, 2005) reported a retrospective analysis, from 
the GHSG, which included 131 patients with stage IA NLPHL treated with either IF-RT 
alone (45 patients), ER-FT alone (45 patients), or the RT combined with two to four cycles of 
ABVD chemotherapy (41 patients). At a median follow-up of 78 months for EF-RT, 17 
months for the IF-RT, and 40 months for the combined modality, the estimated 24-month 
FFTF rates were 100, 92, and 97 percent, respectively for the three treatment groups. In 
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another small series (48 patients), but with longer median follow-up (9.3 years), the M.D 
Anderson study (Wilder, Schlembach, Jones, et al, 2002) showed no difference in treatment 
outcomes for early stage NLPHL with RT alone (37 patients) compared to combined 
modality (11 patients). 
Based on current data and until future convincing evidence is available, we think IF-RT alone 
is the preferred first line treatment modality for early stage favorable NLPHL. There is a 
general agreement for now by most investigators to treat patients with early unfavorable or 
advanced-stage LPHL according to the treatment protocols for cHL. However, with more data 
investigating the role of the monoclonal anti-CD 20 antibody (Rituximab) in patients with 
NLPHL, many investigators recommend incorporating rituximab alone or combined with 
other treatment modalities for unfavorable early stage, advanced stage, and relapsed NLPHL.  
5. Special cases 
5.1 Treatment of elderly patients with HL 
5.1.1 Introduction 
HL is a disease of relatively young patients; however, about 15-30% of patients with HL 
are older than 60 years according to few population-based studies. Elderly patients are 
mostly defined as those above ages 60-65 years. Unfortunately, the reported rates of 
elderly HL patients enrolled in large randomized studies is much lower than its 
prevalence (<5% to 10%) (Evens, Hutchings & Diehl, 2008; Klimm, Diehl & Engert, 2007). 
There is paucity of randomized studies that targeted the elderly HL population alone. 
However, many retrospective analyses derived from large studies have addressed the 
elderly population.  
5.1.2 Presentation and prognosis 
Elderly patients tend to present with increased frequency of mixed cellularity histologic 
subtype, advanced disease, B symptoms, and Epstein-Barr virus-positive disease. Overall, 
patients older than 60 years tend to have poorer outcomes than the younger population as 
reported by most series. Poor outcomes may be attributed to various factors including 
multiple co-morbidities, poor performance and/or mental status, inability to tolerate 
aggressive therapy, and death due to causes other than HL, among other factors as 
discussed below (Evens, Hutchings & Diehl, 2008; Klimm, Diehl & Engert, 2007). 
Kim HK et al (Kim, Silver, Li, et al, 2003) reported treatment outcomes of 86 elderly patients 
(60-93 years) among which 52 patients had early stage disease (stages IA-IIA) and 34 
patients had advanced disease (stages IIB-IV). At a median follow-up of 75 months, the 10-
year FFTF and OS rates for all patients were 62% and 30%, respectively. The 10-year FFTF 
and OS for early stage HL were 71% and 31% and for advanced stage HL were 49% and 
26%, respectively. In this study, the recurrence of HL was found to have a significant 
negative impact on survival. In a more recent report by Engert A et al (Engert, Ballova, 
Haverkamp, et al, 2005), a comprehensive retrospective analysis from the GHSG data base 
was performed and yielded poorer outcomes for elderly patients. From 4251 patients, 372 





were significantly lower than those in younger patients. It was noticed in this study that the 
acute toxicity rate was higher in the elderly and that fewer elderly patients received the 
intended full dose chemotherapy. Hence, the authors concluded that the overall poorer 
outcome of elderly HL patients is attributed to the higher mortality during treatment and 
the lower dose-intensity therapy received. Of notice in this study, and as have been noticed 
with few other reports, adequately staged elderly patients receiving appropriate doses of 
therapy can achieve responses comparable to those of younger patients. However, older 
patients in general have a less favorable outcome which may be attributed to treatment-
related deaths, shorter survival after relapse, death due to other causes, and others as 
mentioned above. Few other reports over the past 3-4 decades have been published with 
similar outcomes as above. 
5.1.3 Treatment options 
To date and until proven otherwise, there is an agreement among different investigators to 
treat the best fit elderly patients according to the management guidelines for the younger 
population, early stage HL with CMT and advanced stage disease with chemotherapy with 
or without RT as indicated. If chemotherapy is indicated, the widely used ABVD regimen 
would probably be the preferred regimen over the less commonly used and/or more 
intense-toxic regimens such as Stanford V and BEACOPP. 
Over the past 10 years, attempts are being made to define the best therapeutic approach for 
elderly patients. Adjusting the chemotherapy and/or RT protocols to maintain high efficacy, 
but decrease the toxicity have been tried.  
For patients with early stage unfavorable HL, Klimm et al. (Klimm, Eich, Haverkamp, et 
al, 2007) reported in 2007 the GHSC experience for the elderly early stage HL after CMT 
with 4 cycles of chemotherapy (COPP/ABVD) followed by EF-RT vs. IF-RT. From 1204 
patients enrolled in the GHSG HD8 study, 89 patients were 60 years or older. Acute 
toxicity from RT was more pronounced in elderly patients receiving EF-RT compared to 
IF-RT. FFTF and OS rates were significantly lower in the elderly patients compared to 
younger population. However, more importantly, this study reported that elderly patients 
had poorer outcome when treated with EF-RT compared to IF-RT in terms of FFTF (58% 
vs. 70%) and OS (59% vs. 81%). 
In regards of best chemotherapy regimen, data suggest that best outcomes in the elderly HL 
patients were received with adriamycin-based therapy. Weekes et al. (Weekes, Vose, Lynch, 
et al, 2002) reported that patients received anthracycline-containing regimen (ChlVPP/ABV) 
survived twice as long as patients given ChlVPP alone. Ballova et al. (Ballova, Ruffer, 
Haverkamp, et al, 2005), on the other hand in the HD9 elderly study, tried more intense 
regimen with baseline BEACOPP compared to COPP-ABVD in patients (>60 years) with 
advanced stage HL. Although there was better tumor control in the BEACOPP arm, that 
didn’t translate into better outcome because of the higher toxicity.  
More recently, and in an attempt to maintain dose intensity and avoid excessive toxicity, 
CHOP-21 regimen which is traditionally used for NHL has been studied as front line 
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al, 2007) reported in 2007 the GHSC experience for the elderly early stage HL after CMT 
with 4 cycles of chemotherapy (COPP/ABVD) followed by EF-RT vs. IF-RT. From 1204 
patients enrolled in the GHSG HD8 study, 89 patients were 60 years or older. Acute 
toxicity from RT was more pronounced in elderly patients receiving EF-RT compared to 
IF-RT. FFTF and OS rates were significantly lower in the elderly patients compared to 
younger population. However, more importantly, this study reported that elderly patients 
had poorer outcome when treated with EF-RT compared to IF-RT in terms of FFTF (58% 
vs. 70%) and OS (59% vs. 81%). 
In regards of best chemotherapy regimen, data suggest that best outcomes in the elderly HL 
patients were received with adriamycin-based therapy. Weekes et al. (Weekes, Vose, Lynch, 
et al, 2002) reported that patients received anthracycline-containing regimen (ChlVPP/ABV) 
survived twice as long as patients given ChlVPP alone. Ballova et al. (Ballova, Ruffer, 
Haverkamp, et al, 2005), on the other hand in the HD9 elderly study, tried more intense 
regimen with baseline BEACOPP compared to COPP-ABVD in patients (>60 years) with 
advanced stage HL. Although there was better tumor control in the BEACOPP arm, that 
didn’t translate into better outcome because of the higher toxicity.  
More recently, and in an attempt to maintain dose intensity and avoid excessive toxicity, 
CHOP-21 regimen which is traditionally used for NHL has been studied as front line 
therapy for elderly HL patients with promising results (Kolstad, Nome, Delabie, et al, 2007). 
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There have been few other regimens tested in single arm phase II studies and others are being 
under investigation with various successes to date. Examples of such regimens include 
vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin 
(VEPEMB) (Levis, Anselmo, Ambrosetti, et al, 2004), vincristine, doxorubicin, bleomycin, 
etoposide and prednisone (ODBEP) (Macpherson, Klasa, Gascoyne, et al, 2002), prednisone, 
vinblastine, doxorubicin and gemcitabine (PVAG) (Boll, Bredenfeld, Gorgen, et al, 2011), and 
bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbacine and prednisone 
(BACOPP) (Halbsguth, Nogova, Mueller, et al, 2010). However, randomized studies are highly 
recommended in this elderly heterogenous population in order to adopt any of the new 
regimens as standard of care compared to traditional regimens such as ABVD. 
We do think that using a comprehensive geriatric assessment (CGA) model for elderly HL 
patients, addressing comorbidity and functional status prior to initiation of therapy, may 
guide medical providers in their decision for the intense of therapy which usually predicts 
treatment outcomes. A similar approach has been studied in elderly patients with diffuse 
large cell lymphoma (Tucci A et al, 2009) where GCA was found to be an efficient method to 
identify elderly patients who may benefit from a curative approach with aggressive therapy 
(well fit patients) compared to unfit patients who have poor outcomes. Until more data is 
available, treatment of well fit elderly patients should follow same guidelines as for younger 
population given the potentially high cure rate of HL even in advanced disease status as 
compared to poor outcomes with other types of cancers. 
5.2 Treatment of HL during pregnancy 
5.2.1 Epidemiology and prognosis 
As the HL high incidence rates coincides with the female reproductive age, it is not 
surprising to mention that it is considered the fourth most common cancer during 
pregnancy (Sadural & Smith, 1995). However, as the overall incidence/prevalence of HL 
is low compared to other cancers the association between pregnancy and HL is low as 
well with only few small series describing the clinical presentation and treatment 
outcomes in this population. Fortunately, most reports showed that pregnancy doesn’t 
have a negative impact on the course of HL with long term treatment outcomes 
comparable to those who were treated while non-pregnant (Gelb, van de Rijn, Warnke, et 
al, 1996). The challenge in managing those cases is attributed to the increased risk on the 
fetus with the different diagnostic and/or therapeutic interventions. Adverse teratogenic 
effects from chemotherapy and/or RT depend mainly on the level of fetal maturation. The 
highest teratogenic effects with increased risk of fetal malformation and death are noticed 
in the first trimester. In the second and third trimester, complications from therapy are 
more subtle with adverse effects such as intrauterine growth retardation, impaired 
functional or mental development, microcephaly, and low birth weight, among others 
(Fisher & Hancock, 1996). 
5.2.2 Presentation and staging 
Clinical presentation of HL during pregnancy is generally similar to non-pregnant patients. 





scans should be avoided if possible. Instead, CXR and abdominal US and/or MRI may be 
used safely to complete staging (Nicklas & Baker, 2000). 
5.2.3 Treatment options 
There are no consensus guidelines to date that address standard of care. However, based on 
the available scattered reports there is an agreement to manage pregnant patients 
conservatively if possible until fetal maturation or delivery. Some authors suggested that in 
specialized cases (such as those with limited stage IA-IIA in their late second and third 
trimester), treatment may be deferred until mature fetal development and delivery, but 
patients should be followed then very closely for any signs of progression and proceed with 
delivery and/or therapy as indicated (Gelb, van de Rijn, Warnke, et al, 1996; Jacobs, 
Donaldson, Rosenberg, et al, 1981). 
Patients who present with HL during the first trimester, in particular those with advanced 
disease, may be offered therapeutic abortion given the high risk of teratogenic effects 
associated with therapy. Data suggest that chemotherapy increases risk of fetal 
malformations to around 15% during the first trimester, with the greatest risk associated 
with the alkylatng and antimetabolite drugs, as opposed to the lowest risk with 
vinblastine (Doll, Ringenberg & Yarbro, 1989; Yahalom, 1990). Of notice, Doll DC et al. 
reported as well that there was low risk of fetal malformation in the second and third 
trimesters. In contrast, RT has been used more safely during pregnancy even in the first 
trimester. Yahalom J (Yahalom, 1990), in a series of 23 patients received 
supradiaphragmatic radiation therapy (five in the first trimester), reported no harm to the 
fetus. Based on these data and other similar reports, if treatment is indicated in the first 
trimester and can’t be delayed for the second trimester, RT (with maximized  
uterine shielding) may be considered the best choice for supradiaphragmatic disease  
(with a dose of less than 10 Gy). However, for patients with infradiaphragmatic  
disease and/or advanced disease chemotherapy may be indicated with vinbastine-based  
therapy. 
For second and third trimesters, treatment may be deferred until complete fetal 
development and safe delivery in specific asymptomatic localized stages. However, most 
patients would need treatment which may include RT alone (10 to 36 Gy in a mantle or IF-
RT fashion) for supradiaphragmatic disease (with maximized uterine shielding) vs. 
chemotherapy for infradiaphragmatic and/or advanced disease as for the first trimester; 
however, in the second and third trimesters the use of chemotherapy is much safer than in 
the first trimester (Barnicle, 1992; Doll, Ringenberg & Yarbro, 1989), but remote side effects 
on long term survivor babies remain of concern. 
6. Novel treatments for early stage HL 
Besides the increased use of the monoclonal anti-CD20 antibody (rituximab) in NLPHL, 
novel targeted therapy is rarely incorporated in the management of early stage HL. This is 
mainly because of the high cure rates achieved with traditional chemotherapy regimens. 
Novel therapies are being more studied in advanced and relapsed/progressive diseases and 
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The treatment of early stage classical HL is mostly, today a combined modality with 
chemotherapy and involved field radiation. Decreasing the long-term side effects of the 
treatment is a goal. Decreasing the dosing of radiation and improving the radiation 
techniques, may demonstrate less complications in long-term follow-up. Incorporation of 
PET scan as a tool may select patients who will have higher risk for relapse. It is imperative 
to consider the acute and long-term side effects of the current therapeutic modalities in the 
treatment planning and future clinical trials. 
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1. Introduction 
Given that a clear, universal definition of advanced Hodgkin lymphoma does not exist, it 
comes as no surprise that the treatment of this disease is a controversial subject. Currently, 
the cure rate of advanced Hodgkin lymphoma is relatively high, although most physicians 
and patients confronting this disease recognize that the cure rate is less than ideal and the 
costs of treatment are substantial in terms of morbidity and mortality. The current research 
focus in this disease, as with any oncologic disorder, is to maximize the curative potential of 
treatment while minimizing patient suffering.  
In this chapter, the following topics will be discussed: the definition of advanced Hodgkin 
lymphoma, the development of combination chemotherapy for this disease, the important 
clinical trials that led to ABVD (a combination chemotherapy regimen consisting of: 
adriamycin, bleomycin, vinblastine, and dacarbazine) becoming the gold standard, the 
emergence of escalated BEACOPP (a combination chemotherapy regimen consisting of: 
bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and 
prednisone), as a challenger to ABVD therapy, utilization and role of other combination 
chemotherapy regimens, the controversial role of radiotherapy, the roles of autologous and 
allogeneic hematopoietic stem cell transplantation, prognostic factors in both untreated and 
relapsed patients, promising therapies of the future, and case studies.  
As a young physician and investigator, the two most exciting areas of research currently 
involve the use of fusion positron emission tomography/ computed tomography (PET/CT) 
imaging and the continued expansion of targeted treatment strategies, such as brentuximab 
vedotin and rituximab, which will hopefully allow both improved treatment tailoring and 
subsequent outcome for patients.    
2. Definition of “advanced” Hodgkin Lymphoma 
Applying the term “advanced” to a patient with Hodgkin lymphoma implies that there is a 
clear definition of the opposite term, or “limited” disease. Precise, universally accepted 
definitions do not exist for either term as applied to Hodgkin lymphoma.  
Eligibility criteria for clinical trial enrollment are an important source of definitions in 





Hodgkin Study Group (GHSG), included all patients with stage IIIB-IV disease in the HD9 
trial (Diehl et al. 1998), but required that patients with stage IIB disease have one of the 
following: an extralymphatic site, a bulky spleen (diffuse infiltration or > 5 focal lesions), or 
a bulky mediastinum (more than one third of the maximum thoracic diameter). Patients 
with stage IIIA disease were required to have either an erythrocyte sedimentation rate  
>50 mm/hr or ≥ 3 affected lymph node areas. Similarly, two major Italian studies, each 
comparing ABVD with other regimens, enrolled patients with stage IIB along with stage III-
IV disease, although one study uses the term “intermediate and advanced” (Gobbi et al. 
2005) and the other “unfavorable” rather than “advanced”(Viviani et al. 2011). Studies 
comparing MOPP with ABVD (Canellos et al. 1992) or ABVD with hybrid regimens (Duggan 
et al. 2003) in North America have included only stage III and IV patients.  
In order to more easily compare results of studies performed all over the globe, the Hodgkin 
lymphoma community should insist upon homogeneity across clinical trials. In spite of the 
fact that there may be prognostic rationale for including patients with “B” symptoms or 
bulky disease with stage III and IV patients, it is probably more important to have 
uniformity across clinical trials internationally. It is reasonable to reserve the term 
“advanced” Hodgkin lymphoma for stage III and IV patients regardless of disease bulk, B 
symptoms, or any other adverse prognostic factor. Patients with adverse features and stage I 
or II disease would fall into a category of “limited unfavorable”.  
3. Role of combination chemotherapy 
Combination chemotherapy for advanced Hodgkin lymphoma was initially developed by 
Vincent DeVita at the National Cancer Institute (NCI) in response to the initial successes in 
childhood leukemia treatment with combinations of agents. MOMP (mechlorethamine, 
vincristine, methotrexate, prednisone) was the initial combination regimen developed. Once 
procarbazine was developed sufficiently, it replaced methotrexate and the regimen was 
termed MOPP (DeVita et al. 1978). In a landmark study on the results of MOPP, 81 percent 
of stage III/IV Hodgkin lymphoma patients achieved a complete remission, a roughly four-
fold higher response rate than with single agents, and the remission duration, when 
compared retrospectively, was increased approximately ten-fold over single agents alone 
(Devita, Serpick, and Carbone 1970). Ultimately, MOPP was shown in a prospective fashion 
to be superior to single agent nitrogen mustard in a small, randomized trial conducted by 
the Southeastern Cancer Group. One hundred eight patients with stage III or IV Hodgkin 
lymphoma were randomized between MOPP and mechlorethamine given biweekly, and 
patients receiving MOPP were found to have superior complete remission rates and overall 
survival (Huguley et al. 1975). From that time on, combination chemotherapy for advanced 
Hodgkin lymphoma became standard, and comparisons between various combination 
regimens ensued. 
The Cancer and Leukemia Group B (CALGB) performed a randomized comparison amongst 
four different combination chemotherapy regimens: the four-drug combinations were BOPP 
(mechlorethamine substituted with BCNU) and MOPP, and the three-drug combinations 
were BOP (procarbazine eliminated) and OPP (BCNU or mechlorethamine eliminated). This 
study demonstrated superiority of four-drug over three-drug combinations, it highlighted 
the importance of the alkylating agents mechlorethamine and procarbazine, and it further 





Hodgkin Study Group (GHSG), included all patients with stage IIIB-IV disease in the HD9 
trial (Diehl et al. 1998), but required that patients with stage IIB disease have one of the 
following: an extralymphatic site, a bulky spleen (diffuse infiltration or > 5 focal lesions), or 
a bulky mediastinum (more than one third of the maximum thoracic diameter). Patients 
with stage IIIA disease were required to have either an erythrocyte sedimentation rate  
>50 mm/hr or ≥ 3 affected lymph node areas. Similarly, two major Italian studies, each 
comparing ABVD with other regimens, enrolled patients with stage IIB along with stage III-
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or II disease would fall into a category of “limited unfavorable”.  
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Vincent DeVita at the National Cancer Institute (NCI) in response to the initial successes in 
childhood leukemia treatment with combinations of agents. MOMP (mechlorethamine, 
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termed MOPP (DeVita et al. 1978). In a landmark study on the results of MOPP, 81 percent 
of stage III/IV Hodgkin lymphoma patients achieved a complete remission, a roughly four-
fold higher response rate than with single agents, and the remission duration, when 
compared retrospectively, was increased approximately ten-fold over single agents alone 
(Devita, Serpick, and Carbone 1970). Ultimately, MOPP was shown in a prospective fashion 
to be superior to single agent nitrogen mustard in a small, randomized trial conducted by 
the Southeastern Cancer Group. One hundred eight patients with stage III or IV Hodgkin 
lymphoma were randomized between MOPP and mechlorethamine given biweekly, and 
patients receiving MOPP were found to have superior complete remission rates and overall 
survival (Huguley et al. 1975). From that time on, combination chemotherapy for advanced 
Hodgkin lymphoma became standard, and comparisons between various combination 
regimens ensued. 
The Cancer and Leukemia Group B (CALGB) performed a randomized comparison amongst 
four different combination chemotherapy regimens: the four-drug combinations were BOPP 
(mechlorethamine substituted with BCNU) and MOPP, and the three-drug combinations 
were BOP (procarbazine eliminated) and OPP (BCNU or mechlorethamine eliminated). This 
study demonstrated superiority of four-drug over three-drug combinations, it highlighted 
the importance of the alkylating agents mechlorethamine and procarbazine, and it further 
solidified the role of four-drug combinations for treating Hodgkin lymphoma (Nissen et al. 
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1979). Interestingly, MOPP and BOPP were equivalent regimens, which demonstrated that 
BCNU and mechlorethamine may have equivalent efficacy. Similarly, a comparison of 
LOPP (lomustine replaces mechlorethamine) with MOPP demonstrated equal efficacy as 
well, further demonstrating that nitrosureas could substitute for alkylating agents in 
treatment of this disease (Hancock 1986).  
In summary, combination chemotherapy became standard on the basis a landmark study of 
MOPP therapy developed at the NCI, with formal confirmation of superiority over single 
agents in one randomized trial. Combination chemotherapy with four drugs was superior to 
three drugs. MOPP, with an alkylating agent meclorethamine, although equivalent in 
efficacy to nitrosurea-containing combinations, was likely favored by most experts in the 
field due to the short and long-term side effects associated with nitrosureas. 
4. ABVD as gold standard 
MOPP combination chemotherapy for advanced Hodgkin lymphoma resulted in twenty to 
thirty percent of patients failing to achieve a complete remission and only fifty percent of 
patients being cured with risks of both sterility and secondary malignancies such as acute 
leukemia (Bonadonna, Valagussa, and Santoro 1986; Longo et al. 1991). Bonadonna Gianni 
developed the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen in order to 
salvage MOPP failures (Bonadonna et al. 1975). In an initial Italian study comparing three 
cycles of ABVD or MOPP with receipt of radiotherapy in both arms, ABVD was superior 
with a seven-year overall survival of 77.4 percent versus 67.9 percent for MOPP (Santoro et 
al. 1987). ABVD therapy became solidified as the gold standard after a landmark three-arm 
CALGB study, which compared ABVD with MOPP and an alternating regimen, 
MOPP/ABVD. The study demonstrated five-year failure-free survival rates of 61 percent for 
ABVD, 50 percent with MOPP, and 65 percent for alternating MOPP/ABVD (Canellos et al. 
1992). The toxicity profile of ABVD was more favorable than either the alternating regimen 
or MOPP, and therefore ABVD became the standard combination chemotherapy regimen 
for advanced Hodgkin lymphoma. 
Interest in the Goldie and Coldman hypothesis (Goldie and Coldman 1979), which 
hypothesized that early introduction of all active agents for a disease would prevent the 
development of resistant clones, led to three major studies comparing hybrid and 
alternating regimens of MOPP and ABVD. No advantage in overall survival was found with 
the hybrid regimens (Connors et al. 1997; Sieber et al. 2002; Viviani et al. 1996). An 
important US Intergroup trial dampened further interest in hybrid regimens by 
demonstrating equivalent efficacy ABVD over a MOPP/ABV hybrid, with a similar failure-
free survival and overall survival at five years but a better toxicity profile of the ABVD 
regimen (Duggan et al. 2003). The solidification of ABVD as the true gold standard would 
take place in the 1990 and 2000’s, in which ABVD became the comparator arm for most 
randomized clinical trials. 
5. The emergence of escalated BEACOPP 
The group with a lead role in the advancement of Hodgkin therapy, the GHSG, developed 
the escalated BEACOPP regimen initially through mathematical modeling of tumor growth 





clinical trial in which doses of cytotoxic agents were increased in a stepwise fashion (Tesch 
et al. 1998). Escalated BEACOPP, the new dose dense regimen relative to COPP/ABVD and 
dose intense regimen relative to standard BEACOPP, was tested against these two regimens 
in the HD9 clinical trial. Ten year follow-up of that study, in which seventy percent of 
patients received additional radiotherapy, demonstrated statistically and clinically 
significant superiority of escalated BEACOPP over COPP/ABVD and standard BEACOPP 
in terms of freedom from treatment failure rate (82, 70, and 64 percent, respectively) and 
overall survival rate (86, 80, and 75 percent, respectively) (Engert et al. 2009).  
BEACOPP, given in different schedules than the German standard of eight escalated cycles, 
has also been compared with other regimens in two prospective, randomized, Italian 
studies. The HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial was initially designed 
as a toxicity trial to compare rates of leucopenia between three arms: a BEACOPP regimen 
(consisting of four escalated cycles and two standard cycles), a CEC regimen, and ABVD 
(Federico et al. 2009). Once the study centers became comfortable with BEACOPP 
administration, which requires the greatest attention and familiarity in the initial cycles, the 
trial was changed to a primary endpoint of failure-free survival. With a median follow-up of 
forty-one months and a suggestion of lower median dose intensity of BEACOPP delivered 
and resulting lower rates of grade III/IV hematologic toxicity compared with the escalated 
BEACOPP arm of the HD9 trial, the five-year estimated rates of failure-free survival were 78 
and 65 percent in the arms of interest, BEACOPP and ABVD, respectively, which reached 
both clinical and statistical significance. The five-year estimated overall survival 
demonstrated numerical superiority of BEACOPP over ABVD with rates of 92 versus 84 
percent, although this failed to meet statistical significance. In a second recently published 
Italian study, conducted in a similar time period as the HD2000 study, four cycles of 
escalated BEACOPP plus four cycles of standard BEACOPP were compared with ABVD 
with a primary endpoint of freedom from first progression (Viviani et al. 2011). With a 
median follow-up of sixty-one months, the estimated seven-year rate of freedom from first 
progression was 85 percent in the BEACOPP group versus 73 percent in the ABVD group. 
The primary endpoint importantly achieved both statistical and clinical significance. 
Counter to this, the secondary endpoints, which did not have statistical power, were overall 
survival and rate of freedom from second progression. These endpoints were 84 and 82 
percent in the ABVD arm, respectively, versus 89 and 88 percent in the BEACOPP arm, and 
they did not reach statistical significance. Details of exact dose intensity were not provided, 
and one could certainly debate, in spite of the author’s conclusions, the relevance of a five 
percent difference in overall survival, which numerically favored the BEACOPP program. 
The final analysis of the HD12 trial (Diehl et al. 2008), a comparison of eight cycles of 
escalated BEACOPP with four escalated cycles followed by four standard cycles of 
BEACOPP, demonstrates statistical equivalence at five year follow-up between the arms, 
with the eight escalated cycles being numerically superior and still the gold standard 
comparator arm for the HD15 study. The HD15 trial (Kobe et al. 2008) compares eight 
escalated cycles of BEACOPP with six escalated cycles of BEACOPP or eight cycles of 
fourteen day compressed BEACOPP. The results of this study, as well as the results of a 
global study comparing four cycles of escalated BEACOPP followed by four cycles of 
baseline BEACOPP with eight cycles of ABVD (European Organization for Research and 
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6. Other chemotherapy regimens 
Stanford V is a regimen incorporating twelve total weeks of alternating weekly cycles of 
myelotoxic and nonmyelotoxic polychemotherapy followed by liberal irradiation of 36 Gy to 
sites > 5 cm or macroscopic splenic disease (Bartlett et al. 1995). It was originally designed at 
Stanford although the chemotherapy backbone was likely drawn from the VACOPB 
regimen designed in Vancouver for non-Hodgkin lymphoma (O'Reilly et al. 1991). Stanford 
V was initially compared with ABVD and a regimen called MOPPEBVCAD by the 
Intergruppo Italiano Linfomi. Focusing on the Stanford V and ABVD arms, the primary 
endpoint of failure-free survival at five years was 76 perecent with Stanford V versus 89 
percent with ABVD, with overall survival of 82 percent versus 90 percent, respectively 
(Gobbi et al. 2005). The trial has been criticized for utilizing radiotherapy differently than 
the original Stanford V report, as 66 versus 89 percent of patients, respectively, received 
radiotherapy. Sites > 6 cm rather than >5 cm were irradiated, and radiotherapy occurred 4-6 
weeks rather than 2-4 weeks post-chemotherapy (so called optional versus adjuvant 
radiotherapy). More recently, a large Intergroup study was reported which compared 
Stanford V with six to eight cycles of ABVD. Somewhat unrealistically, the trial was 
designed to detect a 33 percent reduction in the failure-free survival hazard rate with 
Stanford V versus ABVD, and the failure-free survival at five years with Stanford V was 71 
versus 73 percent with ABVD with 87 and 88 percent overall survival rates, respectively 
(Gordon et al. 2010). This trial further solidifies ABVD as the standard polychemotherapy 
regimen in advanced Hodgkin lymphoma, and is still the comparator arm for further 
investigational work.   
Other polychemotherapy regimens which have been the subject of prospective, randomized 
investigation in advanced Hodgkin lymphoma which have not gained widespread appeal 
include: MEC, CHLVPP/EVA, and VAPEC-B. MEC, or MOPPEBVCAD (a regimen 
consisting of: mechlorethamine, lomustine, vindesine, melphalan, prednisone, 
epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin), was compared with 
Stanford V and ABVD in an Italian study, with all arms receiving optional radiotherapy. 
MEC provided similar disease control as ABVD with similar rates of freedom from first 
progression, although the grade III-IV toxicity rates, particularly hematologic toxicity, were 
higher with MEC than ABVD (Gobbi et al. 2005). Therefore, given the better balance of 
efficacy and toxicity afforded by ABVD, MEC fell out of favor. A United Kingdom/Italian 
study compared the hybrid regimen CHLVPP/EVA to VAPEC-B (Radford et al. 1997), an 
abbreviated 11 week polychemotherapy regimen similar to VACOP-B or Stanford V. 
CHLVPP/EVA resulted in a superior three year disease-free and overall survival, with rates 
of 82 and 89 percent versus 62 and 79 percent, respectively for VAPEC-B. When British 
investigators compared ABVD with CHLVPP/EVA or a similar regimen, 
CHLVPP/PABLOE, the three year event-free survival and overall survival were similar, and 
ABVD was better tolerated (Johnson et al. 2005). Since that study, these hybrid 
polychemotherapy regimens have not been utilized. 
In summary of chapters five and six, there is still controversy regarding the optimal 
chemotherapy approach in untreated Hodgkin lymphoma patients. In spite of the two 
“negative” Italian studies, and considering the difference in patient numbers between those 
studies and HD9, it is reasonable to treat patients with advanced Hodgkin lymphoma with 





recognizing that it has never shown superiority over ABVD or a similar regimen. Further 
refinement of chemotherapy for advanced Hodgkin lymphoma, utilizing both PET/CT 
guidance and monoclonal antibodies, is likely to occur in the future.  
7. Role of radiotherapy 
Radiotherapy is a treatment modality that is believed to be non-crossresistant with standard 
combination chemotherapy (DeVita 2008). Its use can be considered in several contexts in 
advanced Hodgkin lymphoma: as an adjuvant therapy after complete remission is obtained 
with chemotherapy, integrated as combined modality therapy, or utilized as a definitive 
modality when response to chemotherapy is unsatisfactory. 
The first use, as an adjuvant after complete response with polychemotherapy, was assessed 
in four randomized studies. Two studies compared radiotherapy with observation, and two 
studies compared radiotherapy with two additional cycles of chemotherapy. The Southwest 
Oncology Group randomized three hundred and twenty two patients with stage III or IV 
Hodgkin lymphoma who achieved a complete remission by computed tomographic 
assessment after six cycles of MOP-BAP between observation or low-dose (2000 cGy to 
lymph nodes, 1000-1500 cGy to other organs) involved field radiotherapy (IFRT). With a 
median follow-up of eight years, there were no statistically significant differences in relapse-
free or overall survival (Fabian et al. 1994). The GHSG randomized patients with stage III or 
IV disease in complete remission by computed tomographic assessment after six cycles of 
COPP/ABVD to two more cycles of chemotherapy or low-dose (20 Gy) IFRT, and this study 
demonstrated no difference in relapse rate between the two arms (Diehl et al. 1995). A 
GELA study assessed the role of more extensive radiotherapy (subtotal nodal or total) 
versus two more cycles of chemotherapy in stage III/IV patients having achieved a 
complete or very good partial remission (≥ 75% size reduction) with six cycles of either 
MOPP/ABV or ABVPP. With a median follow-up of forty-eight months, the five year 
disease-free survival was 79 percent for the radiotherapy versus 74 percent for continued 
chemotherapy (Ferme et al. 2000). In the largest trial to determine the role of IFRT in stage 
III/IV Hodgkin lymphoma, four hundred twenty-one patients with computed tomogram 
complete remission after MOPP/ABV polychemotherapy were randomly assigned to 
observation versus IFRT. With a median follow-up of seventy-nine months, the five year 
event-free and overall survival rates were 84 percent and 91 percent in the observation 
group, respectively versus 79 percent and 85 percent in the IFRT group, which 
demonstrated that there is no role for IFRT in advanced Hodgkin lymphoma patients who 
achieve a complete remission with polychemotherapy (Aleman et al. 2003).  
The second use, as an integrated therapy with chemotherapy, implies that radiotherapy is a 
pre-planned treatment regardless of response. The most common example of this is the 
administration of 36 Gy radiotherapy to patients receiving the Stanford V regimen who have 
sites of disease > 5cm or macroscopic splenic involvement. Unfortunately, radiotherapy 
administered in this context is completely of unproven value, and the harms are certain. For 
example, with intense polychemotherapy such as escalated BEACOPP, the GHSG has been 
able to reduce the percentage of patients on their studies receiving pre-planned 
radiotherapy from nearly 70 percent to approximately 10 percent without loss of efficacy 
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pre-planned treatment regardless of response. The most common example of this is the 
administration of 36 Gy radiotherapy to patients receiving the Stanford V regimen who have 
sites of disease > 5cm or macroscopic splenic involvement. Unfortunately, radiotherapy 
administered in this context is completely of unproven value, and the harms are certain. For 
example, with intense polychemotherapy such as escalated BEACOPP, the GHSG has been 
able to reduce the percentage of patients on their studies receiving pre-planned 
radiotherapy from nearly 70 percent to approximately 10 percent without loss of efficacy 
and with a clear-cut reduction in the rate of secondary leukemia, from 1.7 to 0.6 percent 
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comparing HD9 data with HD12 data (Diehl et al. 1998; Diehl et al. 2008). Unfortunately, 
many recently completed clinical trials still include pre-planned radiotherapy, such as the 
ECOG 2496 Intergroup study comparing ABVD with Stanford V, which provided 
radiotherapy to all patients on the ABVD arm with bulky mediastinal disease (Gordon et al. 
2010). Fortunately, most of the new generation of clinical trials, such as SWOG 0816 and 
CALGB 50604, which utilize PET/CT to risk stratify patients for subsequent therapeutic 
strategy, only include radiotherapy to patients categorized as high risk with a positive 
PET/CT after a certain number of chemotherapy cycles (Southwest Oncology Group 2011; 
Cancer and Leukemia Group B 2011). 
The third use, with utilization based on an unsatisfactory response to chemotherapy, 
certainly has theoretical appeal in order to improve outcomes of those patients with partial 
response to combination chemotherapy. Many studies include involved field radiotherapy 
for those patients with “residual tumor”, which again has various definitions. Indirect 
justification for this approach is made by analysis of the Aleman study. The cohort of 
patients who were irradiated after achievement of a partial response with chemotherapy 
had five year event-free and overall survivals of 79 and 87 percent, respectively, which 
compared favorably with those patients having achieved a complete response with 
chemotherapy alone, with event-free and overall survivals of 84 and 91 percent, respectively 
(Aleman et al. 2003). An important question is whether a subset of the patients in partial 
response can be spared the additional toxicity of radiotherapy. In a recent analysis of the 
HD15 trial, in which eight cycles of escalated BEACOPP was compared with six cycles of 
escalated BEACOPP or 14 day compressed BEACOPP, thirty-eight percent of patients had 
residual tumor > 2.5 cm at the completion of chemotherapy. Of this patient group, twenty-
one percent had a positive post-therapy PET/CT and seventy-nine percent had a negative 
PET/CT. The patients with a negative PET/CT were observed, and patients with a positive 
PET/CT received IFRT. The 18 month progression-free survival was 95 percent for patients 
who achieved a CR with chemotherapy, 96 percent for patients with > 2.5 cm residual tumor 
with PET/CT negativity who were observed, and 85 percent for PET/CT positive patients 
who received additional IFRT (Kobe et al. 2008). The authors recommend additional study, 
but in the meantime, a reasonable clinical practice would be to omit radiotherapy in those 
patients in complete metabolic remission post-therapy regardless of the initial disease 
features.  
In summary, there is no role for adjuvant radiotherapy in patients who achieve a computed 
tomography defined complete remission based on several randomized studies. There is no 
clear role of a pre-planned chemotherapy plus radiotherapy approach in advanced Hodgkin 
lymphoma, and although preliminary, it appears reasonable to defer decisions about 
radiotherapy until the post-therapy PET/CT is completed. It appears that patients with non-
FDG avid residual tumors can be safely observed, and based on indirect evidence, 
radiotherapy may benefit those with remaining FDG avidity in tumor masses. 
8. Role of autologous hematopoietic stem cell transplantation 
Autologous hematopoietic stem cell transplant has been studied in four separate 
prospective, randomized controlled clinical trials in Hodgkin lymphoma, in two instances in 





First, two studies utilizing transplant as consolidation of upfront polychemotherapy of 
Hodgkin lymphoma will be discussed. In a Scottish and Newcastle Lymphoma Group 
Study, sixty-five patients with “poor risk” disease were administered three cycles of 
PVACE-BOP chemotherapy with or without XRT. Those patients with a good partial or 
complete response were randomized to a melphalan/etoposide-conditioned autologous 
hematopoietic stem cell transplant versus 2 additional cycles of PVACE-BOP chemotherapy 
(Proctor et al. 2002). With a median follow-up of six years, the arms had a similar time to 
treatment failure, 79 percent in the transplant arm versus 85 percent in the non-transplant 
arm. The major conclusion of this study is that for a subset of patients with “poor risk” 
features derived by calculation of a Scottish Newcastle Lymphoma Group prognostic index, 
autologous hematopoietic stem cell transplantation offers no benefit over standard 
chemotherapy if a very good response on computed tomography is obtained after three 
cycles of polychemotherapy. In a second European Intergroup study, the HD 01 trial, one 
hundred sixty-three patients with “poor risk” disease at baseline were randomized after 
four cycles of ABVD or ABVD-like therapy in complete or partial response to a BEAM or 
CVB-conditioned autologous transplant or four additional cycles of chemotherapy (Federico 
et al. 2003). With a median follow-up of 48 months, the five year failure-free survival was 75 
percent in the transplant arm versus 82 percent in the chemotherapy arm. Rates of overall 
survival were 88 percent in each arm. Although the transplant conditioning regimens 
utilized were different, both trials have similar features, such as attempting to identify a 
poor-risk subset of patients in spite of different criteria used. Additionally, an abbreviated 
course of chemotherapy was utilized prior to the randomization of continued chemotherapy 
versus transplant. Both trials only randomized patients with a response to chemotherapy, 
were small in number, and obtained similar results. Based on these data, there appears to be 
no role for performing autologous transplantation in previously untreated Hodgkin 
lymphoma patients with poor risk features who achieve a response on computed 
tomography imaging.  
Two prospective randomized trials of autologous transplant have been conducted in 
patients with relapsed Hodgkin lymphoma. In the first trial, British investigators 
randomized forty patients with both relapsed and refractory “high risk” disease to either a 
chemotherapy regimen, mini-BEAM, or a BEAM-conditioned autologous transplant without 
details of exact number of chemotherapy courses given. The event-free survival at three 
years was 53 percent in the BEAM group versus 10 percent in the mini-BEAM group (Linch 
et al. 1993). The three year overall survival rate favored the BEAM group but did not achieve 
statistical significance. In the second study, German investigators randomized one hundred 
sixty-one patients with relapsed Hodgkin lymphoma to four cycles of Dexa-BEAM versus 2 
cycles of Dexa-BEAM followed by a BEAM-conditioned autologous transplant (Schmitz et 
al. 2002). The three year estimated freedom from treatment failure was significantly better at 
55 percent in the transplant arm versus 34 percent in the chemotherapy alone arm, while the 
overall survival did not reach statistical significance, with a rate of 71 percent in the 
transplant arm versus 65 percent in the chemotherapy alone arm. In spite of the lack of 
overall survival improvement, the disease-free survival improvement demonstrated in the 
above studies has lead to international acceptance that relapsed Hodgkin lymphoma is a 
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cycles of polychemotherapy. In a second European Intergroup study, the HD 01 trial, one 
hundred sixty-three patients with “poor risk” disease at baseline were randomized after 
four cycles of ABVD or ABVD-like therapy in complete or partial response to a BEAM or 
CVB-conditioned autologous transplant or four additional cycles of chemotherapy (Federico 
et al. 2003). With a median follow-up of 48 months, the five year failure-free survival was 75 
percent in the transplant arm versus 82 percent in the chemotherapy arm. Rates of overall 
survival were 88 percent in each arm. Although the transplant conditioning regimens 
utilized were different, both trials have similar features, such as attempting to identify a 
poor-risk subset of patients in spite of different criteria used. Additionally, an abbreviated 
course of chemotherapy was utilized prior to the randomization of continued chemotherapy 
versus transplant. Both trials only randomized patients with a response to chemotherapy, 
were small in number, and obtained similar results. Based on these data, there appears to be 
no role for performing autologous transplantation in previously untreated Hodgkin 
lymphoma patients with poor risk features who achieve a response on computed 
tomography imaging.  
Two prospective randomized trials of autologous transplant have been conducted in 
patients with relapsed Hodgkin lymphoma. In the first trial, British investigators 
randomized forty patients with both relapsed and refractory “high risk” disease to either a 
chemotherapy regimen, mini-BEAM, or a BEAM-conditioned autologous transplant without 
details of exact number of chemotherapy courses given. The event-free survival at three 
years was 53 percent in the BEAM group versus 10 percent in the mini-BEAM group (Linch 
et al. 1993). The three year overall survival rate favored the BEAM group but did not achieve 
statistical significance. In the second study, German investigators randomized one hundred 
sixty-one patients with relapsed Hodgkin lymphoma to four cycles of Dexa-BEAM versus 2 
cycles of Dexa-BEAM followed by a BEAM-conditioned autologous transplant (Schmitz et 
al. 2002). The three year estimated freedom from treatment failure was significantly better at 
55 percent in the transplant arm versus 34 percent in the chemotherapy alone arm, while the 
overall survival did not reach statistical significance, with a rate of 71 percent in the 
transplant arm versus 65 percent in the chemotherapy alone arm. In spite of the lack of 
overall survival improvement, the disease-free survival improvement demonstrated in the 
above studies has lead to international acceptance that relapsed Hodgkin lymphoma is a 
definite indication for autologous hematopoietic stem cell transplantation. 
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A small number of refractory patients were included in the British transplant trial, and 
based on their inclusion in that study plus retrospective datasets indicating possible benefit 
of autologous transplant, (Lazarus et al. 1999; Andre et al. 1999; Josting et al. 2000) patients 
with refractory Hodgkin lymphoma who achieve a response or even disease stabilization 
with a salvage chemotherapy regimen can be considered for autologous transplantation.  
Various conditioning regimens for autologous transplantation exist, and the BEAM (BCNU, 
etoposide,cytarabine, melphalan) regimen has been utilized in both randomized trials for 
relapsed/refractory disease. Other reported high-dose chemotherapy regimens include: 
CBV (cyclophosphamide, BCNU, VP-16), CBVP (CBV + cisplatin), Etoposide/Melphalan, 
high dose Melphalan, CCV (cyclophosphamide, CCNU, VP-16), and TLI (total lymphoid 
irradiation)+VP-16/cyclophosphamide). No prospective comparative trials of these 
regimens exist, and due to heterogeneity in parameters reported, even indirect comparison 
is challenging. In a retrospective comparison of two different condidtioning regimens, one 
radiation based with TBI/ cyclophosphamide/etoposide versus a chemotherapy regimen of 
busulfan/melphalan/ thiotepa (Bu/Mel/T), investigators at Fred Hutchinson Cancer 
Center found no difference in efficacy or toxicity of either preparative regimen. Patients who 
had a history of dose-limiting irradiation were treated with the Bu/Mel/T regimen 
preferentially (Gutierrez-Delgado et al. 2003). The BEAM regimen, given its use in the 
randomized trials, is a reasonable choice in the absence of comparative data, and the 
primary clinical issues with use of this regimen are melphalan-related gastrointestinal 
toxicity and BCNU-related pulmonary toxicity, the latter of which requires corticosteroid 
initiation at recognition.  
Further intensification of a single autologous transplant for relapsed/refractory patients has 
been studied, both by utilizing higher doses of standard chemotherapy pre-transplant and 
by the addition of a planned second, or tandem transplant. In the HD-R2 trial, a European 
multicenter (GHSG, EORTC, EBMT, and GEL/TAMO) study for relapsed Hodgkin 
lymphoma, investigators randomized two hundred forty one patients without progressive 
disease after two cycles of DHAP to either a BEAM conditioned autologous transplant or 
sequential high dose chemotherapy with cyclophosphamide 4gm/m2, methotrexate 
8gm/m2, and etoposide 500mg/m2, followed by a BEAM conditioned autologous 
transplant, with IFRT to residual masses > 1.5cm in both arms. With a median follow-up of 
42 months, the three year OS was 87 percent in the standard arm versus 83 percent in the 
high dose sequential arm, with corresponding rates of freedom from treatment failure of 71 
percent and 65 percent, respectively (Josting et al. 2010). The conclusions of the authors, 
based on the largest randomized trial in relapsed Hodgkin lymphoma to date, is that 
sequential high dose chemotherapy has no role and that patient outcomes were quite good 
with two cycles of DHAP followed by a BEAM conditioned transplant. In the prospective, 
multicenter H96 trial conducted by the GELA/SFGM group, investigators studied the role 
of tandem autologous transplant for relapsed/refractory Hodgkin lymphoma patients with 
poor risk disease, defined as primary refractoriness to initial chemotherapy or ≥ 2 risk 
factors of the following: relapse < 12 months from primary therapy, stage III/IV disease at 
relapse, and relapse within a previously irradiated site with combined modality therapy. 
These poor-risk patients received two cycles of chemotherapy followed by a CBV plus 
mitoxantrone or BEAM-conditioned first transplant, with a second transplant with TAM 





45-90 days later. On an intent-to-treat basis, with a median follow-up of fifty one months, 
the five year freedom treatment failure and overall survival rates were 46 percent and 57 
percent, respectively (Morschhauser et al. 2008). Seventy percent of poor risk patients 
received a second transplant with a transplant-related mortality of four percent. The authors 
concluded that tandem transplant was an advance in the treatment of poor risk patients 
with partial response to salvage chemotherapy and in those with primary refractory disease, 
given the superior results to historical data of single transplant in those populations.  
In summary, autologous hematopoietic stem cell transplant has no role in the upfront 
treatment of patients with Hodgkin lymphoma. For patients with relapsed disease, it is 
considered the standard of care if chemotherapy sensitivity can be demonstrated. For 
patients with primary refractory disease, autologous transplantation is controversial but a 
small amount of retrospective data indicates a possible benefit. Chemotherapy 
intensification over traditional salvage regimens for relapsed/refractory patients appears to 
have no role, and there is possible benefit in tandem transplant for patients who are at high 
risk for poor outcome with a single autologous transplant. 
9. Salvage therapy for relapsed/refractory disease 
For patients who experience relapse after achievement of a complete response or who do not 
achieve a complete response and have biopsy proven residual Hodgkin lymphoma, 
conventional treatment consists of several cycles of non-crossresistant chemotherapy 
followed by autologous hematopoietic stem cell transplantation. In this chapter, the roles of 
radiotherapy and chemotherapy specifically for relapsed disease will be discussed.  
The use of radiotherapy alone or in combination with salvage chemotherapy in 
relapsed/refractory Hodgkin lymphoma is controversial. Several retrospective reports exist 
on utilizing isolated radiotherapy for patients with relapsed/refractory disease after failure 
of combination chemotherapy. In the largest study, the GHSG found that of the one 
hundred patients in their database treated with radiotherapy alone after failure of 
anthracycline-based chemotherapy, the five-year freedom from treatment failure was 28 
percent with an overall survival of 51 percent (Josting et al. 2005). The authors conclude that 
salvage radiotherapy is a treatment option for a subset of patients without B symptoms but 
with good performance status, limited stage, and late relapses, which effectively excludes 
the majority of Hodgkin lymphoma patients with relapsed disease and all patients with 
refractory disease.  
No reports have compared outcomes of patients who do and do not receive radiotherapy as 
a component of salvage chemotherapy with autologous transplantation, and therefore the 
balance of efficacy and toxicity in this scenario is uncertain. Radiotherapy to “residual 
lesions” after the BEAM-conditioned autologous transplant was recommended in the 
German transplant study in relapsed disease, although too few patients received 
radiotherapy to allow comparison of outcomes to those without radiotherapy. Given that 
the opportunity for cure is greatly diminished in relapsed/refractory Hodgkin lymphoma, 
in spite of an absence of evidence of a definite benefit of radiotherapy, it is reasonable to 
include radiotherapy as part of a treatment regimen that includes salvage chemotherapy 
and autologous transplantation, particularly if the relapse is localized on imaging. Based on 
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transplant (Tsang et al. 1999), it may be most reasonable to use this modality post-
transplant.  
Salvage chemotherapy is administered to the majority of patients with relapsed/refractory 
Hodgkin lymphoma with the goal of disease reduction or eradication prior to autologous 
transplantation. In fact, in the era of computed tomography, multiple reports document that 
the response to salvage chemotherapy is a major determinant of the outcome of autologous 
transplant (Sureda et al. 2001; Gutierrez-Delgado et al. 2003; Martin et al. 2001) and that the 
degree of response is associated with the progression-free survival at five years (Sirohi et al. 
2008). 
An ideal salvage regimen has an excellent response rate, non-overlapping organ toxicities 
with the primary regimen, and preserves the ability to mobilize and collect hematopoietic 
stem cells. Because initial treatment of Hodgkin lymphoma nearly always consists of 
anthracycline and bleomycin therapy, and because autologous transplant is the usual goal, 
which is a stress on the cardiopulmonary system, salvage therapy choices are typically made 
to limit cardiopulmonary toxicity.  
Many different salvage polychemotherapy regimens have been utilized in the past, and all 
studies have been phase II investigations with heterogeneous patient populations with 
relapsed/refractory disease. See Table 1. Because only DEXA-BEAM and mini-BEAM 
regimens have been used pre-transplant in randomized clinical trials, the purist would 
utilize these regimens at the exclusion of other choices in spite of a toxic death rate between 
two to five percent. In one-hundred forty four patients, the DEXA-BEAM regimen resulted 
in a complete response rate of 27 percent, a partial response rate of 54 percent, and a toxic 
death rate of 5 percent (Schmitz, 2002). In fifty-five patients, the mini-BEAM regimen 
produced a complete response rate of 49 percent, a partial response rate of 33 percent, a 
toxic death rate of 2 percent, and in another cohort of patients, 82 percent collected ≥ 2 x 106 
CD34 cells/kg (Martin et al. 2001; Kuruvilla et al. 2006). 
The platinum-based salvage regimens include ESHAP (etoposide, solumedrol, high-dose 
cytarabine, and cisplatin), ASHAP (doxorubicin, solumedrol, high-dose cytarabine, and 
cisplatin), DHAP (dexamethasone, cytarabine, and cisplatin), and GDP (gemcitabine, 
dexamethasone, and cisplatin). ASHAP as a salvage regimen has limited applicability given 
that most patients will have anthracycline exposure during initial treatment. In twenty-three 
patients, the GDP regimen was reported to have a complete response rate of 17 percent, 
partial response rate of 52 percent, no toxic deaths, and 97 percent of patients collected ≥ 2 x 
106 CD34 cells/kg. (Baetz et al. 2003; Kuruvilla et al. 2006). In twenty-two patients given the 
ESHAP regimen, the complete response rate was 41 percent, partial response rate 32 
percent, toxic death rate 4 percent, with no stem cell collection data provided (Aparicio et al. 
1999). In a report on one hundred two patients administered DHAP on an every two week 
schedule, the complete response rate was 21 percent, partial response rate 68 percent, and 
toxic death rate zero without collection data provided (Josting, Rudolph, et al. 2002). 
Of the ifosfamide-based salvage regimens, two of the regimens are worth mention, ICE 
(ifosfamide, carboplatin, etoposide) and IGEV (ifosfamide, gemcitabine, vinorelbine, 
prednisolone). The ICE regimen, developed at Memorial Sloan-Kettering in an effort to reduce 
the nonhematologic toxicity of cisplatin-based regimens, resulted in a complete response rate 
of 26 percent, partial response rate of 59 percent, a toxic death rate of zero, and 86 percent of 





al. 2001). In a report of ninety-one patients given the IGEV regimen, the complete response rate 
was 54 percent, partial response rate 37 percent, a toxic death rate of zero, and 98.7 percent 
achieved a stem cell collection of ≥ 3 x 106 CD34 cells/kg (Santoro, 2007).  
In spite of the lack of comparative data, the ICE, IGEV, and GDP regimens appear to have 
the most favorable balance of the three key factors of response, low toxic death rate, and 
stem cell preservation. The ICE regimen is typically administered in the inpatient setting 
with the other two regimens given in an outpatient setting. Individual patient factors, such 
as pre-existing neuropathy or renal dysfunction, do play an important role in the final 
choice of a salvage combination chemotherapy regimen.  
In summary, the role of radiotherapy, particularly isolated radiotherapy, in the management 
of relapsed Hodgkin lymphoma remains uncertain, and the standard of care is salvage 
combination chemotherapy for an arbitrary number of cycles followed by high dose 
preparative chemotherapy with autologous hematopoietic stem cell transplantation. Given the 
poorer results in salvage than upfront treatment, and the belief that disease is ultimately the 
greater problem than therapy toxicity in this younger patient population, erring on the side of 
consolidative radiotherapy post-transplant in those with limited stage relapse is reasonable.  
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Table 1. Comparison of salvage chemotherapy regimens for relapsed/refractory Hodgkin 
lymphoma. 
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10. Role of allogeneic hematopoietic stem cell transplantation 
Patients with Hodgkin lymphoma who relapse after autologous hematopoietic stem cell 
transplantation have a very poor long term outlook, with several series documenting a low 
rate of long term survivors (Crump 2008; Constans et al. 2004). In a retrospective Spanish 
analysis of patients who relapsed after autologous transplant, the progression free survival 
and overall survival were 23 percent and 35 percent at three years, respectively. 
Investigators at Wayne State retrospectively studied this patient population, and found an 
approximate 10 percent survival rate at four years post autologous transplant, and similar 
results were found in a series of patients from Memorial Sloan Kettering (Varterasian et al. 
1995). Two findings were interesting in the Memorial series: one, nearly all of the long term 
survivors received a reduced-intensity allogeneic hematopoietic stem cell transplant, and 
second, the reduced-intensity allogeneic transplant appeared to be of little benefit to patients 
who relapsed within six months of the autologous transplant (Moskowitz et al. 2009).  
Allogeneic transplants are typically divided into myeloablative versus reduced-intensity or 
nonmyeloablative depending on the intensity of the preparative regimen. Multiple reports on 
the efficacy and toxicity of myeloablative transplants for Hodgkin Lymphoma exist in the 
literature, and all are consistent in demonstrating an unacceptably high rate of treatment-
related mortality. In a retrospective assessment of one hundred patients in the International 
Bone Marrow Transplant Registry (IBMTR), eighty-nine percent of the patients had active 
disease at the time of transplant, with a resulting three year disease-free survival rate of 15 
percent, overall survival of 21 percent, and probabilities of acute and chronic graft-versus-host 
disease of 35 and 45 percent, respectively (Gajewski et al. 1996). The authors appropriately 
concluded that myeloablative sibling transplants have little role in the treatment of Hodgkin 
lymphoma. In a similar retrospective analysis, the European Bone Marrow Transplant (EBMT) 
registry retrospectively analyzed the outcomes of one hundred sixty-seven allogeneic 
transplants in patients with Hodgkin lymphoma, and found an actuarial overall survival of 24 
percent at four years, primarily related to a 52 percent procedure-related mortality at four 
years (Peniket et al. 2003). Again, the authors appropriately concluded that the toxicity of 
allogeneic procedures would have to be reduced before broader applicability would be 
realized. In a retrospective matched case analysis by the EBMT of forty five allogeneic and 
forty five autologous transplants, it was found that the four year probability of survival, 
progression-free survival, relapse, and non-relapse mortality were 25, 15, 61, and 48 percent 
after allogeneic transplant with corresponding figures of 37, 24, 81, and 27 percent after 
autologous transplant (Milpied et al. 1996). The authors concluded that the positive effect of a 
decreased relapse rate with allogeneic transplant is offset by the toxicity and transplant-related 
mortality. Hence, multiple retrospective series of myeloablative allogeneic transplantation in 
Hodgkin lymphoma reached the same conclusion, namely the toxicity outweighs the small 
benefit from the treatment. 
The applicability of allogeneic hematopoietic stem cell transplantation in a wide spectrum of 
hematologic disorders has been broadened by the advent of reduced-intensity conditioning, 
in which lower, non or partially myeloablative doses of chemotherapy either with or 
without radiotherapy are administered prior to infusion of allogeneic stem cells. 
A convincing graft versus Hodgkin lymphoma effect was demonstrated after reduced-





up of reduced-intensity allogeneic transplant demonstrate the curative potential of this 
procedure. In an EBMT retrospective analysis, with a median follow-up of seventy-five 
months for survivors, 18 percent were progression free at five years with an overall survival 
rate of 20 percent (Sureda et al. 2008). In another report with a median follow-up of forty-
nine months, the estimated progression-free survival was 34 percent and overall survival 51 
percent at five years.  
In summary, myeloablative allogeneic transplantation appears to have little role in the 
treatment of Hodgkin lymphoma given the morbidity and mortality associated with the 
procedure. However, reduced-intensity allogeneic transplantation is a reasonable 
consideration in patients with a matched donor who have relapsed following an autologous 
transplant given the curative potential of the procedure in a desperate clinical situation.   
11. Prognostic factors along the disease spectrum of advanced disease 
Prognostic factors are measurements on individuals performed at or soon after diagnosis 
which gives likely outcome of the disease. Although far less useful to the clinician than 
predictive factors, which are directly influenced by treatment, prognostic factors can be used 
as guides in choosing an appropriate treatment strategy. Prognostic factors for advanced 
Hodgkin lymphoma are fairly well established because treatment over time has been more 
uniform and relapses are higher in frequency than for limited stage Hodgkin lymphoma.  
The most useful information for prognosis in advanced Hodgkin lymphoma comes from a 
large retrospective analysis, a so-called tour de force, performed by German investigators 
(Hasenclever and Diehl 1998). They analyzed baseline characteristics and determined the 
outcomes of five thousand one hundred forty-one patients with primarily stage III/IV 
disease treated with ABVD or similar regimens in multiple centers. The authors found, on 
multivariate analysis that the prognosis of patients with advanced Hodgkin lymphoma 
depended on seven baseline characteristics including: age, gender, total leukocyte count, 
lymphocyte percentage or absolute number, albumin, hemoglobin, and stage. Because the 
relative risk for poorer outcome was similar between factors, the authors created the 
International Prognostic Score (IPS) for advanced Hodgkin lymphoma by simply adding 
each factor for a total score of 0-7: 1 point for age>45, male gender, total leukocyte count 
>15,000 cells/mcL, absolute lymphocyte count <600 cells/mcL or lymphocyte percentage 
<8%, albumin <4 g/dL, hemoglobin <10.5 g/dL, and stage IV. Higher scores indicate a 
worse prognosis, and this information was confirmed in an independent data set. Although 
many other reports exist describing other adverse prognostic features in advanced Hodgkin 
lymphoma, the significance of other factors in relation to the IPS is uncertain, and the IPS 
appears to be the principal prognostic tool for patients at baseline.  
The risk factors in relapsed Hodgkin lymphoma are more controversial than in untreated 
disease, but the GHSG contributed a large retrospective study analyzing the risk factors for 
poor outcome in four hundred twenty-two relapsed patients. They developed a prognostic 
score based on three factors: time to relapse, clinical stage, and presence of anemia (Josting, 
Franklin, et al. 2002).  
More recently, interest has grown to better refine baseline prognosis with information on 
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More recently, interest has grown to better refine baseline prognosis with information on 
disease response with therapy, which has consistently shown to be an important factor 
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when degree of response in untreated or relapsed patients is considered. In other words, 
attainment of complete response, as is the case for most hematologic malignancies, is the 
name of the game for Hodgkin lymphoma. Computed tomography, an extremely valuable 
tool for assessment of anatomic structures, has been the traditional assessment tool for 
response in lymphomas, with criteria for definition of complete and partial response clearly 
delineated (Cheson et al. 1999). Given that lymph node size may correlate less well with 
viable cancer than functional imaging with positron emission tomography, it is now 
generally accepted that either fusion PET/CT or PET and CT are superior to CT alone at 
baseline and post-therapy restaging. Given the superiority in re-staging, interest grew in 
obtaining information from PET at earlier and earlier timepoints, in order to utilize that 
information, the so-called interim PET, for treatment decisions. A major report in this arena 
was a retrospective study by an Italian group of patients with advanced Hodgkin 
lymphoma treated with ABVD or similar regimens, who underwent PET scanning after two 
cycles of treatment, and outcomes were compared between PET positive and negative 
patients, with a comparison with IPS to delineate the most robust prognostic factor. The 
results of PET essentially made results of IPS inconsequential, with a clear difference 
between patients with positive and negative PET, with progression-free survivals of 12.8 
versus 95 percent, respectively, and only PET was significant for prognosis in multivariate 
analysis, which included the IPS (Gallamini et al. 2007). Based on this result and promising 
information from other similar yet smaller reports, most current clinical trials in Hodgkin 
lymphoma are determining in a prospective fashion the prognostic value of PET/CT. 
Additionally, many are also testing risk-adapted therapeutic strategies to improve 
outcomes.  
Not only has PET scanning been found to be prognostic in untreated patients as a re-staging 
strategy, but it has been utilized prior to autologous or allogeneic transplant (Svoboda et al. 
2006; Jabbour et al. 2007), with a clear improvement in transplant outcome in those patients 
with negative functional imaging prior to transplant.     
12. Promising therapies of the future 
There are many exciting therapies on the horizon for patients with advanced Hodgkin 
lymphoma. Although none of the treatments discussed below have made their way into the 
armamentarium for the newly diagnosed patient, the treatments below have been selected 
as they appear to be associated with the most promise and are furthest in development in 
relapsed/refractory Hodgkin lymphoma. The most important future therapies, in the 
opinion of the author, are brentuximab vedotin, rituximab, bendamustine, panobinostat, 
and lenalidomide. See Table 2. Each will be discussed in further detail in this section. 
Brentuximab vedotin, long known as SGN-35, and now known as Adcetris after the United 
States Food & Drug Administration granted accelerated approval of this antibody-drug 
conjugate on August 19, 2011, appears to be an important new treatment option in Hodgkin 
lymphoma. The approval was long awaited by those who had seen multiple failures of 
unconjugated monoclonal antibodies to CD30, a protein expressed on the surface of Reed 
Sternberg cells. To specifically enhance clinical anti-tumor activity, the antitubulin agent 
monomethyl auristatin E was attached to the CD30-specific monoclonal antibody cAC10 by 





relapsed or refractory Hodgkin’s lymphoma after failure of autologous stem cell transplant 
or at least two prior multi-agent chemotherapy regimens in patients who are not transplant 
candidates. The accelerated approval was based on a single-arm, multicenter clinical trial in 
one hundred two patients with multiply relapsed or refractory Hodgkin lymphoma to 
evaluate the objective response rate as a single agent. Patients were treated with 1.8 mg/kg 
intravenously over thirty minutes every three weeks. The primary efficacy endpoint, the 
overall response rate, was achieved in 73 percent of patients with a complete remission rate 
of 32 percent. The median duration of response was 6.7 months (Chen et al. 2010). The most 
common adverse events were peripheral sensory neuropathy, fatigue, nausea, neutropenia, 
diarrhea, and pyrexia, with most events being grade 1 or 2, and no grade 5 events occurred 
on treatment. The response rate associated with this agent given as monotherapy is highly 
encouraging, and further study of this compound is anxiously anticipated. Currently, it is 
being investigated in a phase I clinical trial in combination with ABVD chemotherapy 
(Seattle Genetics 2011), and in a phase III randomized clinical trial, AETHERA, in which its 
use is compared with placebo in “high risk” Hodgkin lymphoma patients post-autologous 
transplant (Seattle Genetics 2011). This compound appears to represent a major advance in 
the treatment of Hodgkin lymphoma given the unprecedented response rates in multiply 
relapsed and highly refractory patient populations.  
Rituximab is an intravenous chimeric monoclonal antibody directed at the CD20 antigen, 
which is present only on a minority of Reed Sternberg or Hodgkin cells of classic Hodgkin 
lymphoma (Schmid et al. 1991). In spite of this, a pilot study of rituximab was performed in 
patients with relapsed/refractory classic Hodgkin lymphoma regardless of CD20 status 
(Younes et al. 2003). In that study, five of twenty-two patients (22 percent) responded with 
36 percent achieving stable disease with expected excellent tolerability. Further study by the 
same investigators at MD Anderson focused on the addition of rituximab to ABVD therapy. 
One hundred four patients with newly diagnosed advanced disease were treated with six 
weekly doses of rituximab during ABVD chemotherapy, and their outcomes were compared 
with historical patients treated with ABVD. The five year event-free survival with ABVD 
was 66 percent versus a projected 87 percent for R-ABVD with a median follow-up time of 
five years, and all IPS risk groups seemed to benefit from the addition of rituximab 
(Copeland et al. 2009). This study generated great excitement, and it is the springboard for 
two major ongoing advanced Hodgkin lymphoma studies. In the HD18 trial of the GHSG, 
patients with PET positivity after two cycles of escalated BEACOPP are randomly assigned 
to further chemotherapy with or without rituximab (University of Cologne 2011). The 
second trial is a phase II study randomizing patients to R-ABVD versus ABVD at a single 
institution (M.D. Anderson Cancer Center 2011). In summary, rituximab appears to be a 
promising step forward with little toxicity in the treatment of advanced classic Hodgkin 
lymphoma, and the results of the above studies are eagerly anticipated. 
In contrast to classic Hodgkin lymphoma, the neoplastic cells, known as the lymphocyte 
predominant cells of nodular lymphocyte predominant Hodgkin lymphoma, express CD20 
strongly. Importantly, several studies indicate that rituximab as a single agent in both 
previously treated and untreated patients carries a very high response rate in this subtype of 
Hodgkin lymphoma (Ekstrand et al. 2003; Schulz et al. 2008), and it is reasonable, given the 
rarity of advanced disease with nodular lymphocyte predominant Hodgkin lymphoma, to 
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Bendamustine, an intravenous bifunctional alkylator and nucleoside analogue, was 
synthesized in East Germany in 1963 but only recently its use has become popularized in the 
United States with FDA approval for CLL and indolent NHL occurring in 2008. Its activity 
in Hodgkin lymphoma was well known to the East Germans, and recently Memorial Sloan 
Kettering investigators put this compound on the international map in Hodgkin lymphoma. 
Benadmustine was administered at a dose of 120mg/m2 day one and two of twenty-eight 
day cycles with pegylated filgrastim support in a single center phase II study of relapsed 
Hodgkin lymphoma patients post-transplant or transplant-ineligible. Although major 
conclusions are limited by the small evaluable patient number of sixteen, the overall 
response rate of 75 percent and CR rate of 38 percent are encouraging, along with twelve of 
sixteen patients with response becoming eligible for a non-myeloablative allogeneic 
transplant. Currently, an Italian study is investigating in a phase I/II trial its efficacy and 
toxicity combined with another promising agent for Hodgkin lymphoma, lenalidomide 
(Fondazione Giovanni Pascale).  
Another promising new compound in the treatment of advanced Hodgkin lymphoma is the 
oral histone deacetylase inhibitor, panobinostat. Preliminary evidence of activity in 
refractory Hodgkin lymphoma was demonstrated in a small phase I/II prospective, 
multicenter study of thirteen patients, and a remarkable response rate of 38 percent was 
found with computed tomography criteria, with 58 percent of patients responding by 
positron emission tomography criteria (Dickinson et al. 2009). The principal dose-limiting 
toxicity with panobinostat is thrombocytopenia, unfortunately, as many patients with 
relapsed disease have impaired bone marrow reserve. Forty percent of patients in this study 
developed grade 3/4 thrombocytopenia. In a large multicenter, prospective, phase II study, 
40 mg of panobinostat was administered orally three times per week every week in 21 day 
cycles to one hundred twenty-nine relapsed/refractory patients (Sureda et al. 2010). 
Responses were observed in 27 percent of patients with 82 percent of patients having stable 
disease or better. This phase II study, with very promising response rates in a large number 
of heavily pre-treated patients, has led to a number of current studies in Hodgkin 
lymphoma, including a phase III study of panobinostat versus placebo for maintenance 
therapy (Novartis Pharmaceuticals 2011), and a phase I study in combination with ICE and a 
planned follow-on phase II study of panobinostat plus ICE versus ICE alone (M.D. 
Anderson Cancer Center 2011).       
Lenalidomide is an oral immunomodulatory agent with an uncertain mechanism of action 
that appears to have activity in a broad range of hematopoietic malignancies. The use of 
lenalidomide was empiric, and in an initial small cohort of twelve patients with multiply 
relapsed Hodgkin lymphoma treated in Germany, it was found to be safe with no toxicity 
greater than grade two. Additionally, it was efficacious with a response rate of fifty percent 
with at least disease stabilization in all patients (Boll et al. 2010). In a prospective phase II 
Canadian study, fifteen patients with relapsed/refractory disease were enrolled and given 
lenalidomide 25 mg orally day 1-21 of 28 day cycles. The overall response rate was 14 
percent with at least disease stabilization in 64 percent of patients. Hematologic toxicity was 
the predominant toxicity seen, with 29 percent of patients with grade 3/4 neutropenia and 
thrombocytopenia (Kuruvilla et al. 2008). In a similar study conducted by United States 
investigators, thirty-eight patients were enrolled on a prospective phase II study of 
relapsed/refractory patients with lenalidomide administered in the same fashion as the 





was 17 percent with stabilization of disease for greater than six months in 34 percent. Grade 
3/4 toxicity was primarily hematologic, with neutropenia being the most common at 40 
percent of patients. The authors concluded that activity was seen and continuous dosing 
and utilization in combinations would be reasonable in the future. Currently, lenalidomide 
is under evaluation in phase I studies in combination with benadmustine (Fondazione 
Giovanni Pascale 2011), AVD (University of Cologne 2011), and as maintenance post-
autologous transplant (Washington University School of Medicine). 
In summary, there are a number of agents with promising activity in relapsed Hodgkin 
lymphoma currently in development. Further study will define their ultimate role, but the 
favorable toxicity profile and encouraging reports of activity of the monoclonal antibodies 
make these compounds of high interest for further investigation.  
 



























































































Ongoing phase I/II 
studies 
Table 2. Promising Drugs in Development for Hodgkin lymphoma. 
13. Case studies 
In this section, several case scenarios will be presented, and management will be discussed, 
which integrates material covered in prior sections.  
Case 1. A twenty-three year old otherwise healthy Caucasian female was diagnosed with stage 
IIIB nodular sclerosis Hodgkin lymphoma after an excisional biopsy was performed due to left 
neck adenopathy. The mediastinum was bulky at diagnosis. The IPS was 1 for anemia. She 
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IIIB nodular sclerosis Hodgkin lymphoma after an excisional biopsy was performed due to left 
neck adenopathy. The mediastinum was bulky at diagnosis. The IPS was 1 for anemia. She 
was treated with six cycles of ABVD at full dose and schedule and achieved a complete 
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metabolic remission on PET/CT. Fifteen months later, PET/CT revealed asymptomatic FDG 
avid mediastinal adenopathy, and thoracotomy with excisional biopsy revealed a relapse of 
nodular sclerosis Hodgkin lymphoma. Hemoglobin was normal. She was treated with ICE for 
three cycles followed by stem cell mobilization and collection and autologous hematopoietic 
stem cell transplantation with BEAM conditioning. She receives 36 Gy to the mediastinum two 
months post-transplant and is alive and well seven years post-transplant.  
Case 1 Discussion. This young woman was given a standard of care for advanced Hodgkin 
lymphoma at diagnosis, and ABVD was favored in this instance over escalated BEACOPP 
for fertility preservation, as the patient expressed interest in maintaining fertility. The 
author’s preference is to enroll patients with advanced Hodgkin lymphoma on a clinical 
trial if possible, and currently this would be the SWOG 0816 at the author’s institution. The 
lack of thoracic radiotherapy was reasonable given the PET/CT defined complete remission. 
This patient’s relapse can be classified as low risk by the Josting score as she had none of the 
the adverse factors which include: early relapse, advanced stage at relapse, and anemia. 
Therefore, she again received a standard of care including: choice of salvage regimen, 
decision for autologous transplant, and choice of preparative regimen. The exact value of 
thoracic radiotherapy administration post-transplant is uncertain but reasonable given the 
bulky disease of mediastinum initially and the limited stage relapse. The increased risk of 
solid cancers including breast and lung with thoracic radiotherapy should be discussed with 
the patient, and long term follow-up should include counseling on smoking cessation, breast 
and skin examination regularly, breast mammography, and vaccinations yearly for 
influenza, every five years for pneumococcus, and every ten years for tetanus/diphtheria 
(Connors 2005). 
Case 2. A thirty-five year old otherwise healthy African American male is diagnosed with 
stage IVA mixed cellularity Hodgkin lymphoma after excisional biopsy is performed of a 
right inguinal mass. Bone marrow involvement is present at diagnosis and FDG avid lesions 
are seen in the liver. His International Prognostic Score is 5 with the following risk factors: 
low albumin, low lymphocyte count, low hemoglobin, stage IV, and male gender. There are 
no bulky sites of disease. He is treated with escalated BEACOPP for six cycles and achieves 
a complete remission by PET/CT post-therapy. His PET/CT after two cycles of escalated 
BEACOPP was negative as well. Five months later, he has biopsy proven relapsed Hodgkin 
lymphoma after left axillary lymph node enlargement prompts an excisional biopsy. His 
relapse stage is III, and GDP is administered for three cycles. He achieves a partial metabolic 
remission on PET/CT with a negative bone marrow biopsy. Organ function is preserved, 
and he receives a BEAM-conditioned autologous transplant. He suffers another biopsy-
proven relapse with stage III disease seven months post autologous transplant. He is treated 
with IGEV salvage chemotherapy for three cycles, and achieves another partial metabolic 
response. Given that his organ function is preserved, he undergoes a reduced-intensity 
allogeneic hematopoietic stem cell transplant with Flu/Bu conditioning. He is alive three 
years post-allogeneic transplant with mild chronic graft versus host disease.  
Case 2 Discussion. This young man was given an appropriate initial therapy, escalated 
BEACOPP, given his high risk disease. In fact, escalated BEACOPP is reasonable for any 
advanced Hodgkin lymphoma patient <60 years without pregnancy, HIV, or abnormal 
organ function regardless of IPS. He was given six cycles rather than the current standard of 
eight cycles established by the GHSG. Would he still have suffered a relapse if given eight 





obtain interim PET/CT scans outside the context of clinical trials? The answer to each of 
these questions is obviously controversial. The author believes that it is reasonable to 
perform interim PET/CT scans off study, and to make certain therapeutic decisions on the 
basis of those scans. Because the PET/CT was negative after two cycles, the author believes 
that it was a reasonable clinical decision to administer six rather than eight total cycles. 
Although impossible at present to know, the author believes that it is unlikely that two more 
cycles of escalated BEACOPP would have cured the case patient. Again, it is the author’s 
strong preference to obtain further prospective data regarding interim PET/CT and therapy 
adjustment, which is why the optimal treatment for current patients with Hodgkin 
lymphoma is a clinical trial. The choice of GDP as salvage chemotherapy is very reasonable, 
as is the choice to take a patient in partial remission to a BEAM conditioned autologous 
transplant. Given at least three adverse prognostic factors associated with this relapse, 
which are: early relapse, relapse after high intensity initial chemotherapy, and partial rather 
than complete metabolic response pre-transplant, the author believes, even though 
randomized data are not available, that performing a tandem transplant as in the H96 study 
would have been reasonable in this patient. Once relapse after autologous transplant occurs, 
prognosis is poor and this case example illustrates that a reduced-intensity allogeneic 
hematopoietic stem cell transplant can be curative in this setting. In addition to the chronic 
adverse health effects associated with allogeneic transplant, Hodgkin lymphoma survivors 
do have persistent challenges in health related quality of life, particularly in regards to 
chronic fatigue (Baxi and Matasar 2010). This patient would likely benefit from 
multidisciplinary follow-up care including input from psychiatry and social work.          
14. Conclusion 
There are many unanswered questions the clinician faces in the care of the individual 
patient with advanced Hodgkin lymphoma throughout the course of the disease. 
Polychemotherapy with regimens such as ABVD or escalated BEACOPP for six to eight 
cycles are the standard of care for newly diagnosed patients, and the role of radiotherapy is 
uncertain. Refinement of morbidity and mortality related to chemotherapy and 
radiotherapy may be possible in the future with a sincere commitment of physicians to 
enroll patients on the current generation of clinical trials testing PET/CT directed strategies. 
Several newer agents are likely to be incorporated into polychemotherapy in the future 
based on promising results in the relapsed setting. The goal of therapy in the short term is a 
PET/CT without FDG avidity, or complete remission, and in the long term a cure. For most 
patients with relapsed or refractory Hodgkin lymphoma, polychemotherapy for 
approximately three cycles followed by autologous hematopoietic stem cell transplantation 
is the current standard of care. Radiotherapy should be considered in the relapsed setting to 
optimize curative potential of treatment in spite of the potential morbidity and lack of clear 
evidence base. Reduced intensity allogeneic hematopoietic stem cell transplantation should 
be considered as the primary curative treatment modality in those patients without 
significant comorbidity who relapse after autolgous transplantation.  
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Approximately 20% of Hodgkin Lymphoma (HL) patients do not achieve a durable 
remission or fail to respond to front-line chemotherapy. Despite the attempt to improve 
clinical outcomes by using the risk adaptive therapy, a significant number of patients die as 
a results of relapsed/refractory (rel/ref) disease.1 Advances in understanding the etiology 
and molecular biology of HL are leading the development of novel therapeutic strategies 
that could be applied to improve clinical outcome of rel/ref HL patients. The pathologic 
features of HL reflect a defect in immune responses resulting from various cytokines and 
chemokines secreted partially by Hodgkin Reed-Sternberg (HRS) cells. HRS cells are unique 
in the way that they lost typical B cell gene expression pattern but retain the expression of 
surface molecules involving in antigen presentation (tumor necrosis factor receptor (CD30, 
CD40), CD80, MHC class II, and CD86). Aberration of Notch signaling pathway may 
contribute to their reprogramming.2,3 Multiple genetic lesions, deregulated signaling 
pathway and transcription factors play important role in pathogenesis of HL including 
constitutive activation of nuclear factor kappa B (NFκB) and the Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) signaling pathway.4-6 Moreover, the 
role of the microenvironment in HL has been increasingly recognized. The majority of the 
cell population in HL-affected tissue is composition of the inflammatory cellular infiltrate, 
not the HRS cells that represents only small population (<1%). Understanding the complex 
relationship between the HRS cells and the microenvironment and chemokines milieu 
involved in its formation is crucial for the development of new therapeutic strategies. 
In addition, Epstein Barr Virus (EBV) infection may plays a role in the pathogenesis of HL 
since it can influence the expression of certain chemokines (i.e. CXCL9, CXCL10, CCL3, and 
CCL5) that are highly expressed in HRS cells and the EBV gene encoding the latent 
membrane protein 1 (LMP1) can mimic constitutively active TNF receptor (via a 
CD40/CD40L interaction) and promote IκB turnover leading to activation of NFκB and 
downstream signaling events.7 Ongoing efforts are focused in developing adaptive or 
adoptive immune therapies targeting EVB related proteins in rel/ref HL patients.  
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This chapter will provide an overview of the emerging therapeutic strategies for patients 
with relapsed and refractory HL (rel/ref HL) that had failed standard front line therapy, 
salvage chemotherapy and high-dose chemotherapy and autologous stem cell support 
(HDC-ASCS).  
2. Systemic chemotherapy 
Salvage systemic chemotherapy is often used in patients with rel/ref HL failing HDC-ASCS. 
Response rates are modest and response duration is usually short. Participation in clinical 
trials evaluating novel therapeutic approaches is strongly recommended. On the other hand, 
two chemotherapy agents had proven anti-tumor activity in highly refractory HL patients: 
gemcitabine and bendamustine.  
Gemcitabine had been studied in the rel/ref HL either as single agent or combination 
therapy (i.e. with Vinorelbine).8,9 Favorable toxicity profile and significant clinical anti-
tumor activity were observed in heavily pre-treated HL patients, with overall response rates 
(ORR) up to 70% when used in combination regimens.10,11 On the other hand, the duration 
of response is limited stressing the need to develop novel therapeutic strategies or to use 
this agent as a bridge rel/ref HL patient into more definitive treatments (i.e. allogeneic bone 
marrow transplant or other cellular-based therapies).  
Bendamustine hydrochloride is a bifunctional mechlorethamine derivative with alkylating 
and antimetabolite properties. The exact antitumor mechanism is unknown though it 
appears to crosslink macromolecules resulting in DNA damage and subsequently apoptosis. 
It may also inhibit mitotic checkpoints and induce mitotic catastrophe. Bendamustine 
showed marked antiproliferative and proapoptotic effects on HL cell lines.12 Moskowitz et al 
reported the activity of single agent bendamustine in rel/ref HL that previously failed 
HDC-ASCT, allogeneic stem cell transplantation (AlloSCT) or ineligible for transplant.13 In 
this phase II clinical trial, bendamustine was administered at a dose of 120 mg/m2 for two 
consecutive days, every 28 days, for up to maximum of 6 cycles. Of evaluable 16 patients, 
there were 6 complete responses (CRs) (38%) and 6 partial responses (PRs) (38%) for an ORR 
of 75%. Further studies of both single agent bendamustine and in combination with other 
chemotherapy are warranted in rel/ref HL patients.   
3. Passive immunotherapy targeting the tumor microenvironment and/or HRS 
cells (Table 1) 
3.1 CD80 (B7-1) 
Immunohistochemical analysis has shown strong expression of CD80 on HRS cells, antigen 
presenting cells (APCs), T-cells and activated B-cells but not on resting B-cells and plasma 
cells and is absolutely absent on CD34+ cells, making CD80 an excellent target in HL. 
Preclinical data demonstrated that an anti-B7-1 immunotoxin had significant anti-tumor 
activity in HL-cell lines and minimal toxicity to CD34+ hematopoietic stem cell.14,15 
Galiximab is a primatized IgG1 monoclonal antibody, which binds to CD80 with high 
affinity and induces cell death via antibody-dependent cell-mediated cytotoxicity (ADCC). 
Smith et al studied the clinical activity of single agent Galiximab in patients with rel/ref HL 
not eligible for or had failed HDC-ASCT/AlloSCT.16 Galiximab was administered at a dose 
of 500 mg/m2 weekly for 4 weeks followed by 500 mg/m2 every 4 weeks until disease  
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progression or unacceptable toxicity. The results were disappointing with ORR of only 
6.9% and very short median time to progression (TTP) of 1.6 month. The authors 
concluded that single agent galiximab seems to have minimal activity in heavily 
pretreated rel/ref HL. 
3.2 CD40 
CD40 is a member of TNFR family (TNFRSF5) that is constantly expressed in HRS cells. In 
addition, CD40+ HRS cells are surrounded by CD40L-expressing T-cell lymphocytes. The 
CD40/CD40L interaction contributes to the pathobiology of HL possibly by NFκB activation 
and increased autocrine growth factor CCL5 resulting in inhibition of apoptosis, increased 
proliferation and microenvironment formation.17-19 
Lucatumumab is a monoclonal antibody targeting the transmembrane receptor CD40. The 
safety and clinical activity of lucatumumab (HCD122) was evaluated in both NHL and HL 
patients who have progressed after at least two previous therapies [NCT00670592].20 
Patients received lucatumumab at a dose of 3 or 4 or 6 mg/kg intravenous weekly for 4 
weeks followed by a 4-weeks rest period. The maximum tolerated dose (MTD) and dose 
limiting toxicity (DLT) were 4 mg/kg and 6 mg/kg, respectively. DLTs were consisted of 
clinically asymptomatic and reversible grade 3-4 elevation of amylase/lipase or transminase 
enzymes. For rel/ref HL patients, three of eighteen (17%) patients in phase II study 
component achieved a PR.  
3.3 CD52 
CD52 is highly expressed in surrounding reactive B-cells, T-cells and monocytes, although 
not on HRS cells itself. Depleting CD52+ accessory cells, which appear to provide survival 
signals to HRS cells, may have therapeutic value. Alemtuzumab is a humanized monoclonal 
antibody directed against CD52 resulting in cell lysis via antibody dependent cellular-
mediated cytotoxicity. A phase II study addressing the clinical efficacy of alemtuzumab in 
rel/ref HL was unfortunately terminated due to slow accrual [NCT00129753].21 Another 
phase II study focusing on the clinical outcome in rel/ref DLBCL and HL treated with 
alemtuzumab in combination with dose-adjusted EPOCH-Rituximab is currently enrolling 
patients [NCT01030900].22 
3.4 CD20 
A pilot study evaluating rituximab monotherapy in rel/ref HL has shown that depletion of 
B lymphocytes may has therapeutic potential.23 The rationale of using rituximab in classical 
HL (cHL) is based on several laboratory and clinical observations: HRS stem cells express 
CD20 even though HRS cells infrequently express CD20, elimination of CD20+ B 
lymphocytes supporting HRS cells may deprive survival signals and improve immune 
response against HRS cell.24,25 Studies of evaluating the addition of rituximab to 
conventional chemotherapy in patients with rel/ref cHL demonstrated promising 
results.26,27 Copeland et al showed significant improvement of 5-year event free survival 
(EFS) in patients with newly diagnosed advanced stage cHL treated rituximab plus ABVD 
compared to historical data of patients treated with ABVD from the same institute.28 
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Targeting CD20 in patients with lymphocyte predominant HL (LPHL, had show to be an 
effective therapeutic strategy in contrast to other subtypes of HL. The efficacy of rituximab 
in LPHL was documented in several phase II studies with an ORR up to 100% in both 
relapsed and newly diagnosed patients.29-32 Zojer et al and Schnell et al reported 2 cases of 
rel/ref HL patients treated with radiolabeled anti-CD20 monoclonal antibody, Yttrium-90 
ibritumomab tiuxetan.33,34 One patient had LPHL and another patient had cHL (lymphocyte 
rich) both achieved a complete remission following radioimmunotherapy (RIT). A Phase 
I/II study of safety and efficacy of I131 tositumomab rel/ref CD20+ cHL is currently 
enrolling patients [NCT00484874].35  
4. Signaling pathway targets on HRS cells 
4.1 CD30 signaling (Table 2) 
CD30, a member of tumor necrosis factor receptor family (TNFR super family 8) involved in 
the activation of the canonical NFκB pathway and provides tumor cell survival signaling. 
CD30 is express in almost 100% of the HRS cells and serve as an attractive target of 
immunotherapy for cHL.36,37 Borchmann et al had summarized the upsides and downsides 
of immunotherapy in HL.38 Immunotoxins (ITs) containing ricin A, a ribosome inactivating 
protein, linked with surface marker CD30 as well as other ITs had shown disappointing 
clinical results with regard to response and toxicity in HL. Bi-specific constructs of 
monoclonal antibodies or molecules (BSMs) targeting CD30 and CD16 (NK cells) or CD64 
(monocytes) were though well tolerated and showed some objective responses, production 
of BSMs is very expensive and time consuming. Low dose radioimmunotherapy (RIT), I-131 
labeled anti-CD30 antibofy (131I-Ki-4) used in phase I trial in patients with relapsed HL 
showed some clinical activity with limitation to hematotoxicity particularly 
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HL = Hodgkin Lymphoma; Rel/ref = relapsed/refractory; ORR = overall response rate; CR = complete 
response; PR = partial response; Gr = grade; NLPHL = Nodular lymphocyte predominant Hodgkin 
lymphoma; DOR = duration of response; PFS = progression free survival 
Table 2. Selected Clinical studies targeting CD30 in relapsed/refractory Hodgkin Lymphoma. 
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further development of this approach. Preclinical study targeting CD30 demonstrated 
significant anti-tumor activity.40 Initial clinical studies evaluated naked antibodies targeting 
CD30 (MDX-030 and SGN-30) in patients with rel/ref HL. Both antibodies failed to 
demonstrate anti-tumor activity and in some cases accelerated tumor growth was observed 
upon CD30 binding by MDX-060.41   
Previously unknown factors influenced the negative results observed in such trials such as 
1) the agonist effects of the antibodies initially tested, 2) the modulation of CD30 in HRS 
cells (i.e. antigen shedding and/or internalization), and/or 3) impaired immune effector 
function in heavily pre-treated patients with HL. Two therapeutic approaches (i.e. 
development of drug conjugates or antibody re-engineering) had been explored clinically 
with significant improvement in clinical activity.  
SGN-35 (brentuximab vedotin) is a drug conjugated designed to improve the clinical activity 
of SGN-30 in lymphomas. Brentuximab vedotin (SGN-35) is a antibody-drug conjugate 
containing the anti-tubulin agent, monomethylauristatin E (MMAE) linked to antiCD30 
monoclonal antibody to enhance antitumor activity.42  
Younes et al reported encouraging results in a phase I study of brentuximab vedotin in 
patients with relapsed CD30+ lymphomas.43 Most of patients in the study had rel/ref HL 
(42/45), were heavily pre-treated (median number of previous regimens was 3), and almost 
75% had previous HDC-ASCT. Seventeen patients had objective response including 11 CRs. 
Fifty percent (6/12) of patients who received maximum tolerating dose (MTD) 
(1.8mg/kg/dose) had objective responses. 
Subsequently, a pivotal phase II of brentuximab vedotin in patients with rel/ref HL 
reported similar results.44 All patients had failed HDC-ASCT and had median of 3.5 prior 
treatments. The ORR was 75% (76/102) with 34% of the patients achieving a CR (35/102). 
Currently, a randomized, double blind, placebo-controlled phase III study is evaluating 
SGN-35 versus placebo in patients at high-risk for residual disease after HDC-ASCT is 
ongoing [NCT01100502].45 Brentuximab vedotin in combination with standard 
chemotherapy (ABVD) was now being evaluated in patients with newly diagnosed 
Hodgkin lymphoma stage IIA-IV [NCT01060904].46 SGN-35 received fast track designation 
from the U.S. Food and Drug Administration (FDA) for the treatment of HL in 2009. 
5. Downstream signaling targets (Table 3) 
5.1 NFκB activity 
As previously noted, constitutive activation of NFκB is one of the most important events in 
pathogenesis of HL and the result of multiple mechanisms. Downstream signaling of TNF 
receptors, expression of the EBV LMP1, and/or mutation of IκB gene have been described as 
the cause of constitutive NFκB activation. Inhibition of NFκB has been an area of drug 
development for the treatment of multiple hematological malignancies including HL. Pre-
clinical data demonstrated that the proteasome inhibitor, PS-341 (Bortezomib) affects tumor 
cell proliferation and survival via inhibiting NFkB pathway, which is constitutively 
activated in HRS cells. As a result, bortezomib was evaluated in patients with rel/ref HL. 
The Cancer and Leukemia Group B (CALGB) conducted a phase II clinical trials (CALGB 
50206) evaluating bortezomib monotherapy in rel/ref HL. Disappointingly, no clinical 
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activity was observed in treated patients.47 The lack of anti-tumor activity of bortezomib in 
rel/ref HL was confirmed by two subsequent studies reported by Younes et al and Trelle et 
al.48,49 More recent studies that evaluated bortezomib in combination with conventional 
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HL = Hodgkin Lymphoma; Rel/ref = relapsed/refractory; ORR = overall response rate; CR = complete 
response; PR = partial response; Gr = grade; TCP = thrombocytopenia; TTP= time to progression;  
PFS = progression free survival; OS = overall survival; HDC-ASCS = high dose chemotherapy and 
autologous stem cell support; NR = Not reported 
Table 3. Selected clinical studies evaluating target specific agents in relapsed/refractory 
Hodgkin lymphoma. 
More potent and/or irreversible proteasome inhibitors (i.e. carfilzomib, MLN2238) had 
demonstrated high efficacy in rel/ref multiple myeloma and now are being evaluated in 
other hematologic malignancies.52 However, their clinical activity in HL remains unknown. 
5.2 Deacetylation of histone and other cellular proteins in HL biology: The therapeutic 
role of deacetylase inhibitors (DACi) 
Gene expression profiling studies had demonstrated that HL is characterized by the 
silencing of key regulatory genes involved in B-cell maturation (i.e. CD79a, CD19, CD20, 
etc). In general gene expression is a tightly regulated process that is influenced by the 1) 
DNA/mRNA sequence, 2) expression/activity of transcription factors, 3) epigenetics 
(including the DNA, chromatin, and histone modifications); and 4) messenger RNA 
stability. 
Post-transcriptional histone modification plays an important role in regulating gene 
transcription and is mediated by two groups of enzymes: histone acetyltransferase (HATs) 
and histone deacetylase (HDACs). The balance between HATs and HDACs is crucial in 
regulating the expression/function of several proteins involved in cell proliferation, cell 
cycle, apoptosis, angiogenesis, and immune regulation. Altering balance between HATs and 
HDACs had been found to be associated with various malignancies including HL.  
To date, 18 HDACs have been identified in humans. HDACs are grouped in two major 
categories and four classes; zinc-dependent HDACs (Class I, II and IV) and NAD-dependent 
HDACs (Class III). Class I includes HDAC 1, 2, 3, 8, and 11; Class II includes HDAC 4, 5, 6, 
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only HDAC 11. As a group, HDAC are known to regulate several key cellular functions 
such cell proliferation, cell cycle, apoptosis, angiogenesis, migration, antigen presentation, 
and/or immune regulation. The activity spectrum of each HDAC is yet to be defined and 
there is overlap between the function of different HDAC regardless of their group or class.  
HATs and HDACs interact also with non-histone proteins such as transcription factors (i.e. 
p53, STAT3, MYC , E2F, NFκB, etc.), -tubulin, and chaperons (heat shock protein-90 
[HSP90]), adding complexity to their cellular functions in normal and malignant cells. Given 
their influence in multiple regulatory pathways, HDACs became an attractive strategy to 
develop novel pharmacologic inhibitors for the treatment of cancer. Several pan- or 
selective-HDAC inhibitors (class I and IV) had been developed. Pre-clinical studies 
demonstrated significant anti-tumor activity in various cancer models including non-
Hodgkin lymphoma and HL. Laboratory experiments suggest that HDAC inhibitors can 
induce cell cycle arrest, apoptosis or autophagy in cancer cell lines and can potentiate the 
anti-tumor activity of chemotherapy agents including proteasome inhibitors. Two HDAC 
inhibitors had been approved for the management of relapsed/refractory cutaneous T-cell 
lymphoma (vorisnostat and romidepsin). A second generation of more potent and selective 
(i.e. less toxic) of HDAC inhibitors (entinostat, panobinostat and MGCD103) had entered 
into clinical studies for patients with relapsed/refractory HL. 
Vorinostat (SAHA), the first FDA approved HDAC inhibitor, is a potent inhibitor of class I 
and II HDAC and was the first of its class agent evaluated in patients with rel/ref HL. At 
the pre-clinical level, vorinostat has anti-proliferative and pro-apoptotic effects on HL cell 
lines by inducing p21 expression and down regulation of Bcl-xL respectively.53 Kirschbaum 
et al presented on behalf of the South Western Oncology Group (SWOG), the results of a 
phase II clinical trial evaluating the safety and efficacy of Vorinostat in refractory/relapsed 
HL.54 A total of 25 patients were treated with vorinostat at 200 mg given orally twice per 
day for 14 days every 21-day cycle. The activity of vorinostat was modest and only one 
patient achieved a partial remission (PR). Adverse events reported were similarly to those 
reported in vorinostat clinical trials in patients with cutaneous T-cell lymphoma (CTCL). 
Preclinical data by Hartlapp et al demonstrated the activity of depsipeptide (romidepsin) in 
cHL cell lines in vitro.55 In addition, the investigators demonstrated that romidepsin several 
cellular events leading to cell cycle arrest and apoptosis in HL cell lines such as and 
increased DNA binding capacity of RelA/p65, PARP-cleavage, decreased transcription of 
anti-apoptotic proteins (eg. XIAP, Bcl-xL), and down-regulation of STAT6. Romidepsin has 
not been formally evaluated in rel/ref HL patients.  
An isotype-selective histone deacetylase inhibitor, mocetinostat (MGCD-0103), inhibits 
class I and class IV and minimal class II HDAC inhibition. A phase II trial of 2 different 
doses (85 mg and 110 mg thrice weekly every 28 days) of mocetinostat in rel/ref HL had 
shown promising results with ORR of 38%.56 The updated results from the same group 
demonstrated activity of single agent mocetinostat in heavily pretreated rel/ref HL with 
clinical responses observed in approximately 35% of patients with slightly better responses 
with 110 mg cohort.57 Of 51 patients, 2 patients (110 mg cohort) achieved complete 
responses and 6 patients each from both cohort achieved partial response. Over eighty 
percent of patients in the study had previously failed HDC-ASCS and more than half of 
patients received four or more previous treatments. Serum thymus and activation-regulated 
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chemokine (TARC) or CCL17 which is highly expressed in HRS cells, decreased in patients 
treated with mocetinostat.58 This findings were similar what had been previously observed 
following in vitro exposure of HL cell lines to vorinostat.53 Together these findings, suggests 
that a decline in serum TARC may be a biomarker to predict clinical response to DAC 
inhibition therapy. Buglio et al found that MGCD0103 induced apoptosis in HL cell lines via 
the induction of TNFα expression and that inhibition of NF-κB activation with bortezomib 
resulted in synergistic anti-tumor activity.59  
Bhalla et al observed similar findings with PCI-24781, a phenyl hydroxamic acid-based 
broad spectrum HDAC inhibitor.60 PCI-24781 combined with bortezomib enhances 
apoptosis via reactive oxygen species (ROS), caspase activation (increased cleavage of 
caspase 8 and caspase 9), PARP activation, cell cycle arrest (G0/G1), and upregulation of 
p21 in HL cell lines and several non-Hodgkin lymphoma (Burkitt’s lymphoma, follicular 
lymphoma, and large B-cell lymphoma) cell lines. While the biological interaction between 
bortezomib and multiple DAC inhibitors had been demonstrated in pre-clinical models and 
is been pursued in several clinical studies in multiple myeloma and mantle cell lymphoma 
patients, the limited activity of bortezomib as a single agent had damped the interest for 
pursuing this combination strategy in rel/ref HL patients.  
Panobinostat (LBH-589) is a potent pan-HDAC inhibitor with anti-tumor activity observed 
in pre-clinical studies at nanomolar concentrations. Moreover, pre-clinical studies suggest 
that panobinostat is more potent than vorinostat in lymphoma pre-clinical models. 
Panobinostat was evaluated in phase IA/II study in 128 patients with advanced hematologic 
malignancies including rel/ref HL.56 Patients received 2 schedules of oral administration 
(MWF every week at a dose of 20, 30, 40, 60, 80 mg/dose or MWF every other week at a 
dose of 30, 45, 60, 80 mg/dose). Out of 23 patients with rel/ref HL, 13 patients were 
evaluable for response. Five out of thirteen (38%) patients had PR by CT and 7/12 patients 
(58%) had metabolic PR by PET. The maximum tolerated dose (MTD) was 40 mg/dose 
every week schedule and the principal dose-limiting toxicity (DTL) was thrombocytopenia.  
Younes et al confirmed efficacy of panobinostat in phase II study in patients with rel/ref 
HL.61 Panobinostat was administered at a dose of 40 mg thrice weekly in 21-day cycle until 
disease progression. The update results showed encouraging clinical activity of 
panobinostat with 1 patient achieved CR and 10 pateints achieved PR.62 Moreover, disease 
control rate (CR+PR+SD) was 79%. Panobinostat was well tolerated and reversible 
thrombocytopenia was managed by dose delay or dose reduction. The interim results for 
this phase II study continues to demonstrate encouraging activity of panobinostat.63 The 
final results are currently not available. As previously demonstrated with other DAC 
inhibitors, a decrease in serum TARC levels was observed in panobinostat treated patients 
achieving an objective response (i.e. PR or CR).64  
The safety and efficacy of the oral agent belinostat (PXD-101) was evaluated in patients 
with rel/ref NHL or cHL by Zain et al.65 Tumor size reduction found in 1/3 of patients with 
HL using the recommended dose-schedule for patients with solid tumors (750 mg daily, D1-
14 every 21days). 
Entinostat (SNDX-275) is a class I isotype-selective HDAC inhibitor with longer half-life. 
Pre-clinical data from Khaskhely et al demonstrated in vitro activity in HL-derived cell 
lines.66 Entinostat induced cell death with an IC50 of 0.4 μM. At the molecular level, 
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entinostat up-regulates p21 expression, increased H3 acetylation and down-regulates the 
anti-apoptotic X-linked inhibitor of apoptosis (XIAP) resulting in apoptosis. Moreover, the 
combination entinostat with gemcitabine or bortezomib has shown synergistic effects. Jóna 
et al found that entinostat down-regulates anti-apototic Bcl-2 and Bcl-xL expression without 
altering Mcl-1 or Bax levels and its effect was enhanced by two Bcl-2 inhibitors (ABT-737 
and obatoclax).67  
Younes et al recently presented an update of a phase II clinical study evaluating the safety 
and efficacy of entinostat as a single agent in relapsed/refractory HL.68 Interim results from 
a phase II open-label multicenter study of entinostat (ENGAGE-501) administered in an 
alternate dosing schedule (the first stage: 10 mg every 14 days, 28-day cycle; the second 
stage: 15mg every 14 days beginning C1d15) showed that of 23 patients with rel/ref HL, 
65% have disease control (CR+PR+SD). Entinostat was well tolerable with minimal AEs 
consisting of grade 1/2 fatigue, fever and GI symptoms. Serious grade 3/4 AEs were 
primarily hematological and consisted of thrombocytopenia (59.4%) and neutropenia 
(28.1%). Accrual into the study continues and the final results of this clinical trial are eagerly 
anticipated. Given the safety profile of and the long half-life of this promising agent, 
combination studies with chemotherapeutic agents based in pre-clinical studies are 
warranted to further define the role of entinostat in the management of HL. 
Givinostat (ITF-2357) is a hydroxamate pan-HDAC inhibitor with anti-inflammatory 
properties. Furlan et al reported a phase I safety and pharmacokinetics study in healthy 
males.69 They found no serious side effects and no organ toxicity. Several phase II studies of 
givinostat are in process to evaluate the safety and efficacy in rel/ref HL. A phase II open 
label non-randomized study by Viviani et al enrolled 15 patients with rel/ref disease, 13 
patients had failed HDC-ASCT, and 4 of those patients had also failed an alloSCT.70 
Givinostat was administered at a dose of 100 mg orally daily in three 4-week cycles. Seven 
of 13 patients (54%) whom completed at least one cycle of therapy were evaluable for 
response, SD was observed in 46% of the patients. Toxicity includes grade 1-2 
thrombocytopenia, leukopenia, diarrhea and/or abdominal pain; nonetheless, twenty 
percent of patients had transient drug discontinuation due to prolonged QTc. Another 
phase II study evaluated the safety and clinical activity of givinostat in combination with 
meclorethamine in patients with rel/ref HL.71 Anti-tumor activity was observed and 
correlated with a reduction in serum TARC levels. 
5.3 Targeting the PI3K/AKT/mTOR pathway in HL 
Everolimus (RAD001) binds to FK506-binding protein 12 (FKBP12) forming a complex that 
has mTOR kinase inhibition activity, inhibit tumor cell proliferation and angiogenesis by 
decreasing hypoxia-inducible factor 1a (HIF1a) expression.72,73 Everolimus demonstrated 
anti-proliferative effect in several solid tumor and hematologic malignancies including HL. 
Jundt et al showed that everolimus markedly suppress tumor cell proliferation of HL in vivo 
and down-regulates constitutively activated NFκB activity in HL cell lines.74 A phase II trial 
evaluated the clinical activity and toxicity of everolimus in patients with heavily pretreated 
rel/ref HL (median of 6 prior therapies and 84% had prior HDC-ASCS).75 Of 19 patients, one 
patient achieved CR, 8 patients achieved PR resulting in ORR of 47%, although median time 
to response was only 7.2 months.  
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Preclinical data from Georgakis et al showed temsirolimus (CCI-779) induced cell cycle 
arrest at G0/G1 phase and autophagy in HL-derived cell lines suggesting that this particular 
mTOR inhibitor may have therapeutic value in patients with HL.76 Several phase I/II trials 
studying the safety and efficacy of single agent various mTOR inhibitors (i.e. temsirolimus 
or everolimus) monotherapy, or combination with lenalidomide or sorafinib are being 
conducted to test the concept of mTOR inhibition in treatment rel/ref HL.  
5.4 Heat Shock Protein (HSP)  
Heat shock protein acting as chaperones are essential in promoting cell survival by 
maintaining the structure and function of key regulatory proteins involved in cell cycle, 
proliferation and apoptosis. HSP over-expression had been demonstrated in several 
malignancies including HL. Inhibition of HSP is another attractive target in cancer 
therapeutics. Boll et al demonstrated the biological effects of a HSP90 inhibitor, BIIB021 on 
HL-derived cell lines.77 The investigators demonstrated that, BIIB021 inhibited the 
constitutive activity of NFκB independent of IκB mutation status and increased 
susceptibility of HL cells for NK cell-mediated killing via inducing the expression of 
activating NK-cell ligands. Schoof et al showed that inhibition of HSP90 by either 
geldanamycin derivative 17-AAG or RNA interference in HL cells led to decrease cell 
proliferation and inhibition of STAT1, STAT3, STAT5, and STAT6 tyrosine phosphorylation 
possible secondary to reduced protein expression of Janus kinase (Jaks).78 HSP90 may be a 
promising target in patients with rel/ref cHL. 
6. Immune therapy for rel/ref HL 
6.1 Lenalidomide 
Lenalidomide, a novel IMiDs immunomodulatory drug is emerging as an attractive 
therapeutic option for patients with B-cell lymphoproliferative neoplasms, including HL. 
Studies in lymphoma and multiple myeloma (MM) models have demonstrated that 
lenalidomide exerts higher anti-tumor activity than thalidomide, has a unique capacity to 
enhance the innate immune system, enhance the anti-tumor activity of rituximab, and 
inhibit angiogenesis.79,80 Abnormal immune response, increased angiogenesis, and apoptosis 
resistance, which contribute to the development of HL, support the scientific standpoint of 
evaluating lenalidomide in rel/ref HL.81-83 
Lenalidomide was evaluated in patients with relapsed/refractory HL in three phase II 
clinical trials (Table 4). A phase II study presented by Böll et al and subsequently 
validated by Kuruvilla et al suggested lenalidomide had anti-tumor activity in rel/ref HL 
patients achieved a clinical response (CR or PR).84,85 More importantly, lenalidomide 
monotherapy was well tolerated and toxicities were manageable. Fehniger et al reported 
similar anti-neoplastic activity in rel/ref HL patients.86 Recently and as had been observed 
in other lenalidomide treated patients, tumor flare reaction (TFR) syndrome with sudden 
onset painful re-enlargement of tumor following early tumor shrinkage was reported in 3 
cases of relapsed HL after hematopoietic stem cell transplantation which mimic tumor 
progression but manageable with anti-inflammatory/analgesic upon continuation of 
lenalidomide.87  
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Table 4. Clinical trials evaluating lenalidomide monotherapy in relapsed/refractory 
Hodgkin lymphoma patients. 
6.2 EBV specific CTL therapy 
In general, while chemotherapy agents, small molecule inhibitors, drug immunoconjugates 
or immunodulatory drugs exhibit promising anti-tumor activity in patients with rel/ref HL, 
the duration of response to each agent when reported by investigators is rather short. 
Giving the median age of patients with rel/ref HL the incorporation of therapeutic 
strategies with durable remissions is necessary. Two therapeutic approaches are been 
actively evaluated with promising results: 1) Autologous or allogeneic LMP2-specific 
cytotoxic T-cell lymphocytes (CTL) and 2) allogeneic bone marrow transplantation.  
Approximately 30-40% of HL cases are associated with EBV infection of the HRS cells as 
proven by the expression of viral latent membrane protein (LMP).88,89 EBV is known to 
induce the surface expression of three latent antigens in EBV-infected HRS cells: LMP1, 
LMP2 and Epstein Barr nuclear antigen 1 (EBNA1). Immunotherapy targeting EBV related 
proteins in HRS cells is an area of active translational research. The generation and ex vivo 
expansion of cytotoxic T-cell lymphocytes (CTLs) specific for one or more EBV antigens had 
been studied in patients with hematological malignancies such as post-transplant 
lymphorpoliferative disorders and rel/ref HL. In general two EBV-related immunotherapy 
approached had been studied: 1) adoptive immunotherapy (administration of autologous or 
allogeneic EBV specific CTLs) and 2) vaccination of relevant epitopes from one of the EBV 
antigens to boost the patients’ own immune response.90,91   
Lucas et al demonstrated the clinical efficacy of allogeneic EBV-specific CTLs in EBV-positive 
rel/ref HL who had previously failed HDC-ASCT.92 Significant clinical activity was observed 
following allogenic CTLs infusion despite a lack to detect donor chimerism. In addition, in the 
limited number of patients evaluated the administration of fludarabine prior to CTLs infusion 
enhanced the clinical responses observed. While clinical effects had been observed in HL 
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patients treated with EBV-specific CTLs, the anti-tumor effects are not as robust as what has 
been observed in patients with PTLDs. Several observations can account for such differences, 
EBV infected HRS usually express less immunogenic EBV proteins in contrast to PTLD 
patients (LMP2). In addition, HRS cell have mechanisms to evade immune response to EBV 
infection including down-regulation of the immunogenicity of latent EBV antigen (i.e. LMP2) 
and secretion of the immunosuppressive cytokines such as IL10, IL-13, TARC, TRAFs (tumor 
necrosis factor receptor-associated factors) and TGFβ which may suppress the efficacy of EBV 
specific CTL.93-95 Using the strategies to enhance Th1 CTLs development and decrease Th2 
cytokine production may overcome the defective immune recognition of HRS cells and 
improve the efficacy of the EBV specific CTL therapy in rel/ref HL (Table 5).   
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N= number of patients; HL = Hodgkin Lymphoma; NHL = Non-Hodgkin lymphoma; Rel/ref = 
relapsed/refractory; EBV = Epstein Barr Virus; CTL = cytotoxic T-cell lymphocytes; LMP = Latent 
membrane protein;  LMP2a = Latent membrane protein 2a.  
Table 5. Ongoing trials of EBV-Specific CTLs for patients with relapsed/refractory Hodgkin 
lymphoma. 
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6.3 Allogeneic bone marrow transplant (AlloSCT) 
Approximately 50% of patients with relapsed Hodgkin lymphoma who undergo HDC-
ASCT relapse as a consequence of refractory disease, usually within the first year post-
transplant.96,97 Relapsed HL patients after HDC-ASCT have a poor clinical outcome and 
represent a therapeutic challenge for the practicing oncologist. There are several proposed 
risk factors to identify patients at high risk to develop disease progression following HDC-
ASCT such as chemotherapy resistant disease prior to HDC-ASCT, B symptoms at the time 
of relapse, residual disease at the time of transplantation by functional imaging, extra-nodal 
disease at the time of relapse, and bulky disease.98,99 Patients with any of these high risk 
factors may be suited for alternative therapeutic strategies such as tandem transplant, 
allogeneic bone marrow transplant, and/or post-HDC-ASCT maintenance therapy in the 
context of a clinical trial.  
A second HDC-ASCT could be considered for patients with a long period of remission 
following the initial transplant (>3 years) or those whom alloSCT is not feasible.100   
AlloSCT has been used in patients with rel/ref HL with controversial results. Often the high 
incidence of transplant related mortality (TRM) offsets the potential clinical benefit.101 While 
the incorporation of reduced intensity conditioning regimens has been associated with 
lower TRM rates, the long-term PFS rates rarely exceed 20-25% questioning the validity of 
this approach. Patients who have chemotherapy sensitive disease, non-bulky disease, and 
have greater than 1 year of remission after the first HDC-ASCT seem to have most benefited 
with this approach.102  
Despite early good responses, the results of RIC-AlloSCT demonstrate a disappointing 
clinical outcome and lack of long term disease control with 2 year OS of 29-66% and 2 year 
PFS of 20-39% regardless of conditioning regimens or donor types.103-105 Peggs et al reported 
durable response to donor lymphocyte infusion (DLI) in patients with relapsed HL post 
alloSCT that incorporated in vivo T-cell depletion.106 DLI was administered to 46 patients for 
mixed chimerism (n=22) and relapsed disease post-alloSCT (n=24). Eighty-six percent of 
patients with mixed chimerism converted to full donor status and had a 4-year relapse 
incidence of 5%. More importantly, CR and PR were noted in 58.3% and 20.8% of 24 patients 
with relapsed disease respectively, suggesting the existence of graft vs. HL effects. Ongoing 
clinical studies are investigating the role of alloSCT in relapsed HL patients with poor-risk 
features who are at high risk to relapse after HDC-ASCT.  
In summary, promising therapies are emerging for the treatment of rel/ref HL. Substantial 
and occasionally durable remissions have been observed with some therapeutic 
interventions, such as HDACi, drug immunoconjugates, and cellular therapy. Ongoing 
studies will hopefully guide the integration of these therapies in the current treatment of 
high-risk HL in an attempt to improve cure rates. In addition, ongoing scientific and 
translational research and the importance of the development of novel therapeutics for 
patients with ref/rel HL should not be underemphasized. 
7. References 
[1] Kuruvilla J. Standard therapy for advanced Hodgkin lymphoma. Hematology Am Soc 
Hematol Educ Program 2009:497-506 2009. 
 
Hodgkin's Lymphoma 194 
[2] Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 
signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic 
large cell lymphoma. Blood 2002;99:3398-403. 
[3] Jundt F, Acikgoz O, Kwon SH, et al. Aberrant expression of Notch1 interferes with the B-
lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. 
Leukemia 2008;22:1587-94. 
[4] Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of 
transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of 
Hodgkin lymphoma. Blood 2002;99:618-26. 
[5] Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell 
proliferation and is a target of tyrphostin AG17 which confers sensitization for 
apoptosis. Leukemia 2005;19:936-44. 
[6] Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA 
activation is required for proliferation and survival of Hodgkin's disease tumor 
cells. J Clin Invest 1997;100:2961-9. 
[7] Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. 
Leuk Lymphoma 2000;38:363-71. 
[8] Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II 
multicenter trial of single-agent gemcitabine in patients with relapsed or 
chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110-5. 
[9] Aurer I, Radman I, Nemet D, et al. Gemcitabine in the treatment of relapsed and 
refractory Hodgkin's disease. Onkologie 2005;28:567-71. 
[10] Suyani E, Sucak GT, Aki SZ, Yegin ZA, Ozkurt ZN, Yagci M. Gemcitabine and 
vinorelbine combination is effective in both as a salvage and mobilization regimen 
in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 
2011;90:685-91. 
[11] Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM. Phase II 
study of weekly gemcitabine and vinorelbine for children with recurrent or 
refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol 
2009;27:1456-61. 
[12] De Filippi R, Aldinucci, D., Galati, D., Esposito, A, Borghese, C., Crisci, S., Abagnale, G., 
Morelli, E., Frigeri, F., Corazzelli, G., Pinto, A.,. Effects of bendamustine on 
apoptosis and colony-initiating precursors in Hodgkin lymphoma cells [abstract]. 
ASCO Annual Meeting 2011;29 Suppl abstr e18559. 
[13] Moskowitz AJ, Hamin, P.A.,  Gerecitano, J., Horwitz, S.M., Matasar, M., Melkie, J., Noy, 
A., Lia Palomba, M., Portlock, C.S., Straus, D.J., Vanak, J.M., Zelenetz, A.D., 
Moskowitz, C.G. . Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed 
and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem 
Cell Transplant [abstract]. ASH Annual Meeting 114:720 2009. 
[14] Vooijs WC, Otten HG, van Vliet M, et al. B7-1 (CD80) as target for immunotoxin 
therapy for Hodgkin's disease. Br J Cancer 1997;76:1163-9. 
[15] Bolognesi A, Polito L, Tazzari PL, et al. In vitro anti-tumour activity of anti-CD80 and 
anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J 
Haematol 2000;110:351-61. 
[16] Smith SM. Galiximab in relapsed hodgkin lymphoma. Clin Adv Hematol Oncol 
2010;8:669-70. 
 
Hodgkin's Lymphoma 194 
[2] Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 
signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic 
large cell lymphoma. Blood 2002;99:3398-403. 
[3] Jundt F, Acikgoz O, Kwon SH, et al. Aberrant expression of Notch1 interferes with the B-
lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. 
Leukemia 2008;22:1587-94. 
[4] Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of 
transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of 
Hodgkin lymphoma. Blood 2002;99:618-26. 
[5] Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell 
proliferation and is a target of tyrphostin AG17 which confers sensitization for 
apoptosis. Leukemia 2005;19:936-44. 
[6] Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA 
activation is required for proliferation and survival of Hodgkin's disease tumor 
cells. J Clin Invest 1997;100:2961-9. 
[7] Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. 
Leuk Lymphoma 2000;38:363-71. 
[8] Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II 
multicenter trial of single-agent gemcitabine in patients with relapsed or 
chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110-5. 
[9] Aurer I, Radman I, Nemet D, et al. Gemcitabine in the treatment of relapsed and 
refractory Hodgkin's disease. Onkologie 2005;28:567-71. 
[10] Suyani E, Sucak GT, Aki SZ, Yegin ZA, Ozkurt ZN, Yagci M. Gemcitabine and 
vinorelbine combination is effective in both as a salvage and mobilization regimen 
in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 
2011;90:685-91. 
[11] Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM. Phase II 
study of weekly gemcitabine and vinorelbine for children with recurrent or 
refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol 
2009;27:1456-61. 
[12] De Filippi R, Aldinucci, D., Galati, D., Esposito, A, Borghese, C., Crisci, S., Abagnale, G., 
Morelli, E., Frigeri, F., Corazzelli, G., Pinto, A.,. Effects of bendamustine on 
apoptosis and colony-initiating precursors in Hodgkin lymphoma cells [abstract]. 
ASCO Annual Meeting 2011;29 Suppl abstr e18559. 
[13] Moskowitz AJ, Hamin, P.A.,  Gerecitano, J., Horwitz, S.M., Matasar, M., Melkie, J., Noy, 
A., Lia Palomba, M., Portlock, C.S., Straus, D.J., Vanak, J.M., Zelenetz, A.D., 
Moskowitz, C.G. . Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed 
and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem 
Cell Transplant [abstract]. ASH Annual Meeting 114:720 2009. 
[14] Vooijs WC, Otten HG, van Vliet M, et al. B7-1 (CD80) as target for immunotoxin 
therapy for Hodgkin's disease. Br J Cancer 1997;76:1163-9. 
[15] Bolognesi A, Polito L, Tazzari PL, et al. In vitro anti-tumour activity of anti-CD80 and 
anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J 
Haematol 2000;110:351-61. 
[16] Smith SM. Galiximab in relapsed hodgkin lymphoma. Clin Adv Hematol Oncol 
2010;8:669-70. 
 
Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma 195 
[17] Gruss HJ, Hirschstein D, Wright B, et al. Expression and function of CD40 on Hodgkin 
and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 
1994;84:2305-14. 
[18] Aldinucci D, Gloghini A, Pinto A, Colombatti A, Carbone A. The role of CD40/CD40L 
and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk 
Lymphoma 2011. 
[19] Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A. IRF4 silencing inhibits 
Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br J Haematol 
2011;152:182-90. 
[20] Freedman A, Kuruvilla, J., Assouline, S.E., Engert, A., Heo, D., Solal-Celigny, P., 
Corradini, P., Verhoef, G., Fanale, M.A., Bendiske, J., Ewald, B., Dey, J., Baeck, J., 
Younes, A. Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with 
Relapsed/Refractory Hodgkin or non-Hodgkin Lymphoma Treated In a Phase 
Ia/II Clinical Trial (NCT00670592) [abstract]. . ASH Annual Meeting Abstracts 2010 
116:284 2010. 
[21] http://clinicaltrials.gov/ct2/search. NCT00129753. Last access January 23, 2012. 
[22] http://clinicaltrials.gov/ct2/search. NCT01030900. Last access January 23, 2012. 
[23] Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients 
with recurrent, classic Hodgkin disease. Cancer 2003;98:310-4. 
[24] Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic 
Hodgkin lymphoma. Blood 2009;113:5920-6. 
[25] Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor 
immunity. Cancer Res 2006;66:7741-7. 
[26] Corazzelli G, Frigeri, F., Marcacci, G., Capobianco, G., Arcamone, M., Becchimanzi, C., 
Russo, F., Pinto, A. Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) 
as salvage therapy for recurrent Hodgkin lymphoma [abstract]. ASCO Annual 
Meeting 2009;27:Suppl abstr 8579. 
[27] Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with 
rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 
2008;112:831-6. 
[28] Copeland A, Cao, Y., Fanale, M., Fayad, L., McLaughlin, P., Pro, B., Hagemeister, F., 
Romaguera, J., Samaniego, F., Rodriguez, A., Younes, A. Final Report of a Phase-II 
Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced 
Stage Classical Hodgkin Lymphoma : Results of Long Follow up and Comparison 
to Institutional Historical Data [abstract]. ASH Annual Meeting Abstracts 2009 
114:1680 2009. 
[29] Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant 
Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-9. 
[30] Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin 
lymphoma with the monoclonal antibody rituximab is effective and well tolerated: 
results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 
2003;101:420-4. 
[31] Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly 
diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a 
report from the German Hodgkin Study Group. Blood 2011;118:4363-5. 
 
Hodgkin's Lymphoma 196 
[32] Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-
predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the 
German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-11. 
[33] Zojer N, Mirzaei S, Ludwig H. Successful treatment of a patient with lymphocyte-
predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan. Eur J 
Haematol 2008;81:322-4. 
[34] Schnell R, Dietlein M, Schomacker K, et al. Yttrium-90 ibritumomab tiuxetan-induced 
complete remission in a patient with classical lymphocyte-rich Hodgkin's 
Lymphoma. Onkologie 2008;31:49-51. 
[35] http://clinicaltrials.gov/ct2/search. NCT00484874. Last access January 23, 2012. 
[36] Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and 
Hodgkin's disease-involved lymphoid tissues. Am J Pathol 1996;149:469-81. 
[37] Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 
ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 
1996;88:3299-305. 
[38] Borchmann P, Schnell R, Engert A. Immunotherapy of Hodgkin's lymphoma. Eur J 
Haematol Suppl 2005:159-65. 
[39] Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma 
patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin 
Oncol 2005;23:4669-78. 
[40] Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in 
vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-42. 
[41] Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal 
antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. 
J Clin Oncol 2007;25:2764-9. 
[42] Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent 
anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97. 
[43] Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed 
CD30-positive lymphomas. N Engl J Med 2010;363:1812-21. 
[44] Chen R, Gopal, AK., Smith, SE., Ansell, SM., Rosenblatt, JD., Savage KJ., Connors, JM., 
Engert, A., Larsen, EK., Kennedy, DA., Sievers, EL., Younes, A. Results from a 
pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed 
or refractory hodgkin lymphoma (HL) [abstract]. ASCO Annual Meeting 2011;29 
Suppl abstr 8031. 
[45] http://clinicaltrials.gov/ct2/search. NCT01100502. Last access January 23, 2012. 
[46] http://clinicaltrials.gov/ct2/search. NCT01060904. Last access January 23, 2012. 
[47] Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single 
agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: 
cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-9. 
[48] Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients 
with relapsed classical Hodgkin lymphoma. Blood 2006;107:1731-2. 
[49] Trelle S, Sezer O, Naumann R, et al. Bortezomib in combination with dexamethasone 
for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed 
phase II study (NCT00148018). Haematologica 2007;92:568-9. 
[50] Mendler JH, Kelly J, Voci S, et al. Bortezomib and gemcitabine in relapsed or refractory 
Hodgkin's lymphoma. Ann Oncol 2008;19:1759-64. 
 
Hodgkin's Lymphoma 196 
[32] Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-
predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the 
German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-11. 
[33] Zojer N, Mirzaei S, Ludwig H. Successful treatment of a patient with lymphocyte-
predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan. Eur J 
Haematol 2008;81:322-4. 
[34] Schnell R, Dietlein M, Schomacker K, et al. Yttrium-90 ibritumomab tiuxetan-induced 
complete remission in a patient with classical lymphocyte-rich Hodgkin's 
Lymphoma. Onkologie 2008;31:49-51. 
[35] http://clinicaltrials.gov/ct2/search. NCT00484874. Last access January 23, 2012. 
[36] Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and 
Hodgkin's disease-involved lymphoid tissues. Am J Pathol 1996;149:469-81. 
[37] Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 
ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 
1996;88:3299-305. 
[38] Borchmann P, Schnell R, Engert A. Immunotherapy of Hodgkin's lymphoma. Eur J 
Haematol Suppl 2005:159-65. 
[39] Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma 
patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin 
Oncol 2005;23:4669-78. 
[40] Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in 
vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-42. 
[41] Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal 
antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. 
J Clin Oncol 2007;25:2764-9. 
[42] Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent 
anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97. 
[43] Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed 
CD30-positive lymphomas. N Engl J Med 2010;363:1812-21. 
[44] Chen R, Gopal, AK., Smith, SE., Ansell, SM., Rosenblatt, JD., Savage KJ., Connors, JM., 
Engert, A., Larsen, EK., Kennedy, DA., Sievers, EL., Younes, A. Results from a 
pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed 
or refractory hodgkin lymphoma (HL) [abstract]. ASCO Annual Meeting 2011;29 
Suppl abstr 8031. 
[45] http://clinicaltrials.gov/ct2/search. NCT01100502. Last access January 23, 2012. 
[46] http://clinicaltrials.gov/ct2/search. NCT01060904. Last access January 23, 2012. 
[47] Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single 
agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: 
cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-9. 
[48] Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients 
with relapsed classical Hodgkin lymphoma. Blood 2006;107:1731-2. 
[49] Trelle S, Sezer O, Naumann R, et al. Bortezomib in combination with dexamethasone 
for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed 
phase II study (NCT00148018). Haematologica 2007;92:568-9. 
[50] Mendler JH, Kelly J, Voci S, et al. Bortezomib and gemcitabine in relapsed or refractory 
Hodgkin's lymphoma. Ann Oncol 2008;19:1759-64. 
 
Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma 197 
[51] Fanale M, Fayad L, Pro B, et al. Phase I study of bortezomib plus ICE (BICE) for the 
treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 2011;154:284-6. 
[52] Jain S, Diefenbach C, Zain J, O'Connor OA. Emerging role of carfilzomib in treatment of 
relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid 
2011;6:43-57. 
[53] Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 
cytokine and TARC production and induces cell death in Hodgkin lymphoma cell 
lines. Blood 2008;112:1424-33. 
[54] Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for 
treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology 
Group Study S0517. Leuk Lymphoma 2011. 
[55] Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide induces 
cell death in Hodgkin lymphoma-derived cell lines. Leuk Res 2009;33:929-36. 
[56] Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to 
the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin 
Lymphoma. Br J Haematol 2009;147:97-101. 
[57] Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's 
lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-8. 
[58] Younes A PB, Fanale M, McLaughlin P, Neelapu S, Fayad L, Wedgwood A, Buglio D, 
Patterson T, Dubay M, Li Z, Martell RE, Ward R, Bociek RG. Isotype-Selective 
HDAC inhibitor MGCD0103 Decreases Serum TARC Concentrations and produces 
Clinical Response in Heavily Pretreated Patients with Relapsed Classical Hodgkin 
Lymphoma (HL) [abstract]. ASH Annual Meeting Abstracts 2007 110:2566 2007. 
[59] Buglio D, Mamidipudi V, Khaskhely NM, et al. The class-I HDAC inhibitor MGCD0103 
induces apoptosis in Hodgkin lymphoma cell lines and synergizes with 
proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 
2010;151:387-96. 
[60] Bhalla S, Balasubramanian S, David K, et al. PCI-24781 induces caspase and reactive 
oxygen species-dependent apoptosis through NF-kappaB mechanisms and is 
synergistic with bortezomib in lymphoma cells. Clin Cancer Res 2009;15:3354-65. 
[61] Younes A SA, Ben-Yehuda D, Ong TC, Tan D, Engert A, Le Corre C, Gallagher J, 
Hirawat S, Prince M. Phase II Study of Oral Panobinostat in Patients with 
Relapsed/refractory Hodgkin Lymphoma after High-dose Chemotherapy with 
Autologous Stem Cell Transplant [abstract]. Haematologica 2009;94:34 abs. 0088. 
[62] Younes A OT, Ribrag V, Engert a, Ben-Yehuda D, McCabe R, Shen A, Le Corre C, 
Hirawat S, Sureda A. Efficacy of Panobinostat in Phase II study in Patients with 
Relapsed/Refractory Hodgkin Lymphoma (HL) After High-DOse Chemotherapy 
with Autologous Stem Cell Transplant [abstract]. ASH Annual Meeting Abstracts 
2009 114:923 2009. 
[63] Sureda A EA, Browett PJ, Radford JA, Verhoef GE, Ramchandren R, Myke N, Shen A, 
Le Corre C, Younes A. Interim results for the phase II study of panobinostat 
(LBH589) inpatients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) 
after autologous hematopoietic stem cell transplant (AHSCT) [abstract]. ASCO 
Annual Meeting 2010;28. 
[64] HarrisonSJ HA, Meeson PJ, Younes A, Sureda A, Engert A, Li M, Savage P, Bugarini R, 
Le Corre C, Williams DE, Gllagher JD, Shen A, Ritchie D Biomarker analysis of 
 
Hodgkin's Lymphoma 198 
pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin 
lymphoma (HL) patients following autologous stem cell transplant (ASCT) 
[abstract]. ASCO Annual Meeting 2011;29. 
[65] Zain JM FF, Kelly WK, DeBono J, Petrylak D, Narwal A, Neylon E, Blumenschein G, 
Lassen U, O'Connor OA. Final results of a phase I study of oral belinostat (PXD101) 
in patients with lymphoma [abstract]. ASCO Annual Meeting 2009;27. 
[66] Khaskhely NM, Buglio, D., Shafer, J., Younes, A. The Histone Deacetylase (HDAC) 
Inhibitor Entinostat (SNDX-275) Targets Hodgkin lymphoma through a Dual 
Mechnism of Immune Modulation and Apoptosis Induction [abstract]. ASH 
Annual Meeting Abstracts 2009 114:1562 2009. 
[67] Jona A, Khaskhely N, Buglio D, et al. The histone deacetylase inhibitor entinostat 
(SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with 
Bcl-2 family inhibitors. Exp Hematol 2011;39:1007-17 e1. 
[68] Younes A, Hernandez-Ilizaliturri, F.J., Bociek, R.G., Kasamon, Y.L., Lee, P., Gore, L., 
Buglio, D., Copeland, A. . ENGAGE-501:Phase 2 Study Investigating the Role of 
Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory 
Hodgkin's Lymphoma (HL), Interim Results [abstract]. ASH Annual Meeting 
Abstracts 2010 116:3959 2010. 
[69] Furlan A, Monzani V, Reznikov LL, et al. Pharmacokinetics, safety and inducible 
cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor 
ITF2357 (givinostat). Mol Med 2011;17:353-62. 
[70] Viviani S, Bonfante, V., Fasola, C., Valagussa, A., Gianni, M. Phase II study of the 
histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma 
patients [abstract]. ASCO Annual Meeting 2008;26 Suppl abs 8532. 
[71] Carlo-Stella C, Guidetti, A., Viviani, S., Bonfante, V., Marchiano, A., Gatti, B., D'Urzo, 
C., Di Nicola, M.,  Corradini, P., Giannai, AM. Safety and clinical activity of the 
histone deacetylase inhibitor givinostat in combination with meclorethamine in 
relapsed/refractory Hodgkin lymphoma (HL) [abstract]. ASCO Annual Meeting 
2010;28 15 Suppl:3069. 
[72] Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as 
anticancer agents. Nat Rev Drug Discov 2006;5:671-88. 
[73] Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has 
antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase 
inhibitor. Clin Cancer Res 2009;15:1612-22. 
[74] Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls 
proliferation through down-regulation of truncated CCAAT enhancer binding 
protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell 
lymphomas. Blood 2005;106:1801-7. 
[75] Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor 
everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-4. 
[76] Georgakis G, Yazbeck, VY., Li, Y., Younes, A. Preclinical rationale for therapeutic 
targeting of mTOR by CC-I779 and rapamycin in hodgkin lymphoma [abstract]. 
ASCO Annual Meeting Suppl 24:10070 2006. 
[77] Boll B, Eltaib F, Reiners KS, et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) 
depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer 
cell-mediated cytotoxicity. Clin Cancer Res 2009;15:5108-16. 
 
Hodgkin's Lymphoma 198 
pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin 
lymphoma (HL) patients following autologous stem cell transplant (ASCT) 
[abstract]. ASCO Annual Meeting 2011;29. 
[65] Zain JM FF, Kelly WK, DeBono J, Petrylak D, Narwal A, Neylon E, Blumenschein G, 
Lassen U, O'Connor OA. Final results of a phase I study of oral belinostat (PXD101) 
in patients with lymphoma [abstract]. ASCO Annual Meeting 2009;27. 
[66] Khaskhely NM, Buglio, D., Shafer, J., Younes, A. The Histone Deacetylase (HDAC) 
Inhibitor Entinostat (SNDX-275) Targets Hodgkin lymphoma through a Dual 
Mechnism of Immune Modulation and Apoptosis Induction [abstract]. ASH 
Annual Meeting Abstracts 2009 114:1562 2009. 
[67] Jona A, Khaskhely N, Buglio D, et al. The histone deacetylase inhibitor entinostat 
(SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with 
Bcl-2 family inhibitors. Exp Hematol 2011;39:1007-17 e1. 
[68] Younes A, Hernandez-Ilizaliturri, F.J., Bociek, R.G., Kasamon, Y.L., Lee, P., Gore, L., 
Buglio, D., Copeland, A. . ENGAGE-501:Phase 2 Study Investigating the Role of 
Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory 
Hodgkin's Lymphoma (HL), Interim Results [abstract]. ASH Annual Meeting 
Abstracts 2010 116:3959 2010. 
[69] Furlan A, Monzani V, Reznikov LL, et al. Pharmacokinetics, safety and inducible 
cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor 
ITF2357 (givinostat). Mol Med 2011;17:353-62. 
[70] Viviani S, Bonfante, V., Fasola, C., Valagussa, A., Gianni, M. Phase II study of the 
histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma 
patients [abstract]. ASCO Annual Meeting 2008;26 Suppl abs 8532. 
[71] Carlo-Stella C, Guidetti, A., Viviani, S., Bonfante, V., Marchiano, A., Gatti, B., D'Urzo, 
C., Di Nicola, M.,  Corradini, P., Giannai, AM. Safety and clinical activity of the 
histone deacetylase inhibitor givinostat in combination with meclorethamine in 
relapsed/refractory Hodgkin lymphoma (HL) [abstract]. ASCO Annual Meeting 
2010;28 15 Suppl:3069. 
[72] Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as 
anticancer agents. Nat Rev Drug Discov 2006;5:671-88. 
[73] Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has 
antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase 
inhibitor. Clin Cancer Res 2009;15:1612-22. 
[74] Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls 
proliferation through down-regulation of truncated CCAAT enhancer binding 
protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell 
lymphomas. Blood 2005;106:1801-7. 
[75] Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor 
everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-4. 
[76] Georgakis G, Yazbeck, VY., Li, Y., Younes, A. Preclinical rationale for therapeutic 
targeting of mTOR by CC-I779 and rapamycin in hodgkin lymphoma [abstract]. 
ASCO Annual Meeting Suppl 24:10070 2006. 
[77] Boll B, Eltaib F, Reiners KS, et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) 
depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer 
cell-mediated cytotoxicity. Clin Cancer Res 2009;15:5108-16. 
 
Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma 199 
[78] Schoof N, von Bonin F, Trumper L, Kube D. HSP90 is essential for Jak-STAT signaling 
in classical Hodgkin lymphoma cells. Cell Commun Signal 2009;7:17. 
[79] Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of 
human natural killer T cells by lenalidomide: therapeutic implications. Blood 
2006;108:618-21. 
[80] Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-
angiogenic activity independently of immunomodulatory effects. Br J Cancer 
2002;87:1166-72. 
[81] Enblad G, Molin D, Glimelius I, Fischer M, Nilsson G. The potential role of innate 
immunity in the pathogenesis of Hodgkin's lymphoma. Hematol Oncol Clin North 
Am 2007;21:805-23. 
[82] Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin 
Oncol 2005;23:6379-86. 
[83] Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: 
increasing evidence of the importance of the microenvironment. J Clin Oncol 
2011;29:1812-26. 
[84] Boll B, Fuchs, M., Reiners, KS., Engert, A., Borchmann, P. Lenalidomide In Patients with 
Relapsed or Refractory Hodgkin Lymphoma [abstract]. ASH Annual Meeting 
Abstracts 2010 116:2828 2010. 
[85] Kuruvilla J, Taylor, D., Wang, L., Blattler, C., Keating, A., Crump, M. Phase II Trials of 
Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma 
[abstract]. ASH Annual Meeting Abstracts 2008 112:3052 2008. 
[86] Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide 
in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25. 
[87] Corazzelli G, De Filippi R, Capobianco G, et al. Tumor flare reactions and response to 
lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol 
2010;85:87-90. 
[88] Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: 
epidemiologic characteristics in international data. Int J Cancer 1997;70:375-82. 
[89] Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein 
expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A 
1991;88:4766-70. 
[90] Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: 
transcriptional analysis of virus latency in the malignant cells. J Exp Med 
1993;177:339-49. 
[91] Grasser FA, Murray PG, Kremmer E, et al. Monoclonal antibodies directed against the 
Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic 
detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 
1994;84:3792-8. 
[92] Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic 
Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-
positive Hodgkin disease. Cancer 2004;100:1892-901. 
[93] Newcom SR, Gu L. Transforming growth factor beta 1 messenger RNA in Reed-
Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol 1995;48:160-3. 
 
Hodgkin's Lymphoma 200 
[94] Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are 
frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. 
Blood 2001;97:250-5. 
[95] Peh SC, Kim LH, Poppema S. TARC, a CC chemokine, is frequently expressed in classic 
Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell 
lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 
2001;25:925-9. 
[96] Varterasian M, Ratanatharathorn V, Uberti JP, et al. Clinical course and outcome of 
patients with Hodgkin's disease who progress after autologous transplantation. 
Leuk Lymphoma 1995;20:59-65. 
[97] Martinez C, Canals, C., Alessandrino, E., Karakasis, D., Leone, G., Trneny, M., 
Snowden, J., Apperley, J., Milpied, N., Sureda, A. Relapse of Hodgkin's lymphoma 
(HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 
patients registered in the database of the EBMT. ASCO Annual Meeting 2010;15s 
Suppl abstr 8060. 
[98] Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell 
transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol 
Blood Marrow Transplant 2006;12:1065-72. 
[99] Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early 
relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J 
Haematol 2011;153:358-63. 
[100] Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell 
transplantation for relapsed lymphoma after a prior autologous transplant. Biol 
Blood Marrow Transplant 2008;14:904-12. 
[101] Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from 
HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572-8. 
[102] Thomson KJ, Peggs KS, Blundell E, Goldstone AH, Linch DC. A second autologous 
transplant may be efficacious in selected patients with Hodgkin's lymphoma 
relapsing after a previous autograft. Leuk Lymphoma 2007;48:881-4. 
[103] Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic 
stem cell transplantation for Hodgkin's lymphoma: identification of prognostic 
factors predicting outcome. Haematologica 2009;94:230-8. 
[104] Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the 
overall and progression-free survival of Hodgkin lymphoma patients relapsing 
after autologous transplantation: a retrospective study based on the time of HLA 
typing and donor availability. Blood 2010;115:3671-7. 
[105] Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity 
allogeneic hematopoietic stem cell transplantation for relapsed and refractory 
Hodgkin lymphoma. Biol Blood Marrow Transplant 2009;15:109-17. 
[106] Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate 
relapse risk in mixed chimeras and induce durable salvage in relapsed patients 
after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin 
Oncol 2011;29:971-8. 
 
Hodgkin's Lymphoma 200 
[94] Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are 
frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. 
Blood 2001;97:250-5. 
[95] Peh SC, Kim LH, Poppema S. TARC, a CC chemokine, is frequently expressed in classic 
Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell 
lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 
2001;25:925-9. 
[96] Varterasian M, Ratanatharathorn V, Uberti JP, et al. Clinical course and outcome of 
patients with Hodgkin's disease who progress after autologous transplantation. 
Leuk Lymphoma 1995;20:59-65. 
[97] Martinez C, Canals, C., Alessandrino, E., Karakasis, D., Leone, G., Trneny, M., 
Snowden, J., Apperley, J., Milpied, N., Sureda, A. Relapse of Hodgkin's lymphoma 
(HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 
patients registered in the database of the EBMT. ASCO Annual Meeting 2010;15s 
Suppl abstr 8060. 
[98] Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell 
transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol 
Blood Marrow Transplant 2006;12:1065-72. 
[99] Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early 
relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J 
Haematol 2011;153:358-63. 
[100] Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell 
transplantation for relapsed lymphoma after a prior autologous transplant. Biol 
Blood Marrow Transplant 2008;14:904-12. 
[101] Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from 
HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572-8. 
[102] Thomson KJ, Peggs KS, Blundell E, Goldstone AH, Linch DC. A second autologous 
transplant may be efficacious in selected patients with Hodgkin's lymphoma 
relapsing after a previous autograft. Leuk Lymphoma 2007;48:881-4. 
[103] Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic 
stem cell transplantation for Hodgkin's lymphoma: identification of prognostic 
factors predicting outcome. Haematologica 2009;94:230-8. 
[104] Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the 
overall and progression-free survival of Hodgkin lymphoma patients relapsing 
after autologous transplantation: a retrospective study based on the time of HLA 
typing and donor availability. Blood 2010;115:3671-7. 
[105] Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity 
allogeneic hematopoietic stem cell transplantation for relapsed and refractory 
Hodgkin lymphoma. Biol Blood Marrow Transplant 2009;15:109-17. 
[106] Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate 
relapse risk in mixed chimeras and induce durable salvage in relapsed patients 
after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin 
Oncol 2011;29:971-8. 
Part 8 
Therapy for Relapsed and  
Refractory Pediatric Hodgkin’s Lymphoma 
 
 8 
Therapy for Relapsed and Refractory 
Pediatric Hodgkin Lymphoma 
Karen S. Fernández and Pedro A. de Alarcón 
University of Illinois, College of Medicine at Peoria 
Children’s Hospital of Illinois, 
USA  
1. Introduction 
The treatment of Hodgkin lymphoma (HL) has improved dramatically over the past two 
decades. The reported five-year event free survival ranges between 80 – 90% with combined 
modality chemotherapy and radiotherapy. However, 10 - 15% of patients with localized 
disease and 25% of patients with advanced classical Hodgkin Lymphoma (cHL) have 
recurrent disease after first line treatment. (Lohri, Barnett et al. 1991; Longo, Duffey et al. 
1992; Ferme, Mounier et al. 2002). Refractory patients are also problematic occurring in 2 -
5% of patient with low stage (I/II) and 5 – 10% of high stage (III/IV) cHL (Diehl, Franklin et 
al. 2003). Retrieval of patients with relapsed and refractory Hodgkin Lymphoma (RR-HL) 
can be achieved with the use of salvage chemotherapy that includes front-line 
chemotherapy agents and high dose therapy (HDT) followed by autologous stem cell 
transplantation (ASCT) (Andre, Henry-Amar et al. 1999; Lazarus, Rowlings et al. 1999). This 
chapter will discuss the various second line therapeutic approaches for retrieval of patients 
with RR-HL. 
2. Prognostic factors and risk stratification at the time of relapse 
Several adverse risk factors have been identified to have prognostic significance in patients 
with RR-HL. In adults as in the pediatric population, time to initial treatment failure is a 
strong predictor of survival for patients receiving salvage therapy regardless of high dose 
chemotherapy and ASCT. (Josting, Rueffer et al. 2000; Schellong, Dorffel et al. 2005). 
Chemosensitivity to induction or salvage therapy prior to HDT and ASCT is also a strong 
predictor of outcome (Chopra, McMillan et al. 1993), and in fact helps to define subsequent 
treatment plan. Patients with induction failure at the time of relapse have the worse 
outcome (Moskowitz, Kewalramani et al. 2004).  
Over the past 15 years, two retrospective studies demonstrated that time to relapse, site of 
relapse, clinical stage at relapse, and the presence of anemia at the time of relapse were 
significant predictors of outcome (Brice, Bouabdallah et al. 1997; Josting, Engert et al. 2002).  
The scoring system developed by Justing et al, demonstrated that time to relapse 
(<12months vs. > 12 months), clinical stage at relapse (Stage III/IV) and the presence of 





predictors of outcome with a freedom from second failure of 45%, 32% and 18% for patients 
with 0, 1, 2, or 3 of the above mentioned risk factors, respectively (Josting, Engert et al. 2002).  
Another prospective study by Moskowitz et al, indentified the presence of B symptoms, 
extranodal disease, and less than 12 months to relapse as adverse prognostic factors. They 
estimated a EFS of 83% for patients with 0-1 adverse prognostic factors, 27% for patients 
with 2 factors and 10% for patients with 3 factors (Moskowitz, Nimer et al. 2001).  
In the pediatric population significant predictors of poor OS and EFS are extranodal disease, 
mediastinal mass at relapse, stage IV at relapse and primary refractory disease (Lieskovsky, 
Donaldson et al. 2004; Schellong, Dorffel et al. 2005). In adolescents the presence of B 
symptoms at the time of relapse confers an 11-year OS of 27% after HDT and ASCT (Akhtar, 
El Weshi et al. 2010). 
The recognition of adverse risk factors at the time of relapse in cHL defines risk group and 
allows assignment of treatment according to risk stratification. For instance, using time to 
relapse (> 12 months) and extranodal disease as predictors of outcome, Brice proposes that 
adult patients with no adverse prognostic factors (favorable risk), should not be exposed to 
HDT and ASCT to prevent long term toxicity, but instead be treated with conventional 
chemotherapy such as BEACOPP or MOPP/ABV. Patients with one risk factor 
(intermediate risk), may benefit from HDT and ASCT +/- Radiation depending on the site 
of relapse. Finally, patients with two risk factors (high risk for relapse), or those with 
induction failure or refractory disease, stage IIIB or with anemia required  salvage therapy 
prior to HDT and ASCT (Brice 2008).  
In Pediatrics, the identification of prognostic factors is used by individual groups  to select 
therapy, however, there is no agreement across the international groups among a model 
for risk stratification and treatment assignment according to the prognostic parameters. 
The EuroNet-PHL-C1 protocol is using this concept and is stratifying patients, depending 
on time of relapse. Late relapse (< 12 months after primary therapy) is considered low 
risk, primary progression is high risk and intermediate risk are all other relapses (Daw, 
Wynn et al. 2011). 
Patients with RR-HL regardless of their prognostic factors at the time of relapse/recurrence 
have several therapeutic options. The role of salvage chemotherapy, high dose therapy 
followed by ASCT, allogeneic stem cell transplantation (Allo SCT), and other alternatives 
are discussed below. 
3. Salvage chemotherapy regimens (Re-induction chemotherapy) 
There is no consensus on the gold-standard second-line chemotherapy for retrieval of RR-
HL. Several regimens have been used over the past decades, as summarized in Table 1. This 
regimes could be classified into: 
3.1 Intensive conventional regimens 
Mini BEAM (carmustine, etoposide, cytarabine and melphalan); Dexa - BEAM (dexamethasone, 
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3.2 Platinum based regimens 
ESHAP (etoposide, methylprednisolone, high dose cytarabine and cisplatin); DHAP 
(dexamethasone, high-dose cytarabine, cisplatin); APE (cytarabine, cisplatin, etoposide) 
3.3 Ifosfamide-Etoposide based regimens 
ICE (ifosfamide, carboplatin, etoposide); MINE (mitoxantrone, ifosfamide, vinorelbine and 
etoposide); EPIC (etoposide, prednisolone, ifosfamide, and cisplatin); OIE (oxaliplatin, 
ifosfamide, etoposide); IEP-ABVD (ifosfamide, etoposide, prednisolone, adriamycin, 
bleomycin, vinblastine and dacarbazine). 
3.4 Other novel combinations 
IGEV (ifosfamide, gemcitabine and vinorelbine), with reported response rates of 65- 85%in 
RR-HL. GV (gemcitabine, vinorelbine). 
Selection of the salvage regimen should take into consideration the primary therapy. The 
ideal regimen would include non-cross-resistant chemotherapy, produce high response rate 
with acceptable toxicity and allow peripheral stem cell mobilization (Kuruvilla, Keating et 
al. 2011). The number of chemotherapy cycles prior to ASCT is not known, however most 
authors advocate for two to four cycles. The goal of salvage chemotherapy is to assess 
cytoreduction and chemo sensitivity, as those factors are predictors of outcome and define 
the need of subsequent HDT followed by ASCT. Therefore, salvage chemotherapy should 
facilitate stem cell harvesting and enable patients to proceed to ASCT. 
Disease status before HDT and ASCT is the most important prognostic factor for success as 
reported by multiple authors (Bierman, Bagin et al. 1993; Andre, Henry-Amar et al. 1999; 
Popat, Hosing et al. 2004) and discussed previously in this chapter. Response to salvage 
therapy or response to re-induction chemotherapy prior to high dose chemotherapy is a 
significant predictor of overall survival (OS) (Yuen, Rosenberg et al. 1997). Sirohi et al 
reported that patients with complete response prior to transplant, had a 5-year progression-
free survival (PFS) rate of 79% compared to 59% for those with partial response and 17% for 
those with resistant disease (Sirohi, Cunningham et al. 2008).  
In the pediatric population several strategies of combined chemotherapeutic regimens have 
been used in RR-HL. These include the use of ifosfamide, carboplatin and etoposide (ICE) 
pioneered by Memorial Sloan Kettering Cancer Center (MSKCC), reporting an 88% response 
rate in a combined trial with adult and pediatric patients with RR-HL. (Moskowitz, Nimer et 
al. 2001). In Europe the current standard approach for pediatric RR-HL retrieval is 
alternating IEP-ABVD. Furthermore, this regimen is using response to therapy by using 
functional imaging with FDG-PET prior to the use of HDT (Daw, Wynn et al. 2011).  
In the United States, ICE is the most widely used re-induction treatment option in children 
and adolescents. Although, the use of ICE can put patients in second remission, it is not 
optimal, since it is associated to an increased risk of treatment-related secondary malignant 
neoplasm associated with the use of alkylating agents and epipodophyllotoxins. For this 
reason the Children’s Oncology Group (COG) considering this risk of treatment-related 
second malignant neoplasms explored other retrieval regimens, such as the combination of 
ifosfamide with vinorelbine (IV) on their AHOD00P1 protocol. On AHOD00P1, each 





and vinorelbine 25 mg/m2 dose on days 1 and 5. Sixty one of 66 patients (92%) had a 
response after 2 cycles, and 44 (72%) achieved at least a partial response. More than 90% of 
the patients completed induction without disease progression. This study showed 
Ifosfamide/Vinorelbine (IV) regimen to be a safe and effective for  reinduction therapy. The 
toxicity profile was acceptable, with primarily hematologic toxicity (Trippet 2004 ).  
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ORR 75% (Ferme, Mounier et al. 2002) 
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and vinorelbine 25 mg/m2 dose on days 1 and 5. Sixty one of 66 patients (92%) had a 
response after 2 cycles, and 44 (72%) achieved at least a partial response. More than 90% of 
the patients completed induction without disease progression. This study showed 
Ifosfamide/Vinorelbine (IV) regimen to be a safe and effective for  reinduction therapy. The 
toxicity profile was acceptable, with primarily hematologic toxicity (Trippet 2004 ).  
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and 30 mg/m2 of vinorelbine every 21 days. The overall response rate was 62% ( 6 PR and 2 
CR) (Hamlin PA 2002). Ozkaynak also reported a small limited experience in a pediatric 
series (Ozkaynak and Jayabose 2004). The Children’s Oncology Group in the AHOD0321 
protocol evaluated the Children’s Oncology Group in the AHOD0321 protocol, that looked 
at the efficacy and toxicity of the combination of gemcitabine/vinorelbine in pediatric cHL 
patients in in second or greater recurrence. The doses used in the COG study were 
Gemcitabine 1000 mg/m2/dose on day 1 – 8 and Vinorelbine 25 mg/m2 on day 1 and 8. 
The study accrued 26 evaluable patients. Of those, 19 were responders (CR or PR). The 2-
year EFS and OS were 60% and 87% respectively. The regimen proved to be effective and 
well tolerated (Cole, Trippett et al. 2007; Cole, Schwartz et al. 2009).  
Both of these regimens substantiated the use of these novel approaches as acceptable salvage 
or re-induction regimen for pediatric patients with RR-HL. These regimens, VI or GV, were 
very well tolerated with a very acceptable toxicity profile and have the advantage of 
eliminating the use of etoposide and reducing the increased incidence of treatment-related 
secondary myelodysplasia and acute myelocytic leukemia associated with this medication.  
More recently, COG completed another phase II pilot study (AHOD0521) for RR-HL pediatric 
patients. The study evaluated the addition of bortezomib, a proteasome inhibitor, to 
ifosfamide / vinorelbine (IV). The study was designed to test the efficacy and safety of 
bortezomib as a chemo-sensitizing agent in primary RR-HL in first relapse by comparing the 
results to the historical data of AHOD00P1 with IV regimen alone. The study accrued 23 
evaluable patients with RR-HL in first relapse; 48% (11/23patients) had negative FGD-PET 
scans after 2 cycles. The overall response after 4 cycles of chemotherapy was 89%. Fourteen 
patients (74%) achieved complete response, and 3 (16%) had a partial response. Four patients 
had progressive disease and went off protocol. The 2-year EFS and overall survival were 69 
and 87%, respectively, demonstrated better results than with ifosfamide/vinorelbine alone  
(Horton 2010). 
Another single-institution pediatric trial has used a combination of Methotrexate, 
Ifosfamide, etoposide and dexamethasone for children with RR-HL, with an overall 
response of 84% (Sandlund, Pui et al. 2011).  
Table 2. demonstrates the most recent salvage chemotherapy regimens introduced by COG, 
and provides detail of their schema, chemotherapy doses and timing of administration.  
Although all of the salvage regimens produce remission rates in the range of 50 – 65% for 
RR-HL, they are not curative and the disease free survival (DFS) remains low for this group 
of patients. Addition of more intensive chemotherapy regimens followed by stem cell rescue 
has shown to improve DFS compared to salvage chemotherapy alone (Linch, Winfield et al. 
1993; Schmitz, Pfistner et al. 2002). 
4. High Dose Therapy (HDT) as conditioning regime for ASCT 
The current standard therapy for RR-HL, after re-induction or salvage chemotherapy, is 
high dose therapy (HDT) followed by autologous stem cell transplantation (ASCT). The two 
landmark studies that proved that high dose chemotherapy followed by ASCT improved 
survival were conducted by the British National Lymphoma Investigation Group lead by 
Linch in 1993. This small randomized clinical trial for patients with RR-HL compared BEAM 





The 3-year event free survival (EFS) was 53% in the first group and 10% in the second 
group. (Linch, Winfield et al. 1993). 
Later in 2002, the German Hodgkin Lymphoma Study Group performed a larger randomized 
study that included 161 patients. All patients received Dexa-BEAM (dexamethasone, 
carmustine, etoposide, cytarabine and melphalan) for 2 cycles. Patients with complete or 
partial response where randomized to receive two additional cycles of Dexa-BEAM vs. high 
dose BEAM followed by ASCT. The 3-year failure free survival (FFS) was 55% in the 
transplant group compared to 34% in the Dexa-BEAM group (Schmitz, Pfistner et al. 2002). 
Josting et al compared intensification of the pre ASCT conditioning regimen, by using two 
cycles of DHAP (dexamethasone, high-dose cytarabine, cisplatin) followed by ASCT vs. 
DHAP plus cyclophosphamide, high dose MTX, vincristine and etoposide. The 30 months 
freedom from treatment failure (FFTF) was 69% with no difference in the two arms (Josting, 
Rudolph et al. 2005).  
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Table 2. Pediatric Salvage Chemotherapy Regimen for Relapsed / Recurrent Hodgkin 
Lymphoma. 
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Although the outcome with HDT followed by ASCT has proven superior to salvage 
chemotherapy alone, nospecific regimen has shown to be superior. Comparing toxicity and 
efficacy of the various conditioning regimen using HDT prior to ASCT is somewhat 
difficult, because the doses used in each of the trials are different. For comparison, Table 3 
contrasts the specific chemotherapy doses.  
 






BEAM + ASCT 
Carmustine: 300 mg/m2 x1  
Etoposide: 800 mg/m2 x1  
Cytarabine: 1600 mg/m2 x1  






BCNU /Carmustine:60 mg/m2  
Etoposide: 300 mg/m2 
Cytarabine: 800 mg/m2 








Dexamethasone 24 mg x 10   
Carmustine 60 mg/m2 x 
Etoposide 250 mg/m2 x 4  
Cytarabine 200 mg/m2 IV x 4 





BEAM + ASCT 
Carmustine 300 mg/m2 x 1 
Etoposide 300 mg/m2 x 4 
Cytarabine 400 mg/m2 x 4 








DHAP + ASCT 
Dexamethasone 40 mg/m2 x 4  
HD-Cytarabine 4000mg/m2 x 2  
Cisplatin 100 mg/m2 x 1  
Median Follow 











Dexamethasone 40 mg/m2 x 4  
HD-Cytarabine 4000mg/m2 x 2  
Cisplatin 100 mg/m2 x 1  
Cyclophosphamide 4 g/m2  
High dose MTX 8 g/m2 
Vincristine 1.4 g/m2 
Etoposide 2500 mg/m2  
 
BEAM + ASCT 
Bendamustine 200 mg /m2 
Etoposide 800 mg/m2 
Cytarabine 1600 mg/m2  
Melphalan 140 mg/m2 




al. 2011)  
EFS: event free survival; FF2F: freedom from second failure; FFTF: freedom from treatment failure; DFS: 
disease free survival ; ASCT autologous stem cell transplantation 
Table 3. High Dose Therapy as Conditioning Regimen Prior to ASCT Comparative Doses. 
It is important to recognized that although carmustine (BCNU)-containing regimens are the 
most widely used as conditioning regimen for the treatment of RR-HL, there are some major 





still high incidence of relapse, and the risk of non-relapse related death (Seiden, Elias et al. 
1992; Reece, Nevill et al. 1999; Alessandrino, Bernasconi et al. 2000). In addition, the increase of 
secondary malignancies after treatment with alkylating agents and epidophylotoxins is of 
great concern, particularly in children and adolescents and young adults (AYA). For these 
reasons the search for new and optimal conditioning regimens continues.  
In search for this optimal conditional regimen, Visai et al. recently presented the results of 
a phase I / II trial using BeEAM (bendamustine, etoposide, cytarabine and melphalan) as 
a conditioning regimen for ASCT in patients with lymphomas.  The phase I study used 
escalating doses of bendamustine (160 mg/m2, 180 mg/m2 and 200 mg/m2). This study 
included 15 HL patients out of the 43. None of the 43 patients had dose limiting toxicities. 
The regimen was well tolerated with minimal treatment related mortality. Although the 
regimen seemed to have worked better for non-Hodgkin lymphoma (NHL) patients, the 
median DFS for HL patients was 19 months after ASCT. The major limitations of this 
study is the small number of patients with HL, and therefore this regimen warrants 
further studies to confirm the efficacy of this novel regimen in the treatment of RR-HL 
(Visani, Malerba et al. 2011).  
Even with the use of HDT and ASCT approximately 50% of patients continue to have 
refractory disease or recur after ASCT (Chopra, McMillan et al. 1993) so that more effective 
therapy is still needed. 
In Pediatrics, the use of HDT and ASCT is reserved for patients with high risk for relapse or 
those with primary progressive disease. There is very little evidence to support the use of 
this approach in first relapse for children and adolescents. The implementation of this 
approach in the pediatric population has been adapted from the adult experience described 
above.  
5. Tandem autologous transplantation 
The use of tandem autologous transplants seem to have a role for a subset of patients with 
RR-HL and certain risk factors at the time of initial salvage therapy.  
Brice et al used two different conditioning regimen CBV (cyclophosphamide, carmustine, 
etoposide) vs. CBV (cyclophosphamide, carmustine, etoposide) plus mitoxantrone (30 
mg/m2) for the first ASCT and a second conditioning regimen with total body irradiation 
(TBI) of 12 Gy or busulfan (12 mg/kg) followed by high dose cytarabine (6 g/m2) and 
melphalan (140 mg/m2). The two-year survival rate from the date of progression were 
respectively at 65% and at 74%.(Brice, Divine et al. 1999)   
A US group lead by Fung used a preparative regimen of melphalan (150 mg/m2) and a 
second preparative regimen with fractionated TBI (1200cGy) or carmustine (450 mg/m2) 
plus etoposide (60mg/kg) and cyclophosphamide (100mg/kg). This US group reported a 5-
year FF2F of 55% and a OS of 54% suggesting that in patients with primary progressive or 
poor risk recurrent HL, tandem ASCT is well tolerated and compares favorably with the 
conventional single transplant. (Fung, Stiff et al. 2007).  
Castagna et al investigated the feasibility and toxicity of ifosfamide, gemcitabine and 
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etoposide) vs. CBV (cyclophosphamide, carmustine, etoposide) plus mitoxantrone (30 
mg/m2) for the first ASCT and a second conditioning regimen with total body irradiation 
(TBI) of 12 Gy or busulfan (12 mg/kg) followed by high dose cytarabine (6 g/m2) and 
melphalan (140 mg/m2). The two-year survival rate from the date of progression were 
respectively at 65% and at 74%.(Brice, Divine et al. 1999)   
A US group lead by Fung used a preparative regimen of melphalan (150 mg/m2) and a 
second preparative regimen with fractionated TBI (1200cGy) or carmustine (450 mg/m2) 
plus etoposide (60mg/kg) and cyclophosphamide (100mg/kg). This US group reported a 5-
year FF2F of 55% and a OS of 54% suggesting that in patients with primary progressive or 
poor risk recurrent HL, tandem ASCT is well tolerated and compares favorably with the 
conventional single transplant. (Fung, Stiff et al. 2007).  
Castagna et al investigated the feasibility and toxicity of ifosfamide, gemcitabine and 
vinorelbine (IGEV) as salvage therapy followed by two tandem ASCT using melphalan 
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(200mg/m2) alone as the first conditioning regimen and BEAM as the second conditioning 
regimen. The response rate increased with each step, from 47% after salvage chemotherapy, 
to 65% after first ASCT to 75% after second transplant.  The 3-year FFP was 63% and the OS 
was 72% (Castagna, Magagnoli et al. 2007).  
The Group d’Etude des Lymphomes de L’adulte (GELA) tested the feasibility of tandem 
ASCT vs. single ASCT in patients with primary refractory disease or high risk for relapse as 
defined by the presence of at least two of the following three adverse risk factors: 1) relapse 
in a previous radiation field, 2) stage III/IV at the time of relapse or 3) time to relapse < 12 
months; or intermediate-risk patients those with one risk factor. Intermediate risk patients 
received single ASCT showing a FF2F and OS of 73% and 85%, respectively. High risk 
patients received tandem ASCT with a FF2F and OS of 46% and 57% respectively, which 
was comparable to previous reports.   The results of this study suggest that single ASCT is 
appropriate for intermediate-risk patients, and that high risk patients with RR-HL may 
benefit of tandem ASCT (Morschhauser, Brice et al. 2008). In spite of these encouraging 
results the use of tandem ASCT for RR-HL is still considered experimental. 
6. Second autologous transplants 
For patients who relapse after a previous ASCT a second auto graft is a viable option, 
although very limited data exist to support this strategy (Smith, van Besien et al. 2008). This 
option can be considered as a treatment alternative in patient with a time to relapse > 1 year 
after the initial transplant. Allografting after ASCT in general is not recommended 
(Kuruvilla, Keating et al. 2011). Nonetheless, it can still be used in certain circumstances as 
described below. 
7. Allogeneic stem cell transplantation  
In the past, allogeneic stem cell transplant (Allo-SCT) offered a chance for a better disease 
free survival (DFS) but the procedure associated mortality has negated this advantage 
yielding a worse event free survival. ASCT substituted allo-SCT due to this high treatment-
related mortality and the non-infrequent incidence of relapse. However, the introduction of 
reduced-intensity chemotherapy (RIC) as the preparative regimen for allogeneic 
transplantation has improved the safety of the procedure. RIC allo-SCT is now being 
considered an effective approach for selected patients, including those who have failed HDT 
with ASCT, or for patients with bone marrow involvement at relapse or insufficient stem-
cell collection for a second HDT (Brice 2008; Salit, Bishop et al. 2010). Although, the 
feasibility of RIC allo-SCT has improved, there is still a lack of durable response (Peggs, 
Sureda et al. 2007; Devetten, Hari et al. 2009). The use of a RIC allo-SCT strategy is best used 
within the context of prospective clinical trials, as its use remain highly controversial. 
8. Standard-dose chemotherapy  
A non-ASCT-based strategy has a role in some patients with late relapse ( >1 year after 
completion of induction chemotherapy) and chemo sensitive disease. The Italian group lead 
by Bonfante found an 8-year freedom from second progression (FF2P) and OS of 53% and 





prednisone (MOPP) and Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) 
(Bonfante, Santoro et al. 1997). The German group demonstrated good results for patient 
with the above mentioned characteristics treated with IEP-ABVD regimen followed by 
radiation therapy to nodal regions involved at the time of relapse and original regions had 
they not been irradiate. A 10-year DFS and OS was 57% and 75% respectively was reported 
(Schellong, Dorffel et al. 2005). 
9. Role of radiotherapy for RR-HL 
Radiotherapy alone can achieve long-term remission, but only in a small proportion of 
patients. Radiotherapy (RT) is used less as a first line therapy in RR-HL due to its limited 
efficacy in patients with advanced disease. In some ongoing pediatric clinical trials the use 
of RT has been omitted from the upfront therapy for patients with good response to initial 
chemotherapy. Therefore, some patients may be radiation naïve at the time of relapse or 
have received only limited RT. This fact, makes the use of RT at the time of relapse an 
attractive alternative for certain relapsed patients, particularly the ones with limited stage 
disease and relapse  at the site of original disease only.  
Josting et al reported a 5-year freedom from treatment failure (FFTF) and OS of 29% and 
51% respectively for RR-HL treated with radiotherapy alone. The presence of B symptoms, 
advanced stage (III/IV) at relapse, Karnofsky of < 90% were identified as poor prognostic 
factors for those patients (Josting, Nogova et al. 2005).  
10. Role of chemotherapy plus radiation without ASCT 
Combined modality therapy with multi-agent chemotherapy followed by radiotherapy is 
the standard treatment for limited-stage HL (Press, LeBlanc et al. 2001; Engert, Franklin et 
al. 2007; Ferme, Eghbali et al. 2007). This modality is particularly attractive for patients who 
have not received radiotherapy with prior treatment or have relapsed with disease in sites 
that have not previously been radiated (Press, LeBlanc et al. 2001; Kuruvilla, Keating et al. 
2011). Radiotherapy can also be given to patients with RR-HL and bulky disease after 
standard HDT therapy and ASCT.  
Kurovilla et al suggested the use of standard dose chemotherapy plus radiotherapy as a 
salvage therapy for patients with very late relapse (>5 years) after primary therapy who 
suffer localized relapse without B symptoms (Kuruvilla, Keating et al. 2011) 
11. Salvage therapies following ASCT  
More than 50% of patients with RR-HL will not be cured, either because their tumors are not 
chemotherapy sensitive to proceed with ASCT or because they do not achieve a durable 
response after ASCT. For those patients, single or combined conventional therapies that can 
provide disease control such as Gemcitabine / Vinorelbine or Vinorelbine / Ifosfamide plus 
bortezomib are possible re-induction regimens. As previously mentioned an allo-RIC SCT is 
also an alternative and should always be considered when in the context of a prospective 
clinical trial.  
The Children’s Oncology Group, in the US is performing a trial to evaluate 
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The Children’s Oncology Group, in the US is performing a trial to evaluate 
immunomodulation after HDT and ASCT. The study had two parts. The first one is to 
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determine toxicity and feasibility of administering cyclosporine, interferon-γ, and 
interleukin-2 following BEAM chemotherapy with ASCT. The second part aims to assess 
whether greater levels of autologous GVHD and/or autoreactive cytolytic lymphocytes are 
associated with improved survival, whether expression of the target molecule of autologous 
GVHD is associated with improved survival, and whether immunotherapy can produce 
better outcomes in patients identified as having high risk disease on the basis of high serum 
levels of interleukin-10 or soluble interleukin-2 receptor. The results of this trial have not 
been reported yet. 
12. New agents 
The development of novel drugs for the treatment of cHL has been slow partially due to the 
high success rate of the treatment of the disease. However, the better understanding of the 
pathology, biology and immunology has allow the introduction of  several therapeutic 
targets. This new drug development not only is aiming for better survival but also to 
decrease toxic effects.  
12.1 Antibody/receptor therapy  
One of the defining features of cHL is CD30 expression by Reed-Stenberg cells. The use of 
an anti-CD30 molecule has been an attractive target in the treatment for HL (Forero-Torres, 
Leonard et al. 2009). Several anti CD30 antibodies have been engineered: MDX-060 
(Medarex) a fully humanized antibody to CD30 (SGN-30), a chimeric monoclonal anti-CD30 
antibody, both have shown to inhibit cell proliferation and to induce cell death in CD30 
positive lymphomas. However, when used alone they were not effective as single agents, 
showing response rates much lower than traditional cytotoxic chemotherapy.  
Newer generation of anti-CD30 antibodies with enhanced Fc receptor-antibody activity 
(Medarex, MDX-1401 ) and with antibody-drug conjugates are currently under study (Foyil 
and Bartlett 2010).  
The recent introduction of a conjugated anti-CD30 antibody conjugated to the antitubuline 
agent, Brentuximab Vedotin, (SGN-35) has shown excellent results in CD30 positive 
lymphomas. In a phase I, open label, multicenter dose-escalation study published in the 
New England Journal of Medicine, 42 evaluable patients with refractory CD30 lymphomas 
demonstrated tumor regression of 86%. (Younes, Bartlett et al. 2010). An additional phase II 
clinical trials using Brentuximab Vedotin intravenously at a dose of 1.8 mg/kg every 3 
weeks was reported at ASCO in 2011. The study found a response of 75% (76 out of 102) in 
patient with HL, with a complete remission in 34% of them. The average duration of 
response was 6.7 months. The excellent results of these studies resulted in the recent FDA 
approval of Brentuximab Vedotin for the treatment of patients with HL whose disease has 
progressed after autologous stem cell transplant, or after two prior multiagent 
chemotherapy treatments among patients ineligible to receive a transplant. Prospective 
studies in the pediatric population are warranted.  
The use of the anti-CD20 antibody, Rituximab, has demonstrated excellent activity against 
nodular lymphocyte predominant HL (NLPHL) with overall response rates of 94% 
(Ekstrand, Lucas et al. 2003; Rehwald, Schulz et al. 2003). Rituximab is currently being 





12.2 Radioimmunotherapy (RIT) 
Radioimmunotherapy uses the concept of targeted antibodies, typically antiferritin and anti-
CD30 to deliver radiation with Yttrium-90 or iodine-131 to the tumor cells (Klimm, Schnell 
et al. 2005). The use of polyclonal antibodies, Ytrium 90-labelled antiferritin, In-labeled 
antiferritin antibody recently became available. They have been well tolerated and have 
shown activity in RR-HL with a response of approximately 8 months. Other attempts to 
increase the efficacy of antiCD30 monoclonal antibody include conjugation with Iodine-131 
(Schnell, Dietlein et al. 2005). 
The German group has developed an antiCD25 also known as anti IL-2 receptor (Daclizumab)  
and anti-CD25 linked to Ytrium-90. CD25 is found in a large proportion of Hodgkin Reed 
Stenberg cells and in the surrounding tumor-associated T-cell and therefore represents an 
attractive target therapy. Some preliminary studies using Y-90-CD25 (90Y-daclizumab) every 
6 – 10 weeks yielded an overall response of 70% (O'Mahony D. Janik JE 2007). 
12.3 Antiapoptotic molecules  
Other novel pharmacological approaches include inhibition of NF-kB pathway. NF-kB is a 
transcription factor that is constitutively activated in HL, and that is thought to be 
responsible for cell proliferation and antiapoptosis in HL (Pajonk, Pajonk et al. 2000).  
Bortezomib (Velcade) is a proteasome inhibitor that also inhibits NF-kB pathway. 
Bortezomib has shown some limited efficacy when used as a single agent or in combination 
with dexamethasone (Younes, Pro et al. 2006; Trelle, Sezer et al. 2007). However, NF-kB 
inhibition is postulated to sensitize malignant cells to chemotherapy, including Gemcitabine 
(Moskowitz, Nimer et al. 2001), TNF-related apoptosis-inducing ligand (TRAIL) (Zheng, 
Georgakis et al. 2004), dexamethasone and vinorelbine (Hinz, Lemke et al. 2002). Inhibition 
of the antiapoptotic molecule XIAP has shown some encouraging results in preclinical 
studies (LaCasse, Cherton-Horvat et al. 2006). As mentioned above the Children’s Oncology 
Group recently completed a study that assess the safety of bortezomib in addition to 
ifosfamide / vinorelbine, the preliminary data suggest that bortezomib may have added 
additional efficacy to the backbone regimen of ifosfamide and vinorelbine .  
12.4 Transcriptional pathways  
The use of other molecules that are mediators of apoptosis, such as the histone deacetylase 
(HDAC) inhibitors in HL is currently under investigation. Some of these are Panobinostat, 
Vorinostat, Entinosat. A phase II study demonstrated 40% response in patients with RR-HL 
(Younes 2007; Jona and Younes 2010).  
M-TOR inhibitors, particularly everolimus, have also shown some promising results with 
up to 42% overall response rate in patients with RR-HL (Johnston PB 2007 ) . The small 
molecule Nutlin 3A, stabilizes p53 protein via MDM2 binding, allowing to activate 
apoptotic pathways in Hodgkin Reed Stenberg cells (Drakos, Thomaides et al. 2007). This 
three novel molecules may have an interesting potential therapeutic intervention in cHL. 
12.5 EBV-directed therapy 
Nearly 50% of cHL patients are known to be EBV positive, making the use of EBV-targeted 





12.2 Radioimmunotherapy (RIT) 
Radioimmunotherapy uses the concept of targeted antibodies, typically antiferritin and anti-
CD30 to deliver radiation with Yttrium-90 or iodine-131 to the tumor cells (Klimm, Schnell 
et al. 2005). The use of polyclonal antibodies, Ytrium 90-labelled antiferritin, In-labeled 
antiferritin antibody recently became available. They have been well tolerated and have 
shown activity in RR-HL with a response of approximately 8 months. Other attempts to 
increase the efficacy of antiCD30 monoclonal antibody include conjugation with Iodine-131 
(Schnell, Dietlein et al. 2005). 
The German group has developed an antiCD25 also known as anti IL-2 receptor (Daclizumab)  
and anti-CD25 linked to Ytrium-90. CD25 is found in a large proportion of Hodgkin Reed 
Stenberg cells and in the surrounding tumor-associated T-cell and therefore represents an 
attractive target therapy. Some preliminary studies using Y-90-CD25 (90Y-daclizumab) every 
6 – 10 weeks yielded an overall response of 70% (O'Mahony D. Janik JE 2007). 
12.3 Antiapoptotic molecules  
Other novel pharmacological approaches include inhibition of NF-kB pathway. NF-kB is a 
transcription factor that is constitutively activated in HL, and that is thought to be 
responsible for cell proliferation and antiapoptosis in HL (Pajonk, Pajonk et al. 2000).  
Bortezomib (Velcade) is a proteasome inhibitor that also inhibits NF-kB pathway. 
Bortezomib has shown some limited efficacy when used as a single agent or in combination 
with dexamethasone (Younes, Pro et al. 2006; Trelle, Sezer et al. 2007). However, NF-kB 
inhibition is postulated to sensitize malignant cells to chemotherapy, including Gemcitabine 
(Moskowitz, Nimer et al. 2001), TNF-related apoptosis-inducing ligand (TRAIL) (Zheng, 
Georgakis et al. 2004), dexamethasone and vinorelbine (Hinz, Lemke et al. 2002). Inhibition 
of the antiapoptotic molecule XIAP has shown some encouraging results in preclinical 
studies (LaCasse, Cherton-Horvat et al. 2006). As mentioned above the Children’s Oncology 
Group recently completed a study that assess the safety of bortezomib in addition to 
ifosfamide / vinorelbine, the preliminary data suggest that bortezomib may have added 
additional efficacy to the backbone regimen of ifosfamide and vinorelbine .  
12.4 Transcriptional pathways  
The use of other molecules that are mediators of apoptosis, such as the histone deacetylase 
(HDAC) inhibitors in HL is currently under investigation. Some of these are Panobinostat, 
Vorinostat, Entinosat. A phase II study demonstrated 40% response in patients with RR-HL 
(Younes 2007; Jona and Younes 2010).  
M-TOR inhibitors, particularly everolimus, have also shown some promising results with 
up to 42% overall response rate in patients with RR-HL (Johnston PB 2007 ) . The small 
molecule Nutlin 3A, stabilizes p53 protein via MDM2 binding, allowing to activate 
apoptotic pathways in Hodgkin Reed Stenberg cells (Drakos, Thomaides et al. 2007). This 
three novel molecules may have an interesting potential therapeutic intervention in cHL. 
12.5 EBV-directed therapy 
Nearly 50% of cHL patients are known to be EBV positive, making the use of EBV-targeted 
therapy very attractive. EBV specific cytotoxic T lymphocytes (CTL) can be generated in 
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vitro and then given to the patients with the intent of targeting specific EBV-infected cancer 
cells. Portis et al demonstrated that by using this technology 30% of treated patients 
achieved a complete remission (Portis and Longnecker 2004).  
13. Conclusions 
The treatment of RR-HL has improved over the years. The use of HDT followed by ASCT 
has allow 50% of patients to have durable remission. However, the management of the 
patient with refractory disease is a real challenge. Treatment intensification with traditional 
chemotherapy agents is not sufficient and new approaches are needed. As the 
armamentarium for the treatment of patients that have failed initial therapy continuous to 
expand, we are foreseeing novel treatment modalities. Some of such agents, particularly the 
biologically target agents, have the potential to be incorporated into front line therapy of 
cHL as they may have a better therapeutic profile than our current cytotoxic chemotherapy 
agents. The use of novel biological and targeted therapies is very attractive for the retrieval 
of patients with RR-HL. As we develop a better understanding of the biology of cHL, we are 
likely to see more effective treatment strategies that will overcome resistance, and reduced 
short and long term toxicity for patients with primary and refractory cHL.  
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1. Introduction  
1.1 Definition 
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT 
lymphoma) is an extranodal lymphoma composed of morphologically heterogeneous small 
B-cells including marginal zone (centrocyte-like) cells, cells resembling monocytoid cells, 
small lymphocytes, and scattered immunoblasts and centroblast-like cells. There is plasma 
cell differentiation in a proportion of the cases. The infiltrate is in the marginal zone of 
reactive B-cell follicles and extends into the interfollicular region. In epithelial tissues, the 
neoplastic cells typically infiltrate the epithelium forming lymphoepithelial lesions. 
(Swerdlow et al., 2008) (Isaacson et al., 2004) 
1.2 Epidemiology 
MALT lymphoma accounts for 7% of all newly diagnosed lymphomas and is therefore one 
of the more common types of lymphoma (Swerdlow et al., 2008). Most cases occur in adults 
with a median age of 61 and a slight female preponderance (male:female ratio 1:1.2). (Anon, 
1997) There appears to be a higher incidence of gastric MALT lymphomas in north-east Italy 
(Doglioni et al., 1992) and a special subtype previously known as alpha heavy chain disease 
and now called immunoproliferative small intestinal disease (IPSID) occurs in the Middle 
East (Pinkel, 1998), the Cape region of South Africa (Price, 1990) and a variety of other 
tropical and subtropical locations. 
1.3 Etiology 
MALT lymphoma is a unique tumor in that it originates from acquired MALT associated 
with chronic inflammation or autoimmune responses, e.g. Helicobacter pylori (H. pylori)–
associated chronic gastritis, Hashimoto’s thyroiditis, and Sjögren’s syndrome (Swerdlow et 
al., 2008, Isaacson, 1999a). MALT lymphoma affects various organs, with the stomach being 
the most frequently involved (Swerdlow et al., 2008, Isaacson, 1999a, 1999b). Interestingly, 
the majority of gastric low-grade MALT lymphoma cases, those proven to be neoplastic by 
detection of monoclonal rearrangement in immunoglobulin heavy chain (IgH) genes, 






MALT lymphomas have an indolent natural course and are slow to disseminate. 
Recurrences, that can occur after many years, may involve other extranodal sites and occur 
more often in patients with extragastric MALT lymphomas than in patients with primary 
gastric disease (Raderer et al., 2005). The tumors are sensitive to radiation therapy, and local 
treatment may be followed by prolonged disease-free intervals. Involvement of multiple 
extranodal sites and even BM involvement do not appear to confer a worse prognosis 
(Thieblemont et al., 2000). Protracted remissions may be included in H. pylori-associated 
gastric MALT lymphoma by antibiotic therapy for H. pylori (Neubauer et al., 1997, 
Wotherspoon et al., 1993). Cases with the t(14;18)(q21;q21) appear to be resistant to H. pylori 
eradication therapy (Liu et al., 2001). In IPSID, remissions have followed therapy with 
broad-spectrum antibiotics (Ben Ayed et al., 1989, Lecuit et al., 2004). Antibiotics have also 
been used to successfully treat selected other MALT lymphomas. Transformation to diffuse 
large B-cell lymphoma may occur. 
2. Regression of rectal MALT lymphoma after antibiotic treatments 
2.1 Introduction 
MALT lymphoma is less frequently seen in the rectum(Isaacson, 1999b, Morton et al., 1993, 
Koch et al., 2001), while the presence of MALT1 gene translocation in rectal MALT 
lymphoma has occasionally been reported (Motegi et al., 2000, Remstein et al., 2000, 
Yonezumi et al., 2001). In addition, a few reports have described the regression of rectal 
MALT lymphomas after antibiotic treatments that are generally found to be successful for 
gastric MALT lymphomas(Raderer et al., 2000, Matsumoto et al., 1997). 
In addition to H. pylori, various other infectious agents have been reported to be related to 
the development of MALT lymphoma, such as Borrelia burgdorferi in cutaneous(Roggero et 
al., 2000), Chlamydia psittaci in orbital(Ferreri et al., 2004), and Campylobacter jejuni in small 
intestinal lymphoma(Al-Saleem & Al-Mondhiry, 2005). However, few data are available on 
the pathogenesis of MALT lymphoma of organs other than the stomach. 
In this study, we examined 8 rectal MALT lymphomas to determine whether they regressed 
after antibiotic treatments. We report here our findings and also discuss the relationship 
between rectal MALT lymphomas and MALT1 gene genetic abnormalities (Niino et al., 2010). 
2.2 Materials and methods 
2.2.1 Rectal MALT lymphoma cases 
Formalin-fixed, paraffin-embedded tissues obtained between 2004 and 2007 from 8 cases 
of rectal MALT lymphoma treated with antibiotic treatments were retrieved from the 
pathology files at Kurume University School. The patients consisted of 2 men and 6 
women, ranging in age from 41 to 80 years (median, 66 years). Lymphomas constituting 
secondary involvement of the rectum were not included in the study. Clinical data for all 
cases were obtained from pathological reports and medical reports, and all cases were 
reviewed to confirm that the histological diagnosis conformed to the criteria of the World 
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(Swerdlow et al., 2008). Diagnosis of rectal MALT lymphomas was based on the following 
findings: centrocyte-like cells and/or monocytoid cell proliferation, especially at the 
outside of the mantle zone (marginal zone distribution); presence of plasmacytic 
differentiation and/or follicular colonization in some cases; and absence of CD5, CD10, 
and cyclin D1 overexpression. Lymphoepithelial lesions in rectal MALT lymphomas were 
not as obvious as those in gastric tumors (representative histologies are shown in Fig. 1.). 
All patients were Japanese. H. pylori infection was assessed by rapid- urease test or 
histological examination.  
 
 
Fig. 1. Hematoxylin and eosin staining show the histopathologic features of rectal mucosa-
associated lymphoid tissue (MALT) lymphoma. (A) Dense, diffuse atypical lymphocyte 
infiltration, mainly in submucosal layer. (B) MALT lymphoma cells showing small nuclei and 
abundant pale staining cytoplasm, resulting in a monocytoid appearance. (Niino et al., 2010) 
Because Inoue and Chiba reported a case without infection of H. pylori whose rectal MALT 
lymphoma regressed after administration of antibiotics(Inoue & Chiba, 1999), the patients 
were treated with antibiotic treatments. After informed consent had been obtained, 8 





and amoxicillin), and follow-up endoscopic examinations including biopsies were 
performed. Tumor regression after antibiotic treatments was histologically evaluated. 
Complete regression (CR) was defined as the total disappearance of lymphoma and absence 
of histopathological evidence of lymphoma on endoscopic biopsy. No regression (NR) was 
diagnosed when no macroscopic or histologic changes were present. This study was carried 
out in accordance with the Helsinki Declaration as revised in 1989 and with the ethical 
guidelines of the participating centers and countries.  
2.2.2 Polymerase Chain Reaction (PCR) for the detection of IgH rearrangements 
DNA was extracted from 5-μm-thich sections of a paraffin block. Gene amplification of 
the IgH gene from the framework 2 part of the V segment to the J region by a seminested 
PCR was performed by using the consensus primers complementary to the framework  
2 portion of the VH region (FR2B) and the JH region (CFW1) from genomic DNA.  
The following primer sequences were used: FR2B, 5’-GTCCTGCAGGC(C/T)(C/T) 
CC-GG(A/G)AA(A/G)(A/G)GTCTGGAGTGG-3’; CFW1, 5’-ACCTGAGGAGACGGT-
GACCAGGGT-3’. The PCR conditions were as follows: after initial denaturation at 95°C 
for 10 min, 5 cycles (95°C for 30 s, 63°C for 30 s and 72°C for 30 s) followed by 45 cycles 
(95°C for 30 s, 60°C for 30 s and 72°C for 30 s) with a final extension at 72°C for 10 min. 
The size of the IgH rearrangement fragments was usually between 250 and 300 bp. 
2.2.3 MALT 1 gene translocation analysis 
All cases were analyzed using a MALT1 break-apart probe (Vysis, Downer’s Grove, IL, 
USA). Interphase fluorescence in situ hybridization (FISH) studies were performed on intact 
5-μm sections of formalin-fixed, paraffin-embedded material as previously described in 
detail(Wongchaowart et al., 2006). Briefly, slides were baked overnight at 60°C, 
deparaffinized, and subjected to proteinase K treatment. After washing, 10 mL of the probe 
solution was applied, and probe and target DNA were allowed to codenature at 73°C for 5 
minutes and to hybridize overnight at 3°C. Slides were counterstained with DAPI, and 
signals were visualized on an Axioskop photomicroscope (Zeiss, Oberkochen, Germany). 
For each probe 100-200 nuclei were scored. Nuclei were considered to be positive for a 
break-apart probe when a nucleus contained separate red and green signals at least three 
signal widths apart. Nuclei were scored as positive for +MALT1 when three or more signals 
were identified within one nucleus. Cutoffs for interpretation as a positive result were 
determined for each abnormality based on the analysis of six formalin-fixed, paraffin-
embedded sections of benign lymph nodes and tonsils used as control. Cutoff thresholds for 
each abnormality were established as the mean plus three standard deviations of the mean, 
so that positivity for MALT1 translocation, or +MALT1, was defined as >4% nuclei with a 
positive signal pattern. 
2.3 Results 
2.3.1 Clinical features of rectal MALT lymphoma 
Clinical characteristics of this study are shown in Table 1. The clinical records of all cases 
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2.3 Results 
2.3.1 Clinical features of rectal MALT lymphoma 
Clinical characteristics of this study are shown in Table 1. The clinical records of all cases 
showed rectal origin. Four of eight patients (50%) were positive and one patient (13%) was 
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negative for H. pylori. The remaining patients were not evaluated for H. pylori. Five cases 
occurred as a single tumor, whereas the remaining three cases occurred as multiple tumors. 
Elevated lesions (polypoid or flat elevation) were formed in 7 cases, whereas circumferential 
lesion was formed in one case (Case 4). Representative endoscopic image before antibiotic 
treatment demonstrated multiple small polyps (Case 2) (Fig. 2.). The size of MALT 
lymphoma ranged from 5 to 100 mm. Seven cases were localized in the submucosa, whereas 
one case (Case 4) involved the subserosa. 
 
Fig. 2. Representative endoscopic image before antibiotic treatment (Case 2): Colonoscopy 
demonstrated multiple small polyps. (Niino et al., 2010) 
Case Age Sex Number Shape Size Depth LDH IL2R H.pylori 
no. (y) (mm) (IU/l) (U/ml) status 
1 67 F multiple polypoid 5-10 SM 178 888 positive 
2 68 F single flat elevation 25 SM 192 NA positive 
3 76 F single polypoid 10 SM NA NA NA 
4 65 M single circumferential 100 SS NA NA NA 
5 41 M multiple flat elevation 10 SM 215 530 negative 
6 80 F single polypoid 20 SM 160 369 positive 
7 54 F single polypoid 15 SM 156 NA positive 
8 46 F multiple polypoid 5-7 SM NA NA NA 
Abbreviations: LDH, lactate dehydrogenase; IL2R, interleukin 2 receptor; SM, submucosa;  
H.pylori, Helicobacter pyroli; SS, subserosa; NA, not available 
Table 1. Clinical characteristics of rectal MALT lymphoma. (Niino et al., 2010) 
2.3.2 Detection of IgH rearrangements and MALT1 gene translocation 
PCR for the detection of IgH rearrangement resulted in the identification of a monoclonal 





Results of interphase FISH studies are shown in Table 2 and Fig.3. All cases were 
successfully analyzed for MALT1 translocation by FISH. One case demonstrated MALT 1 
gene translocation (one fusion, one orange, and one green signal pattern), while another case 
demonstrated partial deletion of the MALT1 gene (one fusion and one green signal pattern). 
The others showed the normal pattern (two fusion signal patterns). That is, two cases (25%) 
showed genetic abnormality. 
 
Case PCR-IgH MALT1 FISH Response 
no. 
1 Monoclonal Negative CR 
2 Monoclonal Negative CR 
3 Monoclonal Negative CR 
4 Monoclonal Partial deletion NR 
5 Monoclonal Negative NR 
6 Polyclonal Negative CR 
7 Monoclonal Rearrangement NR 
8 Monoclonal Negative CR 
Abbreviations: PCR, polymerase chain reaction;  
IgH, immunoglobulin heavy chain; 
MALT, mucosa associated lymphoid tissue;  
FISH, fluorescence in situ hybridization; 
CR, complete regression; NR, no regression. 
Table 2. Results and clinical outcomes. (Niino et al., 2010) 
2.3.3 Therapeutic outcomes 
Therapeutic outcomes are shown in Table 2, 3. Eight patients who had undergone antibiotic 
treatments were subjected to follow-up colonoscopy after the treatment. Five patients 
(62.5%) achieved CR after a median follow-up from antibiotic treatments of 5 months (range, 
3 to 58 months). Three patients (37.5%) showed NR, among which received further 
treatment, including chemotherapy. These findings strongly indicate that these cases of 
rectal MALT lymphoma were responsive to antibiotic treatments. None of the patients who 
responded to antibiotic treatments harbored MALT1 gene genetic abnormality, but it was 
detected in two of the three patients who did not respond. The cases with MALT1 gene 
genetic abnormality thus tended to be resistant to antibiotic treatments. 
 
 Antibiotic treatments Antibiotic treatments  
  sensitive cases resistant cases Total 
Genetic abnormality (+) 0 2 2 
Genetic abnormality (-) 5 1 6 
Total 5 3 8 
Table 3. Relationship between antibiotic treatments sensitivity and MALT1 gene genetic 
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Fig. 3. Interphase fluorescence in situ hybridization (FISH) patterns in representative cases. 
(A) Normal pattern (two fusion signal patterns). (B) Partial deletion of MALT1 gene (one 
fusion and one green signal pattern; arrows). (Niino et al., 2010) 
2.4 Discussion 
Gastric MALT lymphoma is often associated with infection by H. pylori. Eradication of H. 
pylori has therefore been investigated as the first line of treatment for patients with MALT 
lymphoma of the stomach, and has been found to be highly effective for patients with 
localized low-grade disease. On the other hand, regression of rectal MALT lymphoma after 
antibiotic treatments has also been reported. Matsumoto et al. reported the first case with 
rectal MALT lymphoma that regressed after antibiotic treatment in 1997 (Matsumoto et al., 
1997). They also stated that the association of MALT lymphoma with H. pylori is not limited 
to the stomach, but involves other organs in which MALT is the predominant tissue for host 
defense. Inoue and Chiba reported a case without infection of H. pylori whose rectal MALT 





reported three H. pylori-negative cases of rectal MALT lymphoma which regressed after 
antibiotic treatments(Nakase et al., 2002). Regression of rectal MALT lymphoma after 
administration of quinolones has also been reported (Ferreri et al., 2005). These results 
suggest that some antigenic stimuli other than H. pylori may play a role in the pathogenesis 
of MALT lymphoma of the rectum, which is constantly exposed to intestinal bacteria and 
contents. However, for the time being this must remain an unproven hypothesis. 
Recently, the t(11;18) chromosomal translocation was identified as a specific chromosomal 
abnormality in some MALT lymphomas, and the API2-MALT1 fusion gene was found to be 
associated with this abnormality(Yonezumi et al., 2001). The MALT1 gene is cloned by 
18q21, while API2, an apoptosis inhibitor, is present in 11q21. Yonezumi et al. used RT-PCR 
to test a large series of MALT lymphomas for the presence of the AP12-MALT1 fusion gene 
and found that pulmonary MALT lymphomas showed the highest incidence of the AP12-
MALT1 gene (62.5%) while the occurrence rates of MALT lymphomas of the stomach, orbit 
and large intestine ranged from 10 to 20%(Yonezumi et al., 2001). Sakugawa et al. used RT-
PCR to examine 47 colorectal MALT lymphomas, including 27 primary rectal MALT 
lymphomas, for the API2-MALT1 fusion gene. API2-MALT1 fusion gene positivity was 
observed in 3 (11%) of 27 cases of rectal MALT lymphoma, and in 7 (15%) of 47 cases of 
colorectal MALT lymphoma(Sakugawa et al., 2003). In our study, the positive ratio for 
MALT1 gene genetic abnormality was 2 (25%) of 8 cases of rectal MALT lymphoma. In 
addition, we found that rectal MALT lymphomas with MALT1 gene genetic abnormality 
tend to be resistant for antibiotic treatments. 
3. Conclusion 
Ours is the first investigation of the regression of rectal MALT lymphoma after antibiotic 
treatments (Niino et al., 2010). Further follow-up will be needed to determine whether 
MALT lymphoma of the rectum regresses completely or is actually cured by antibiotic 
treatments. In addition, a large number of such cases needs to be analyzed to establish 
suitable standards for antibiotic treatments. 
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tend to be resistant for antibiotic treatments. 
3. Conclusion 
Ours is the first investigation of the regression of rectal MALT lymphoma after antibiotic 
treatments (Niino et al., 2010). Further follow-up will be needed to determine whether 
MALT lymphoma of the rectum regresses completely or is actually cured by antibiotic 
treatments. In addition, a large number of such cases needs to be analyzed to establish 
suitable standards for antibiotic treatments. 
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1. Introduction 
In Hodgkin Lymphoma therapy chemotherapy and radiotherapy are applied, and both of 
them can cause early or late toxicity. Optimal treatment of Hodgkin Lymphoma understands 
applying “enough therapy, not too few or too much”. Early and late toxicities, caused by 
applying chemotherapy and radiotherapy, will be analyzed with respect to system toxicity 
(haematological, gastrointestinal, cardiopulmonary toxicity, neurological, etc).  
All anti tumour drugs that are used in treatment of this disease will be individually 
analyzed. These drugs are recommended by protocols suggested in the up to date 
guidelines. Also early and late toxicity of earlier applied types of radio therapy and 
Involved field (IF) irradiation will be observed. Late toxicity and development of secondary 
malignancy and sterility will be discussed separately. This will stress importance of 
applying special steps that will provide possibility of having offspring even in population of 
diseased and treated HL patients.  
World-wide studies that confirmed toxicity of earlier applied protocols and irradiation 
treatments (total nodal, subtotal nodal and extended field) will also be discussed. These 
findings influenced new views of treating HL that understand applying chemotherapy in all 
clinical stages with or without IF irradiation.  
Personal experiences will also be listed based on a studies of patients diagnosed with HL 
and treated at Haematology Clinic at Clinical Centre University Sarajevo. One such study 
had primary goal in determining secondary malignancies as a consequence of late toxicity in 
HL treatment. The study was conducted from 1992 – 2001. In the first group of patients in 
that study 10 patients (7.9%) were with secondary malignancy out of which one was with 
myelodysplasia, three with Non Hodgkin Lymphoma, six with solid carcinoma (Ca 
planocellulare papillae – one patient, Ca planocellulare laringys – one patient, Neo palatum 
molae – one patient and Ca mammae – three patients). In the same group, epidemiologically 
observed, the most patients ware aged from 14 to 24 years.  
In our country, which is listed as undeveloped, first peak in age bimodal graph was shifted 
towards younger aged group (15-24 years). This indicates that even maximal success in HL 
treatment of these patients can, in 15-20 years after the treatment, question this success. This 
time span is cumulative period needed to develop malignant mutation. Second analyzed 
period is targeted towards analyzing patients with HL treated from 2002 – 2011 with 





To fully understand toxicity of the Hodgkin lymphoma therapy it is necessary to shortly 
review therapy applications. First therapy approaches in Hodgkin Lymphoma treatment 
appeared in period from 1932-1950 when treatment was conducted using herbs, X-rays and 
surgery. Vera Peters and her colleagues from Sanford University pioneered in the field of 
radiotherapy. They created high dose radiation therapy that was dominant from 1950 to 
1970. (Peters M, 1950) Toxicities of such therapy approach were analyzed in the studies 
conducted in the upcoming years. Those studies changed further chemotherapy approaches 
from 1970 till 2008. (Kaplan HS, 1996) 
Prior to the mid-1960s advanced-stage Hodgkin lymphoma was treated with single-agent 
chemotherapy. In 1964 Vincent DeVita and George Canellos at the National Cancer Institute 
(United States) developed the MOPP regimen. National Cancer Institute developed the first 
combination chemotherapy that cured a number of patients who relapsed after standard 
radiation therapy. (DeVita V. et al, 1970; De Vita V. et al, 1992.) ABVD was developed as a 
potentially less toxic end more effective alternative to MOPP. Initial results of ABVD 
regimen were published at Universita degli Studi di Milano in academic year 1974/1975 
(thesis of a student led by Bonadonna Gianni) and these initial results were also published 
in 1975 by an Italian group led by Bonadonna. (Bonadonna G et al, 1975) 
In 1994 German Hodgkin’s Lymphoma study Group (GHSG), lead by Volker Dihel, 
developed a regimen BEACOPP in an attempt to improve the prospect for patients with 
advanced disease stages. Results were published subsequently for a large prospectively 
randomised trial HD9 in patients with previously untreated advanced Hodgkin lymphoma. 
(Diehl V. et al, 1998). 
Further improvement of Hodgkin lymphoma treatment is introduction of high dose therapy 
followed by autologous stem cell transplantation (HDT-ASCT). New findings in the field of 
immunology and molecular biology, as well as many studies that analyzed response and 
toxicity of previous therapy options, influenced adoption of contemporary individual 
treatment approach with application of targeted immunotherapy. This does not conclude 
HL as there are large numbers of Hodgkin Lymphoma patients that do not achieve required 
response. Also different treatment complications require constant improvement of therapy 
approach. Contemporary approach is ever more directed towards researching targeted 
therapy using antibodies, immunomodulators, HDAC inhibitors and m-TOR inhibitors.  
In Hodgkin Lymphoma therapy currently Chemotherapy and Radiotherapy are most often 
used. 
1.1 Chemotherapy 
Most often protocol is ABVD which gives 82% CR and 72% OS with follow up of 8 years. On 
the other side, BEACOPP gives 88% CR1 baseline (B) vs. 96% escalated (E), FFS 76%(B) and 
87%(E) and OS of 88% (B) and 91% (E) and follow up of 5 years (Michael C. et al, 2008a; 
Griffin R. et al., 2010). Up to date treatment options (from 2011) are conducted using 
EORTC, NCCN and GHSG guidelines. These guidelines state that following protocols 
(along with ABVD and BEACOPP) are to be used: Stanford V, DHAP, ICE, ASHAP, MINE, 
Mini-BEAM, HDT+SCT; and rarely: VIM-D, MIME, GVD, GDP, GCD, GEM-P, IGEV, 
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Radiation volume in HL was used in three ways: mantle field, paraaortic region and pelvis. 
The mantle field region encompassed the cervical, supraclavicular, infraclavicular, axillary, 
mediastinal and hilar nodes. (Sandra J. Horning 2001) Paraaortic understands irradiation of 
spleen and pelvis area individually or in continuity when marked as inverse Y. If all stated 
areas are used, irradiation is marked as total nodal (TN). If mantle field and paraaortic area 
are used irradiation is named subtotal nodal (STNI), while only mantle field is marked as 
extended field (EFRT). There is also involved field (IF) that encompasses lymph node in 
question and complete lymph drain.( Griffin R. et al., 2010) 
Optimal treatment of Hodgkin Lymphoma understands applying “enough therapy, not too 
few or too much”. In creating HL treatment plan, it is very important to define illness and its 
risks, and fully review patient’s condition. Meaning, early favourable and early 
unfavourable, as well as advanced stage with risk factors (IPS: age, gender, Hgb, albumin < 
40g/l, advanced stage IV, white cell count > 15000/mm2 absolute lymphocyte count) with 
respect to comorbidity. Pet CT gives significant data regarding disease stage and evaluation 
of disease location as well as its absence, and hence it gives possibility of optimal therapy 
dosage. Special attention is required when dealing with younger patients and females 
younger than 30 years as infertility and secondary malignancies can occur.  
1.3 Toxic effects 
In Hodgkin Lymphoma therapy, application of chemotherapy and radiotherapy has healing 
effect but also has different toxic side effects. These side effects can cause early and late 
toxicity (acute and chronic side effects) which can occur in different systems: 
haematological, cardiovascular, respiratory, gastrointestinal, renal, urogenital, neurological, 
reproduction system and skin. These toxicities affect pregnancy and can have carcinogenic 
effect. Early toxicities are relatively easy to overcome, while late toxicity occurs in the form 
of: sterility, cardiovascular disease, pulmotoxicity, neurotoxicity and secondary malignancy 
what poses significant complications. Quality of life and reduction of early and late toxicity 
represent significant goals in the Hodgkin Lymphoma treatment.  
2. Toxicities according to affected system during HL treatment 
By applying chemotherapy and radiotherapy different toxicities can occur. Most significant 
toxicities are named in the remaining of this section and for each of them most important 
characteristics are listed.  
2.1 Hematotoxicity 
This toxicity causes secondary leukaemia, hemolytic anemia and myelosuppression which is most 
often followed by neutropenia which is further most often followed by sepsis. Most difficult 
cases are when sepsis is caused by gram-negative bacteria or respiratory infection with 
possibility of ARDS. Thrombocytopenia with grade 4 (according to WHO) can cause 
significant bleedings. Anemia can reduce working ability, tissue ischemia or worsened 






Pericardium: acute pericarditis, Constrictive pericarditis from 1-6 months of radiotherapy 
Myocardium: myocardial fibrosis, Progressive and restrictive cardiomyopathy 
Blood vessels: coronary arterial disease (CAD) and structural changes in coronary arteries 
which are similar to atherosclerosis 
Valvular disease: Predominantly affects mitral valve and aortic valve (both regurgitation 
and stenosis possible) 
Conduction system: arrhythmia (persistent tachycardia) and complete or incomplete 
atrioventricular block. (Christopher F. 2010) 
2.3 Pulmonary toxicity 
Most often toxicities are lung fibrosis and pneumonitis. 
2.4 Gastrointestinal complications of chemotherapy 
Following gastrointestinal complications can occur: nausea, vomiting, emesis, diarrhea, 
ileus, mucositis, ventricular and colon neoplasm . 
Hepatotoxicity: laesio hepatis.  
2.5 Urogenital/Renal toxicity 
Most often toxicities are cystitis and renal insufficiency. 
2.6 Endocrine 
Following can occur in the endocrine system: hypothyroidism, Grave’s disease, thyroiditis, 
thyrotoxicosis, thyroid nodule, thyroid malignancies. 
2.7 Gonadal complications teratogenicity of cancer therapy 
Infertility occurs in both genders. Azoospermia and hormonal elevation occur in male 
patients while amenorrhoea and FSH elevation occur in females.  
2.8 Dermatologic toxicity 
Alopecia, erythema and exanthema, striae, hyperpigmentation, oedema, hyperkeratosis, 
pruritus and nail changes are often dermatologic toxicities.  
Local toxicity: Extravasation (necrotizing is possible) 
2.9 Secondary malignancies after chemotherapy 
Most difficult complications occur on lungs, breast, stomach, colon and thyroid gland. Also 
malignant melanoma, aggressive and indolent lymphoma and acute secondary leukaemia 
can occur as secondary malignancies.  
2.10 Other 
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3. Early and late toxicity of drugs used in HL treatment 
When applying drugs it is extremely important to know the cumulative dosage that causes 
toxicity.  
 
Drug Cumulative dosage Substance 
Adriamycin / Doxorubicin 450-550 mg/m2 Anthracyclines 
Bleomicin Pulmotoxicity >300mg (age <15 and >65 years) Antibiotic 
Lomustin/CCNU Cumulative dosage of nephrotoxicity >1200-1500mg/m2 Alkylating agent 
Dacarbazin/DTIC 
standard doze 200-375/m2 /d i.v, 
during 3-4 weeks 750-850mg/m2//d 
i.v during 4 weeks 
non classic Alkylating 
agent 
Carmustin/BCNU Pulmotoxicity >1000mg/m2 Alkylating agent 
Prokarbazin >/=4g/m2 non classic Alkylating agent 
Vinkristin neurotoxicity >20 mg cumulative dosage Vinca alkaloids 
Cisplatin >100-200 mg/m2 Alkylating agent 
Cyclophosphamide 
>7,5g/m2 , Mega dose 16 -19 g/m2/ 
(application of these dosages only in 
specialized haematological and 
oncology centres) 
Alkylating agent 
Chlorambucil Lung fibrosis >2000mg Alkylating agent 
Melphalan >/=140 mg/m2 Alkylating agent 
Carboplatin </2g/m2 Alkylating agent 
Rituximab/Mabthera* standard dosage 375/ m2 monoclonal antibody 
Table 1. Drugs used in HL treatment and their cumulative dosages (Berger D.P. et al, 2002). 
3.1 Adriamycin/Doxorubicin 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: acute (arrhythmia, ischemia, infarct) and 
chronic (dilatative cardiomyopathy) side effects. Risk groups: earlier cardiac illness, younger 
than 15 and older than 65 years, bolus injection, mediastinum irradiation, cumulative 
dosage larger than 450-550/mg/m2; Gastrointestinal complications of Chemotherapy: nausea, 
vomiting, mucositis, stomatitis, diarrhea; Dermatologic Toxicity: exanthem, urticaria, alopecia, 
rarely hyperpigmentation.Local toxicity: extravasation; Gonadal Complications: infertility; 
Second Malignancies after Chemotherapy: potentially mutagenic, teratogenic and carcinogenic. 
(Berger D.P. et al, 2002)  
3.2 Bleomycin 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: interstitial pneumonitis and lung 





mucositis, diarrhea; Dermatologic Toxicity: alopecia, erythema, exanthem, striae, 
hyperpigmentation, oedema, hyperkeratosis, pruritus, nail changes; Other: fever, myalgia, 
shivering. (Berger D.P. et al, 2002)   
3.3 Carboplatin  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: nausea, 
emesis, loss of appetite, mucositis. Liver: transitory increase of transaminase; Renal Toxicity: 
rarely nephrotoxicity which appears upon inadequate rehydration; Dermatologic Toxicity: 
alopecia, erythema, dermatitis, allergies, pruritus; Neurotoxicity: rarely peripheral 
neurotoxicity, rarely hearing problems and optic neuritis; Gonadal Complications: infertility; 
Other: fever, shivering. (Berger D.P. et al, 2002)   
3.4 Carmustin (BCNU)  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: interstitial pneumonitis, lung 
infiltrate and lung fibrosis upon administering cumulative dosage; Gastrointestinal 
complications of Chemotherapy: nausea, emesis, mucositis, diarrhoea, rarely esophagitis, ulcer, 
gastrointestinal bleeding. Liver: transitory increase of transaminase, veno-occlusive-disease 
(VOD); Renal toxicity: renal insufficiency; Dermatologic Toxicity: alopecia, dermatitis, 
erythema, hyperpigmentation; Neurotoxicity: peripheral and central neurotoxicity, 
psychoorganic syndrome, neuroretinitis, optic neuritis, ataxia; Gonadal Complications: 
infertility, azoospermia, amenorrhoea. (Berger D.P. et al, 2002)  
3.5 Chlorambucil  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmotoxicity: lung fibrosis, cumulative dosage larger 
than 2000mg; Gastrointestinal complications of Chemotherapy: nausea, emesis, mucositis. Liver: 
transitory transaminase increase, rarely heavier liver toxicity; Dermatologic Toxicity: alopecia, 
erythema; Neurotoxicity: rarely peripheral and central neurotoxicity; Gonadal Complications: 
infertility (cumulative dose > 400mg) amenorrhoea and azoospermia; Other: fever, rarely 
cystitis; Second Malignancies after Chemotherapy: potentially mutagen, carcinogen and 
teratogenic. (Berger D.P. et al, 2002)  
3.6 Cisplatin  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: rarely rhythm disorders, cardiac 
insufficiency; Gastrointestinal Complications of Chemotherapy: nausea, emesis, loss of appetite, 
mucositis, diarrhoea, enteritis. Liver: transitory transaminase increase; Renal toxicity: 
electrolyte disbalance: decrease of level of Na, K, Ca and Mg. Cumulative dosage – 
nephrotoxicity followed with tubular insufficiency; Dermatologic Toxicity: alopecia, 
dermatitis, allergy reactions; Neurotoxicity: peripheral neurotoxicity, ototoxicity, when 
applying cumulative dosage > 100-200mg/m2, dizziness, rarely focal encephalopathy, optic 
neuritis; Gonadal Complications: infertility; Other: Local toxicity: local phlebitis, possible 





mucositis, diarrhea; Dermatologic Toxicity: alopecia, erythema, exanthem, striae, 
hyperpigmentation, oedema, hyperkeratosis, pruritus, nail changes; Other: fever, myalgia, 
shivering. (Berger D.P. et al, 2002)   
3.3 Carboplatin  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: nausea, 
emesis, loss of appetite, mucositis. Liver: transitory increase of transaminase; Renal Toxicity: 
rarely nephrotoxicity which appears upon inadequate rehydration; Dermatologic Toxicity: 
alopecia, erythema, dermatitis, allergies, pruritus; Neurotoxicity: rarely peripheral 
neurotoxicity, rarely hearing problems and optic neuritis; Gonadal Complications: infertility; 
Other: fever, shivering. (Berger D.P. et al, 2002)   
3.4 Carmustin (BCNU)  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: interstitial pneumonitis, lung 
infiltrate and lung fibrosis upon administering cumulative dosage; Gastrointestinal 
complications of Chemotherapy: nausea, emesis, mucositis, diarrhoea, rarely esophagitis, ulcer, 
gastrointestinal bleeding. Liver: transitory increase of transaminase, veno-occlusive-disease 
(VOD); Renal toxicity: renal insufficiency; Dermatologic Toxicity: alopecia, dermatitis, 
erythema, hyperpigmentation; Neurotoxicity: peripheral and central neurotoxicity, 
psychoorganic syndrome, neuroretinitis, optic neuritis, ataxia; Gonadal Complications: 
infertility, azoospermia, amenorrhoea. (Berger D.P. et al, 2002)  
3.5 Chlorambucil  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmotoxicity: lung fibrosis, cumulative dosage larger 
than 2000mg; Gastrointestinal complications of Chemotherapy: nausea, emesis, mucositis. Liver: 
transitory transaminase increase, rarely heavier liver toxicity; Dermatologic Toxicity: alopecia, 
erythema; Neurotoxicity: rarely peripheral and central neurotoxicity; Gonadal Complications: 
infertility (cumulative dose > 400mg) amenorrhoea and azoospermia; Other: fever, rarely 
cystitis; Second Malignancies after Chemotherapy: potentially mutagen, carcinogen and 
teratogenic. (Berger D.P. et al, 2002)  
3.6 Cisplatin  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: rarely rhythm disorders, cardiac 
insufficiency; Gastrointestinal Complications of Chemotherapy: nausea, emesis, loss of appetite, 
mucositis, diarrhoea, enteritis. Liver: transitory transaminase increase; Renal toxicity: 
electrolyte disbalance: decrease of level of Na, K, Ca and Mg. Cumulative dosage – 
nephrotoxicity followed with tubular insufficiency; Dermatologic Toxicity: alopecia, 
dermatitis, allergy reactions; Neurotoxicity: peripheral neurotoxicity, ototoxicity, when 
applying cumulative dosage > 100-200mg/m2, dizziness, rarely focal encephalopathy, optic 
neuritis; Gonadal Complications: infertility; Other: Local toxicity: local phlebitis, possible 
necrotizing extravasation. (Berger D.P. et al, 2002)  
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3.7 Cyclophosphamide  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: high dosage – in 5-10% cases acute 
myopericarditis, cardio insufficiency, and hemorrhagic myocardium necrosis; Pulmotoxicity: 
high dosage – lung fibrosis, pneumonitis; Gastrointestinal complications of Chemotherapy: 
nausea, emesis, mucositis, stomatitis, loss of appetite Liver: transitory transaminase 
increase, rarely cholestasis; Urogenital Toxicity: hemorrhagic cystitis when applying high 
therapy doses; Renal toxicity: renal insufficiency; Dermatologic Toxicity: alopecia, rarely 
hyperpigmentation, dermatitis, erythema; Neurotoxicity: when applying high dosages – 
acute encephalopathy; Gonadal Complications: infertility, azoospermia, amenorrhea; Other: 
fever, allergy reactions. (Berger D.P. et al, 2002) 
3.8 Cytarabin  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: when applying high dosages – 
pulmotoxicity, lung oedema, ARDS (acute respiratory distress syndrome); Gastrointestinal 
Complications of Chemotherapy: nausea, emesis, mucositis, diarrhoea, loss of appetite, when 
applying high dosages rarely pancreatitis, ulcer, esophagitis, colon necrosis Liver: transitory 
transaminase increase, cholestasis; Dermatologic Toxicity: dermatitis, erythema, exanthema, 
conjunctivitis, keratitis, alopecia; Neurotoxicity: peripheral and central neurotoxicity, cerebral 
and cerebellum disorders at patients > 60 years and high dose therapy (48 g/m2). After 
intrathecal application - acute arachnoiditis and leukoencephalopathy; Other: fever, myalgia, 
arthralgia, bone pain. (Berger D.P. et al, 2002) 
3.9 Dacarbazine (DTIC)  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: nausea, 
emesis, rarely mucositis, diarrhoea, Liver: transitory transaminase increase, veno-occlusive-
disease (VOD); Renal toxicity: Kidneys: rarely renal insufficiency; Dermatologic Toxicity: alopecia, 
erythema, exanthem, photosensitivity, allergy reactions; Neurotoxicity: rarely CNS disorders 
(headache, sight disorders, confusion, lethargy, spasms, paresthesia); Other: fever, myalgia, 
shivering. Local toxicity: extravasation, local thromboflebitis. (Berger D.P. et al, 2002) 
3.10 Etopozid/VP-16 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: rarely arrhythmia, hypotonia at 
intravenous application, ischemia; Gastrointestinal complications of Chemotherapy: nausea, 
emesis, rarely mucositis, dysphagia, diarrhea, constipation, Liver: transitory transaminase 
increase; Dermatologic Toxicity: alopecia, rarely erythema, hyperpigmentation, allergy 
reactions; Neurotoxicity: rarely peripheral neuropathy and CNS disorders (somnolence); 
Gonadal Complications: infertility. (Berger D.P. et al, 2002) 
3.11 Gemcitabin  





Hematotoxicity: myelosuppression; Pulmonary Toxicity: Lung oedema (rarely); Gastrointestinal 
complications of Chemotherapy: nausea, emesis, rarely mucositis, diarrhoea; Renal toxicity: 
proteinuria, hematuria, Liver: transitory transaminase increase; Dermatologic Toxicity: rarely 
erythema, pruritus, rarely alopecia, oedema; Other: peripheral oedema. (Berger D.P. et al, 
2002) 
3.12 Ifosfamid 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: loss of 
appetite, nausea, emesis, mucositis, diarrhoea. Liver: transitory transaminase increase, 
rarely cholestasis; Urogenital: hemorrhaging cystitis when applying cumulative dosage; 
Renal toxicity: renal insufficiency; Dermatologic Toxicity: alopecia, rarely urticaria, 
hyperpigmentation; Neurotoxicity: acute encephalopathy, cerebellum neurotoxicity, 
confusion, psychosis, ataxia, spasms, somnolence, coma. Prophylaxis natriumbicarbonat, 
therapy: methylene blue; Gonadal Complications: infertility; Other: fever, allergy reactions. 
(Berger D.P. et al, 2002) 
3.13 Lomustin (CCNU) 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: rarely lung infiltration, lung fibrosis; 
Gastrointestinal complications of Chemotherapy: nausea, emesis, mucositis, diarrhea; Renal 
toxicity: renal insufficiency when applying cumulative dosage; Dermatologic Toxicity: 
alopecia, dermatitis, hyperpigmentation; Neurotoxicity: peripheral and central neurotoxicity; 
Gonadal Complications: infertility, amenorrhea, azoospermia. (Berger D.P. et al, 2002) 
3.14 Mechlorethamine/Nitrogen mustard 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression, hemolytic anemia; Gastrointestinal complications of 
Chemotherapy: nausea, vomiting (almost 100%) onest may be within minutes of drug 
administration, diarrhea, and anorexia. Liver: hepatotoxicity; Dermatologic Toxicity: alopecia, 
hyperpigmentation of veins, contact and allergic dermatitis (50% with topical use); Gonadal 
Complications: azoospermia, chromosomal abnormalities, delayed menstrual cycle, 
oligomenorrhea, amenorrhea, impaired spermatogenesis; Neurotoxicity: peripheral neuropathy; 
Second Malignancies after Chemotherapy: carcinogenicity, mutagenicity, teratogenicity.  
3.15 Melfalan 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: rarely lung fibrosis; Gastrointestinal 
complications of Chemotherapy: loss of appetite, nausea, emesis, mucositis, diarrhoea; 
Dermatologic Toxicity: rarely alopecia, exanthem, erythema, urticaria, pruritus, oedema; 
Gonadal Complications: infertility; Other: rarely allergy reactions. (Berger D.P. et al, 2002)  
3.16 Methotrexat 





Hematotoxicity: myelosuppression; Pulmonary Toxicity: Lung oedema (rarely); Gastrointestinal 
complications of Chemotherapy: nausea, emesis, rarely mucositis, diarrhoea; Renal toxicity: 
proteinuria, hematuria, Liver: transitory transaminase increase; Dermatologic Toxicity: rarely 
erythema, pruritus, rarely alopecia, oedema; Other: peripheral oedema. (Berger D.P. et al, 
2002) 
3.12 Ifosfamid 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: loss of 
appetite, nausea, emesis, mucositis, diarrhoea. Liver: transitory transaminase increase, 
rarely cholestasis; Urogenital: hemorrhaging cystitis when applying cumulative dosage; 
Renal toxicity: renal insufficiency; Dermatologic Toxicity: alopecia, rarely urticaria, 
hyperpigmentation; Neurotoxicity: acute encephalopathy, cerebellum neurotoxicity, 
confusion, psychosis, ataxia, spasms, somnolence, coma. Prophylaxis natriumbicarbonat, 
therapy: methylene blue; Gonadal Complications: infertility; Other: fever, allergy reactions. 
(Berger D.P. et al, 2002) 
3.13 Lomustin (CCNU) 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: rarely lung infiltration, lung fibrosis; 
Gastrointestinal complications of Chemotherapy: nausea, emesis, mucositis, diarrhea; Renal 
toxicity: renal insufficiency when applying cumulative dosage; Dermatologic Toxicity: 
alopecia, dermatitis, hyperpigmentation; Neurotoxicity: peripheral and central neurotoxicity; 
Gonadal Complications: infertility, amenorrhea, azoospermia. (Berger D.P. et al, 2002) 
3.14 Mechlorethamine/Nitrogen mustard 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression, hemolytic anemia; Gastrointestinal complications of 
Chemotherapy: nausea, vomiting (almost 100%) onest may be within minutes of drug 
administration, diarrhea, and anorexia. Liver: hepatotoxicity; Dermatologic Toxicity: alopecia, 
hyperpigmentation of veins, contact and allergic dermatitis (50% with topical use); Gonadal 
Complications: azoospermia, chromosomal abnormalities, delayed menstrual cycle, 
oligomenorrhea, amenorrhea, impaired spermatogenesis; Neurotoxicity: peripheral neuropathy; 
Second Malignancies after Chemotherapy: carcinogenicity, mutagenicity, teratogenicity.  
3.15 Melfalan 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Pulmonary Toxicity: rarely lung fibrosis; Gastrointestinal 
complications of Chemotherapy: loss of appetite, nausea, emesis, mucositis, diarrhoea; 
Dermatologic Toxicity: rarely alopecia, exanthem, erythema, urticaria, pruritus, oedema; 
Gonadal Complications: infertility; Other: rarely allergy reactions. (Berger D.P. et al, 2002)  
3.16 Methotrexat 
Application of this drug can cause following toxicities: 
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Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: mucositis, 
nausea, vomiting, emesis, diarrhea, gastrointestinal bleeding; Liver: acute and chronic liver 
insufficiency; Renal toxicity: Renal insufficiency; Dermatologic Toxicity: exanthem, dermatitis, 
pruritus, conjunctivitis, allergy reactions; Neurotoxicity: reversible acute encephalopathy 
after intravenous and intrathecal application, leukoencephalopathy; Other: rarely allergies. 
(Berger D.P. et al, 2002)  
3.17 Mitoxantron  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: chronic cardiotoxicity, cardiomyopathy, 
heart insufficiency; Gastrointestinal complications of Chemotherapy: nausea, emesis, mucositis, 
rarely gastrointestinal bleeding. Liver: transitory transaminase increase, rarely cholestasis 
Renal toxicity: rarely renal insufficiency; Dermatologic Toxicity: alopecia, allergy reactions, 
dermatitis, pruritus; Gonadal Complications: infertility; Second Malignancies after Chemotherapy: 
secondary acute leukaemia. (Berger D.P. et al, 2002) 
3.18 Prednisone 
Application of this drug can cause following toxicities: 
Immunosuppression, affects apoptosis in internal signal path, thrombosis with 
consequential infarct of the affected tissue, suppression adrenal gland, retention Na, 
decrease of K, iatrogenic diabetes mellitus, psychoses especially severe in older patients.  
3.19 Prokarbazin  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: tachycardia, hypotonia; Gastrointestinal 
complications of Chemotherapy: nausea, emesis, rarely mucositis, dysphagia, diarrhoea, Liver: 
transitory transaminase increase; Dermatologic Toxicity: alopecia, erythema, exanthem, 
photosensitivity, hyperpigmentation, allergy reactions; Neurotoxicity: reversible peripheral 
neurotoxicity, rarely CNS disorders (Somnolence), agitation, depression, hallucinations; Gonadal 
Complications: infertility; Second Malignancies after Chemotherapy: secondary malignancies; Other: 
fever, shivering, myalgia, arthralgia, gynecomasty. (Berger D.P. et al, 2002) 
3.20 Vinblastin  
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Cardiotoxicity: cardiovascular complications, hypertonia, 
hypotonia; Pulmonary Toxicity: acute interstitial pneumonitis, bronchospasm; Gastrointestinal 
complications of Chemotherapy: rarely constipation, ileus, nausea, emesis, diarrhoea, mucositis, 
rarely gastrointestinal bleeding; Dermatologic Toxicity: alopecia, erythema, exanthem, photo 
sensation; Neurotoxicity: peripheral neurotoxicity when applying cumulative dosage, 
paresthesia, rarely motoric disorders; Other: muscle spasms, Local toxicity: necrotizing 
extravasation. (Berger D.P. et al, 2002)  
3.21 Vinkristin 





Hematotoxicity: myelosuppression; Cardiotoxicity: cardiovascular complications, hypertonia, 
hypotonia; Pulmonary Toxicity: acute interstitial pneumonitis, bronchospasm; Gastrointestinal 
complications of Chemotherapy: constipation, Ileus, nausea, emesis, mucositis, rarely 
pancreatitis.Renal toxicity: polyuria (decrease of pad secretion ADH), dysuria; Dermatologic 
Toxicity: alopecia, erythema; Neurotoxicity: peripheral neurotoxicity (cumulative dosage), 
CNS disorders: hypesthesia, paresthesia, motoric disorders, areflexia, rarely severe 
complications like paralysis, ataxia, paralytic ileus, optic atrophia, blindness, spasms; 
Gonadal Complications: infertility. Local toxicity: necrotizing extravasation; Other: rarely 
fever, shivering. (Berger D.P. et al, 2002) 
3.22 Vinorelbina 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: rarely 
constipation, nausea, emesis, diarrhoea, Mucositis; Dermatologic Toxicity: alopecia; 
Neurotoxicity: peripheral neurotoxicity when applying cumulative dosage, paresthesia, 
rarely motoric disorders; Other: muscle spasms, Local toxicity: necrotizing extravasation. 
(Berger D.P. et al, 2002) 
4. Toxicities that occur when applying most often used protocols 
4.1 Chemotherapy toxicities 
Early complications: nausea, vomiting, emesis, alopecia, myelosuppression.  
Late complications: Sterility (primarily with MOPP-based regimens, BEACOPP, least with 
ABVD), Neuropathy (primarily with Vincristine), Cardiomyopathy (primarily with 
doxorubicin ABVD, COPP/ABVD), Pulmonary fibrosis (primarily with Bleomycin 
COPP/ABVD, BEACOPP) and Secondary leukaemia (primarily with MOPP, Radiotherapy 
(RT), BEACOPP escalating more than baseline). (Griffin R. et al., 2010) 
4.1.1 ABVD vs. BEACOPP 
The most used protocol is ABVD and most studies suggest that it is protocol with least 
toxicity. One of the largest randomized studies, conducted in multiple centres, is “The 
GHSG- Successor-trials De-escalation of BEACOPP Advanced stages of Hodgkin 
lymphoma“. It summarized data from three studies (HD9, HD12 and HD15) and is still 
conducted on HD18. In analysis of the treatment of advanced HL stages it used data from 
more than 500 centres including 220 oncologists and over 4500 patients treated with 
BEACOPP and ABVD. The study confirmed that ABVD had less toxicity (40-90%), lower 
infertility rate (90% male/52% female in BEACOPP E vs. 34% in ABVD), AML/MDS (1.2% 
in BEACOPP E vs. <0.5% in ABVD). On the other hand BEACOPP E had higher CR rates 
(>90%), Higher tumour cell kill PFS (90% vs. 79% in ABVD), Cure rate of 11% (higher at 10 
years) and 20% less need for salvage therapy. (Diehl V, 2009) 
Study GHSG HD14 compared BEACOPP with ABVD in early unfavourable HL. Two cycles 
of BEACOPP escalated followed by 2xABVD and IFRT results in a significant improvement 
in tumor control compared to 4x ABVD + IFT. Toxicities for ABVD x4+IFT were following: 





Hematotoxicity: myelosuppression; Cardiotoxicity: cardiovascular complications, hypertonia, 
hypotonia; Pulmonary Toxicity: acute interstitial pneumonitis, bronchospasm; Gastrointestinal 
complications of Chemotherapy: constipation, Ileus, nausea, emesis, mucositis, rarely 
pancreatitis.Renal toxicity: polyuria (decrease of pad secretion ADH), dysuria; Dermatologic 
Toxicity: alopecia, erythema; Neurotoxicity: peripheral neurotoxicity (cumulative dosage), 
CNS disorders: hypesthesia, paresthesia, motoric disorders, areflexia, rarely severe 
complications like paralysis, ataxia, paralytic ileus, optic atrophia, blindness, spasms; 
Gonadal Complications: infertility. Local toxicity: necrotizing extravasation; Other: rarely 
fever, shivering. (Berger D.P. et al, 2002) 
3.22 Vinorelbina 
Application of this drug can cause following toxicities: 
Hematotoxicity: myelosuppression; Gastrointestinal complications of Chemotherapy: rarely 
constipation, nausea, emesis, diarrhoea, Mucositis; Dermatologic Toxicity: alopecia; 
Neurotoxicity: peripheral neurotoxicity when applying cumulative dosage, paresthesia, 
rarely motoric disorders; Other: muscle spasms, Local toxicity: necrotizing extravasation. 
(Berger D.P. et al, 2002) 
4. Toxicities that occur when applying most often used protocols 
4.1 Chemotherapy toxicities 
Early complications: nausea, vomiting, emesis, alopecia, myelosuppression.  
Late complications: Sterility (primarily with MOPP-based regimens, BEACOPP, least with 
ABVD), Neuropathy (primarily with Vincristine), Cardiomyopathy (primarily with 
doxorubicin ABVD, COPP/ABVD), Pulmonary fibrosis (primarily with Bleomycin 
COPP/ABVD, BEACOPP) and Secondary leukaemia (primarily with MOPP, Radiotherapy 
(RT), BEACOPP escalating more than baseline). (Griffin R. et al., 2010) 
4.1.1 ABVD vs. BEACOPP 
The most used protocol is ABVD and most studies suggest that it is protocol with least 
toxicity. One of the largest randomized studies, conducted in multiple centres, is “The 
GHSG- Successor-trials De-escalation of BEACOPP Advanced stages of Hodgkin 
lymphoma“. It summarized data from three studies (HD9, HD12 and HD15) and is still 
conducted on HD18. In analysis of the treatment of advanced HL stages it used data from 
more than 500 centres including 220 oncologists and over 4500 patients treated with 
BEACOPP and ABVD. The study confirmed that ABVD had less toxicity (40-90%), lower 
infertility rate (90% male/52% female in BEACOPP E vs. 34% in ABVD), AML/MDS (1.2% 
in BEACOPP E vs. <0.5% in ABVD). On the other hand BEACOPP E had higher CR rates 
(>90%), Higher tumour cell kill PFS (90% vs. 79% in ABVD), Cure rate of 11% (higher at 10 
years) and 20% less need for salvage therapy. (Diehl V, 2009) 
Study GHSG HD14 compared BEACOPP with ABVD in early unfavourable HL. Two cycles 
of BEACOPP escalated followed by 2xABVD and IFRT results in a significant improvement 
in tumor control compared to 4x ABVD + IFT. Toxicities for ABVD x4+IFT were following: 
acute grade III/IV toxicity 50.7 %, leucopoenia 24%, thrombocytopenia 0.1%, anemia 1%, 
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Gr.III/IV infection 3.4% and total of 19 secondary malignancies. On the other hand, toxicity 
in group 2x BEACOPP E + 2xABVD+IFT were: acute grade III/IV toxicity 87.1%, 
leucopoenia 79%, thrombocytopenia 22%, anaemia 9%, Gr.III/IV infection 7.3% and total of 
16 secondary malignancies. It is important to state that OS was same in the two groups. 
(Engert A. et al, 2010).  
Results from the HD 2000 - Gruppo Italiano study conducted on patients with advanced 
stage HL indicate that BEACOPP improved FFS/PFS but has no difference in RFS or OS 
with increased toxicity, especially hematotoxicity. Hematotoxicity in the BEACOPP group 
(98 patients) was Gr.3/4 WHO, WBC/Plts 57/22, and in the ABVD group (99 patients) it 
was 3/34. BEACOPP was associated with higher severe infection rates than ABVD. 
(Federico M. et al, 2009) In the study “ABVD vs. BEACOPP for Hodgkin’s lymphoma when 
High Dose Salvage Is Planned” Simonetta Viviani also concludes that “Treatment with 
BEACOPP, as compared with ABVD, resulted in better initial tumour control, but the long-
term clinical outcome did not differ significantly between the two regimens”. (Simoneta V. 
et al, 2011). 
A randomized trial conducted from 2000 to 2007 by the Michelangelo, GITIL and IIL 
cooperative group in the analysis of the 3 year outcome ABVD vs. BEACOPP in advanced 
HL analyzed 321 patients diseased with HL stage IIB/IV and/or ≥3IPS, compared efficiency 
of 6-8 ABVD cycles vs. BEACOPP 4 escalating cycles + BEACOPP 4 baseline cycles in the 
first line. It confirmed significant difference of FFP (71±4% vs. 87±3%) but non-significant 3-
yr OS (91±3% vs. 90±3%). Results of later relapses and secondary malignancies were not 
represented due to a longer follow up. (Gianni A.M. et al, 2008). 
Other HD12 study of GHSG at IIB and advanced stage III and IV with IPI ≥ 3 in application 
of 8 cycles BE vs. 4 BE+ 4BB confirmed that treatment-related toxicity of WHO grade III/IV 
was observed in 97% of patients. Most prominent differences between pooled chemotherapy 
(8x BEACOPP escalating + 0 Gy), was anaemia (65% 8BE vs. 51% 4BE+4BB) and 
thrombopenia (65% vs. 51%). There was 9.9% deaths (22 vs. 32 acute or salvage treatment 
toxicity; 15 vs. 24 HL; 22 vs. 13 secondary neoplasia). Secondary neoplasias were observed in 
77 patients (4.9%). (Diehl V. et al, 2009) 
Analysis of BEACOPP baseline vs. BEACOPP escalating confirmed acute haematological 
toxicity: Leucopoenia gr.4 WHO 37% vs. 93%, thrombocytopenia gr.4 WHA 5% vs. 49%, 
anemia gr. 3 WHO 17% vs. 50%, anemia gr. 4 WHO 4% vs. 19%. (Diehl V. et al, 1998)  
4.1.2 Secondary malignancies 
Increased risk of solid tumours was noted by numerous authors (Tucker MA et al, 1988; 
Boivin JF. Et al, 1984). When applying ABVD protocol, risk of NHL is increased where 
DLBCL can occur both early and later after treatment. (Van LF. et al, 1989) 
After 10 years of follow up of the GHSG HD9 study final results in the treatment of 
advanced stage and application of 6 COPP/ABVD vs. 6 BEACOPP baseline vs. 6 BEACOPP 
escalating, confirmed following toxicity: total of 74 secondary malignancies (6.2%) were 
documented including acute myeloid leukaemia (0.4%, 1.5% and 3.0%), non Hodgkin 





overall secondary malignancy rates were 5.7%, 6.6% and 6.0% respectively. (Andreas E. et 
al, 2009). The same study with results published in 2007 confirmed that cardiac toxicity is 
mostly expressed in COPP/ABVD, pulmotoxicity in COPP/ABVD and baseline BEACOPP. 
Cardiotoxicity was 1.2%, 0.9% and 0.9%, while pulmotoxicity 0.4%, 0.4% and 0.2%. (Diehl V. 
et al, 1998) 
Preliminary results of the HD9 Causes of Death at 10 years indicate higher death events at 
COPP/ABVD 24% vs. 19% vs. 12%. (Diehl V. et al, 1998)  
When applying MOPP regimen in more than 6 cycles +/- irradiation confirm risk of acute 
leukaemia. (Kaldor JM, et al, 1990) Early splenectomy increased this risk by two times. (Van 
LF, et al, 1989; Kaldor JM, et al, 1990) Application of alkylating agents proportional to 
cumulative dose confirmed 1-10% of cases caused toxicity after 7-10 years. (Boivin JF et al, 
1984; Blayney DW, et al, 1987; Arseneau JC, et al, 1972; Coleman CN, et al, 1977) 
4.2 Radiotherapy toxicities 
Early Complications: Mantle field radiation can cause mouth dryness, pharyngitis, cough, 
dermatitis. Sub-diaphragmatic radiation can cause anorexia and nausea. 
Late Complications: Hyperthyroidism, Graves' ophthalmopathy or thyroid neoplasm was 
seen after neck radiotherapy. Elevation of TSH level with or without lowered T3 or T4 was 
seen at 30% of patients which had mantle irradiation with often followed with 
Hypothyroidism. 
4.2.1 Toxicity after lungs irradiation 
Pericarditis and pneumonitis can occur. Incidence of radial pneumonitis (characterized by 
shivering, dyspnoea and cough) depends on volume of lung irradiation and total dose, with 
recovery seen from 12 to 24 months. (Smith LM, et al, 1989; Horning SJ, et al, 1994; Griffin R, 
et al, 2010)  
4.2.2 Toxicity after heart irradiation 
Toxic effect is possible on pericardium, myocardium, blood vessels, cardiac valve and 
conduction system. Cardiac mortality is significantly improved at patients who were 
administered with > 30 Gy on mediastinum. Mediastinum radiotherapy is joined with 
increased risk of heart disease. Increased risk and mortality rate due to coronary arterial 
disease and acute infarct of myocardium was seen both at adult and child patients. 
(Hancock SL, et al, 1993; Boivin JF, et al, 1992) 
Patients whose heart was irradiated have increased risk of coronary arterial disease. Hence 
continual monitoring and evaluation is needed together with other risk factors. Follow up of 
these patients, according to NCCN (National Comprehensive Cancer Network, 2010) 
predicts basic ECHO of the heart 10 years after treatment with control of the lipid profile 
once per year. On the other side, according to ESMO base ECHO of the heart should be 
done 4-10 years after treatment, stress ECHO in patients with earlier RT and follow up of 





overall secondary malignancy rates were 5.7%, 6.6% and 6.0% respectively. (Andreas E. et 
al, 2009). The same study with results published in 2007 confirmed that cardiac toxicity is 
mostly expressed in COPP/ABVD, pulmotoxicity in COPP/ABVD and baseline BEACOPP. 
Cardiotoxicity was 1.2%, 0.9% and 0.9%, while pulmotoxicity 0.4%, 0.4% and 0.2%. (Diehl V. 
et al, 1998) 
Preliminary results of the HD9 Causes of Death at 10 years indicate higher death events at 
COPP/ABVD 24% vs. 19% vs. 12%. (Diehl V. et al, 1998)  
When applying MOPP regimen in more than 6 cycles +/- irradiation confirm risk of acute 
leukaemia. (Kaldor JM, et al, 1990) Early splenectomy increased this risk by two times. (Van 
LF, et al, 1989; Kaldor JM, et al, 1990) Application of alkylating agents proportional to 
cumulative dose confirmed 1-10% of cases caused toxicity after 7-10 years. (Boivin JF et al, 
1984; Blayney DW, et al, 1987; Arseneau JC, et al, 1972; Coleman CN, et al, 1977) 
4.2 Radiotherapy toxicities 
Early Complications: Mantle field radiation can cause mouth dryness, pharyngitis, cough, 
dermatitis. Sub-diaphragmatic radiation can cause anorexia and nausea. 
Late Complications: Hyperthyroidism, Graves' ophthalmopathy or thyroid neoplasm was 
seen after neck radiotherapy. Elevation of TSH level with or without lowered T3 or T4 was 
seen at 30% of patients which had mantle irradiation with often followed with 
Hypothyroidism. 
4.2.1 Toxicity after lungs irradiation 
Pericarditis and pneumonitis can occur. Incidence of radial pneumonitis (characterized by 
shivering, dyspnoea and cough) depends on volume of lung irradiation and total dose, with 
recovery seen from 12 to 24 months. (Smith LM, et al, 1989; Horning SJ, et al, 1994; Griffin R, 
et al, 2010)  
4.2.2 Toxicity after heart irradiation 
Toxic effect is possible on pericardium, myocardium, blood vessels, cardiac valve and 
conduction system. Cardiac mortality is significantly improved at patients who were 
administered with > 30 Gy on mediastinum. Mediastinum radiotherapy is joined with 
increased risk of heart disease. Increased risk and mortality rate due to coronary arterial 
disease and acute infarct of myocardium was seen both at adult and child patients. 
(Hancock SL, et al, 1993; Boivin JF, et al, 1992) 
Patients whose heart was irradiated have increased risk of coronary arterial disease. Hence 
continual monitoring and evaluation is needed together with other risk factors. Follow up of 
these patients, according to NCCN (National Comprehensive Cancer Network, 2010) 
predicts basic ECHO of the heart 10 years after treatment with control of the lipid profile 
once per year. On the other side, according to ESMO base ECHO of the heart should be 
done 4-10 years after treatment, stress ECHO in patients with earlier RT and follow up of 
lipid profile at patients which had RT in their therapy. (Bovelli et al. 2010) 
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4.2.3 Secondary malignancies (solid tumour and secondary acute leukaemia as 
consequence of irradiation) 
According to Stanford study, risk of secondary solid tumours 15 years after treatment was 
about 18%. (Boivin JF, et al, 1984). Patients that were primarily treated with radiotherapy 
had increased risk of tumour formation on lungs, breast, bone marrow, soft tissues and 
thyroid gland. 
Possibility of lung cancer, 5 years after irradiation treatment and further during next 20 
years, was two to eight times higher what was especially true with patients that smoke. 
(Griffin R, et al, 2010).  
Increased risk of breast cancer was noted at female patients that were treated before age of 
30 and was increased in children and adolescent population as well. (Donaldson SS, et al, 
1982). Radiotherapy toxicity was especially noted at patients aged from 15-30 years what 
restricts irradiation of females before age of 30. Average interval of irradiation and 
diagnostics Ca Thyroid and breast cancer is 10 - 15 years. Hence it is needed to do routine 
mammography 8 years after completion of irradiation treatment in this group of patients. 
(Griffin R, et al, 2010) These findings influenced new recommendations in irradiation 
application by reducing mantle radiotherapy volume. By modifying mantle field and 
aborting axilla and heart from the radiation area treatments converged towards involved 
field radiotherapy (IFTT).  
Reduction of the radiation area involved exclusion of irradiation of thyroid gland, heart and 
axilla and decrease risk of Brest Cancer and lung cancer. Low-dose (20Gy) IFRT was 
associated with decrease risk of Brest Cancer by 77% and lung cancer by 57%. (Hodgson DC, 
et al, 2007) 
Contemporary therapy approach is using IFRT and is preferred for the patients that respond 
to the first line therapy with PR/SD and/or have bulky. High dose therapy followed by 
ASCT therapy in large measure suppressed irradiation or it was postponed for after ASCT 
for unfavourable disease, advanced disease, bulky, borderline zone and transformation.  
15 % of patients that were administered with mantle field radiation can develop electric 
shock sensation radiating down the back of the legs when the head is flexed. This happens 6 
to 12 weeks after the treatment due to transitory demyelination of spine cord and what 
resolves spontaneously. (Griffin R, et al, 2010) 
4.2.4 Toxicity after thyroid gland irradiation  
The data provided by the Christofer F. suggests that the actual risk of hypothyroidism after 
radiation therapy for HL at 26 years was 47%. Other less common thyroid abnormalities 
observed include: Graves’s disease, thyroiditis, thyrotoxicosis, thyroid nodules and thyroid 
malignancies. (Christopher F, 2010). 
My personal experience involves a study on patients diagnosed with HL from 1992 to 2001 
and treated at Haematology Clinic at Clinical Centre University Sarajevo. The study was 
aimed to determining secondary malignancies as a consequence of late toxicity in HL 





Our treatments at that time involved RT for I and IIA stage and for IE, IIB, III and IV stage 
MOPP or ABVD or ChLVPP with PR+MOPP or RT. In that study 10 patients (7.9%) were 
with secondary malignancy out of which one was with myelodysplasia, three with Non 
Hodgkin Lymphoma, six with solid carcinoma (Ca planocellulare papilarae – one patient, 
Ca planocellulare laringys – one patient, Neo palatum molae – one patient and Brest cancer– 
three patients). In the same group, epidemiologically observed, the most patients ware aged 
from 14 to 24 years. In the further follow up of 10 years (2002 to 2011) of the patients 
diagnosed by 2001, we noted 3 more diseased with secondary malignancy (1 with breast 
cancer, 1 Myeloma Multiplex and one with MDS). (Sofo Hafizovic A. 2002). 
Second analyzed period is targeted towards analyzing patients with HL treated from 2002 – 
2011 with applying chemotherapy using ABVD and BEACOPP protocol with or without 
IFRT. This study is currently being conducted and its results will be published in the 
upcoming period. 
 
Chemotherapy ± RT 1992 – 2001 Chemotherapy ± RT 2002 - 2011 
Hematology complications – total 4 (3.2%) 
sAML: 0 
MDS: 1 (0.8%) 
NHL: 3 (2.4%) 
Hematology complications – total 2 (1.6%) 
MDS: 1 (0.8%) 
Myeloma Multiplex: 1 (0.8%) 
Solid neoplasm – total 6 (4.8%) 
Ca planocellulare papilarae: 1 
Ca planocellulare laringys: 1 
Neo palatum molae: 1 
Brest cancer 3 (2.4 %) 
Solid neoplasm – total 1 (0.8%) 
Brest cancer 1 (0.8%) 
Table 2. Therapy toxicity in HL treatment (secondary malignancies) in KCUS. 
In follow up of 10 years, secondary malignancies occurred in 10 cases (7.9%) and in follow 
up of 20 years secondary malignancies occurred in 13 cases (10%). 
Case report: One 63 years old patient which had HL (NLP) CS IIA bulky diagnosed in 
August 2001. In the first line therapy the patient was treated using chemotherapy using 
ABVD protocol with irradiation of mediastinum and CR1 achieved. After 6 years Myeloma 
Multiplex was diagnosed and further VAD protocol therapy was applied. Next autologous 
transplantation of peripheral stem cells was conducted without significant complications. 
However, in 2010 she develops POEMS (Polyneuropathy Organomegaly Endocrinopathy 
M-protein Skin-abnormalities) followed with thrombocytopenia immunogene which were 
successfully treated with Prednisolon and Imuran. On her last control in April 2011 she is 
still in HL and MM complete remission with good life quality.  
5. Gonadal complications in Hodgkin lymphoma treatment 
Teratogenic influence of chemotherapy is formed in application of individual, or as a 
synergy effect of more drugs or in combination with radiotherapy. It is especially stressed in 
the first trimester of pregnancy. Incidence of difficult congenital malformations in 
chemotherapy application is 3% from the total number of born and 90% is incidence of 
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chemotherapy application is 3% from the total number of born and 90% is incidence of 
minor malformations. (Michael CP. 2008b)  
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Factors during pregnancy (FDP) determine risk factors from teratogenic effect. According to 
that Prednisone is in B group, Methotrexte is in X group, Rituximab and Dacarbazine are in 
C group, and finally Cytosin arabinosid, Gemcitabine, Chlorambucil, Ifosfamid, Mepphalan, 
busulfan, Cisplatin, carboplatin, Procarbazine, Doxorubicin, Bleomxcin, Mitoxantron, 
vincristin, Vinblastin, Etoposide, Cytarabine are in D group. (Michael CP. 2008b) 1 
Reproduction effect: about 90% males become permanently sterile if they were administered 
with 6 cycles of MOPP chemotherapy. (Chapman RM, 1979a) Risk is correlated with 
cumulative dose of alkylating agents and 2-3 cycles result in azoospermia in about 50% 
patients. (Da CM, et al, 1984) Fertility in females, after applying MOPP chemotherapy, is in 
relation to age and treatment and as well as cumulative dosage of alkylating agent dose. (Da 
CM, et al, 1984; Horning SJ, et al, 1979; Chopman RM, et al,1979b). Also females in the age 
around 25, which are treated with 6 cycles of MOPP have 80% chance of sterility. ABVD is 
joined with temporary amenorrhea or azoospermia with total recovery which was noted in 
50-90% of patients. (Anselmo AP, et al, 1990; Viviani S, et al, 1985) 
Study conducted by Karolin Behringer confirmed teratogenic influence in males and females 
as follows COPP/MOPP/COPP+ABVD: Azoospermia 86-100%, Recovery of 
spermatogenesis between 12-20% after 2 years, Dysspermia prior to therapy 70-77%. In 
treatment of advanced stage HL with use of BEACOPP regimen had 89% azoospermia. In all 
early stage and use of alkylating agent elevation of FSH is 60%, recovery of fertility 52% and 
with use of RT recovery was 3%. Using Non-alkylating agent elevation of FSH is 8%, 
recovery is 82%. Fertility in female HL patients’ therapy associated amenorrhea 0-4% ABVD, 
51% BEACOPP escalating. (Karolin B. 2008) 
Same author states that Ovarion toxicity is 2 years after chemotherapy treatment and in 
usage of 4xABVD regular cycle 95.9% Amenorrhea 4.1%, 2xABVD regular cycle 98.8% 
Amenorrhea 1.2%. 4xBEACOPP base regular cycle 87.1% Amenorrhea 12.9%. 8xBEACOPP 
escalating regular cycle 55% Amenorrhea 45%, 4xBEACOPP baseline +4xBEACOPP 
escalating regular cycle 81% Amenorrhea 19%. (Karolin B. 2008) 
Christopher Flowers discovered that irradiation influenced fertility as follows: 1x dose 0.35 
Gy or higher can cause transitory azoospermia (recovery time is longer when higher dose 
was administered). Dose 2 Gy and higher in germinal epithelium can result in permanent 
azoospermia. Dose of 15 Gy and higher Leydig cell function can be affected with potential 
need for testosterone replacement therapy. Ovarion dose of 4 Gy may cause a 30% incidence 
of sterility in young women but 100% sterility in women ≥ 40 years. (Christopher F. 2010).  
Sterility formation stresses importance of applying procedures that will create good 
conditions for healthy offspring in the population of diseased and treated HL patients. 
Females should use contraception to protect the unwanted pregnancy on one side, and on 
                                                 
1FDA category B drugs are those for which studies in pregnant women did not demonstrate a risk to the 
fetus in any trimester; For C drugs animal reproduction studies have shown an adverse effect on the 
fetus and even though there are no adequate studies in humans potential benefits justify use in 
pregnant women; D drugs are those for which studies demonstrated human fetal risk, but the benefit 
from use in pregnant women patients justify the risk; for X drugs studies demonstrated fetal 
abnormalities and clearly risk of using this drug in pregnant women outweighs potential benefits. 





the other to keep the hormonal level in boundaries that do not cause amenorrhea. Also 
cryopreservation enables offspring planning even before HL treatment application.  
Among adults and adolescents after puberty, semen cryopreservation is proposed before 
first line treatment with BEACOPP or salvage treatment for relapse, and it is optional in 
cases of localized Hodgkin lymphoma treated with ABVD and radiotherapy. For women 
with a stable partner, in vitro fertilization for embryo cryopreservation is a standard 
procedure but it can be offered to only a small number of patients and requires delayed 
treatment initiation. Oocyte cryopreservation remains experimental, although its usage is 
being increased. Ovarian tissue cryopreservation is still experimental. (Harel S. 2011)  
6. Conclusion 
Optimal treatment of Hodgkin Lymphoma understands therapy application that will 
achieve complete remission with as few toxic effects as possible. This is especially true for 
the late toxic effects. Taking care of secondary malignancies and sterility is of uttermost 
significance and this is the force that drives constant treatment modification and creation of 
new therapy options of Hodgkin Lymphoma treatment. In current treatment options there is 
still large percentage of early and late toxicities which reduce life quality of the affected 
patients. Keeping in mind that high life quality is one of the main goals of any treatment, it 
should be assessed with appropriate attention and toxicities should be reduced to as low 
level as possible.  
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1. Introduction 
Hodgkin lymphoma (HL), formerly called Hodgkin’s disease, is a malignancy of mature B-
cell lineage (germinal or post-germinal center), with over 8,000 new cases diagnosed 
annually in the United States.[1] HL has historically been characterized by many histologic 
subtypes with the finding of Reed-Sternberg cells unify the diagnosis. HL is well known to 
have a bimodal distribution of incidence, occurring most frequently in two distinct age 
groups: young adults (age 15-35) and those ages greater than 55 years old. For the purpose 
of this chapter, we will focus on the young adults treated for and cured of HL with radiation 
therapy (RT), chemotherapy, or combined modality therapy (CMT). 
HL remains in many ways the archetype within oncology with regards to incremental 
improvements, established through well-performed clinical trials, turning an incurable and 
universally fatal illness into one that is, more often than not, cured with first-line therapy. 
The need for an understanding of how best to care for survivors of HL is predicated upon 
patients being cured of their HL. This was first achieved in the 1960’s when HL was shown 
to be a curable disease, first with high-dose extended field RT,[2] and subsequently with 
multi-agent chemotherapeutic regimens such as MOPP (nitrogen mustard, vincristine, 
procarbazine, and prednisone).[3] Increasingly intensive treatments, however, were 
handcuffed to increasing toxicity.[4] As the likelihood of cure started to plateau in the 1990’s 
at approximately 80%, the toxic consequences of these intensified treatment regimens – 
acute as well as late effects – increasingly came into focus.[5] As HL is largely a disease of 
young, functional, and fertile, with survivors often living long lives (with whatever 
impairment resulting from disease and treatment), the need to better understand the 
medical needs of survivors of HL began to receive significant attention from the medical 
community. Additionally, investigators began to pursue improvement in HL therapy from a 
very different perspective – seeking not to identify further intensifications of therapy, but 
rather to attempt to delineate how treatment toxicities could be limited without sacrificing 
the excellent outcomes gained over the past decades. Accordingly, improvements in 
radiation delivery have led to preferential use of smaller fields (involved field radiation 
therapy, and now even involved nodal field radiation in select circumstances.[6, 7] Efforts in 
the development of systemic chemotherapy for HL have been focused upon not only 
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intensification of therapy, but in the selective application of such treatment. Currently, the 
management of HL is driven by patient- and disease-specific characteristic including age 
and gender, stage, bulk, location, and risk models specific for early or advanced stage 
disease.[8-12] Early-stage patients, particularly those with bulky disease (most often defined 
as a mass greater than 10 cm in long-axis diameter or encompassing more than a third of the 
intrathoracic diameter) are commonly treated with combined modality approaches of 
varying intensity.[13] Advanced disease is frequently treated with chemotherapy alone with 
consolidation radiation therapy to sites of bulk [14], although here, intensity of treatment is 
often dictated by risk prediction. The next generation of clinical trials seeks more 
individualized and specific ways to tailor treatment intensity, particularly using response-
adapted strategies with early restaging functional imaging with 18-fluorodeoxyglucose 
(FDG) positron emission tomography (PET). As treatments continue to emerge, and evolve, 
the needs of survivors will of course develop in kind. Nonetheless, there exist over 160,000 
patients living after being cured of HL; having received treatments with long-term effects, 
and it is the optimal care of these patients that is the focus of survivorship efforts.[15]  
2. Importance of post-treatment care 
During the first 10 years following diagnosis of HL, relapse remains the leading cause of 
death. [16] However, by 15-20 years following diagnosis, risk of death due to causes other 
than HL will have surpassed those due to the lymphoma itself.[17, 18]  By risk stratification, 
those with early stage disease are more likely to have secondary malignancy and 
cardiovascular disease when compared to those with advance disease, an observation 
attributable to improved prognosis as well as effects from RT, more often a component of 
therapy for early stage disease. As the risk of relapse diminishes after treatment the 
subsequent quality of life altering comorbidities become apparent and accelerated.[19] 
Although second primary malignancy and cardiovascular disease are the most frequent 
causes of non-lymphoma mortality among patients with HL, they are far from the only 
medical conditions for which they are at risk. Pulmonary, musculoskeletal, endocrine, 
neurologic, and psychiatric illness all occur at increased frequency among HL survivors, 
typically as direct sequelae of the disease or its treatment. Tellingly, a single-institution 
series investigating the global effects of late morbidity found that, among survivors an 
average of 21 years post-treatment, 94% reported at least one morbidity of any grade 
severity, 50% at least one morbidity of grade 3 or greater (according to a modification of the 
Common Terminology Criteria for Adverse Events, version 3), and 23% two or more 
morbidities of grade 3 or greater.[18] In order for a physician to offer optimal care for 
survivors of HL, such care should be built upon an understanding of these risks, both 
individually and collectively.[20] 
3. Second primary malignancy 
Unfortunately, among those cured of HL, second primary malignancy remains the leading 
cause of mortality 15 years after disease-free survival.[21] For instance, a risk model 
approximated that those diagnosed at the age of 30 with HL will have a 30 year cumulative 
risk of second primary malignancy for men and women at 18% and 26%, respectively, 
compared to age-matched risks of 7% and 9%.[22, 23]  The latency of the various second 
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malignancies seen following therapy for HL varies by histology. Risk for myelodysplastic 
syndrome (MDS) and acute myelogenous leukemia (AML) peak at three to five years after 
therapy and return to population baseline, or at most remain minimally elevated, by 10 
years after.[24-26] The inverse is true for solid tumor malignancies, where increased risk 
only first becoming appreciable by 10 years after the completion of therapy.[27] 
4. Hematologic malignancies 
Already survivors of one hematologic malignancy, the fact that they are at heightened risk 
for the development of additional hematologic malignancies – particularly MDS, AML, and 
non-Hodgkin lymphoma (NHL) – are a source of frustration to doctors and patients alike. 
Treatment-induced MDS or AML is a well-established risk of HL therapy; the relative risk of 
acute leukemia among patients cured of HL is 80 times greater than the general population, 
although the absolute excess risk is low.[28] The risk of MDS/AML is largely predicated 
upon the treatment delivered, as the cumulative dose of potent alkylating chemotherapy 
(e.g., mechlorethamine) or topoisomerase inhibitors (e.g., doxorubicin or etoposide) and the 
delivery of radiotherapy account for much of this increased risk.[24, 29] Despite ongoing 
advancements in the treatment of the acute leukemias, treatment-related AML remains 
profoundly dangerous, with median survival measured in months.[28] Indeed, it was in part 
the leukemogenicity of the older MOPP regimen that helped fuel the ascendance of ABVD 
(doxorubicin, bleomycin, vinblastine, and dacarbazine) as the chemotherapeutic standard of 
care for average-risk HL. The absolute excess risk of AML following treatment with ABVD 
is between 0 and 0.4%, whereas with MOPP was 2.8% (and with MOPP and radiotherapy as 
CMT, 5.5%).[25, 30, 31] The modern intensified regimen, escalated BEACOPP (bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and 
is associated with a risk of AML of 3.2%. This observation has largely led to the selective use 
of this highly effective regimen only in high-risk patients – patients in whom the risk of poor 
outcomes with ABVD merit exposure to more leukemogenic therapy.[32] The risk of 
secondary acute leukemia in patients receiving consolidative RT for HL appears to be more 
closely related to the field of therapy than to the delivered dose.[27] This contribution to 
leukemia risk has been somewhat mitigated, as modern RT strives to limit therapeutic 
exposure, preferring involved fields to extended fields, although these efforts are not 
expected to entirely obviate the contribution to risk of leukemia from radiotherapy.  
In addition to acute myelogenous leukemia, HL survivors are also at increased risk for the 
subsequent development of non-Hodgkin lymphoma (NHL).[21, 33, 34] The risk appears to 
be influenced by the selection of treatment, with alkylator therapy and radiotherapy 
emerging as the likely causes of oncogenesis. Estimates of the relative risk of NHL among 
survivors of HL are varied across reports, ranging from 2 to 22, but the absolute risks are 
low: The 25-year cumulative risk of NHL is less than 4%, and the absolute excess risk (AER) 
of NHL is less than 10 cases per 10,000 person-years.[21]  
5. Solid tumor malignancies 
Although the development of a second primary hematologic neoplasms following curative 
treatment for HL is a potentially life-threatening event, and one for which survivors are at 
far greater risk than age-matched controls, solid tumors collectively comprise a much 
greater risk for survivors – 75% of second primary malignancies will not be AML or NHL, 
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but rather will be of solid organ origin, and unlike the risk of AML, the risk (and excess risk) 
of solid organ malignancy has no apparent plateau among HL survivors. Unlike AML, 
however, much of the risk of solid tumors arising from treatment of HL is attributable to 
local genotoxic damage due to radiation therapy; each routine involved field of 




Reprinted with permission from: Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and 
musculoskeletal complications in cancer survivors. PM&R 2011;3:1041-54. 
Fig. 1. Radiation therapy fields in the treatment of classical Hodgkin lymphoma. 
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6. Lung cancer  
HL survivors are at increased risk for developing lung cancer; with a relative risk of 7 and 
an AER of 7 per 10,000 person-years, lung cancer represents a serious cause of morbidity 
and mortality.[22, 35-39]  This risk is mediated by the volume and dose of lung tissue 
exposure to ionizing radiation, cumulative dose of alkylating chemotherapy, and 
environmental factors.[22] HL patients who had a positive smoking history and received 
radiation therapy as a part of their management have a markedly higher incidence of lung 
cancer when compared to HL who non-smokers and received radiation therapy, with 
relative risks as high as 50 times that of the general population.[40] Interestingly, regardless 
of smoking history, incident lung cancers develop within the radiation-exposed lung 
parenchyma. HL survivors who develop lung cancer have a median survival of less than a 
year [41, 42], and recently have been shown to have a 60% less chance of survival than cases 
of stage-matched de novo lung cancer.[43] We continue to adamantly recommend smoking 
cessation (with the support of a smoking cessation clinic) to patients at the time of diagnosis 
given the interaction between cigarette smoking and therapy in augmenting the subsequent 
risk of lung cancer. Whether to screen at-risk patients with a history of HL, and if so, how 
best to do so, remain unanswered questions. National Comprehensive Cancer Network 
(NCCN) guidelines recommend annual chest imaging (either X-ray or CT scan) for all 
patients except those who were treated without alkylator therapy, mediastinal RT, and who 
have no other risk factors.[44] The recommendation of screening CT has been supported by 
cost modeling, showing it to be cost effective, particularly in smokers.[45] However, perhaps 
the greatest impetus, albeit indirect, for lung cancer screening in HL survivors comes from 
the National Lung Screening Trial.[46] This large randomized trial of non-cancer patients 
with strong smoking histories demonstrated that, with annual low-dose CT scans of the 
chest for three consecutive years, lung cancer-specific and overall survival could be 
improved. How best to extrapolate these findings to the HL survivor population is unclear, 
and the duration and intensity of screening will require further clarification, but an annual 
low-dose chest CT scan in at-risk survivors may well emerge as the de facto standard of 
care, and given the current body of data should be discussed with patients at risk. 
7. Breast cancer 
After 15 years of follow-up, women treated with mantle field radiation before the age of 20 
had a 40-fold increased risk of developing breast cancer compared to age-matched 
controls.[47] In a retrospective study of HL survivors treated with more modern radiation 
dose and delivery, doses as low as 4.0Gy to the breast were associated with a 3.2 fold cancer 
risk compared to women who were treated with lower doses of radiation. This risk 
increased to 8-fold for women treated with >40 Gy to the breast. Age at radiation dominates 
the risk assessment for second primary breast neoplasia; in one study, for instance, the 
actuarial risks of breast cancer for patients receiving mantle radiation by 25 years after 
treatment were 34%, 22%, and 3.5% for patients under age 20, age 20-30, and over age 30, 
respectively; radiation therapy to patients over the age of 30 appears to confer at most a 
minimal risk of subsequent breast cancer.[48] Concomitant use of alkylating agents or pelvic 
radiation can have protective effects against development of breast cancer, presumably due 
to the low-estrogen state induced by premature ovarian failure.[47, 49] The question of how 
best to monitor patients who have received treatment likely to increase breast cancer risk 
remains unanswered, and an area of active research.  
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Guidelines for the screening of women for breast cancer continue to evolve, as do 
recommendations for screening high-risk patients, such as those with hereditary risk for 
breast cancer due to the inheritance of BRCA1 or BRCA2.[52] Unfortunately, many female 
HL survivors will also be at an increased risk for subsequent breast cancer, risk that is 
associated with exposure of breast tissue to ionizing radiation when contained in RT fields. 
For instance, women treated with mantle radiation under age 20 have a 40-fold increased 
risk of developing breast cancer compared to age matched controls at a median of 15 years 
follow-up.[21] Developmental age of breast tissue also strongly influences the risk of 
radiation induced carcinogenesis, as in patients who received mantle RT under the age of 20, 
age 20-30, and over 30 the risk of breast cancer was 34%, 22.3%, and 3.5% respectfully at 25 
years post treatment.[48] Given the many changes that have taken place in the delivery of 
RT in the treatment of HL (extended fields giving way to more limited involved fields; 
efforts at limiting dose; and improved simulation techniques, to name but three), it is hoped 
that risks of breast cancer following RT may be lower for patients treated in the current era. 
Nonetheless, recent data suggest that modern radiotherapy techniques may not in fact lead 
to reductions in second malignancy;[53] estimating risks of breast cancer will require 
ongoing reassessment so as to permit the most appropriate screening approach for 
individual patients given their individual risk profiles. Interestingly, concomitant use of 
alkylating agents or pelvic radiation can have protective effects against development of 
breast cancer, thought to be related to decreased estrogen production induced by treatment-
related ovarian suppression or premature ovarian failure.[54] If efforts at fertility 
preservation with administration of gonadotropin releasing hormone agonists prove 
successful, as may be the case in breast cancer therapy[55], it is possible this benefit may be 
either abrogated or nullified.[56] 
The optimal surveillance strategy for patients placed at increased risk for breast cancer by 
their HL therapy remains a subject of investigation, but standards of care are beginning to 
emerge. The National Comprehensive Cancer Network (NCCN) and the American Cancer 
Society (ACS) have recommended that, for those who received mediastinal radiotherapy 
before the age of 30, breast cancer surveillance should begin between eight and ten years 
following treatment.[50, 51] Mammography remains an important modality for breast 
cancer screening in this patient population, although the addition of an annual breast 
magnetic resonance imaging is reasonable for high-risk patients (particularly those with 
dense breasts on mammography, a finding that limits the sensitivity of mammography for 
early detection); the use of MRI in screening is extrapolated from a comparable risk group, 
women with BRCA1 mutation, in whom breast MRI has been validated as a useful element 
in screening programs.  
Many other types of solid tumor malignancies remain overrepresented in HL survivors. 
Papillary thyroid carcinoma is the most notable among them and is clearly associated with 
radiation therapy, although the risk of thyroid cancer decreases with doses above 30 Gy, 
consistent with increased cell kill of normal thyroid tissue.[58] Other radiation-associated 
cancers can be seen as well, including gastrointestinal carcinomata and soft tissue 
sarcomata, as well as a strong association with non-melanoma skin cancer, both basal and 
squamous cell histologies.[22] Given these risks, surveillance for second primary 
malignancy should take such risks into account, including modification of colorectal 
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screening for patients receiving infradiaphragmatic radiation, and special attention to skin 
examination in radiation fields.  
8. Cardiovascular toxicities 
While secondary malignancies remain the leading cause of mortality in long-term HL 
survivors, death due to cardiac causes places second and cardiovascular morbidity and 
mortality is far more common among HL survivors than among comparable untreated 
individuals. The specific cardiovascular toxicities for which HL survivors are at increased 
risk can include coronary artery disease (CAD), valvular heart disease, congestive heart 
failure (CHF), pericardial disease, electrical conduction abnormalities, and cerebrovascular 
disease.[59] 
9. Coronary artery disease 
HL survivors who receive radiotherapy to the mediastinum are at increased risk of early 
onset CAD. A British cohort of HL survivors was found to be 3.2 times more likely to suffer 
a myocardial infarction (MI) than population controls. [60] In Dutch HL survivors treated 
with mediastinal radiation, the 20-year cumulative risk of myocardial infraction was 
21.2%.[61] In a similar cohort Aleman et al. reported the risk of development of a myocardial 
infarction at 30 years post-radiation was 12.4%.[62] The selection of chemotherapy, 
including the use of anthracyclines, does not appear to definitively impact risks of CAD 
among survivors. Classical CAD risk factors (hypertension, diabetes, cigarette smoking, and 
hyperlipidemia) continue to play a role in promoting atherosclerosis in HL survivors, 
necessitating optimal medical management.[63] At present, there have only been two 
prospective studies of cardiac screening in HL survivors. Heidenreich et al. [64] reported an 
abnormal stress test (echocardiogram and/or radionucleotide myocardial perfusion scan) in 
21% of asymptomatic HL survivors fifty percent of those with an abnormal functional study 
demonstrated an obstructive lesion at the time of definitive coronary angiography. 
Furthermore, Kupeli et al. [65] use CT angiogram to detect subclinical CAD in survivors of 
childhood HL, and found a 6.8 times greater post-radiation HL survivors. CT angiography 
is felt to represent the non-invasive gold standard for detection of CAD, with sensitivity and 
specificity of 94% and 97%, respectfully, compared to fluoroscopic angiography.[66] 
Whether screening CT angiography is appropriate for adult HL survivors remains an open 
question, and indeed no standard of care yet exists for the surveillance for subclinical CAD 
in HL survivors. 
10. Valvular heart disease 
The risk of subsequent valvular heart disease is significantly increased among HL survivors 
treated with mediastinal RT, again believed due to direct toxic effects on the valve 
apparatus. Investigators have observed a seven- or eight-fold increase in the likelihood of 
experiencing significant valvular heart disease among irradiated survivors, risks that appear 
not to be mediated by chemotherapy agents or dosages.[62, 67] The aortic valve is the most 
commonly affected, and female gender appears to predispose to disease.[68] 
Echocardiographic surveillance to assess valvular competence is often included as an 
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element of routine follow-up of HL survivors treated with mediastinal radiation, although 
as of yet no guidelines for adult survivors have been developed. 
11. Congestive heart failure 
Although the most common cause of congestive heart failure (CHF) in HL survivors is 
ischemic cardiomyopathy, significant concerns remain about the risk of late non-ischemic 
cardiomyopathy. While cumulative dose of anthracycline is associated with risks of CHF, 
currently the maximum cumulative dose of doxorubicin would not exceed 400 mg/m2 and 
typically would not exceed 300 mg/m2, the dose exposure from 6 cycles of ABVD, dose 
levels that would be expected to be associated with low risks of cardiomyopathy.[69, 70]  
Doxorubicin is not the only therapeutic agent for HL associated with CHF; It has long been 
recognized that mediastinal RT can predispose to CHF as well.[71] The impact of therapy on 
risk of subsequent CHF has been convincingly elucidated in patients treated as children for 
HL; data from the Childhood Cancer Survivor Study estimate a hazard ratio of 6.8 in HL 
survivors, with young age (<10y), female gender, higher doses of doxorubicin, and 
mediastinal RT all contributing to risk in multivariate modeling.[72] Subclinical LV 
dysfunction in survivors of childhood HL appears also to be common, although estimates of 
cumulative incidence are heterogeneous, ranging from 0 to 57% in 25 studies using 
traditional echocardiographic metrics (studies that were themselves heterogeneous in how 
subclinical LV dysfunction was defined).[73] Among patients treated for adult HL, long-
term survivors are at increased risk for developing CHF, with one set of estimates (among 
patients who largely did not receive anthracycline-based chemotherapy) of absolute excess 
risk ranging from 16-35 cases/10,000 person-years.[74] Furthermore, while mediastinal RT 
appears contributes to the increased cardiac morbidity in HL survivors treated as adults,[59] 
how this risk interacts with the risk attributable to anthracycline-based chemotherapy has 
not been well described. How best to monitor the LV function, or even to identify early or 
subclinical LV dysfunction, in HL survivors needs to be more rigorously investigated if 
evidence-based screening guidelines are to be developed. 
12. Pulmonary toxicity 
Beyond the risk of lung cancer (discussed above), therapy for HL has the potential of 
causing both acute and chronic lung disease. The three most common first-line regimens for 
HL – ABVD, Stanford V, and BEACOPP – all contain bleomycin, an agent with a well-
described association with pneumonitis. Baseline pulmonary function prior to initiation of 
bleomycin-containing therapy is standard, both to select a group of patients for whom such 
therapy is inappropriate as well as to establish baselines against which future tests (either 
routine surveillance in the absence of symptoms or testing to delineate the cause of dyspnea 
or cough) can be compared. Such complaints are common; as many as 30% of HL survivors 
will report the symptom of dyspnea during or after treatment.[19] Acute bleomycin 
pneumonitis is a serious, and potentially life-threatening condition, with mortality rates 
reported as high as 27%.[75] Patients who experience bleomycin pneumonitis, even when 
having survived and recovered from the acute episode, are more likely to report chronic 
fatigue and dyspnea than unaffected patients. Furthermore, when fields include pulmonary 
parenchyma, radiation therapy can also lead to acute pneumonitis or, later, pulmonary 
fibrosis, conditions that can compound the damage from bleomycin exposure. Given these 
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risks, many experts will elect to monitor PFT’s serially both during treatment as well as 
periodically among survivors. 
13. Endocrinopathies 
Endocrine systems are typically characterized by homeostatic balance supported by positive 
and negative feedback. The organs involved in such systems may be susceptible to damage 
or disruption from cytotoxic chemotherapy or ionizing radiation, and indeed survivors of 
HL are at risk for dysfunction of several hormonal systems. Therapy for HL can be toxic to 
the thyroid and the gonads, resulting in hypothyroidism and compromised fertility, 
respectively. 
14. Thyroid disease 
Hypothyroidism is a potential long-term consequence of radiotherapy involving the thyroid 
bed. Unlike papillary thyroid cancer, an uncommon late sequela of thyroid irradiation, 
hypothyroidism is seen in at least half of HL survivors who are more then 10 years from 
treatment cancer having undergone RT involving the thyroid.[76] Risk factors associated 
with higher rates of hypothyroidism in HL survivors in addition to dose and field of 
radiation include female gender, treatment with combined-modality therapy, and duration 
of time since radiation. [77] There is no consensus on the optimal frequency of thyroid 
stimulating hormone screening or the value at which to initiate thyroid hormone 
replacement in the absence of symptomatic hypothyroidism, but treatment with thyroid 
hormone replacement is routine and effective at minimizing the impact of hypothyroidism.  
15. Gonadal dysfunction   
Given the epidemiology of the disease, survivors of HL are often young, functional, and 
potentially fertile.[78] Unfortunately, treatments for HL may lead to temporary infertility, 
primary gonadal failure (azoospermia or primary ovarian failure), or subfertility 
(dysspermatogenesis or early onset of menopause). Given high cure rates among patients 
who will often go on to want to have children, investigators have sought to understand the 
impact of treatment on fertility, as well as how best to safeguard fertility prospectively. 
While a full discussion of fertility preservation is beyond the scope of this chapter, choice of 
chemotherapeutic agents, total dose of chemotherapy, radiation field and dose, and age at 
treatment are influence the outcomes with regards to fertility. The selection of therapy, 
including alkylating chemotherapy and pelvic radiation, has the potential to impact fertility 
in both men and women.[79, 80]  In male patients, semen cryopreservation when possible 
should be encouraged before commencing chemotherapy so as to preserve fertility should 
azoospermia result from treatment, although some patients will be incapable of banking 
adequate semen, presumed to be due to the cytokine milieu caused by the underlying 
lymphoma. While ABVD chemotherapy results in temporary azoospermia in approximately 
one third of patients, permanent azoospermia is rare. This stands in contrast to more 
intensified regimen using bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, and prednisone (baseline or escalated BEACOPP), which typically 
leads to durable azoospermia.[81]  
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In female patients, risk of infertility or subfertility is thought to be influenced by delivered 
therapy, intensity of therapy (number of cycles), and perhaps age at treatment. The leading 
cause of infertility is related to premature ovarian failure as a result of chemotherapy, 
radiation or combined modality therapy.[82] While egg preservation is commonly discussed 
at the time of consultation prior to proceeding to definitive treatment, not infrequently the 
pace of the disease, financial constraints, or patient choice are barriers to fertility 
preservation for women. For those who have been treated and subsequently attempt natural 
pregnancy, the data support optimism regarding likelihood of conception. In females who 
had received ABVD without pelvic radiation therapy and had no evidence of relapsed at 
three years were surveyed on their experience on fertility. Hodgson et al. found that of those 
that attempted to become pregnant 70% were successful with a median time to pregnancy of 
2 months.[83] Interestingly, in this report the age at diagnosis or the number of cycles of 
chemotherapy did not demonstrate an increase risk of subfertility compared to controls. 
Further data is emerging with patients with aggressive disease by prognostic modeling 
warranting initial intense treatment with BEACOPP, a regimen felt by most to be 
significantly more pituitary-gonadal axis. Dann et al. [84] reported that in patients younger 
than 40 with locally unfavorable or advanced HL whom underwent up to 4 cycles of initial 
BEACOPP therapy an astounding 94% of had preserved cyclic ovarian function. 
Furthermore, they reported numerous successful pregnancies in this cohort up to 7 years 
after commencement of BEACOPP. While this data is encouraging egg preservation or other 
options to facilitate preservation of fertility in an imperative part of the treatment plan. 
Recent research into ovarian suppression with gonadotropin releasing hormone agonists 
prior to initiation of chemotherapy has shown promise, with a recent large randomized 
clinical trial in women with breast cancer showing a statistically significant decrease in rates 
of amenorrhea 12 months after completion of adjuvant therapy from 26% to 9%.[55] More 
definitive efforts at preservation of female fertility include cryopreservation of fertilized 
embryos or, more recently, unfertilized ova elective oophorectomy with cryopreservation 
and re-implantation after therapy; and transposition of the ovary outside of pelvic 
radiotherapy fields.[56] For the survivor of HL, however, pre-treatment fertility 
preservation is something that was, or was not, done, and there are no established 
interventions to promote or restore fertility in the post-treatment setting. Recently, however, 
investigations into the use of anti-Müllerian hormone (AMH) levels to predict both the 
ability to conceive as well as the likelihood of early menopause in cancer survivors, have 
offered future promise for a more individualized assessment of fertility prospects and 
guidance regarding family planning.[85] 
16. Health related quality of life 
In addition to the medical morbidities that survivors of Hodgkin lymphoma may experience 
due to their disease and its treatment, there exist significant risks as well of impaired  
quality of life, with fatigue, anxiety and depression, and impaired vocational success having 
been well described among HL survivors. An understanding of the global well-being of 
survivors requires incorporation of psychosocial support into the delivered multi-
disciplinary care.  
Health related quality of life (HRQOL) encompasses a patient’s perception of physical, 
psychological, and social well-being. In a 10-year follow-up of survivors of early stage HL in 
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Europe, women tended to have a lower HRQOL and higher symptoms scores than did men. 
Regardless of gender, younger age was associated with higher functioning and lower 
symptom severity score, and emotional suffering was generally reported to be more severe 
than physical symptoms.[86] Of note, results in this study did not demonstrate a 
relationship between type of treatment and HRQOL outcomes. In a study out of the 
Southwest Oncology Group in the United States, a comparison of HRQOL in patients 
treated with either EFRT or CMT found persistent fatigue reported by survivors of each 
treatment modality, but again without differences according to treatment.[87] Effects seem 
to wane as length of time post-treatment increases; HL survivor 10 years from treatment 
continue to report lower general health scores, but many specific QOL domains no longer 
differ between treated patients and age-matched controls.[88, 89]  
17. Chronic fatigue 
A common theme among investigations into the quality of life of survivors of HL has been 
the impact of persistent and pervasive fatigue.[86, 87, 90] Chronic fatigue is three times 
more likely in HL survivors than in age matched controls, and is less likely to be associated 
with poor mental health than in untreated patients who experience chronic fatigue.[89, 91]  
Retrospective studies have attempted to characterize pre-existing risk factors that can 
predict post-treatment chronic fatigue, and reports have implicated B symptoms at 
diagnosis, social isolation, and presence of treatment-related pulmonary toxicity.[91, 92]  
The underlying cause of chronic fatigue in HL survivors remains incompletely understood, 
although ongoing research suggests a link between chronic fatigue in cancer survivors and 
inappropriate elevation of proinflammatory cytokines.[93-95] At this time, however, the 
interventions that have been shown to impact chronic fatigue in HL survivors the most 
favorably are cognitive behavioral therapy and structured aerobic exercise.[96-98] 
18. Psychiatric morbidity 
An extensive literature exists describing the frequency and severity of psychological and 
psychiatric morbidity among cancer survivors in general, and recent investigations have 
attempted to characterize the impact on mental health resulting from diagnosis and 
treatment of Single-institution data has found that, at a median follow-up of 21 years, 17% of 
HL survivors reported having being diagnosed with major depression, and of these 90% had 
been prescribed one or more anti-depressant medications; an additional 12% denied 
depression but reported significant anxiety in the post-treatment period.[99] In an analysis 
of survivors of HL in Norway, both anxiety and depression were overrepresented, and risk 
of mental illness was associated with lower economic status, having received combined-
modality therapy (as opposed to radiation alone), and having had a prior history of a 
psychiatric diagnosis.[100] It appears the peak risk of depression is at 2 years post diagnosis 
with a gradual decline thereafter, but the risk of depression, anxiety, and post-traumatic 
stress disorder can be lifelong and requires collaboration with mental health professionals in 
the delivery of multi-disciplinary care to HL survivors.[101-103] 
19. Occupational outcomes 
For many patients diagnosed with HL, symptoms from the illness, time for testing and 
treatment, and the resultant acute and chronic toxicities from therapy can significantly 
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disrupt careers and limit employment opportunities post-treatment. Several factors 
including limit the ability to continue working or return to work include disease 
characteristics at the time of diagnosis (site, stage, treatment, and disease response), patient 
characteristics (age, gender, comorbidity, socioeconomic status), and work-related factors 
(physical workload, stress, and social support).[104] Younger patients with good disease 
control and higher educational attainment are more likely to return to pre-diagnosis 
socioeconomic stature.[102, 104]  Among HL survivors 20 years from treatment, 18% 
reported that treatment for their HL interfered with their career 11% that it prevented 
subsequent full-time employment, and 9% that they were incapable even of routinely 
completing household chores.[99] While employment status in the United States is closely 
linked to both health and life insurance, HL survivors often suffer a negative impact on their 
insurance status, even after prolonged remissions.[105] Collectively, these challenges may 
ultimately disrupt the family support network, but interestingly, despite these challenges 
HL survivors who were married at the time of diagnosis do not appear to experience higher 
divorce rates than the general population in either the United States nor the Netherlands, to 
name but two examples.[102, 106] 
20. Future research in the care of survivors 
As clinical research in the management of HL continues to develop, with reduction in 
radiation fields, further limitation of chemotherapy dosages, response-adapted therapy, and 
possibly eliminating or replacing the most offensive agents in current multi-agent 
chemotherapeutic programs, opportunities for understanding and discovery in the field of 
HL survivorship will endure. With the recent FDA approval of brentuximab vedotin in the 
treatment of relapsed CD30+ HL – the first drug specifically approved for HL – this agent is 
now be tested earlier in the course of therapy, potentially replacing bleomycin in 
ABVD.[107] Many additional classes of agents have shown promise in HL, including 
immunomodulatory agents, histone deacetylase inhibitors, inhibitors of the mammalian 
target of rapamycin (mTOR), and phosphoinositide-3 kinase (PI3K) inhibitors, to name but 
four. In this era of rapidly expanding armamentarium of therapeutics, it is imperative that 
prospective protocols employ thoughtful correlative studies that ask and are powered to 
answer not only the question regarding acute toxicity, but also late medical morbidity and 
impact upon quality of life. Also sorely needed are guidelines to aide physicians in 
monitoring their patients for the myriad late effects associated with therapy – and the data 
to inform such guidelines. And as HL survival continues to improve (and as oncologists 
become an increasingly limited resource), models of efficient and effective multi-
disciplinary care for survivors of HL need to be developed, tested, and propagated.[108]  
21. Conclusion  
Survivors of Hodgkin lymphoma represent a unique group of patients who, despite having 
been cured of an aggressive and life-threatening malignancy, continue to suffer from late 
medical and psychosocial morbidities associated with their diagnosis, treatment, and the 
sequelae thereof. Risks of second primary malignancy, cardiovascular disease, pulmonary 
disease, and endocrine dysfunction are influenced by patient characteristics such as age and 
gender, and treatment characteristics, such as selected chemotherapy and the inclusion, 
dose, and field of radiotherapy. Psychosocial challenges appear to be less treatment-
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dependent, but represent no less of a challenge to well-being among survivors. As 
treatments continue to evolve, and as our understanding of these risks – who is at risk, how 
best to identify or screen for them, and even how best to prevent them – evolves as well, the 
need will only become greater for evidence-based management guidelines. With the 
appropriate tools, engaged physicians can become all the more capable of promoting and 
preserving health among patients with, and survivors of, Hodgkin lymphoma.  
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